sentence	label	e1	e2
<e1> Antacids </e1> : Absorption of a single dose of <e2> Myfortic </e2> was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	0	Antacids	Myfortic
<e1> Antacids </e1> : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking <e2> magnesium </e2> -aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	0	Antacids	magnesium
<e1> Antacids </e1> : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium- <e2> aluminum </e2> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	0	Antacids	aluminum
<e1> Antacids </e1> : Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e2> Myfortic </e2> was administered alone under fasting conditions.	0	Antacids	Myfortic
Antacids: Absorption of a single dose of <e1> Myfortic </e1> was decreased when administered to 12 stable renal transplant patients also taking <e2> magnesium </e2> -aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	1	Myfortic	magnesium
Antacids: Absorption of a single dose of <e1> Myfortic </e1> was decreased when administered to 12 stable renal transplant patients also taking magnesium- <e2> aluminum </e2> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	1	Myfortic	aluminum
Antacids: Absorption of a single dose of <e1> Myfortic </e1> was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing <e2> antacids </e2> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	0	Myfortic	antacids
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking <e1> magnesium </e1> - <e2> aluminum </e2> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	0	magnesium	aluminum
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking <e1> magnesium </e1> -aluminum containing <e2> antacids </e2> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	0	magnesium	antacids
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking <e1> magnesium </e1> -aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e2> Myfortic </e2> was administered alone under fasting conditions.	0	magnesium	Myfortic
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium- <e1> aluminum </e1> containing <e2> antacids </e2> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions.	0	aluminum	antacids
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium- <e1> aluminum </e1> containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e2> Myfortic </e2> was administered alone under fasting conditions.	0	aluminum	Myfortic
Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing <e1> antacids </e1> (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when <e2> Myfortic </e2> was administered alone under fasting conditions.	0	antacids	Myfortic
It is recommended that <e1> Myfortic </e1> and <e2> antacids </e2> not be administered simultaneously.	0	Myfortic	antacids
<e1> Cyclosporine </e1> : When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of <e2> Myfortic </e2> .	0	Cyclosporine	Myfortic
Cyclosporine: When studied in stable renal transplant patients, <e1> cyclosporine </e1> , USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of <e2> Myfortic </e2> .	0	cyclosporine	Myfortic
<e1> Acyclovir </e1> / <e2> Ganciclovir </e2> : may be taken with Myfortic;	0	Acyclovir	Ganciclovir
<e1> Acyclovir </e1> /Ganciclovir: may be taken with <e2> Myfortic </e2> ;	0	Acyclovir	Myfortic
Acyclovir/ <e1> Ganciclovir </e1> : may be taken with <e2> Myfortic </e2> ;	0	Ganciclovir	Myfortic
Both <e1> acyclovir </e1> / <e2> ganciclovir </e2> and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.	0	acyclovir	ganciclovir
Both <e1> acyclovir </e1> /ganciclovir and <e2> MPAG </e2> concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.	0	acyclovir	MPAG
Both acyclovir/ <e1> ganciclovir </e1> and <e2> MPAG </e2> concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.	0	ganciclovir	MPAG
<e1> Azathioprine </e1> / <e2> Mycophenolate Mofetil </e2> : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	0	Azathioprine	Mycophenolate Mofetil
<e1> Azathioprine </e1> /Mycophenolate Mofetil: Given that azathioprine and <e2> mycophenolate mofetil </e2> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	0	Azathioprine	mycophenolate mofetil
<e1> Azathioprine </e1> /Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e2> Myfortic </e2> not be administered concomitantly with azathioprine or mycophenolate mofetil.	0	Azathioprine	Myfortic
<e1> Azathioprine </e1> /Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or <e2> mycophenolate mofetil </e2> .	0	Azathioprine	mycophenolate mofetil
Azathioprine/ <e1> Mycophenolate Mofetil </e1> : Given that <e2> azathioprine </e2> and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	0	Mycophenolate Mofetil	azathioprine
Azathioprine/ <e1> Mycophenolate Mofetil </e1> : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e2> Myfortic </e2> not be administered concomitantly with azathioprine or mycophenolate mofetil.	0	Mycophenolate Mofetil	Myfortic
Azathioprine/ <e1> Mycophenolate Mofetil </e1> : Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e2> azathioprine </e2> or mycophenolate mofetil.	0	Mycophenolate Mofetil	azathioprine
Azathioprine/Mycophenolate Mofetil: Given that <e1> azathioprine </e1> and <e2> mycophenolate mofetil </e2> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil.	0	azathioprine	mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that <e1> azathioprine </e1> and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e2> Myfortic </e2> not be administered concomitantly with azathioprine or mycophenolate mofetil.	0	azathioprine	Myfortic
Azathioprine/Mycophenolate Mofetil: Given that <e1> azathioprine </e1> and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or <e2> mycophenolate mofetil </e2> .	0	azathioprine	mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and <e1> mycophenolate mofetil </e1> inhibit purine metabolism, it is recommended that <e2> Myfortic </e2> not be administered concomitantly with azathioprine or mycophenolate mofetil.	0	mycophenolate mofetil	Myfortic
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and <e1> mycophenolate mofetil </e1> inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e2> azathioprine </e2> or mycophenolate mofetil.	0	mycophenolate mofetil	azathioprine
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e1> Myfortic </e1> not be administered concomitantly with <e2> azathioprine </e2> or mycophenolate mofetil.	0	Myfortic	azathioprine
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that <e1> Myfortic </e1> not be administered concomitantly with azathioprine or <e2> mycophenolate mofetil </e2> .	0	Myfortic	mycophenolate mofetil
Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with <e1> azathioprine </e1> or <e2> mycophenolate mofetil </e2> .	0	azathioprine	mycophenolate mofetil
<e1> Cholestyramine </e1> and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce <e2> MPA </e2> exposure when coadministered with mycophenolate mofetil.	0	Cholestyramine	MPA
<e1> Cholestyramine </e1> and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with <e2> mycophenolate mofetil </e2> .	0	Cholestyramine	mycophenolate mofetil
Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce <e1> MPA </e1> exposure when coadministered with <e2> mycophenolate mofetil </e2> .	0	MPA	mycophenolate mofetil
Therefore, do not administer <e1> Myfortic </e1> with <e2> cholestyramine </e2> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic.	0	Myfortic	cholestyramine
Therefore, do not administer <e1> Myfortic </e1> with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral <e2> activated charcoal </e2> , because of the potential to reduce the efficacy of Myfortic.	0	Myfortic	activated charcoal
Therefore, do not administer Myfortic with <e1> cholestyramine </e1> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral <e2> activated charcoal </e2> , because of the potential to reduce the efficacy of Myfortic.	0	cholestyramine	activated charcoal
Therefore, do not administer Myfortic with <e1> cholestyramine </e1> or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of <e2> Myfortic </e2> .	0	cholestyramine	Myfortic
Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral <e1> activated charcoal </e1> , because of the potential to reduce the efficacy of <e2> Myfortic </e2> .	0	activated charcoal	Myfortic
Oral <e1> Contraceptives </e1> : Given the different metabolism of <e2> Myfortic </e2> and oral contraceptives, no drug interaction between these two classes of drug is expected.	0	Contraceptives	Myfortic
Oral Contraceptives: Given the different metabolism of <e1> Myfortic </e1> and oral <e2> contraceptives </e2> , no drug interaction between these two classes of drug is expected.	0	Myfortic	contraceptives
However, in a drug-drug interaction study, mean <e1> levonorgesterol </e1> AUC was decreased by 15% when coadministered with <e2> mycophenolate mofetil </e2> .	1	levonorgesterol	mycophenolate mofetil
Therefore, it is recommended that oral <e1> contraceptives </e1> are co- administered with <e2> Myfortic </e2> with caution and additional birth control methods be considered.	0	contraceptives	Myfortic
<e1> Live Vaccines </e1> : During treatment with <e2> Myfortic </e2> , the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective.	0	Live Vaccines	Myfortic
<e1> Live Vaccines </e1> : During treatment with Myfortic, the use of <e2> live attenuated vaccines </e2> should be avoided and patients should be advised that vaccinations may be less effective.	0	Live Vaccines	live attenuated vaccines
Live Vaccines: During treatment with <e1> Myfortic </e1> , the use of <e2> live attenuated vaccines </e2> should be avoided and patients should be advised that vaccinations may be less effective.	0	Myfortic	live attenuated vaccines
Interference of <e1> MPAG </e1> hydrolysis may lead to less <e2> MPA </e2> available for absorption.	0	MPAG	MPA
However, <e1> ketoconazole </e1> , a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of <e2> mometasone furoate </e2> during concomitant dosing.	1	ketoconazole	mometasone furoate
<e1> Tetracycline </e1> , a bacteriostatic <e2> antibiotic </e2> , may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.	0	Tetracycline	antibiotic
<e1> Tetracycline </e1> , a bacteriostatic antibiotic, may antagonize the bactericidal effect of <e2> penicillin </e2> and concurrent use of these drugs should be avoided.	1	Tetracycline	penicillin
Tetracycline, a bacteriostatic <e1> antibiotic </e1> , may antagonize the bactericidal effect of <e2> penicillin </e2> and concurrent use of these drugs should be avoided.	0	antibiotic	penicillin
Drugs which may potentiate the myeloproliferative effects of <e1> Leukine </e1> , such as <e2> lithium </e2> and corticosteroids, should be used with caution.	1	Leukine	lithium
Drugs which may potentiate the myeloproliferative effects of <e1> Leukine </e1> , such as lithium and <e2> corticosteroids </e2> , should be used with caution.	1	Leukine	corticosteroids
Drugs which may potentiate the myeloproliferative effects of Leukine, such as <e1> lithium </e1> and <e2> corticosteroids </e2> , should be used with caution.	0	lithium	corticosteroids
The interaction of <e1> Streptase </e1> , <e2> Streptokinase </e2> , with other drugs has not been well studied.	0	Streptase	Streptokinase
Use of <e1> Anticoagulants </e1> and <e2> Antiplatelet Agents </e2> -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	0	Anticoagulants	Antiplatelet Agents
Use of <e1> Anticoagulants </e1> and Antiplatelet Agents -- <e2> Streptase </e2> , Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	0	Anticoagulants	Streptase
Use of <e1> Anticoagulants </e1> and Antiplatelet Agents -- Streptase, <e2> Streptokinase </e2> , alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	0	Anticoagulants	Streptokinase
Use of <e1> Anticoagulants </e1> and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with <e2> antiplatelet agents </e2> and anticoagulants, may cause bleeding complications.	0	Anticoagulants	antiplatelet agents
Use of Anticoagulants and <e1> Antiplatelet Agents </e1> -- <e2> Streptase </e2> , Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	0	Antiplatelet Agents	Streptase
Use of Anticoagulants and <e1> Antiplatelet Agents </e1> -- Streptase, <e2> Streptokinase </e2> , alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	0	Antiplatelet Agents	Streptokinase
Use of Anticoagulants and <e1> Antiplatelet Agents </e1> -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and <e2> anticoagulants </e2> , may cause bleeding complications.	0	Antiplatelet Agents	anticoagulants
Use of Anticoagulants and Antiplatelet Agents -- <e1> Streptase </e1> , <e2> Streptokinase </e2> , alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications.	0	Streptase	Streptokinase
Use of Anticoagulants and Antiplatelet Agents -- <e1> Streptase </e1> , Streptokinase, alone or in combination with <e2> antiplatelet agents </e2> and anticoagulants, may cause bleeding complications.	1	Streptase	antiplatelet agents
Use of Anticoagulants and Antiplatelet Agents -- <e1> Streptase </e1> , Streptokinase, alone or in combination with antiplatelet agents and <e2> anticoagulants </e2> , may cause bleeding complications.	1	Streptase	anticoagulants
Use of Anticoagulants and Antiplatelet Agents -- Streptase, <e1> Streptokinase </e1> , alone or in combination with <e2> antiplatelet agents </e2> and anticoagulants, may cause bleeding complications.	1	Streptokinase	antiplatelet agents
Use of Anticoagulants and Antiplatelet Agents -- Streptase, <e1> Streptokinase </e1> , alone or in combination with antiplatelet agents and <e2> anticoagulants </e2> , may cause bleeding complications.	1	Streptokinase	anticoagulants
Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with <e1> antiplatelet agents </e1> and <e2> anticoagulants </e2> , may cause bleeding complications.	0	antiplatelet agents	anticoagulants
In the treatment of acute MI, <e1> aspirin </e1> , when not otherwise contraindicated, should be administered with <e2> Streptokinase </e2> ( see below ).	0	aspirin	Streptokinase
Anticoagulation and <e1> Antiplatelets </e1> After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of <e2> aspirin </e2> has been shown to reduce the incidence of reinfarction and stroke.	0	Antiplatelets	aspirin
The addition of <e1> aspirin </e1> to <e2> Streptokinase </e2> causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see	1	aspirin	Streptokinase
Other <e1> short-acting beta adrenergic aerosol bronchodilators </e1> should not be used concomitantly with <e2> MAXAIR AUTOHALER </e2> because they may have additive effects.	0	short-acting beta adrenergic aerosol bronchodilators	MAXAIR AUTOHALER
Usage with <e1> Alcohol </e1> : Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving <e2> pentazocine </e2> .	0	Alcohol	pentazocine
Usage with Alcohol: Due to the potential for increased CNS depressants effects, <e1> alcohol </e1> should be used with caution in patients who are currently receiving <e2> pentazocine </e2> .	0	alcohol	pentazocine
<e1> Digoxin </e1> : There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg <e2> sitagliptin </e2> for 10 days.	0	Digoxin	sitagliptin
Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of <e1> digoxin </e1> with the co-administration of 100 mg <e2> sitagliptin </e2> for 10 days.	1	digoxin	sitagliptin
No dosage adjustment of <e1> digoxin </e1> or <e2> JANUVIA </e2> is recommended.	0	digoxin	JANUVIA
Although specific drug or food interactions with <e1> mifepristone </e1> have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that <e2> ketoconazole </e2> , itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	0	mifepristone	ketoconazole
Although specific drug or food interactions with <e1> mifepristone </e1> have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, <e2> itraconazole </e2> , erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	0	mifepristone	itraconazole
Although specific drug or food interactions with <e1> mifepristone </e1> have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, <e2> erythromycin </e2> , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	0	mifepristone	erythromycin
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that <e1> ketoconazole </e1> , <e2> itraconazole </e2> , erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	0	ketoconazole	itraconazole
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that <e1> ketoconazole </e1> , itraconazole, <e2> erythromycin </e2> , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	0	ketoconazole	erythromycin
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that <e1> ketoconazole </e1> , itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2> mifepristone </e2> ).	1	ketoconazole	mifepristone
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, <e1> itraconazole </e1> , <e2> erythromycin </e2> , and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone).	0	itraconazole	erythromycin
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, <e1> itraconazole </e1> , erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2> mifepristone </e2> ).	1	itraconazole	mifepristone
Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, <e1> erythromycin </e1> , and grapefruit juice may inhibit its metabolism (increasing serum levels of <e2> mifepristone </e2> ).	1	erythromycin	mifepristone
Furthermore, <e1> rifampin </e1> , <e2> dexamethasone </e2> , St.	0	rifampin	dexamethasone
John s Wort, and certain <e1> anticonvulsants </e1> ( <e2> phenytoin </e2> , phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	0	anticonvulsants	phenytoin
John s Wort, and certain <e1> anticonvulsants </e1> (phenytoin, <e2> phenobarbital </e2> , carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	0	anticonvulsants	phenobarbital
John s Wort, and certain <e1> anticonvulsants </e1> (phenytoin, phenobarbital, <e2> carbamazepine </e2> ) may induce mifepristone metabolism (lowering serum levels of mifepristone).	0	anticonvulsants	carbamazepine
John s Wort, and certain <e1> anticonvulsants </e1> (phenytoin, phenobarbital, carbamazepine) may induce <e2> mifepristone </e2> metabolism (lowering serum levels of mifepristone).	1	anticonvulsants	mifepristone
John s Wort, and certain <e1> anticonvulsants </e1> (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of <e2> mifepristone </e2> ).	0	anticonvulsants	mifepristone
John s Wort, and certain anticonvulsants ( <e1> phenytoin </e1> , <e2> phenobarbital </e2> , carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone).	0	phenytoin	phenobarbital
John s Wort, and certain anticonvulsants ( <e1> phenytoin </e1> , phenobarbital, <e2> carbamazepine </e2> ) may induce mifepristone metabolism (lowering serum levels of mifepristone).	0	phenytoin	carbamazepine
John s Wort, and certain anticonvulsants ( <e1> phenytoin </e1> , phenobarbital, carbamazepine) may induce <e2> mifepristone </e2> metabolism (lowering serum levels of mifepristone).	1	phenytoin	mifepristone
John s Wort, and certain anticonvulsants ( <e1> phenytoin </e1> , phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of <e2> mifepristone </e2> ).	0	phenytoin	mifepristone
John s Wort, and certain anticonvulsants (phenytoin, <e1> phenobarbital </e1> , <e2> carbamazepine </e2> ) may induce mifepristone metabolism (lowering serum levels of mifepristone).	0	phenobarbital	carbamazepine
John s Wort, and certain anticonvulsants (phenytoin, <e1> phenobarbital </e1> , carbamazepine) may induce <e2> mifepristone </e2> metabolism (lowering serum levels of mifepristone).	1	phenobarbital	mifepristone
John s Wort, and certain anticonvulsants (phenytoin, <e1> phenobarbital </e1> , carbamazepine) may induce mifepristone metabolism (lowering serum levels of <e2> mifepristone </e2> ).	0	phenobarbital	mifepristone
John s Wort, and certain anticonvulsants (phenytoin, phenobarbital, <e1> carbamazepine </e1> ) may induce <e2> mifepristone </e2> metabolism (lowering serum levels of mifepristone).	1	carbamazepine	mifepristone
John s Wort, and certain anticonvulsants (phenytoin, phenobarbital, <e1> carbamazepine </e1> ) may induce mifepristone metabolism (lowering serum levels of <e2> mifepristone </e2> ).	0	carbamazepine	mifepristone
Interaction with <e1> Guanethidine </e1> : Although <e2> minoxidil </e2> does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects.	0	Guanethidine	minoxidil
Interaction with Guanethidine: Although <e1> minoxidil </e1> does not itself cause orthostatic hypotension, its administration to patients already receiving <e2> guanethidine </e2> can result in profound orthostatic effects.	1	minoxidil	guanethidine
If at all possible <e1> guanethidine </e1> should be discontinued well before <e2> minoxidil </e2> is begun.	0	guanethidine	minoxidil
<e1> Vindesine </e1> can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e2> Phenytoin </e2> : can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	0	Vindesine	Phenytoin
<e1> Vindesine </e1> can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e2> Live virus vaccines </e2> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	0	Vindesine	Live virus vaccines
<e1> Vindesine </e1> can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e2> vaccine </e2> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	0	Vindesine	vaccine
<e1> Vindesine </e1> can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e2> Mitomycin-C </e2> : may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	0	Vindesine	Mitomycin-C
<e1> Vindesine </e1> can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e2> Killed virus vaccines </e2> : may decrease patient's response to the vaccine	0	Vindesine	Killed virus vaccines
<e1> Vindesine </e1> can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2> vaccine </e2>	0	Vindesine	vaccine
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1> Phenytoin </e1> : can increase seizure activity - <e2> Live virus vaccines </e2> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	0	Phenytoin	Live virus vaccines
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1> Phenytoin </e1> : can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e2> vaccine </e2> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	0	Phenytoin	vaccine
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1> Phenytoin </e1> : can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e2> Mitomycin-C </e2> : may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	0	Phenytoin	Mitomycin-C
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1> Phenytoin </e1> : can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e2> Killed virus vaccines </e2> : may decrease patient's response to the vaccine	0	Phenytoin	Killed virus vaccines
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - <e1> Phenytoin </e1> : can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2> vaccine </e2>	0	Phenytoin	vaccine
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e1> Live virus vaccines </e1> : may potentiate the replication of the <e2> vaccine </e2> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	0	Live virus vaccines	vaccine
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e1> Live virus vaccines </e1> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e2> Mitomycin-C </e2> : may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	0	Live virus vaccines	Mitomycin-C
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e1> Live virus vaccines </e1> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e2> Killed virus vaccines </e2> : may decrease patient's response to the vaccine	0	Live virus vaccines	Killed virus vaccines
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - <e1> Live virus vaccines </e1> : may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2> vaccine </e2>	0	Live virus vaccines	vaccine
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e1> vaccine </e1> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e2> Mitomycin-C </e2> : may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine	0	vaccine	Mitomycin-C
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the <e1> vaccine </e1> virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e2> Killed virus vaccines </e2> : may decrease patient's response to the vaccine	0	vaccine	Killed virus vaccines
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e1> Mitomycin-C </e1> : may cause shortness of breath and bronchospasm - <e2> Killed virus vaccines </e2> : may decrease patient's response to the vaccine	0	Mitomycin-C	Killed virus vaccines
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - <e1> Mitomycin-C </e1> : may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the <e2> vaccine </e2>	0	Mitomycin-C	vaccine
Vindesine can interact with the drugs of the following categories: - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - <e1> Killed virus vaccines </e1> : may decrease patient's response to the <e2> vaccine </e2>	0	Killed virus vaccines	vaccine
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : <e2> amantadine </e2> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	amantadine
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, <e2> antiarrhythmic agents of class I </e2> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	antiarrhythmic agents of class I
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., <e2> quinidine </e2> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	quinidine
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e2> antihistamines </e2> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	antihistamines
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e2> antipsychotic agents </e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	antipsychotic agents
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	phenothiazines
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	benzodiazepines
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	MAO inhibitors
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	narcotic analgesics
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	meperidine
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	nitrates
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	nitrites
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	1	anticholinergic drugs	sympathomimetic agents
The following agents may increase certain actions or side effects of <e1> anticholinergic drugs </e1> : amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	1	anticholinergic drugs	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , <e2> antiarrhythmic agents of class I </e2> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	amantadine	antiarrhythmic agents of class I
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., <e2> quinidine </e2> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	amantadine	quinidine
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), <e2> antihistamines </e2> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	amantadine	antihistamines
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e2> antipsychotic agents </e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	amantadine	antipsychotic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	amantadine	phenothiazines
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	amantadine	benzodiazepines
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	amantadine	MAO inhibitors
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	amantadine	narcotic analgesics
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	amantadine	meperidine
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	amantadine	nitrates
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	amantadine	nitrites
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	0	amantadine	sympathomimetic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: <e1> amantadine </e1> , antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	amantadine	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., <e2> quinidine </e2> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antiarrhythmic agents of class I	quinidine
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), <e2> antihistamines </e2> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antiarrhythmic agents of class I	antihistamines
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, <e2> antipsychotic agents </e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antiarrhythmic agents of class I	antipsychotic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antiarrhythmic agents of class I	phenothiazines
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antiarrhythmic agents of class I	benzodiazepines
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antiarrhythmic agents of class I	MAO inhibitors
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antiarrhythmic agents of class I	narcotic analgesics
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antiarrhythmic agents of class I	meperidine
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antiarrhythmic agents of class I	nitrates
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antiarrhythmic agents of class I	nitrites
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antiarrhythmic agents of class I	sympathomimetic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, <e1> antiarrhythmic agents of class I </e1> (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	antiarrhythmic agents of class I	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), <e2> antihistamines </e2> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	quinidine	antihistamines
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, <e2> antipsychotic agents </e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	quinidine	antipsychotic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	quinidine	phenothiazines
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	quinidine	benzodiazepines
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	quinidine	MAO inhibitors
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	quinidine	narcotic analgesics
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	quinidine	meperidine
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	quinidine	nitrates
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	quinidine	nitrites
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	0	quinidine	sympathomimetic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., <e1> quinidine </e1> ), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	quinidine	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , <e2> antipsychotic agents </e2> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antihistamines	antipsychotic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antihistamines	phenothiazines
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antihistamines	benzodiazepines
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antihistamines	MAO inhibitors
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antihistamines	narcotic analgesics
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antihistamines	meperidine
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antihistamines	nitrates
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antihistamines	nitrites
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antihistamines	sympathomimetic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), <e1> antihistamines </e1> , antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	antihistamines	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., <e2> phenothiazines </e2> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antipsychotic agents	phenothiazines
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antipsychotic agents	benzodiazepines
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antipsychotic agents	MAO inhibitors
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antipsychotic agents	narcotic analgesics
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antipsychotic agents	meperidine
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antipsychotic agents	nitrates
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antipsychotic agents	nitrites
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	0	antipsychotic agents	sympathomimetic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, <e1> antipsychotic agents </e1> (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	antipsychotic agents	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1> phenothiazines </e1> ), <e2> benzodiazepines </e2> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	phenothiazines	benzodiazepines
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1> phenothiazines </e1> ), benzodiazepines, <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	phenothiazines	MAO inhibitors
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1> phenothiazines </e1> ), benzodiazepines, MAO inhibitors, <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	phenothiazines	narcotic analgesics
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1> phenothiazines </e1> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	phenothiazines	meperidine
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1> phenothiazines </e1> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	phenothiazines	nitrates
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1> phenothiazines </e1> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	phenothiazines	nitrites
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1> phenothiazines </e1> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	0	phenothiazines	sympathomimetic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., <e1> phenothiazines </e1> ), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	phenothiazines	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1> benzodiazepines </e1> , <e2> MAO inhibitors </e2> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	benzodiazepines	MAO inhibitors
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1> benzodiazepines </e1> , MAO inhibitors, <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	benzodiazepines	narcotic analgesics
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1> benzodiazepines </e1> , MAO inhibitors, narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	benzodiazepines	meperidine
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1> benzodiazepines </e1> , MAO inhibitors, narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	benzodiazepines	nitrates
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1> benzodiazepines </e1> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	benzodiazepines	nitrites
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1> benzodiazepines </e1> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	0	benzodiazepines	sympathomimetic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), <e1> benzodiazepines </e1> , MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	benzodiazepines	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1> MAO inhibitors </e1> , <e2> narcotic analgesics </e2> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	MAO inhibitors	narcotic analgesics
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1> MAO inhibitors </e1> , narcotic analgesics (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	MAO inhibitors	meperidine
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1> MAO inhibitors </e1> , narcotic analgesics (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	MAO inhibitors	nitrates
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1> MAO inhibitors </e1> , narcotic analgesics (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	MAO inhibitors	nitrites
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1> MAO inhibitors </e1> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	0	MAO inhibitors	sympathomimetic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, <e1> MAO inhibitors </e1> , narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	MAO inhibitors	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1> narcotic analgesics </e1> (e.g., <e2> meperidine </e2> ), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	narcotic analgesics	meperidine
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1> narcotic analgesics </e1> (e.g., meperidine), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	narcotic analgesics	nitrates
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1> narcotic analgesics </e1> (e.g., meperidine), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	narcotic analgesics	nitrites
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1> narcotic analgesics </e1> (e.g., meperidine), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	0	narcotic analgesics	sympathomimetic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, <e1> narcotic analgesics </e1> (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	narcotic analgesics	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e1> meperidine </e1> ), <e2> nitrates </e2> and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	meperidine	nitrates
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e1> meperidine </e1> ), nitrates and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	meperidine	nitrites
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e1> meperidine </e1> ), nitrates and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	0	meperidine	sympathomimetic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., <e1> meperidine </e1> ), nitrates and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	meperidine	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e1> nitrates </e1> and <e2> nitrites </e2> , sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity.	0	nitrates	nitrites
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e1> nitrates </e1> and nitrites, <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	0	nitrates	sympathomimetic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), <e1> nitrates </e1> and nitrites, sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	nitrates	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e1> nitrites </e1> , <e2> sympathomimetic agents </e2> , tricyclic antidepressants, and other drugs having anticholinergic activity.	0	nitrites	sympathomimetic agents
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and <e1> nitrites </e1> , sympathomimetic agents, <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	nitrites	tricyclic antidepressants
The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, <e1> sympathomimetic agents </e1> , <e2> tricyclic antidepressants </e2> , and other drugs having anticholinergic activity.	0	sympathomimetic agents	tricyclic antidepressants
<e1> Anticholinergics </e1> antagonize the effects of <e2> antiglaucoma agents </e2> .	1	Anticholinergics	antiglaucoma agents
<e1> Anticholinergic drugs </e1> in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as <e2> corticosteroids </e2> .	1	Anticholinergic drugs	corticosteroids
<e1> Anticholinergic agents </e1> may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of <e2> digoxin </e2> ;	1	Anticholinergic agents	digoxin
<e1> Anticholinergic drugs </e1> may antagonize the effects of drugs that alter gastrointestinal motility, such as <e2> metoclopramide </e2> .	1	Anticholinergic drugs	metoclopramide
Because <e1> antacids </e1> may interfere with the absorption of <e2> anticholinergic agents </e2> , simultaneous use of these drugs should be avoided.	1	antacids	anticholinergic agents
DRUG INTERACTIONS There are no known drug/drug interactions with oral <e1> ALKERAN </e1> Vaccinations with <e2> live organism vaccines </e2> are not recommended in immunocompromised individuals Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.	0	ALKERAN	live organism vaccines
DRUG INTERACTIONS There are no known drug/drug interactions with oral <e1> ALKERAN </e1> Vaccinations with live organism vaccines are not recommended in immunocompromised individuals <e2> Nalidixic acid </e2> together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.	0	ALKERAN	Nalidixic acid
DRUG INTERACTIONS There are no known drug/drug interactions with oral <e1> ALKERAN </e1> Vaccinations with live organism vaccines are not recommended in immunocompromised individuals Nalidixic acid together with high-dose intravenous <e2> melphalan </e2> has caused deaths in children due to haemorrhagic enterocolitis.	0	ALKERAN	melphalan
DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with <e1> live organism vaccines </e1> are not recommended in immunocompromised individuals <e2> Nalidixic acid </e2> together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.	0	live organism vaccines	Nalidixic acid
DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with <e1> live organism vaccines </e1> are not recommended in immunocompromised individuals Nalidixic acid together with high-dose intravenous <e2> melphalan </e2> has caused deaths in children due to haemorrhagic enterocolitis.	0	live organism vaccines	melphalan
DRUG INTERACTIONS There are no known drug/drug interactions with oral ALKERAN Vaccinations with live organism vaccines are not recommended in immunocompromised individuals <e1> Nalidixic acid </e1> together with high-dose intravenous <e2> melphalan </e2> has caused deaths in children due to haemorrhagic enterocolitis.	1	Nalidixic acid	melphalan
Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous <e1> melphalan </e1> and who subsequently received <e2> cyclosporin </e2> to prevent graft-versus-host disease	1	melphalan	cyclosporin
<e1> Streptozocin </e1> has been reported to prolong the elimination half-life of <e2> doxorubicin </e2> and may lead to severe bone marrow suppression;	1	Streptozocin	doxorubicin
a reduction of the <e1> doxorubicin </e1> dosage should be considered in patients receiving <e2> ZANOSAR </e2> concurrently.	0	doxorubicin	ZANOSAR
The concurrent use of <e1> streptozocin </e1> and <e2> phenytoin </e2> has been reported in one case to result in reduced streptozocin cytotoxicity.	1	streptozocin	phenytoin
The concurrent use of streptozocin and <e1> phenytoin </e1> has been reported in one case to result in reduced <e2> streptozocin </e2> cytotoxicity.	0	phenytoin	streptozocin
<e1> Thiazide diuretics </e1> may accentuate the orthostatic hypotension that may occur with <e2> phenothiazines </e2> .	1	Thiazide diuretics	phenothiazines
Antihypertensive effects of <e1> guanethidine </e1> and related compounds may be counteracted when <e2> phenothiazines </e2> are used concomitantly.	1	guanethidine	phenothiazines
Concomitant administration of <e1> propranolol </e1> with <e2> phenothiazines </e2> results in increased plasma levels of both drugs.	1	propranolol	phenothiazines
Concomitant administration of <e1> vancomycin </e1> and <e2> anesthetic agents </e2> has been associated with erythema and histamine-like flushing and anaphylactoid reactions.	1	vancomycin	anesthetic agents
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1> amphotericin B </e1> , <e2> aminoglycosides </e2> , bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	0	amphotericin B	aminoglycosides
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1> amphotericin B </e1> , aminoglycosides, <e2> bacitracin </e2> , polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	0	amphotericin B	bacitracin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1> amphotericin B </e1> , aminoglycosides, bacitracin, <e2> polymyxin B </e2> , colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	0	amphotericin B	polymyxin B
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1> amphotericin B </e1> , aminoglycosides, bacitracin, polymyxin B, <e2> colistin </e2> , viomycin, or cisplatin, when indicated, requires careful monitoring.	0	amphotericin B	colistin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1> amphotericin B </e1> , aminoglycosides, bacitracin, polymyxin B, colistin, <e2> viomycin </e2> , or cisplatin, when indicated, requires careful monitoring.	0	amphotericin B	viomycin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as <e1> amphotericin B </e1> , aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or <e2> cisplatin </e2> , when indicated, requires careful monitoring.	0	amphotericin B	cisplatin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, <e1> aminoglycosides </e1> , <e2> bacitracin </e2> , polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	0	aminoglycosides	bacitracin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, <e1> aminoglycosides </e1> , bacitracin, <e2> polymyxin B </e2> , colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	0	aminoglycosides	polymyxin B
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, <e1> aminoglycosides </e1> , bacitracin, polymyxin B, <e2> colistin </e2> , viomycin, or cisplatin, when indicated, requires careful monitoring.	0	aminoglycosides	colistin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, <e1> aminoglycosides </e1> , bacitracin, polymyxin B, colistin, <e2> viomycin </e2> , or cisplatin, when indicated, requires careful monitoring.	0	aminoglycosides	viomycin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, <e1> aminoglycosides </e1> , bacitracin, polymyxin B, colistin, viomycin, or <e2> cisplatin </e2> , when indicated, requires careful monitoring.	0	aminoglycosides	cisplatin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, <e1> bacitracin </e1> , <e2> polymyxin B </e2> , colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.	0	bacitracin	polymyxin B
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, <e1> bacitracin </e1> , polymyxin B, <e2> colistin </e2> , viomycin, or cisplatin, when indicated, requires careful monitoring.	0	bacitracin	colistin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, <e1> bacitracin </e1> , polymyxin B, colistin, <e2> viomycin </e2> , or cisplatin, when indicated, requires careful monitoring.	0	bacitracin	viomycin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, <e1> bacitracin </e1> , polymyxin B, colistin, viomycin, or <e2> cisplatin </e2> , when indicated, requires careful monitoring.	0	bacitracin	cisplatin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, <e1> polymyxin B </e1> , <e2> colistin </e2> , viomycin, or cisplatin, when indicated, requires careful monitoring.	0	polymyxin B	colistin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, <e1> polymyxin B </e1> , colistin, <e2> viomycin </e2> , or cisplatin, when indicated, requires careful monitoring.	0	polymyxin B	viomycin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, <e1> polymyxin B </e1> , colistin, viomycin, or <e2> cisplatin </e2> , when indicated, requires careful monitoring.	0	polymyxin B	cisplatin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, <e1> colistin </e1> , <e2> viomycin </e2> , or cisplatin, when indicated, requires careful monitoring.	0	colistin	viomycin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, <e1> colistin </e1> , viomycin, or <e2> cisplatin </e2> , when indicated, requires careful monitoring.	0	colistin	cisplatin
Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, <e1> viomycin </e1> , or <e2> cisplatin </e2> , when indicated, requires careful monitoring.	0	viomycin	cisplatin
In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving <e1> methadone </e1> , treatment with <e2> PEG-Intron </e2> once weekly for 4 weeks was associated with a mean increase of 16% in methadone AUC;	1	methadone	PEG-Intron
In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving methadone, treatment with <e1> PEG-Intron </e1> once weekly for 4 weeks was associated with a mean increase of 16% in <e2> methadone </e2> AUC;	0	PEG-Intron	methadone
Oral <e1> metronidazole </e1> has been reported to potentiate the anticoagulant effect of <e2> coumarin </e2> and warfarin, resulting in a prolongation of prothrombin time.	1	metronidazole	coumarin
Oral <e1> metronidazole </e1> has been reported to potentiate the anticoagulant effect of coumarin and <e2> warfarin </e2> , resulting in a prolongation of prothrombin time.	1	metronidazole	warfarin
Oral metronidazole has been reported to potentiate the anticoagulant effect of <e1> coumarin </e1> and <e2> warfarin </e2> , resulting in a prolongation of prothrombin time.	0	coumarin	warfarin
Drug interactions should be kept in mind when <e1> METROGEL </e1> ( <e2> metronidazole </e2> gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.	0	METROGEL	metronidazole
Drug interactions should be kept in mind when <e1> METROGEL </e1> (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical <e2> metronidazole </e2> administration because of low absorption.	0	METROGEL	metronidazole
Concurrent use of <e1> alcohol </e1> and other <e2> CNS depression-producing drugs </e2> may increase the CNS depressant effects of methyprylon or these other medications.	0	alcohol	CNS depression-producing drugs
Concurrent use of <e1> alcohol </e1> and other CNS depression-producing drugs may increase the CNS depressant effects of <e2> methyprylon </e2> or these other medications.	1	alcohol	methyprylon
Concurrent use of alcohol and other <e1> CNS depression-producing drugs </e1> may increase the CNS depressant effects of <e2> methyprylon </e2> or these other medications.	1	CNS depression-producing drugs	methyprylon
Concomitant administrations not recommended: - <e1> Terfenadine </e1> and <e2> astemizole </e2> : Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	0	Terfenadine	astemizole
Concomitant administrations not recommended: - <e1> Terfenadine </e1> and astemizole: Certain <e2> macrolides </e2> interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	0	Terfenadine	macrolides
Concomitant administrations not recommended: - <e1> Terfenadine </e1> and astemizole: Certain macrolides interact with terfenadine and <e2> astemizole </e2> leading to increased serum concentrations of the latter.	0	Terfenadine	astemizole
Concomitant administrations not recommended: - Terfenadine and <e1> astemizole </e1> : Certain <e2> macrolides </e2> interact with terfenadine and astemizole leading to increased serum concentrations of the latter.	0	astemizole	macrolides
Concomitant administrations not recommended: - Terfenadine and <e1> astemizole </e1> : Certain macrolides interact with <e2> terfenadine </e2> and astemizole leading to increased serum concentrations of the latter.	0	astemizole	terfenadine
Concomitant administrations not recommended: - Terfenadine and astemizole: Certain <e1> macrolides </e1> interact with <e2> terfenadine </e2> and astemizole leading to increased serum concentrations of the latter.	0	macrolides	terfenadine
Concomitant administrations not recommended: - Terfenadine and astemizole: Certain <e1> macrolides </e1> interact with terfenadine and <e2> astemizole </e2> leading to increased serum concentrations of the latter.	0	macrolides	astemizole
Concomitant administrations not recommended: - Terfenadine and astemizole: Certain macrolides interact with <e1> terfenadine </e1> and <e2> astemizole </e2> leading to increased serum concentrations of the latter.	0	terfenadine	astemizole
Although such a reaction has not been demonstrated with <e1> roxithromycin </e1> , concomitant administration of roxithromycin with <e2> terfenadine </e2> or astemizole is not recommended.	0	roxithromycin	terfenadine
Although such a reaction has not been demonstrated with <e1> roxithromycin </e1> , concomitant administration of roxithromycin with terfenadine or <e2> astemizole </e2> is not recommended.	0	roxithromycin	astemizole
Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of <e1> roxithromycin </e1> with <e2> terfenadine </e2> or astemizole is not recommended.	0	roxithromycin	terfenadine
Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of <e1> roxithromycin </e1> with terfenadine or <e2> astemizole </e2> is not recommended.	0	roxithromycin	astemizole
Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with <e1> terfenadine </e1> or <e2> astemizole </e2> is not recommended.	0	terfenadine	astemizole
- <e1> Cisapride </e1> , <e2> pimozide </e2> : Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	0	Cisapride	pimozide
- <e1> Cisapride </e1> , pimozide: Other drugs such as cisapride or <e2> pimozide </e2> , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	0	Cisapride	pimozide
- <e1> Cisapride </e1> , pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e2> macrolide antibacterials </e2> .	0	Cisapride	macrolide antibacterials
- Cisapride, <e1> pimozide </e1> : Other drugs such as <e2> cisapride </e2> or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	0	pimozide	cisapride
- Cisapride, <e1> pimozide </e1> : Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e2> macrolide antibacterials </e2> .	1	pimozide	macrolide antibacterials
- Cisapride, pimozide: Other drugs such as <e1> cisapride </e1> or <e2> pimozide </e2> , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials.	0	cisapride	pimozide
- Cisapride, pimozide: Other drugs such as <e1> cisapride </e1> or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e2> macrolide antibacterials </e2> .	1	cisapride	macrolide antibacterials
- Cisapride, pimozide: Other drugs such as cisapride or <e1> pimozide </e1> , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some <e2> macrolide antibacterials </e2> .	0	pimozide	macrolide antibacterials
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: <e2> theophylline </e2> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	theophylline
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e2> cisapride </e2> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	cisapride
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e2> antipyrine </e2> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	antipyrine
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e2> caffeine </e2> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	caffeine
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e2> carbamazepine </e2> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	carbamazepine
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e2> diazepam </e2> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	diazepam
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e2> desmethyldiazepam </e2> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	desmethyldiazepam
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e2> diclofenac </e2> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	diclofenac
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	naproxen
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	piroxicam
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	digoxin
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	ethanol
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	glyburide
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	contraceptive
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	levonorgestrel
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	ethinyl estradiol
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	metoprolol
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	nifedipine
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	phenytoin
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	warfarin
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	pantoprazole	midazolam
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	pantoprazole	clarithromycin
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	pantoprazole	metronidazole
Based on studies evaluating possible interactions of <e1> pantoprazole </e1> with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	pantoprazole	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , <e2> cisapride </e2> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	cisapride
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, <e2> antipyrine </e2> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	antipyrine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, <e2> caffeine </e2> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	caffeine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, <e2> carbamazepine </e2> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	carbamazepine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, <e2> diazepam </e2> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	diazepam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e2> desmethyldiazepam </e2> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	desmethyldiazepam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e2> diclofenac </e2> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	diclofenac
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	naproxen
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	piroxicam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	digoxin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	ethanol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	glyburide
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	theophylline	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	theophylline	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	theophylline	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	theophylline	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: <e1> theophylline </e1> , cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	theophylline	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , <e2> antipyrine </e2> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	antipyrine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, <e2> caffeine </e2> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	caffeine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, <e2> carbamazepine </e2> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	carbamazepine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, <e2> diazepam </e2> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	diazepam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e2> desmethyldiazepam </e2> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	desmethyldiazepam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e2> diclofenac </e2> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	diclofenac
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	naproxen
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	piroxicam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	digoxin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	ethanol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	glyburide
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	cisapride	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	cisapride	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	cisapride	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	cisapride	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, <e1> cisapride </e1> , antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	cisapride	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , <e2> caffeine </e2> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	caffeine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, <e2> carbamazepine </e2> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	carbamazepine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, <e2> diazepam </e2> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	diazepam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, <e2> desmethyldiazepam </e2> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	desmethyldiazepam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e2> diclofenac </e2> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	diclofenac
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	naproxen
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	piroxicam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	digoxin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	ethanol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	glyburide
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	antipyrine	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	antipyrine	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	antipyrine	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, <e1> antipyrine </e1> , caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	antipyrine	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , <e2> carbamazepine </e2> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	carbamazepine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, <e2> diazepam </e2> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	diazepam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, <e2> desmethyldiazepam </e2> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	desmethyldiazepam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e2> diclofenac </e2> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	diclofenac
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	naproxen
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	piroxicam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	digoxin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	ethanol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	glyburide
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	caffeine	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	caffeine	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	caffeine	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	caffeine	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, <e1> caffeine </e1> , carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	caffeine	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , <e2> diazepam </e2> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	diazepam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, <e2> desmethyldiazepam </e2> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	desmethyldiazepam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), <e2> diclofenac </e2> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	diclofenac
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	naproxen
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	piroxicam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	digoxin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	ethanol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	glyburide
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	carbamazepine	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	carbamazepine	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	carbamazepine	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, <e1> carbamazepine </e1> , diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	carbamazepine	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, <e2> desmethyldiazepam </e2> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	desmethyldiazepam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), <e2> diclofenac </e2> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	diclofenac
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	naproxen
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	piroxicam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	digoxin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	ethanol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	glyburide
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diazepam	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	diazepam	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	diazepam	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	diazepam	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, <e1> diazepam </e1> (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	diazepam	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), <e2> diclofenac </e2> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	diclofenac
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	naproxen
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	piroxicam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	digoxin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	ethanol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	glyburide
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	desmethyldiazepam	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	desmethyldiazepam	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	desmethyldiazepam	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, <e1> desmethyldiazepam </e1> ), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	desmethyldiazepam	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , <e2> naproxen </e2> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	naproxen
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	piroxicam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	digoxin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	ethanol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	glyburide
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	diclofenac	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	diclofenac	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	diclofenac	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), <e1> diclofenac </e1> , naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	diclofenac	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , <e2> piroxicam </e2> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	naproxen	piroxicam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	naproxen	digoxin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	naproxen	ethanol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, ethanol, <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	naproxen	glyburide
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	naproxen	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	naproxen	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	naproxen	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	naproxen	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	naproxen	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	naproxen	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	naproxen	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	naproxen	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	naproxen	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	naproxen	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, <e1> naproxen </e1> , piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	naproxen	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , <e2> digoxin </e2> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	piroxicam	digoxin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	piroxicam	ethanol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, ethanol, <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	piroxicam	glyburide
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	piroxicam	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	piroxicam	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	piroxicam	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	piroxicam	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	piroxicam	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	piroxicam	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	piroxicam	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	piroxicam	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	piroxicam	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	piroxicam	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, <e1> piroxicam </e1> , digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	piroxicam	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , <e2> ethanol </e2> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	digoxin	ethanol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , ethanol, <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	digoxin	glyburide
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , ethanol, glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	digoxin	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	digoxin	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	digoxin	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	digoxin	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	digoxin	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	digoxin	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	digoxin	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	digoxin	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	digoxin	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	digoxin	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, <e1> digoxin </e1> , ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	digoxin	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1> ethanol </e1> , <e2> glyburide </e2> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	ethanol	glyburide
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1> ethanol </e1> , glyburide, an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	ethanol	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1> ethanol </e1> , glyburide, an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	ethanol	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	ethanol	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	ethanol	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	ethanol	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	ethanol	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	ethanol	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	ethanol	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	ethanol	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	ethanol	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, <e1> ethanol </e1> , glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	ethanol	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1> glyburide </e1> , an oral <e2> contraceptive </e2> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	glyburide	contraceptive
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1> glyburide </e1> , an oral contraceptive ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	glyburide	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	glyburide	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	glyburide	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	glyburide	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	glyburide	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	glyburide	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	glyburide	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	glyburide	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	glyburide	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, <e1> glyburide </e1> , an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	glyburide	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1> contraceptive </e1> ( <e2> levonorgestrel </e2> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	contraceptive	levonorgestrel
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1> contraceptive </e1> (levonorgestrel/ <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	contraceptive	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1> contraceptive </e1> (levonorgestrel/ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	contraceptive	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1> contraceptive </e1> (levonorgestrel/ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	contraceptive	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1> contraceptive </e1> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	contraceptive	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1> contraceptive </e1> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	contraceptive	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1> contraceptive </e1> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	contraceptive	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1> contraceptive </e1> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	contraceptive	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1> contraceptive </e1> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	contraceptive	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral <e1> contraceptive </e1> (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	contraceptive	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e1> levonorgestrel </e1> / <e2> ethinyl estradiol </e2> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	levonorgestrel	ethinyl estradiol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e1> levonorgestrel </e1> /ethinyl estradiol), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	levonorgestrel	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e1> levonorgestrel </e1> /ethinyl estradiol), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	levonorgestrel	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e1> levonorgestrel </e1> /ethinyl estradiol), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	levonorgestrel	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e1> levonorgestrel </e1> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	levonorgestrel	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e1> levonorgestrel </e1> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	levonorgestrel	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e1> levonorgestrel </e1> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	levonorgestrel	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e1> levonorgestrel </e1> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	levonorgestrel	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive ( <e1> levonorgestrel </e1> /ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	levonorgestrel	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ), <e2> metoprolol </e2> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	ethinyl estradiol	metoprolol
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ), metoprolol, <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	ethinyl estradiol	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ), metoprolol, nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	ethinyl estradiol	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ), metoprolol, nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	ethinyl estradiol	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ), metoprolol, nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	ethinyl estradiol	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	ethinyl estradiol	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	ethinyl estradiol	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ <e1> ethinyl estradiol </e1> ), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	ethinyl estradiol	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1> metoprolol </e1> , <e2> nifedipine </e2> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	metoprolol	nifedipine
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1> metoprolol </e1> , nifedipine, <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	metoprolol	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1> metoprolol </e1> , nifedipine, phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	metoprolol	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1> metoprolol </e1> , nifedipine, phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	metoprolol	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1> metoprolol </e1> , nifedipine, phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	metoprolol	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1> metoprolol </e1> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	metoprolol	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), <e1> metoprolol </e1> , nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	metoprolol	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e1> nifedipine </e1> , <e2> phenytoin </e2> , warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin.	0	nifedipine	phenytoin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e1> nifedipine </e1> , phenytoin, <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	nifedipine	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e1> nifedipine </e1> , phenytoin, warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	nifedipine	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e1> nifedipine </e1> , phenytoin, warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	nifedipine	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e1> nifedipine </e1> , phenytoin, warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	nifedipine	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, <e1> nifedipine </e1> , phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	nifedipine	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e1> phenytoin </e1> , <e2> warfarin </e2> , midazolam, clarithromycin, metronidazole, or amoxicillin.	0	phenytoin	warfarin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e1> phenytoin </e1> , warfarin, <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	phenytoin	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e1> phenytoin </e1> , warfarin, midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	phenytoin	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e1> phenytoin </e1> , warfarin, midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	phenytoin	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, <e1> phenytoin </e1> , warfarin, midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	phenytoin	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e1> warfarin </e1> , <e2> midazolam </e2> , clarithromycin, metronidazole, or amoxicillin.	0	warfarin	midazolam
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e1> warfarin </e1> , midazolam, <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	warfarin	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e1> warfarin </e1> , midazolam, clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	warfarin	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, <e1> warfarin </e1> , midazolam, clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	warfarin	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e1> midazolam </e1> , <e2> clarithromycin </e2> , metronidazole, or amoxicillin.	0	midazolam	clarithromycin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e1> midazolam </e1> , clarithromycin, <e2> metronidazole </e2> , or amoxicillin.	0	midazolam	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, <e1> midazolam </e1> , clarithromycin, metronidazole, or <e2> amoxicillin </e2> .	0	midazolam	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e1> clarithromycin </e1> , <e2> metronidazole </e2> , or amoxicillin.	0	clarithromycin	metronidazole
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, <e1> clarithromycin </e1> , metronidazole, or <e2> amoxicillin </e2> .	0	clarithromycin	amoxicillin
Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, <e1> metronidazole </e1> , or <e2> amoxicillin </e2> .	0	metronidazole	amoxicillin
There have been postmarketing reports of increased INR and prothrombin time in patients receiving <e1> proton pump inhibitors </e1> , including <e2> pantoprazole </e2> , and warfarin concomitantly.	0	proton pump inhibitors	pantoprazole
There have been postmarketing reports of increased INR and prothrombin time in patients receiving <e1> proton pump inhibitors </e1> , including pantoprazole, and <e2> warfarin </e2> concomitantly.	1	proton pump inhibitors	warfarin
There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including <e1> pantoprazole </e1> , and <e2> warfarin </e2> concomitantly.	1	pantoprazole	warfarin
Patients treated with <e1> proton pump inhibitors </e1> and <e2> warfarin </e2> concomitantly should be monitored for increases in INR and prothrombin time.	0	proton pump inhibitors	warfarin
Because of profound and long lasting inhibition of gastric acid secretion, <e1> pantoprazole </e1> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, <e2> ketoconazole </e2> , ampicillin esters, and iron salts).	1	pantoprazole	ketoconazole
Because of profound and long lasting inhibition of gastric acid secretion, <e1> pantoprazole </e1> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, <e2> ampicillin </e2> esters, and iron salts).	1	pantoprazole	ampicillin
Because of profound and long lasting inhibition of gastric acid secretion, <e1> pantoprazole </e1> may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and <e2> iron </e2> salts).	1	pantoprazole	iron
Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, <e1> ketoconazole </e1> , <e2> ampicillin </e2> esters, and iron salts).	0	ketoconazole	ampicillin
Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, <e1> ketoconazole </e1> , ampicillin esters, and <e2> iron </e2> salts).	0	ketoconazole	iron
Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, <e1> ampicillin </e1> esters, and <e2> iron </e2> salts).	0	ampicillin	iron
Laboratory Tests There have been reports of false-positive urine screening tests for <e1> tetrahydrocannabinol </e1> ( <e2> THC </e2> ) in patients receiving most proton pump inhibitors, including pantoprazole.	0	tetrahydrocannabinol	THC
Laboratory Tests There have been reports of false-positive urine screening tests for <e1> tetrahydrocannabinol </e1> (THC) in patients receiving most <e2> proton pump inhibitors </e2> , including pantoprazole.	0	tetrahydrocannabinol	proton pump inhibitors
Laboratory Tests There have been reports of false-positive urine screening tests for <e1> tetrahydrocannabinol </e1> (THC) in patients receiving most proton pump inhibitors, including <e2> pantoprazole </e2> .	0	tetrahydrocannabinol	pantoprazole
Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol ( <e1> THC </e1> ) in patients receiving most <e2> proton pump inhibitors </e2> , including pantoprazole.	0	THC	proton pump inhibitors
Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol ( <e1> THC </e1> ) in patients receiving most proton pump inhibitors, including <e2> pantoprazole </e2> .	0	THC	pantoprazole
Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most <e1> proton pump inhibitors </e1> , including <e2> pantoprazole </e2> .	0	proton pump inhibitors	pantoprazole
Patients studied in clinical trials of <e1> TNKase </e1> were routinely treated with <e2> heparin </e2> and aspirin.	0	TNKase	heparin
Patients studied in clinical trials of <e1> TNKase </e1> were routinely treated with heparin and <e2> aspirin </e2> .	0	TNKase	aspirin
Patients studied in clinical trials of TNKase were routinely treated with <e1> heparin </e1> and <e2> aspirin </e2> .	0	heparin	aspirin
<e1> Anticoagulants </e1> (such as <e2> heparin </e2> and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	0	Anticoagulants	heparin
<e1> Anticoagulants </e1> (such as heparin and <e2> vitamin K antagonists </e2> ) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	0	Anticoagulants	vitamin K antagonists
<e1> Anticoagulants </e1> (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as <e2> acetylsalicylic acid </e2> , dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	0	Anticoagulants	acetylsalicylic acid
<e1> Anticoagulants </e1> (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, <e2> dipyridamole </e2> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	0	Anticoagulants	dipyridamole
<e1> Anticoagulants </e1> (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2> TNKase </e2> therapy.	1	Anticoagulants	TNKase
Anticoagulants (such as <e1> heparin </e1> and <e2> vitamin K antagonists </e2> ) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	0	heparin	vitamin K antagonists
Anticoagulants (such as <e1> heparin </e1> and vitamin K antagonists) and drugs that alter platelet function (such as <e2> acetylsalicylic acid </e2> , dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	0	heparin	acetylsalicylic acid
Anticoagulants (such as <e1> heparin </e1> and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, <e2> dipyridamole </e2> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	0	heparin	dipyridamole
Anticoagulants (such as <e1> heparin </e1> and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2> TNKase </e2> therapy.	1	heparin	TNKase
Anticoagulants (such as heparin and <e1> vitamin K antagonists </e1> ) and drugs that alter platelet function (such as <e2> acetylsalicylic acid </e2> , dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	0	vitamin K antagonists	acetylsalicylic acid
Anticoagulants (such as heparin and <e1> vitamin K antagonists </e1> ) and drugs that alter platelet function (such as acetylsalicylic acid, <e2> dipyridamole </e2> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	0	vitamin K antagonists	dipyridamole
Anticoagulants (such as heparin and <e1> vitamin K antagonists </e1> ) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2> TNKase </e2> therapy.	1	vitamin K antagonists	TNKase
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as <e1> acetylsalicylic acid </e1> , <e2> dipyridamole </e2> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy.	0	acetylsalicylic acid	dipyridamole
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as <e1> acetylsalicylic acid </e1> , dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2> TNKase </e2> therapy.	1	acetylsalicylic acid	TNKase
Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, <e1> dipyridamole </e1> , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after <e2> TNKase </e2> therapy.	1	dipyridamole	TNKase
<e1> Aminoglutethimide </e1> administered concomitantly with <e2> depo-subQ provera 104 </e2> may significantly decrease the serum concentrations of MPA.	1	Aminoglutethimide	depo-subQ provera 104
<e1> Aminoglutethimide </e1> administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of <e2> MPA </e2> .	0	Aminoglutethimide	MPA
Aminoglutethimide administered concomitantly with <e1> depo-subQ provera 104 </e1> may significantly decrease the serum concentrations of <e2> MPA </e2> .	0	depo-subQ provera 104	MPA
<e1> Posicor </e1> inhibits some of the liver's ability to metabolize some other drugs - <e2> terfenadine </e2> , astemizole, cisapride, cyclosporine, and tricyclic antidepressants.	1	Posicor	terfenadine
<e1> Posicor </e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine, <e2> astemizole </e2> , cisapride, cyclosporine, and tricyclic antidepressants.	1	Posicor	astemizole
<e1> Posicor </e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, <e2> cisapride </e2> , cyclosporine, and tricyclic antidepressants.	1	Posicor	cisapride
<e1> Posicor </e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, <e2> cyclosporine </e2> , and tricyclic antidepressants.	1	Posicor	cyclosporine
<e1> Posicor </e1> inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and <e2> tricyclic antidepressants </e2> .	1	Posicor	tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - <e1> terfenadine </e1> , <e2> astemizole </e2> , cisapride, cyclosporine, and tricyclic antidepressants.	0	terfenadine	astemizole
Posicor inhibits some of the liver's ability to metabolize some other drugs - <e1> terfenadine </e1> , astemizole, <e2> cisapride </e2> , cyclosporine, and tricyclic antidepressants.	0	terfenadine	cisapride
Posicor inhibits some of the liver's ability to metabolize some other drugs - <e1> terfenadine </e1> , astemizole, cisapride, <e2> cyclosporine </e2> , and tricyclic antidepressants.	0	terfenadine	cyclosporine
Posicor inhibits some of the liver's ability to metabolize some other drugs - <e1> terfenadine </e1> , astemizole, cisapride, cyclosporine, and <e2> tricyclic antidepressants </e2> .	0	terfenadine	tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, <e1> astemizole </e1> , <e2> cisapride </e2> , cyclosporine, and tricyclic antidepressants.	0	astemizole	cisapride
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, <e1> astemizole </e1> , cisapride, <e2> cyclosporine </e2> , and tricyclic antidepressants.	0	astemizole	cyclosporine
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, <e1> astemizole </e1> , cisapride, cyclosporine, and <e2> tricyclic antidepressants </e2> .	0	astemizole	tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, <e1> cisapride </e1> , <e2> cyclosporine </e2> , and tricyclic antidepressants.	0	cisapride	cyclosporine
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, <e1> cisapride </e1> , cyclosporine, and <e2> tricyclic antidepressants </e2> .	0	cisapride	tricyclic antidepressants
Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, <e1> cyclosporine </e1> , and <e2> tricyclic antidepressants </e2> .	0	cyclosporine	tricyclic antidepressants
<e1> Zidovudine </e1> competitively inhibits the intracellular phosphorylation of <e2> stavudine </e2> .	1	Zidovudine	stavudine
Therefore, use of <e1> zidovudine </e1> in combination with <e2> ZERIT </e2> should be avoided.	0	zidovudine	ZERIT
In vitro data indicate that the phosphorylation of <e1> stavudine </e1> is also inhibited at relevant concentrations by <e2> doxorubicin </e2> and ribavirin.	1	stavudine	doxorubicin
In vitro data indicate that the phosphorylation of <e1> stavudine </e1> is also inhibited at relevant concentrations by doxorubicin and <e2> ribavirin </e2> .	1	stavudine	ribavirin
In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by <e1> doxorubicin </e1> and <e2> ribavirin </e2> .	0	doxorubicin	ribavirin
No pharmacokinetic interaction between 85 mg/m2 <e1> ELOXATIN </e1> and infusional <e2> 5-FU </e2> has been observed in patients treated every 2 weeks.	0	ELOXATIN	5-FU
Increases of <e1> 5-FU </e1> plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 <e2> ELOXATIN </e2> dosed every 3 weeks.	1	5-FU	ELOXATIN
In addition to bleeding associated with <e1> heparin </e1> and <e2> vitamin K antagonists </e2> , drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase therapy.	0	heparin	vitamin K antagonists
In addition to bleeding associated with <e1> heparin </e1> and vitamin K antagonists, drugs that alter platelet function (such as <e2> aspirin </e2> , dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase therapy.	0	heparin	aspirin
In addition to bleeding associated with <e1> heparin </e1> and vitamin K antagonists, drugs that alter platelet function (such as aspirin, <e2> dipyridamole </e2> , and abciximab) may increase the risk of bleeding if administered prior to or after Retavase therapy.	0	heparin	dipyridamole
In addition to bleeding associated with <e1> heparin </e1> and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and <e2> abciximab </e2> ) may increase the risk of bleeding if administered prior to or after Retavase therapy.	0	heparin	abciximab
In addition to bleeding associated with <e1> heparin </e1> and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after <e2> Retavase </e2> therapy.	1	heparin	Retavase
In addition to bleeding associated with heparin and <e1> vitamin K antagonists </e1> , drugs that alter platelet function (such as <e2> aspirin </e2> , dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after Retavase therapy.	0	vitamin K antagonists	aspirin
In addition to bleeding associated with heparin and <e1> vitamin K antagonists </e1> , drugs that alter platelet function (such as aspirin, <e2> dipyridamole </e2> , and abciximab) may increase the risk of bleeding if administered prior to or after Retavase therapy.	0	vitamin K antagonists	dipyridamole
In addition to bleeding associated with heparin and <e1> vitamin K antagonists </e1> , drugs that alter platelet function (such as aspirin, dipyridamole, and <e2> abciximab </e2> ) may increase the risk of bleeding if administered prior to or after Retavase therapy.	0	vitamin K antagonists	abciximab
In addition to bleeding associated with heparin and <e1> vitamin K antagonists </e1> , drugs that alter platelet function (such as aspirin, dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after <e2> Retavase </e2> therapy.	1	vitamin K antagonists	Retavase
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as <e1> aspirin </e1> , <e2> dipyridamole </e2> , and abciximab) may increase the risk of bleeding if administered prior to or after Retavase therapy.	0	aspirin	dipyridamole
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as <e1> aspirin </e1> , dipyridamole, and <e2> abciximab </e2> ) may increase the risk of bleeding if administered prior to or after Retavase therapy.	0	aspirin	abciximab
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as <e1> aspirin </e1> , dipyridamole, and abciximab) may increase the risk of bleeding if administered prior to or after <e2> Retavase </e2> therapy.	1	aspirin	Retavase
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, <e1> dipyridamole </e1> , and <e2> abciximab </e2> ) may increase the risk of bleeding if administered prior to or after Retavase therapy.	0	dipyridamole	abciximab
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, <e1> dipyridamole </e1> , and abciximab) may increase the risk of bleeding if administered prior to or after <e2> Retavase </e2> therapy.	1	dipyridamole	Retavase
In addition to bleeding associated with heparin and vitamin K antagonists, drugs that alter platelet function (such as aspirin, dipyridamole, and <e1> abciximab </e1> ) may increase the risk of bleeding if administered prior to or after <e2> Retavase </e2> therapy.	1	abciximab	Retavase
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled <e2> paricalcitol </e2> AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	1	ketoconazole	paricalcitol
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled paricalcitol AUC0- . Since <e2> paricalcitol </e2> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	paricalcitol
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e2> paricalcitol </e2> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	paricalcitol
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e2> atazanavir </e2> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	atazanavir
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	clarithromycin
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	indinavir
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	itraconazole
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	nefazodone
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	nelfinavir
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole.	0	ketoconazole	ritonavir
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin or voriconazole.	0	ketoconazole	saquinavir
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> or voriconazole.	0	ketoconazole	telithromycin
A multiple dose drug-drug interaction study demonstrated that <e1> ketoconazole </e1> approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2> voriconazole </e2> .	0	ketoconazole	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1> paricalcitol </e1> AUC0- . Since paricalcitol is partially metabolized by CYP3A and <e2> ketoconazole </e2> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	ketoconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1> paricalcitol </e1> AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e2> ketoconazole </e2> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	ketoconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1> paricalcitol </e1> AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e2> atazanavir </e2> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	atazanavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1> paricalcitol </e1> AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	clarithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1> paricalcitol </e1> AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	indinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1> paricalcitol </e1> AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	itraconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1> paricalcitol </e1> AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	nefazodone
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1> paricalcitol </e1> AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	nelfinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1> paricalcitol </e1> AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole.	0	paricalcitol	ritonavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1> paricalcitol </e1> AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin or voriconazole.	0	paricalcitol	saquinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1> paricalcitol </e1> AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> or voriconazole.	0	paricalcitol	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled <e1> paricalcitol </e1> AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2> voriconazole </e2> .	0	paricalcitol	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since <e1> paricalcitol </e1> is partially metabolized by CYP3A and <e2> ketoconazole </e2> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	ketoconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since <e1> paricalcitol </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e2> ketoconazole </e2> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	ketoconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since <e1> paricalcitol </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e2> atazanavir </e2> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	atazanavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since <e1> paricalcitol </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	clarithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since <e1> paricalcitol </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	indinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since <e1> paricalcitol </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	itraconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since <e1> paricalcitol </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	nefazodone
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since <e1> paricalcitol </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	nelfinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since <e1> paricalcitol </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole.	0	paricalcitol	ritonavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since <e1> paricalcitol </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin or voriconazole.	0	paricalcitol	saquinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since <e1> paricalcitol </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> or voriconazole.	0	paricalcitol	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since <e1> paricalcitol </e1> is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2> voriconazole </e2> .	0	paricalcitol	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and <e1> ketoconazole </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e2> paricalcitol </e2> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	paricalcitol
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and <e1> ketoconazole </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e2> atazanavir </e2> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	atazanavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and <e1> ketoconazole </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	clarithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and <e1> ketoconazole </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	indinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and <e1> ketoconazole </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	itraconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and <e1> ketoconazole </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	nefazodone
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and <e1> ketoconazole </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	nelfinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and <e1> ketoconazole </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole.	0	ketoconazole	ritonavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and <e1> ketoconazole </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin or voriconazole.	0	ketoconazole	saquinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and <e1> ketoconazole </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> or voriconazole.	0	ketoconazole	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and <e1> ketoconazole </e1> le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2> voriconazole </e2> .	0	ketoconazole	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1> paricalcitol </e1> with <e2> ketoconazole </e2> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	ketoconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1> paricalcitol </e1> with ketoconazole and other strong P450 3A inhibitors including <e2> atazanavir </e2> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	atazanavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1> paricalcitol </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	clarithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1> paricalcitol </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	indinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1> paricalcitol </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	itraconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1> paricalcitol </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	nefazodone
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1> paricalcitol </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole.	0	paricalcitol	nelfinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1> paricalcitol </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole.	0	paricalcitol	ritonavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1> paricalcitol </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin or voriconazole.	0	paricalcitol	saquinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1> paricalcitol </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> or voriconazole.	0	paricalcitol	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing <e1> paricalcitol </e1> with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2> voriconazole </e2> .	0	paricalcitol	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1> ketoconazole </e1> and other strong P450 3A inhibitors including <e2> atazanavir </e2> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	atazanavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1> ketoconazole </e1> and other strong P450 3A inhibitors including atazanavir, <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	clarithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1> ketoconazole </e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	indinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1> ketoconazole </e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	itraconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1> ketoconazole </e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	nefazodone
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1> ketoconazole </e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole.	0	ketoconazole	nelfinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1> ketoconazole </e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole.	0	ketoconazole	ritonavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1> ketoconazole </e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin or voriconazole.	0	ketoconazole	saquinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1> ketoconazole </e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> or voriconazole.	0	ketoconazole	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with <e1> ketoconazole </e1> and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2> voriconazole </e2> .	0	ketoconazole	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> atazanavir </e1> , <e2> clarithromycin </e2> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	atazanavir	clarithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> atazanavir </e1> , clarithromycin, <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	atazanavir	indinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> atazanavir </e1> , clarithromycin, indinavir, <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	atazanavir	itraconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> atazanavir </e1> , clarithromycin, indinavir, itraconazole, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	atazanavir	nefazodone
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> atazanavir </e1> , clarithromycin, indinavir, itraconazole, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole.	0	atazanavir	nelfinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> atazanavir </e1> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole.	0	atazanavir	ritonavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> atazanavir </e1> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin or voriconazole.	0	atazanavir	saquinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> atazanavir </e1> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> or voriconazole.	0	atazanavir	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including <e1> atazanavir </e1> , clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2> voriconazole </e2> .	0	atazanavir	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1> clarithromycin </e1> , <e2> indinavir </e2> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	clarithromycin	indinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1> clarithromycin </e1> , indinavir, <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	clarithromycin	itraconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1> clarithromycin </e1> , indinavir, itraconazole, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	clarithromycin	nefazodone
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1> clarithromycin </e1> , indinavir, itraconazole, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole.	0	clarithromycin	nelfinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1> clarithromycin </e1> , indinavir, itraconazole, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole.	0	clarithromycin	ritonavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1> clarithromycin </e1> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin or voriconazole.	0	clarithromycin	saquinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1> clarithromycin </e1> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> or voriconazole.	0	clarithromycin	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, <e1> clarithromycin </e1> , indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2> voriconazole </e2> .	0	clarithromycin	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1> indinavir </e1> , <e2> itraconazole </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	indinavir	itraconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1> indinavir </e1> , itraconazole, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	indinavir	nefazodone
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1> indinavir </e1> , itraconazole, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole.	0	indinavir	nelfinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1> indinavir </e1> , itraconazole, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole.	0	indinavir	ritonavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1> indinavir </e1> , itraconazole, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin or voriconazole.	0	indinavir	saquinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1> indinavir </e1> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> or voriconazole.	0	indinavir	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, <e1> indinavir </e1> , itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2> voriconazole </e2> .	0	indinavir	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e1> itraconazole </e1> , <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole.	0	itraconazole	nefazodone
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e1> itraconazole </e1> , nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole.	0	itraconazole	nelfinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e1> itraconazole </e1> , nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole.	0	itraconazole	ritonavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e1> itraconazole </e1> , nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin or voriconazole.	0	itraconazole	saquinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e1> itraconazole </e1> , nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> or voriconazole.	0	itraconazole	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, <e1> itraconazole </e1> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or <e2> voriconazole </e2> .	0	itraconazole	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e1> nefazodone </e1> , <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin or voriconazole.	0	nefazodone	nelfinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e1> nefazodone </e1> , nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole.	0	nefazodone	ritonavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e1> nefazodone </e1> , nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin or voriconazole.	0	nefazodone	saquinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e1> nefazodone </e1> , nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> or voriconazole.	0	nefazodone	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, <e1> nefazodone </e1> , nelfinavir, ritonavir, saquinavir, telithromycin or <e2> voriconazole </e2> .	0	nefazodone	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e1> nelfinavir </e1> , <e2> ritonavir </e2> , saquinavir, telithromycin or voriconazole.	0	nelfinavir	ritonavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e1> nelfinavir </e1> , ritonavir, <e2> saquinavir </e2> , telithromycin or voriconazole.	0	nelfinavir	saquinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e1> nelfinavir </e1> , ritonavir, saquinavir, <e2> telithromycin </e2> or voriconazole.	0	nelfinavir	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, <e1> nelfinavir </e1> , ritonavir, saquinavir, telithromycin or <e2> voriconazole </e2> .	0	nelfinavir	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e1> ritonavir </e1> , <e2> saquinavir </e2> , telithromycin or voriconazole.	0	ritonavir	saquinavir
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e1> ritonavir </e1> , saquinavir, <e2> telithromycin </e2> or voriconazole.	0	ritonavir	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, <e1> ritonavir </e1> , saquinavir, telithromycin or <e2> voriconazole </e2> .	0	ritonavir	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e1> saquinavir </e1> , <e2> telithromycin </e2> or voriconazole.	0	saquinavir	telithromycin
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, <e1> saquinavir </e1> , telithromycin or <e2> voriconazole </e2> .	0	saquinavir	voriconazole
A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0- . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e1> telithromycin </e1> or <e2> voriconazole </e2> .	0	telithromycin	voriconazole
Dose adjustment of <e1> Zemplar </e1> Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as <e2> ketoconazole </e2> .	0	Zemplar	ketoconazole
Drugs that impair intestinal absorption of <e1> fat-soluble vitamins </e1> , such as <e2> cholestyramine </e2> , may interfere with the absorption of Zemplar Capsules.	1	fat-soluble vitamins	cholestyramine
Drugs that impair intestinal absorption of <e1> fat-soluble vitamins </e1> , such as cholestyramine, may interfere with the absorption of <e2> Zemplar </e2> Capsules.	0	fat-soluble vitamins	Zemplar
Drugs that impair intestinal absorption of fat-soluble vitamins, such as <e1> cholestyramine </e1> , may interfere with the absorption of <e2> Zemplar </e2> Capsules.	1	cholestyramine	Zemplar
Caution should be exercised when administering <e1> ZADAXIN </e1> therapy in combination with other <e2> immunomodulating drugs </e2> .	0	ZADAXIN	immunomodulating drugs
The CNS depressant effects of <e1> oxycodone hydrochloride </e1> may be additive with that of other <e2> CNS depressants </e2> ..	1	oxycodone hydrochloride	CNS depressants
CYP3A4 Inhibitors: <e1> Ketoconazole </e1> , an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of <e2> tolterodine </e2> when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).	1	Ketoconazole	tolterodine
For patients receiving <e1> ketoconazole </e1> or other potent CYP3A4 inhibitors such as other <e2> azole antifungals </e2> (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	ketoconazole	azole antifungals
For patients receiving <e1> ketoconazole </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e2> itraconazole </e2> , miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	ketoconazole	itraconazole
For patients receiving <e1> ketoconazole </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e2> miconazole </e2> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	ketoconazole	miconazole
For patients receiving <e1> ketoconazole </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or <e2> macrolide antibiotics </e2> (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	ketoconazole	macrolide antibiotics
For patients receiving <e1> ketoconazole </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, <e2> erythromycin </e2> , clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	ketoconazole	erythromycin
For patients receiving <e1> ketoconazole </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, <e2> clarithromycin </e2> ) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	ketoconazole	clarithromycin
For patients receiving <e1> ketoconazole </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or <e2> cyclosporine </e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	ketoconazole	cyclosporine
For patients receiving <e1> ketoconazole </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily.	0	ketoconazole	vinblastine
For patients receiving <e1> ketoconazole </e1> or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of <e2> DETROL LA </e2> is 2 mg daily.	0	ketoconazole	DETROL LA
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> azole antifungals </e1> (eg, <e2> itraconazole </e2> , miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	azole antifungals	itraconazole
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> azole antifungals </e1> (eg, itraconazole, <e2> miconazole </e2> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	azole antifungals	miconazole
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> azole antifungals </e1> (eg, itraconazole, miconazole) or <e2> macrolide antibiotics </e2> (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	azole antifungals	macrolide antibiotics
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> azole antifungals </e1> (eg, itraconazole, miconazole) or macrolide antibiotics (eg, <e2> erythromycin </e2> , clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	azole antifungals	erythromycin
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> azole antifungals </e1> (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, <e2> clarithromycin </e2> ) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	azole antifungals	clarithromycin
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> azole antifungals </e1> (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or <e2> cyclosporine </e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	azole antifungals	cyclosporine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> azole antifungals </e1> (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily.	0	azole antifungals	vinblastine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other <e1> azole antifungals </e1> (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of <e2> DETROL LA </e2> is 2 mg daily.	0	azole antifungals	DETROL LA
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1> itraconazole </e1> , <e2> miconazole </e2> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	itraconazole	miconazole
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1> itraconazole </e1> , miconazole) or <e2> macrolide antibiotics </e2> (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	itraconazole	macrolide antibiotics
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1> itraconazole </e1> , miconazole) or macrolide antibiotics (eg, <e2> erythromycin </e2> , clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	itraconazole	erythromycin
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1> itraconazole </e1> , miconazole) or macrolide antibiotics (eg, erythromycin, <e2> clarithromycin </e2> ) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	itraconazole	clarithromycin
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1> itraconazole </e1> , miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or <e2> cyclosporine </e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	itraconazole	cyclosporine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1> itraconazole </e1> , miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily.	0	itraconazole	vinblastine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, <e1> itraconazole </e1> , miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of <e2> DETROL LA </e2> is 2 mg daily.	0	itraconazole	DETROL LA
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1> miconazole </e1> ) or <e2> macrolide antibiotics </e2> (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	miconazole	macrolide antibiotics
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1> miconazole </e1> ) or macrolide antibiotics (eg, <e2> erythromycin </e2> , clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	miconazole	erythromycin
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1> miconazole </e1> ) or macrolide antibiotics (eg, erythromycin, <e2> clarithromycin </e2> ) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	miconazole	clarithromycin
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1> miconazole </e1> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or <e2> cyclosporine </e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	miconazole	cyclosporine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1> miconazole </e1> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily.	0	miconazole	vinblastine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, <e1> miconazole </e1> ) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of <e2> DETROL LA </e2> is 2 mg daily.	0	miconazole	DETROL LA
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or <e1> macrolide antibiotics </e1> (eg, <e2> erythromycin </e2> , clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	macrolide antibiotics	erythromycin
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or <e1> macrolide antibiotics </e1> (eg, erythromycin, <e2> clarithromycin </e2> ) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	macrolide antibiotics	clarithromycin
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or <e1> macrolide antibiotics </e1> (eg, erythromycin, clarithromycin) or <e2> cyclosporine </e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	macrolide antibiotics	cyclosporine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or <e1> macrolide antibiotics </e1> (eg, erythromycin, clarithromycin) or cyclosporine or <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily.	0	macrolide antibiotics	vinblastine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or <e1> macrolide antibiotics </e1> (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of <e2> DETROL LA </e2> is 2 mg daily.	0	macrolide antibiotics	DETROL LA
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, <e1> erythromycin </e1> , <e2> clarithromycin </e2> ) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	erythromycin	clarithromycin
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, <e1> erythromycin </e1> , clarithromycin) or <e2> cyclosporine </e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	erythromycin	cyclosporine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, <e1> erythromycin </e1> , clarithromycin) or cyclosporine or <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily.	0	erythromycin	vinblastine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, <e1> erythromycin </e1> , clarithromycin) or cyclosporine or vinblastine, the recommended dose of <e2> DETROL LA </e2> is 2 mg daily.	0	erythromycin	DETROL LA
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, <e1> clarithromycin </e1> ) or <e2> cyclosporine </e2> or vinblastine, the recommended dose of DETROL LA is 2 mg daily.	0	clarithromycin	cyclosporine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, <e1> clarithromycin </e1> ) or cyclosporine or <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily.	0	clarithromycin	vinblastine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, <e1> clarithromycin </e1> ) or cyclosporine or vinblastine, the recommended dose of <e2> DETROL LA </e2> is 2 mg daily.	0	clarithromycin	DETROL LA
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or <e1> cyclosporine </e1> or <e2> vinblastine </e2> , the recommended dose of DETROL LA is 2 mg daily.	0	cyclosporine	vinblastine
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or <e1> cyclosporine </e1> or vinblastine, the recommended dose of <e2> DETROL LA </e2> is 2 mg daily.	0	cyclosporine	DETROL LA
For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or <e1> vinblastine </e1> , the recommended dose of <e2> DETROL LA </e2> is 2 mg daily.	0	vinblastine	DETROL LA
<e1> Cholestyramine </e1> : Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of <e2> raloxifene </e2> and should not be coadministered with EVISTA.	0	Cholestyramine	raloxifene
<e1> Cholestyramine </e1> : Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with <e2> EVISTA </e2> .	0	Cholestyramine	EVISTA
Cholestyramine: <e1> Cholestyramine </e1> causes a 60% reduction in the absorption and enterohepatic cycling of <e2> raloxifene </e2> and should not be coadministered with EVISTA.	1	Cholestyramine	raloxifene
Cholestyramine: <e1> Cholestyramine </e1> causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with <e2> EVISTA </e2> .	0	Cholestyramine	EVISTA
Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of <e1> raloxifene </e1> and should not be coadministered with <e2> EVISTA </e2> .	0	raloxifene	EVISTA
<e1> Warfarin </e1> : The coadministration of <e2> EVISTA </e2> and warfarin has not been assessed under chronic conditions.	0	Warfarin	EVISTA
Warfarin: The coadministration of <e1> EVISTA </e1> and <e2> warfarin </e2> has not been assessed under chronic conditions.	0	EVISTA	warfarin
If <e1> EVISTA </e1> is given concurrently with <e2> warfarin </e2> , prothrombin time should be monitored.	0	EVISTA	warfarin
In vitro, <e1> raloxifene </e1> did not affect the binding of <e2> warfarin </e2> , phenytoin, or tamoxifen.	0	raloxifene	warfarin
In vitro, <e1> raloxifene </e1> did not affect the binding of warfarin, <e2> phenytoin </e2> , or tamoxifen.	0	raloxifene	phenytoin
In vitro, <e1> raloxifene </e1> did not affect the binding of warfarin, phenytoin, or <e2> tamoxifen </e2> .	0	raloxifene	tamoxifen
In vitro, raloxifene did not affect the binding of <e1> warfarin </e1> , <e2> phenytoin </e2> , or tamoxifen.	0	warfarin	phenytoin
In vitro, raloxifene did not affect the binding of <e1> warfarin </e1> , phenytoin, or <e2> tamoxifen </e2> .	0	warfarin	tamoxifen
In vitro, raloxifene did not affect the binding of warfarin, <e1> phenytoin </e1> , or <e2> tamoxifen </e2> .	0	phenytoin	tamoxifen
Caution should be used when <e1> EVISTA </e1> is coadministered with other highly protein-bound drugs, such as <e2> clofibrate </e2> , indomethacin, naproxen, ibuprofen, diazepam, and diazoxide.	0	EVISTA	clofibrate
Caution should be used when <e1> EVISTA </e1> is coadministered with other highly protein-bound drugs, such as clofibrate, <e2> indomethacin </e2> , naproxen, ibuprofen, diazepam, and diazoxide.	0	EVISTA	indomethacin
Caution should be used when <e1> EVISTA </e1> is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, <e2> naproxen </e2> , ibuprofen, diazepam, and diazoxide.	0	EVISTA	naproxen
Caution should be used when <e1> EVISTA </e1> is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, <e2> ibuprofen </e2> , diazepam, and diazoxide.	0	EVISTA	ibuprofen
Caution should be used when <e1> EVISTA </e1> is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, <e2> diazepam </e2> , and diazoxide.	0	EVISTA	diazepam
Caution should be used when <e1> EVISTA </e1> is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and <e2> diazoxide </e2> .	0	EVISTA	diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as <e1> clofibrate </e1> , <e2> indomethacin </e2> , naproxen, ibuprofen, diazepam, and diazoxide.	0	clofibrate	indomethacin
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as <e1> clofibrate </e1> , indomethacin, <e2> naproxen </e2> , ibuprofen, diazepam, and diazoxide.	0	clofibrate	naproxen
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as <e1> clofibrate </e1> , indomethacin, naproxen, <e2> ibuprofen </e2> , diazepam, and diazoxide.	0	clofibrate	ibuprofen
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as <e1> clofibrate </e1> , indomethacin, naproxen, ibuprofen, <e2> diazepam </e2> , and diazoxide.	0	clofibrate	diazepam
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as <e1> clofibrate </e1> , indomethacin, naproxen, ibuprofen, diazepam, and <e2> diazoxide </e2> .	0	clofibrate	diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, <e1> indomethacin </e1> , <e2> naproxen </e2> , ibuprofen, diazepam, and diazoxide.	0	indomethacin	naproxen
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, <e1> indomethacin </e1> , naproxen, <e2> ibuprofen </e2> , diazepam, and diazoxide.	0	indomethacin	ibuprofen
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, <e1> indomethacin </e1> , naproxen, ibuprofen, <e2> diazepam </e2> , and diazoxide.	0	indomethacin	diazepam
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, <e1> indomethacin </e1> , naproxen, ibuprofen, diazepam, and <e2> diazoxide </e2> .	0	indomethacin	diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, <e1> naproxen </e1> , <e2> ibuprofen </e2> , diazepam, and diazoxide.	0	naproxen	ibuprofen
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, <e1> naproxen </e1> , ibuprofen, <e2> diazepam </e2> , and diazoxide.	0	naproxen	diazepam
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, <e1> naproxen </e1> , ibuprofen, diazepam, and <e2> diazoxide </e2> .	0	naproxen	diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, <e1> ibuprofen </e1> , <e2> diazepam </e2> , and diazoxide.	0	ibuprofen	diazepam
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, <e1> ibuprofen </e1> , diazepam, and <e2> diazoxide </e2> .	0	ibuprofen	diazoxide
Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, <e1> diazepam </e1> , and <e2> diazoxide </e2> .	0	diazepam	diazoxide
Reduced absorption of <e1> folic acid </e1> and <e2> digoxin </e2> have been reported when those agents were administered concomitantly with sulfasalazine.	0	folic acid	digoxin
Reduced absorption of <e1> folic acid </e1> and digoxin have been reported when those agents were administered concomitantly with <e2> sulfasalazine </e2> .	1	folic acid	sulfasalazine
Reduced absorption of folic acid and <e1> digoxin </e1> have been reported when those agents were administered concomitantly with <e2> sulfasalazine </e2> .	1	digoxin	sulfasalazine
When daily doses of <e1> sulfasalazine </e1> 2 g and weekly doses of <e2> methotrexate </e2> 7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered.	0	sulfasalazine	methotrexate
Daily doses of <e1> sulfasalazine </e1> 2 g (maximum 3 g) and weekly doses of <e2> methotrexate </e2> 7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies.	0	sulfasalazine	methotrexate
<e1> Sulfoxone </e1> may increase the effects of <e2> barbiturates </e2> , tolbutamide, and uricosurics.	1	Sulfoxone	barbiturates
<e1> Sulfoxone </e1> may increase the effects of barbiturates, <e2> tolbutamide </e2> , and uricosurics.	1	Sulfoxone	tolbutamide
<e1> Sulfoxone </e1> may increase the effects of barbiturates, tolbutamide, and <e2> uricosurics </e2> .	1	Sulfoxone	uricosurics
Sulfoxone may increase the effects of <e1> barbiturates </e1> , <e2> tolbutamide </e2> , and uricosurics.	0	barbiturates	tolbutamide
Sulfoxone may increase the effects of <e1> barbiturates </e1> , tolbutamide, and <e2> uricosurics </e2> .	0	barbiturates	uricosurics
Sulfoxone may increase the effects of barbiturates, <e1> tolbutamide </e1> , and <e2> uricosurics </e2> .	0	tolbutamide	uricosurics
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), <e2> cyclosporine </e2> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	thiazides	cyclosporine
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e2> sulfonylurea agents </e2> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	thiazides	sulfonylurea agents
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e2> warfarin </e2> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	thiazides	warfarin
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e2> methotrexate </e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	thiazides	methotrexate
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).	0	thiazides	methotrexate
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2> phenytoin </e2> (decreased hepatic clearance of phenytoin).	0	thiazides	phenytoin
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2> phenytoin </e2> ).	0	thiazides	phenytoin
It may also interact with thiazides (increased thrombocytopenia), <e1> cyclosporine </e1> (increased nephrotoxicity), <e2> sulfonylurea agents </e2> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	cyclosporine	sulfonylurea agents
It may also interact with thiazides (increased thrombocytopenia), <e1> cyclosporine </e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e2> warfarin </e2> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	cyclosporine	warfarin
It may also interact with thiazides (increased thrombocytopenia), <e1> cyclosporine </e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e2> methotrexate </e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	cyclosporine	methotrexate
It may also interact with thiazides (increased thrombocytopenia), <e1> cyclosporine </e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).	0	cyclosporine	methotrexate
It may also interact with thiazides (increased thrombocytopenia), <e1> cyclosporine </e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2> phenytoin </e2> (decreased hepatic clearance of phenytoin).	0	cyclosporine	phenytoin
It may also interact with thiazides (increased thrombocytopenia), <e1> cyclosporine </e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2> phenytoin </e2> ).	0	cyclosporine	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1> sulfonylurea agents </e1> (increased hypoglycemic response), <e2> warfarin </e2> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	sulfonylurea agents	warfarin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1> sulfonylurea agents </e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e2> methotrexate </e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	sulfonylurea agents	methotrexate
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1> sulfonylurea agents </e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).	0	sulfonylurea agents	methotrexate
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1> sulfonylurea agents </e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2> phenytoin </e2> (decreased hepatic clearance of phenytoin).	0	sulfonylurea agents	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1> sulfonylurea agents </e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2> phenytoin </e2> ).	0	sulfonylurea agents	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1> warfarin </e1> (increased anticoagulant effect), <e2> methotrexate </e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	warfarin	methotrexate
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1> warfarin </e1> (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).	0	warfarin	methotrexate
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1> warfarin </e1> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2> phenytoin </e2> (decreased hepatic clearance of phenytoin).	0	warfarin	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1> warfarin </e1> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2> phenytoin </e2> ).	0	warfarin	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e1> methotrexate </e1> (decreased renal excretion of methotrexate), <e2> phenytoin </e2> (decreased hepatic clearance of phenytoin).	0	methotrexate	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e1> methotrexate </e1> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2> phenytoin </e2> ).	0	methotrexate	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e1> methotrexate </e1> ), <e2> phenytoin </e2> (decreased hepatic clearance of phenytoin).	0	methotrexate	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e1> methotrexate </e1> ), phenytoin (decreased hepatic clearance of <e2> phenytoin </e2> ).	0	methotrexate	phenytoin
To minimize CNS depression and possible potentiation, <e1> barbiturates </e1> , <e2> antihistamines </e2> , narcotics, hypotensive agents or phenothiazines should be used with caution.	0	barbiturates	antihistamines
To minimize CNS depression and possible potentiation, <e1> barbiturates </e1> , antihistamines, <e2> narcotics </e2> , hypotensive agents or phenothiazines should be used with caution.	0	barbiturates	narcotics
To minimize CNS depression and possible potentiation, <e1> barbiturates </e1> , antihistamines, narcotics, <e2> hypotensive agents </e2> or phenothiazines should be used with caution.	0	barbiturates	hypotensive agents
To minimize CNS depression and possible potentiation, <e1> barbiturates </e1> , antihistamines, narcotics, hypotensive agents or <e2> phenothiazines </e2> should be used with caution.	0	barbiturates	phenothiazines
To minimize CNS depression and possible potentiation, barbiturates, <e1> antihistamines </e1> , <e2> narcotics </e2> , hypotensive agents or phenothiazines should be used with caution.	0	antihistamines	narcotics
To minimize CNS depression and possible potentiation, barbiturates, <e1> antihistamines </e1> , narcotics, <e2> hypotensive agents </e2> or phenothiazines should be used with caution.	0	antihistamines	hypotensive agents
To minimize CNS depression and possible potentiation, barbiturates, <e1> antihistamines </e1> , narcotics, hypotensive agents or <e2> phenothiazines </e2> should be used with caution.	0	antihistamines	phenothiazines
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, <e1> narcotics </e1> , <e2> hypotensive agents </e2> or phenothiazines should be used with caution.	0	narcotics	hypotensive agents
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, <e1> narcotics </e1> , hypotensive agents or <e2> phenothiazines </e2> should be used with caution.	0	narcotics	phenothiazines
To minimize CNS depression and possible potentiation, barbiturates, antihistamines, narcotics, <e1> hypotensive agents </e1> or <e2> phenothiazines </e2> should be used with caution.	0	hypotensive agents	phenothiazines
Because <e1> Matulane </e1> exhibits some monoamine oxidase inhibitory activity, <e2> sympathomimetic drugs </e2> , tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	Matulane	sympathomimetic drugs
Because <e1> Matulane </e1> exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, <e2> tricyclic antidepressant </e2> drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	Matulane	tricyclic antidepressant
Because <e1> Matulane </e1> exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., <e2> amitriptyline HCl </e2> , imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	Matulane	amitriptyline HCl
Because <e1> Matulane </e1> exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, <e2> imipramine HCl </e2> ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	Matulane	imipramine HCl
Because <e1> Matulane </e1> exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high <e2> tyramine </e2> content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	Matulane	tyramine
Because Matulane exhibits some monoamine oxidase inhibitory activity, <e1> sympathomimetic drugs </e1> , <e2> tricyclic antidepressant </e2> drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	sympathomimetic drugs	tricyclic antidepressant
Because Matulane exhibits some monoamine oxidase inhibitory activity, <e1> sympathomimetic drugs </e1> , tricyclic antidepressant drugs (e.g., <e2> amitriptyline HCl </e2> , imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	sympathomimetic drugs	amitriptyline HCl
Because Matulane exhibits some monoamine oxidase inhibitory activity, <e1> sympathomimetic drugs </e1> , tricyclic antidepressant drugs (e.g., amitriptyline HCl, <e2> imipramine HCl </e2> ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	sympathomimetic drugs	imipramine HCl
Because Matulane exhibits some monoamine oxidase inhibitory activity, <e1> sympathomimetic drugs </e1> , tricyclic antidepressant drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high <e2> tyramine </e2> content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	sympathomimetic drugs	tyramine
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, <e1> tricyclic antidepressant </e1> drugs (e.g., <e2> amitriptyline HCl </e2> , imipramine HCl) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	tricyclic antidepressant	amitriptyline HCl
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, <e1> tricyclic antidepressant </e1> drugs (e.g., amitriptyline HCl, <e2> imipramine HCl </e2> ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	tricyclic antidepressant	imipramine HCl
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, <e1> tricyclic antidepressant </e1> drugs (e.g., amitriptyline HCl, imipramine HCl) and other drugs and foods with known high <e2> tyramine </e2> content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	tricyclic antidepressant	tyramine
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., <e1> amitriptyline HCl </e1> , <e2> imipramine HCl </e2> ) and other drugs and foods with known high tyramine content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	amitriptyline HCl	imipramine HCl
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., <e1> amitriptyline HCl </e1> , imipramine HCl) and other drugs and foods with known high <e2> tyramine </e2> content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	amitriptyline HCl	tyramine
Because Matulane exhibits some monoamine oxidase inhibitory activity, sympathomimetic drugs, tricyclic antidepressant drugs (e.g., amitriptyline HCl, <e1> imipramine HCl </e1> ) and other drugs and foods with known high <e2> tyramine </e2> content, such as wine, yogurt, ripe cheese and bananas, should be avoided.	0	imipramine HCl	tyramine
No cross-resistance with other <e1> chemotherapeutic agents </e1> , radiotherapy or <e2> steroids </e2> has been demonstrated.	0	chemotherapeutic agents	steroids
Potential for <e1> INVEGA </e1> to Affect Other Drugs <e2> Paliperidone </e2> is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes.	0	INVEGA	Paliperidone
Given the primary CNS effects of <e1> paliperidone </e1> , <e2> INVEGA </e2> should be used with caution in combination with other centrally acting drugs and alcohol.	0	paliperidone	INVEGA
Given the primary CNS effects of <e1> paliperidone </e1> , INVEGA should be used with caution in combination with other <e2> centrally acting drugs </e2> and alcohol.	0	paliperidone	centrally acting drugs
Given the primary CNS effects of <e1> paliperidone </e1> , INVEGA should be used with caution in combination with other centrally acting drugs and <e2> alcohol </e2> .	0	paliperidone	alcohol
Given the primary CNS effects of paliperidone, <e1> INVEGA </e1> should be used with caution in combination with other <e2> centrally acting drugs </e2> and alcohol.	0	INVEGA	centrally acting drugs
Given the primary CNS effects of paliperidone, <e1> INVEGA </e1> should be used with caution in combination with other centrally acting drugs and <e2> alcohol </e2> .	0	INVEGA	alcohol
Given the primary CNS effects of paliperidone, INVEGA should be used with caution in combination with other <e1> centrally acting drugs </e1> and <e2> alcohol </e2> .	0	centrally acting drugs	alcohol
<e1> Paliperidone </e1> may antagonize the effect of <e2> levodopa </e2> and other dopamine agonists.	1	Paliperidone	levodopa
<e1> Paliperidone </e1> may antagonize the effect of levodopa and other <e2> dopamine agonists </e2> .	1	Paliperidone	dopamine agonists
Paliperidone may antagonize the effect of <e1> levodopa </e1> and other <e2> dopamine agonists </e2> .	0	levodopa	dopamine agonists
Potential for Other Drugs to Affect <e1> INVEGA </e1> <e2> Paliperidone </e2> is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely.	0	INVEGA	Paliperidone
Drug Interactions: The use of <e1> ZEMURON </e1> ( <e2> rocuronium bromide </e2> ) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.	0	ZEMURON	rocuronium bromide
Drug Interactions: The use of <e1> ZEMURON </e1> (rocuronium bromide) Injection before <e2> succinylcholine </e2> , for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.	0	ZEMURON	succinylcholine
Drug Interactions: The use of <e1> ZEMURON </e1> (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of <e2> succinylcholine </e2> , has not been studied.	0	ZEMURON	succinylcholine
Drug Interactions: The use of ZEMURON ( <e1> rocuronium bromide </e1> ) Injection before <e2> succinylcholine </e2> , for the purpose of attenuating some of the side effects of succinylcholine, has not been studied.	0	rocuronium bromide	succinylcholine
Drug Interactions: The use of ZEMURON ( <e1> rocuronium bromide </e1> ) Injection before succinylcholine, for the purpose of attenuating some of the side effects of <e2> succinylcholine </e2> , has not been studied.	0	rocuronium bromide	succinylcholine
If <e1> ZEMURON </e1> is administered following administration of <e2> succinylcholine </e2> , it should not be given until recovery from succinylcholine has been observed.	0	ZEMURON	succinylcholine
If <e1> ZEMURON </e1> is administered following administration of succinylcholine, it should not be given until recovery from <e2> succinylcholine </e2> has been observed.	0	ZEMURON	succinylcholine
The median duration of action of <e1> ZEMURON </e1> 0.6 mg/kg administered after a 1 mg/kg dose of <e2> succinylcholine </e2> when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs.	0	ZEMURON	succinylcholine
There are no controlled studies documenting the use of <e1> ZEMURON </e1> before or after other <e2> nondepolarizing muscle relaxants </e2> .	0	ZEMURON	nondepolarizing muscle relaxants
<e1> Diuretics </e1> : Excessive reductions in blood pressure may occur in patients on diuretic therapy when <e2> ACE inhibitors </e2> are started.	0	Diuretics	ACE inhibitors
The possibility of hypotensive effects with <e1> UNIVASC </e1> can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC . If this is not possible, the starting dose of <e2> moexpril </e2> should be reduced..	0	UNIVASC	moexpril
The possibility of hypotensive effects with UNIVASC can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with <e1> UNIVASC </e1> . If this is not possible, the starting dose of <e2> moexpril </e2> should be reduced..	0	UNIVASC	moexpril
<e1> Potassium </e1> Supplements and <e2> Potassium-Sparing Diuretics </e2> : UNIVASC can increase serum potassium because it decreases aldosterone secretion.	0	Potassium	Potassium-Sparing Diuretics
<e1> Potassium </e1> Supplements and Potassium-Sparing Diuretics: <e2> UNIVASC </e2> can increase serum potassium because it decreases aldosterone secretion.	0	Potassium	UNIVASC
Potassium Supplements and <e1> Potassium-Sparing Diuretics </e1> : <e2> UNIVASC </e2> can increase serum potassium because it decreases aldosterone secretion.	0	Potassium-Sparing Diuretics	UNIVASC
Use of <e1> potassium-sparing diuretics </e1> ( <e2> spironolactone </e2> , triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	0	potassium-sparing diuretics	spironolactone
Use of <e1> potassium-sparing diuretics </e1> (spironolactone, <e2> triamterene </e2> , amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	0	potassium-sparing diuretics	triamterene
Use of <e1> potassium-sparing diuretics </e1> (spironolactone, triamterene, <e2> amiloride </e2> ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	0	potassium-sparing diuretics	amiloride
Use of <e1> potassium-sparing diuretics </e1> (spironolactone, triamterene, amiloride) or <e2> potassium </e2> supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	0	potassium-sparing diuretics	potassium
Use of <e1> potassium-sparing diuretics </e1> (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with <e2> ACE inhibitors </e2> can increase the risk of hyperkalemia.	1	potassium-sparing diuretics	ACE inhibitors
Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , <e2> triamterene </e2> , amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	0	spironolactone	triamterene
Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , triamterene, <e2> amiloride </e2> ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	0	spironolactone	amiloride
Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , triamterene, amiloride) or <e2> potassium </e2> supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	0	spironolactone	potassium
Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , triamterene, amiloride) or potassium supplements concomitantly with <e2> ACE inhibitors </e2> can increase the risk of hyperkalemia.	1	spironolactone	ACE inhibitors
Use of potassium-sparing diuretics (spironolactone, <e1> triamterene </e1> , <e2> amiloride </e2> ) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	0	triamterene	amiloride
Use of potassium-sparing diuretics (spironolactone, <e1> triamterene </e1> , amiloride) or <e2> potassium </e2> supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	0	triamterene	potassium
Use of potassium-sparing diuretics (spironolactone, <e1> triamterene </e1> , amiloride) or potassium supplements concomitantly with <e2> ACE inhibitors </e2> can increase the risk of hyperkalemia.	1	triamterene	ACE inhibitors
Use of potassium-sparing diuretics (spironolactone, triamterene, <e1> amiloride </e1> ) or <e2> potassium </e2> supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia.	0	amiloride	potassium
Use of potassium-sparing diuretics (spironolactone, triamterene, <e1> amiloride </e1> ) or potassium supplements concomitantly with <e2> ACE inhibitors </e2> can increase the risk of hyperkalemia.	1	amiloride	ACE inhibitors
Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or <e1> potassium </e1> supplements concomitantly with <e2> ACE inhibitors </e2> can increase the risk of hyperkalemia.	1	potassium	ACE inhibitors
Oral <e1> Anticoagulants </e1> : Interaction studies with <e2> warfarin </e2> failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect.	0	Anticoagulants	warfarin
Oral <e1> Anticoagulants </e1> : Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the <e2> anticoagulant </e2> or on its anticoagulant effect.	0	Anticoagulants	anticoagulant
Oral Anticoagulants: Interaction studies with <e1> warfarin </e1> failed to identify any clinically important effect on the serum concentrations of the <e2> anticoagulant </e2> or on its anticoagulant effect.	0	warfarin	anticoagulant
<e1> Lithium </e1> : Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <e2> ACE inhibitors </e2> during therapy with lithium.	0	Lithium	ACE inhibitors
Lithium: Increased serum <e1> lithium </e1> levels and symptoms of lithium toxicity have been reported in patients receiving <e2> ACE inhibitors </e2> during therapy with lithium.	0	lithium	ACE inhibitors
Lithium: Increased serum lithium levels and symptoms of <e1> lithium </e1> toxicity have been reported in patients receiving <e2> ACE inhibitors </e2> during therapy with lithium.	0	lithium	ACE inhibitors
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving <e1> ACE inhibitors </e1> during therapy with <e2> lithium </e2> .	1	ACE inhibitors	lithium
If a <e1> diuretic </e1> is also used, the risk of <e2> lithium </e2> toxicity may be increased.	1	diuretic	lithium
Other Agents: No clinically important pharmacokinetic interactions occurred when <e1> UNIVASC </e1> was administered concomitantly with <e2> hydrochlorothiazide </e2> , digoxin, or cimetidine.	0	UNIVASC	hydrochlorothiazide
Other Agents: No clinically important pharmacokinetic interactions occurred when <e1> UNIVASC </e1> was administered concomitantly with hydrochlorothiazide, <e2> digoxin </e2> , or cimetidine.	0	UNIVASC	digoxin
Other Agents: No clinically important pharmacokinetic interactions occurred when <e1> UNIVASC </e1> was administered concomitantly with hydrochlorothiazide, digoxin, or <e2> cimetidine </e2> .	0	UNIVASC	cimetidine
Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with <e1> hydrochlorothiazide </e1> , <e2> digoxin </e2> , or cimetidine.	0	hydrochlorothiazide	digoxin
Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with <e1> hydrochlorothiazide </e1> , digoxin, or <e2> cimetidine </e2> .	0	hydrochlorothiazide	cimetidine
Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC was administered concomitantly with hydrochlorothiazide, <e1> digoxin </e1> , or <e2> cimetidine </e2> .	0	digoxin	cimetidine
<e1> UNIVASC </e1> has been used in clinical trials concomitantly with <e2> calcium-channel-blocking agents </e2> , diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	0	UNIVASC	calcium-channel-blocking agents
<e1> UNIVASC </e1> has been used in clinical trials concomitantly with calcium-channel-blocking agents, <e2> diuretics </e2> , H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	0	UNIVASC	diuretics
<e1> UNIVASC </e1> has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, <e2> H2 blockers </e2> , digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	0	UNIVASC	H2 blockers
<e1> UNIVASC </e1> has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, <e2> digoxin </e2> , oral hypoglycemic agents, and cholesterol-lowering agents.	0	UNIVASC	digoxin
<e1> UNIVASC </e1> has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral <e2> hypoglycemic agents </e2> , and cholesterol-lowering agents.	0	UNIVASC	hypoglycemic agents
UNIVASC has been used in clinical trials concomitantly with <e1> calcium-channel-blocking agents </e1> , <e2> diuretics </e2> , H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	0	calcium-channel-blocking agents	diuretics
UNIVASC has been used in clinical trials concomitantly with <e1> calcium-channel-blocking agents </e1> , diuretics, <e2> H2 blockers </e2> , digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	0	calcium-channel-blocking agents	H2 blockers
UNIVASC has been used in clinical trials concomitantly with <e1> calcium-channel-blocking agents </e1> , diuretics, H2 blockers, <e2> digoxin </e2> , oral hypoglycemic agents, and cholesterol-lowering agents.	0	calcium-channel-blocking agents	digoxin
UNIVASC has been used in clinical trials concomitantly with <e1> calcium-channel-blocking agents </e1> , diuretics, H2 blockers, digoxin, oral <e2> hypoglycemic agents </e2> , and cholesterol-lowering agents.	0	calcium-channel-blocking agents	hypoglycemic agents
UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents, <e1> diuretics </e1> , <e2> H2 blockers </e2> , digoxin, oral hypoglycemic agents, and cholesterol-lowering agents.	0	diuretics	H2 blockers
UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents, <e1> diuretics </e1> , H2 blockers, <e2> digoxin </e2> , oral hypoglycemic agents, and cholesterol-lowering agents.	0	diuretics	digoxin
UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents, <e1> diuretics </e1> , H2 blockers, digoxin, oral <e2> hypoglycemic agents </e2> , and cholesterol-lowering agents.	0	diuretics	hypoglycemic agents
UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, <e1> H2 blockers </e1> , <e2> digoxin </e2> , oral hypoglycemic agents, and cholesterol-lowering agents.	0	H2 blockers	digoxin
UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, <e1> H2 blockers </e1> , digoxin, oral <e2> hypoglycemic agents </e2> , and cholesterol-lowering agents.	0	H2 blockers	hypoglycemic agents
UNIVASC has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, <e1> digoxin </e1> , oral <e2> hypoglycemic agents </e2> , and cholesterol-lowering agents.	0	digoxin	hypoglycemic agents
<e1> Vasopressors </e1> , particularly <e2> metaraminol </e2> , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.	0	Vasopressors	metaraminol
<e1> Vasopressors </e1> , particularly metaraminol, may cause serious cardiac arrhythmias during <e2> halothane </e2> anesthesia and therefore should be used only with great caution or not at all.	1	Vasopressors	halothane
Vasopressors, particularly <e1> metaraminol </e1> , may cause serious cardiac arrhythmias during <e2> halothane </e2> anesthesia and therefore should be used only with great caution or not at all.	1	metaraminol	halothane
<e1> MAO Inhibitors </e1> : The pressor effect of <e2> sympathomimetic pressor amines </e2> is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).	0	MAO Inhibitors	sympathomimetic pressor amines
<e1> MAO Inhibitors </e1> : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving <e2> monoamine oxidase inhibitors </e2> (MAOI).	0	MAO Inhibitors	monoamine oxidase inhibitors
<e1> MAO Inhibitors </e1> : The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( <e2> MAOI </e2> ).	0	MAO Inhibitors	MAOI
MAO Inhibitors: The pressor effect of <e1> sympathomimetic pressor amines </e1> is markedly potentiated in patients receiving <e2> monoamine oxidase inhibitors </e2> (MAOI).	1	sympathomimetic pressor amines	monoamine oxidase inhibitors
MAO Inhibitors: The pressor effect of <e1> sympathomimetic pressor amines </e1> is markedly potentiated in patients receiving monoamine oxidase inhibitors ( <e2> MAOI </e2> ).	1	sympathomimetic pressor amines	MAOI
MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving <e1> monoamine oxidase inhibitors </e1> ( <e2> MAOI </e2> ).	0	monoamine oxidase inhibitors	MAOI
The pressor response of <e1> adrenergic agents </e1> may also be potentiated by <e2> tricyclic antidepressants </e2> .	1	adrenergic agents	tricyclic antidepressants
Use with Other <e1> Central Nervous System Depressants </e1> : The depressant effects of <e2> morphine </e2> are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	0	Central Nervous System Depressants	morphine
Use with Other <e1> Central Nervous System Depressants </e1> : The depressant effects of morphine are potentiated by the presence of other <e2> CNS depressants </e2> such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	0	Central Nervous System Depressants	CNS depressants
Use with Other <e1> Central Nervous System Depressants </e1> : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as <e2> alcohol </e2> , sedatives, antihistaminics, or psychotropic drugs.	0	Central Nervous System Depressants	alcohol
Use with Other <e1> Central Nervous System Depressants </e1> : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, <e2> sedatives </e2> , antihistaminics, or psychotropic drugs.	0	Central Nervous System Depressants	sedatives
Use with Other <e1> Central Nervous System Depressants </e1> : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, <e2> antihistaminics </e2> , or psychotropic drugs.	0	Central Nervous System Depressants	antihistaminics
Use with Other <e1> Central Nervous System Depressants </e1> : The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or <e2> psychotropic drugs </e2> .	0	Central Nervous System Depressants	psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of <e1> morphine </e1> are potentiated by the presence of other <e2> CNS depressants </e2> such as alcohol, sedatives, antihistaminics, or psychotropic drugs.	1	morphine	CNS depressants
Use with Other Central Nervous System Depressants: The depressant effects of <e1> morphine </e1> are potentiated by the presence of other CNS depressants such as <e2> alcohol </e2> , sedatives, antihistaminics, or psychotropic drugs.	1	morphine	alcohol
Use with Other Central Nervous System Depressants: The depressant effects of <e1> morphine </e1> are potentiated by the presence of other CNS depressants such as alcohol, <e2> sedatives </e2> , antihistaminics, or psychotropic drugs.	1	morphine	sedatives
Use with Other Central Nervous System Depressants: The depressant effects of <e1> morphine </e1> are potentiated by the presence of other CNS depressants such as alcohol, sedatives, <e2> antihistaminics </e2> , or psychotropic drugs.	1	morphine	antihistaminics
Use with Other Central Nervous System Depressants: The depressant effects of <e1> morphine </e1> are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or <e2> psychotropic drugs </e2> .	1	morphine	psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other <e1> CNS depressants </e1> such as <e2> alcohol </e2> , sedatives, antihistaminics, or psychotropic drugs.	0	CNS depressants	alcohol
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other <e1> CNS depressants </e1> such as alcohol, <e2> sedatives </e2> , antihistaminics, or psychotropic drugs.	0	CNS depressants	sedatives
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other <e1> CNS depressants </e1> such as alcohol, sedatives, <e2> antihistaminics </e2> , or psychotropic drugs.	0	CNS depressants	antihistaminics
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other <e1> CNS depressants </e1> such as alcohol, sedatives, antihistaminics, or <e2> psychotropic drugs </e2> .	0	CNS depressants	psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as <e1> alcohol </e1> , <e2> sedatives </e2> , antihistaminics, or psychotropic drugs.	0	alcohol	sedatives
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as <e1> alcohol </e1> , sedatives, <e2> antihistaminics </e2> , or psychotropic drugs.	0	alcohol	antihistaminics
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as <e1> alcohol </e1> , sedatives, antihistaminics, or <e2> psychotropic drugs </e2> .	0	alcohol	psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, <e1> sedatives </e1> , <e2> antihistaminics </e2> , or psychotropic drugs.	0	sedatives	antihistaminics
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, <e1> sedatives </e1> , antihistaminics, or <e2> psychotropic drugs </e2> .	0	sedatives	psychotropic drugs
Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, <e1> antihistaminics </e1> , or <e2> psychotropic drugs </e2> .	0	antihistaminics	psychotropic drugs
Use of <e1> neuroleptics </e1> in conjunction with oral <e2> morphine </e2> may increase the risk of respiratory depression, hypotension and profound sedation or coma.	1	neuroleptics	morphine
Interaction with <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : <e2> Agonist/antagonist analgesics </e2> (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	Mixed Agonist/Antagonist Opioid Analgesics	Agonist/antagonist analgesics
Interaction with <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : Agonist/antagonist analgesics (i.e., <e2> pentazocine </e2> , nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	Mixed Agonist/Antagonist Opioid Analgesics	pentazocine
Interaction with <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : Agonist/antagonist analgesics (i.e., pentazocine, <e2> nalbuphine </e2> , butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	Mixed Agonist/Antagonist Opioid Analgesics	nalbuphine
Interaction with <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, <e2> butorphanol </e2> , or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	Mixed Agonist/Antagonist Opioid Analgesics	butorphanol
Interaction with <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or <e2> buprenorphine </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	Mixed Agonist/Antagonist Opioid Analgesics	buprenorphine
Interaction with <e1> Mixed Agonist/Antagonist Opioid Analgesics </e1> : Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2> opioid agonist analgesic </e2> .	0	Mixed Agonist/Antagonist Opioid Analgesics	opioid agonist analgesic
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: <e1> Agonist/antagonist analgesics </e1> (i.e., <e2> pentazocine </e2> , nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	Agonist/antagonist analgesics	pentazocine
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: <e1> Agonist/antagonist analgesics </e1> (i.e., pentazocine, <e2> nalbuphine </e2> , butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	Agonist/antagonist analgesics	nalbuphine
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: <e1> Agonist/antagonist analgesics </e1> (i.e., pentazocine, nalbuphine, <e2> butorphanol </e2> , or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	Agonist/antagonist analgesics	butorphanol
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: <e1> Agonist/antagonist analgesics </e1> (i.e., pentazocine, nalbuphine, butorphanol, or <e2> buprenorphine </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	Agonist/antagonist analgesics	buprenorphine
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: <e1> Agonist/antagonist analgesics </e1> (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2> opioid agonist analgesic </e2> .	0	Agonist/antagonist analgesics	opioid agonist analgesic
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., <e1> pentazocine </e1> , <e2> nalbuphine </e2> , butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	pentazocine	nalbuphine
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., <e1> pentazocine </e1> , nalbuphine, <e2> butorphanol </e2> , or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	pentazocine	butorphanol
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., <e1> pentazocine </e1> , nalbuphine, butorphanol, or <e2> buprenorphine </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	pentazocine	buprenorphine
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., <e1> pentazocine </e1> , nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2> opioid agonist analgesic </e2> .	0	pentazocine	opioid agonist analgesic
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, <e1> nalbuphine </e1> , <e2> butorphanol </e2> , or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	nalbuphine	butorphanol
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, <e1> nalbuphine </e1> , butorphanol, or <e2> buprenorphine </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	nalbuphine	buprenorphine
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, <e1> nalbuphine </e1> , butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2> opioid agonist analgesic </e2> .	0	nalbuphine	opioid agonist analgesic
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, <e1> butorphanol </e1> , or <e2> buprenorphine </e2> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic.	0	butorphanol	buprenorphine
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, <e1> butorphanol </e1> , or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2> opioid agonist analgesic </e2> .	0	butorphanol	opioid agonist analgesic
Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or <e1> buprenorphine </e1> ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof <e2> opioid agonist analgesic </e2> .	0	buprenorphine	opioid agonist analgesic
The induction dose requirements of <e1> DIPRIVAN </e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with <e2> narcotics </e2> (eg, morphine, meperidine, and fentanyl, etc.)	1	DIPRIVAN	narcotics
The induction dose requirements of <e1> DIPRIVAN </e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, <e2> morphine </e2> , meperidine, and fentanyl, etc.)	1	DIPRIVAN	morphine
The induction dose requirements of <e1> DIPRIVAN </e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, <e2> meperidine </e2> , and fentanyl, etc.)	1	DIPRIVAN	meperidine
The induction dose requirements of <e1> DIPRIVAN </e1> Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and <e2> fentanyl </e2> , etc.)	1	DIPRIVAN	fentanyl
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with <e1> narcotics </e1> (eg, <e2> morphine </e2> , meperidine, and fentanyl, etc.)	0	narcotics	morphine
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with <e1> narcotics </e1> (eg, morphine, <e2> meperidine </e2> , and fentanyl, etc.)	0	narcotics	meperidine
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with <e1> narcotics </e1> (eg, morphine, meperidine, and <e2> fentanyl </e2> , etc.)	0	narcotics	fentanyl
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, <e1> morphine </e1> , <e2> meperidine </e2> , and fentanyl, etc.)	0	morphine	meperidine
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, <e1> morphine </e1> , meperidine, and <e2> fentanyl </e2> , etc.)	0	morphine	fentanyl
The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, <e1> meperidine </e1> , and <e2> fentanyl </e2> , etc.)	0	meperidine	fentanyl
and combinations of <e1> opioids </e1> and <e2> sedatives </e2> (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.).	0	opioids	sedatives
and combinations of <e1> opioids </e1> and sedatives (eg, <e2> benzodiazepines </e2> , barbiturates, chloral hydrate, droperidol, etc.).	0	opioids	benzodiazepines
and combinations of <e1> opioids </e1> and sedatives (eg, benzodiazepines, <e2> barbiturates </e2> , chloral hydrate, droperidol, etc.).	0	opioids	barbiturates
and combinations of <e1> opioids </e1> and sedatives (eg, benzodiazepines, barbiturates, <e2> chloral hydrate </e2> , droperidol, etc.).	0	opioids	chloral hydrate
and combinations of <e1> opioids </e1> and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, <e2> droperidol </e2> , etc.).	0	opioids	droperidol
and combinations of opioids and <e1> sedatives </e1> (eg, <e2> benzodiazepines </e2> , barbiturates, chloral hydrate, droperidol, etc.).	0	sedatives	benzodiazepines
and combinations of opioids and <e1> sedatives </e1> (eg, benzodiazepines, <e2> barbiturates </e2> , chloral hydrate, droperidol, etc.).	0	sedatives	barbiturates
and combinations of opioids and <e1> sedatives </e1> (eg, benzodiazepines, barbiturates, <e2> chloral hydrate </e2> , droperidol, etc.).	0	sedatives	chloral hydrate
and combinations of opioids and <e1> sedatives </e1> (eg, benzodiazepines, barbiturates, chloral hydrate, <e2> droperidol </e2> , etc.).	0	sedatives	droperidol
and combinations of opioids and sedatives (eg, <e1> benzodiazepines </e1> , <e2> barbiturates </e2> , chloral hydrate, droperidol, etc.).	0	benzodiazepines	barbiturates
and combinations of opioids and sedatives (eg, <e1> benzodiazepines </e1> , barbiturates, <e2> chloral hydrate </e2> , droperidol, etc.).	0	benzodiazepines	chloral hydrate
and combinations of opioids and sedatives (eg, <e1> benzodiazepines </e1> , barbiturates, chloral hydrate, <e2> droperidol </e2> , etc.).	0	benzodiazepines	droperidol
and combinations of opioids and sedatives (eg, benzodiazepines, <e1> barbiturates </e1> , <e2> chloral hydrate </e2> , droperidol, etc.).	0	barbiturates	chloral hydrate
and combinations of opioids and sedatives (eg, benzodiazepines, <e1> barbiturates </e1> , chloral hydrate, <e2> droperidol </e2> , etc.).	0	barbiturates	droperidol
and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, <e1> chloral hydrate </e1> , <e2> droperidol </e2> , etc.).	0	chloral hydrate	droperidol
During maintenance of anesthesia or sedation, the rate of <e1> DIPRIVAN </e1> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental <e2> analgesic agents </e2> (eg, nitrous oxide or opioids).	0	DIPRIVAN	analgesic agents
During maintenance of anesthesia or sedation, the rate of <e1> DIPRIVAN </e1> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, <e2> nitrous oxide </e2> or opioids).	0	DIPRIVAN	nitrous oxide
During maintenance of anesthesia or sedation, the rate of <e1> DIPRIVAN </e1> Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or <e2> opioids </e2> ).	0	DIPRIVAN	opioids
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental <e1> analgesic agents </e1> (eg, <e2> nitrous oxide </e2> or opioids).	0	analgesic agents	nitrous oxide
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental <e1> analgesic agents </e1> (eg, nitrous oxide or <e2> opioids </e2> ).	0	analgesic agents	opioids
During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, <e1> nitrous oxide </e1> or <e2> opioids </e2> ).	0	nitrous oxide	opioids
The concurrent administration of potent inhalational agents (eg, <e1> isoflurane </e1> , <e2> enflurane </e2> , and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated.	0	isoflurane	enflurane
The concurrent administration of potent inhalational agents (eg, <e1> isoflurane </e1> , enflurane, and <e2> halothane </e2> ) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated.	0	isoflurane	halothane
The concurrent administration of potent inhalational agents (eg, <e1> isoflurane </e1> , enflurane, and halothane) during maintenance with <e2> DIPRIVAN </e2> Injectable Emulsion has not been extensively evaluated.	0	isoflurane	DIPRIVAN
The concurrent administration of potent inhalational agents (eg, isoflurane, <e1> enflurane </e1> , and <e2> halothane </e2> ) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated.	0	enflurane	halothane
The concurrent administration of potent inhalational agents (eg, isoflurane, <e1> enflurane </e1> , and halothane) during maintenance with <e2> DIPRIVAN </e2> Injectable Emulsion has not been extensively evaluated.	0	enflurane	DIPRIVAN
The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and <e1> halothane </e1> ) during maintenance with <e2> DIPRIVAN </e2> Injectable Emulsion has not been extensively evaluated.	0	halothane	DIPRIVAN
<e1> DIPRIVAN </e1> Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used <e2> neuromuscular blocking agents </e2> (eg, succinylcholine and nondepolarizing muscle relaxants).	0	DIPRIVAN	neuromuscular blocking agents
<e1> DIPRIVAN </e1> Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, <e2> succinylcholine </e2> and nondepolarizing muscle relaxants).	0	DIPRIVAN	succinylcholine
<e1> DIPRIVAN </e1> Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and <e2> nondepolarizing muscle relaxants </e2> ).	0	DIPRIVAN	nondepolarizing muscle relaxants
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used <e1> neuromuscular blocking agents </e1> (eg, <e2> succinylcholine </e2> and nondepolarizing muscle relaxants).	0	neuromuscular blocking agents	succinylcholine
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used <e1> neuromuscular blocking agents </e1> (eg, succinylcholine and <e2> nondepolarizing muscle relaxants </e2> ).	0	neuromuscular blocking agents	nondepolarizing muscle relaxants
DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, <e1> succinylcholine </e1> and <e2> nondepolarizing muscle relaxants </e2> ).	0	succinylcholine	nondepolarizing muscle relaxants
No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of <e1> muscle relaxants </e1> , inhalational agents, <e2> analgesic agents </e2> , and local anesthetic agents) have been observed.	0	muscle relaxants	analgesic agents
No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of <e1> muscle relaxants </e1> , inhalational agents, analgesic agents, and local <e2> anesthetic agents </e2> ) have been observed.	0	muscle relaxants	anesthetic agents
No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, <e1> analgesic agents </e1> , and local <e2> anesthetic agents </e2> ) have been observed.	0	analgesic agents	anesthetic agents
<e1> Methscopolamine </e1> may interact with <e2> antidepressants </e2> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	antidepressants
<e1> Methscopolamine </e1> may interact with antidepressants ( <e2> tricyclic </e2> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	tricyclic
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), <e2> MAO inhibitors </e2> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	MAO inhibitors
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e2> phenelzine </e2> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	phenelzine
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e2> linezolid </e2> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	linezolid
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e2> tranylcypromine </e2> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	tranylcypromine
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e2> isocarboxazid </e2> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	isocarboxazid
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e2> selegiline </e2> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	selegiline
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	furazolidone
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	quinidine
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	amantadine
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	antihistamines
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	diphenhydramine
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	anticholinergics
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	potassium chloride
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	antacids
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	absorbent-type anti-diarrhea medicines
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	kaolin
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	Methscopolamine	pectin
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	Methscopolamine	phenothiazines
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	Methscopolamine	chlorpromazine
<e1> Methscopolamine </e1> may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	Methscopolamine	promethazine
Methscopolamine may interact with <e1> antidepressants </e1> ( <e2> tricyclic </e2> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	tricyclic
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), <e2> MAO inhibitors </e2> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	MAO inhibitors
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., <e2> phenelzine </e2> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	phenelzine
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, <e2> linezolid </e2> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	linezolid
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e2> tranylcypromine </e2> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	tranylcypromine
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e2> isocarboxazid </e2> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	isocarboxazid
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e2> selegiline </e2> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	selegiline
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	furazolidone
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	quinidine
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	amantadine
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	antihistamines
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	diphenhydramine
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	anticholinergics
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	potassium chloride
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	antacids
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	kaolin
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	antidepressants	pectin
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	antidepressants	phenothiazines
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	antidepressants	chlorpromazine
Methscopolamine may interact with <e1> antidepressants </e1> (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	antidepressants	promethazine
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), <e2> MAO inhibitors </e2> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	MAO inhibitors
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., <e2> phenelzine </e2> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	phenelzine
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, <e2> linezolid </e2> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	linezolid
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, <e2> tranylcypromine </e2> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	tranylcypromine
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e2> isocarboxazid </e2> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	isocarboxazid
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e2> selegiline </e2> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	selegiline
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	furazolidone
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	quinidine
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	amantadine
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	antihistamines
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	diphenhydramine
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	anticholinergics
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	potassium chloride
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	antacids
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	kaolin
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	tricyclic	pectin
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	tricyclic	phenothiazines
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	tricyclic	chlorpromazine
Methscopolamine may interact with antidepressants ( <e1> tricyclic </e1> type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	tricyclic	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., <e2> phenelzine </e2> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	phenelzine
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, <e2> linezolid </e2> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	linezolid
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, <e2> tranylcypromine </e2> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	tranylcypromine
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, <e2> isocarboxazid </e2> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	isocarboxazid
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e2> selegiline </e2> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	selegiline
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	furazolidone
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	quinidine
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	amantadine
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	antihistamines
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	diphenhydramine
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	anticholinergics
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	potassium chloride
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	antacids
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	pectin
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	MAO inhibitors	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	MAO inhibitors	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), <e1> MAO inhibitors </e1> (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	MAO inhibitors	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , <e2> linezolid </e2> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	linezolid
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, <e2> tranylcypromine </e2> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	tranylcypromine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, <e2> isocarboxazid </e2> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	isocarboxazid
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, <e2> selegiline </e2> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	selegiline
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	furazolidone
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	quinidine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	amantadine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	antihistamines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	diphenhydramine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	anticholinergics
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	potassium chloride
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	antacids
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	phenelzine	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	phenelzine	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	phenelzine	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., <e1> phenelzine </e1> , linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	phenelzine	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , <e2> tranylcypromine </e2> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	tranylcypromine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, <e2> isocarboxazid </e2> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	isocarboxazid
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, <e2> selegiline </e2> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	selegiline
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	furazolidone
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	quinidine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	amantadine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	antihistamines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	diphenhydramine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	anticholinergics
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	potassium chloride
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	antacids
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	linezolid	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	linezolid	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	linezolid	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, <e1> linezolid </e1> , tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	linezolid	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , <e2> isocarboxazid </e2> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	isocarboxazid
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, <e2> selegiline </e2> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	selegiline
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	furazolidone
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	quinidine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	amantadine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	antihistamines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	diphenhydramine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	anticholinergics
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	potassium chloride
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	antacids
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	tranylcypromine	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	tranylcypromine	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	tranylcypromine	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, <e1> tranylcypromine </e1> , isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	tranylcypromine	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , <e2> selegiline </e2> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	isocarboxazid	selegiline
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	isocarboxazid	furazolidone
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	isocarboxazid	quinidine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	isocarboxazid	amantadine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	isocarboxazid	antihistamines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	isocarboxazid	diphenhydramine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	isocarboxazid	anticholinergics
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	isocarboxazid	potassium chloride
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	isocarboxazid	antacids
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	isocarboxazid	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	isocarboxazid	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	isocarboxazid	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	isocarboxazid	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	isocarboxazid	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, <e1> isocarboxazid </e1> , selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	isocarboxazid	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , <e2> furazolidone </e2> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	selegiline	furazolidone
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	selegiline	quinidine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), quinidine, <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	selegiline	amantadine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), quinidine, amantadine, <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	selegiline	antihistamines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	selegiline	diphenhydramine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	selegiline	anticholinergics
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	selegiline	potassium chloride
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	selegiline	antacids
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	selegiline	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	selegiline	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	selegiline	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	selegiline	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	selegiline	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, <e1> selegiline </e1> , furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	selegiline	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), <e2> quinidine </e2> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	furazolidone	quinidine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	furazolidone	amantadine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, amantadine, <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	furazolidone	antihistamines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	furazolidone	diphenhydramine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	furazolidone	anticholinergics
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	furazolidone	potassium chloride
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	furazolidone	antacids
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	furazolidone	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	furazolidone	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	furazolidone	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	furazolidone	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	furazolidone	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, <e1> furazolidone </e1> ), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	furazolidone	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1> quinidine </e1> , <e2> amantadine </e2> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	quinidine	amantadine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1> quinidine </e1> , amantadine, <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	quinidine	antihistamines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1> quinidine </e1> , amantadine, antihistamines (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	quinidine	diphenhydramine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	quinidine	anticholinergics
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	quinidine	potassium chloride
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	quinidine	antacids
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	quinidine	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	quinidine	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	quinidine	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	quinidine	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	quinidine	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), <e1> quinidine </e1> , amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	quinidine	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1> amantadine </e1> , <e2> antihistamines </e2> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	amantadine	antihistamines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1> amantadine </e1> , antihistamines (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	amantadine	diphenhydramine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	amantadine	anticholinergics
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	amantadine	potassium chloride
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	amantadine	antacids
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	amantadine	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	amantadine	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	amantadine	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	amantadine	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	amantadine	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, <e1> amantadine </e1> , antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	amantadine	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1> antihistamines </e1> (e.g., <e2> diphenhydramine </e2> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antihistamines	diphenhydramine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1> antihistamines </e1> (e.g., diphenhydramine), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antihistamines	anticholinergics
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1> antihistamines </e1> (e.g., diphenhydramine), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antihistamines	potassium chloride
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1> antihistamines </e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antihistamines	antacids
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1> antihistamines </e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antihistamines	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1> antihistamines </e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antihistamines	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1> antihistamines </e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	antihistamines	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1> antihistamines </e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	antihistamines	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1> antihistamines </e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	antihistamines	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, <e1> antihistamines </e1> (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	antihistamines	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1> diphenhydramine </e1> ), other <e2> anticholinergics </e2> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	diphenhydramine	anticholinergics
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1> diphenhydramine </e1> ), other anticholinergics, <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	diphenhydramine	potassium chloride
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1> diphenhydramine </e1> ), other anticholinergics, potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	diphenhydramine	antacids
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1> diphenhydramine </e1> ), other anticholinergics, potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	diphenhydramine	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1> diphenhydramine </e1> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	diphenhydramine	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1> diphenhydramine </e1> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	diphenhydramine	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1> diphenhydramine </e1> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	diphenhydramine	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1> diphenhydramine </e1> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	diphenhydramine	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., <e1> diphenhydramine </e1> ), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	diphenhydramine	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1> anticholinergics </e1> , <e2> potassium chloride </e2> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	anticholinergics	potassium chloride
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1> anticholinergics </e1> , potassium chloride supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	anticholinergics	antacids
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1> anticholinergics </e1> , potassium chloride supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	anticholinergics	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1> anticholinergics </e1> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	anticholinergics	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1> anticholinergics </e1> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	anticholinergics	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1> anticholinergics </e1> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	anticholinergics	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1> anticholinergics </e1> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	anticholinergics	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other <e1> anticholinergics </e1> , potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	anticholinergics	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1> potassium chloride </e1> supplements, <e2> antacids </e2> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	potassium chloride	antacids
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1> potassium chloride </e1> supplements, antacids, <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	potassium chloride	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1> potassium chloride </e1> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	potassium chloride	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1> potassium chloride </e1> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	potassium chloride	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1> potassium chloride </e1> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	potassium chloride	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1> potassium chloride </e1> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	potassium chloride	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, <e1> potassium chloride </e1> supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	potassium chloride	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e1> antacids </e1> , <e2> absorbent-type anti-diarrhea medicines </e2> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antacids	absorbent-type anti-diarrhea medicines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e1> antacids </e1> , absorbent-type anti-diarrhea medicines (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	antacids	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e1> antacids </e1> , absorbent-type anti-diarrhea medicines (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	antacids	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e1> antacids </e1> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	antacids	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e1> antacids </e1> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	antacids	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, <e1> antacids </e1> , absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	antacids	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e1> absorbent-type anti-diarrhea medicines </e1> (e.g., <e2> kaolin </e2> -pectin), phenothiazines (e.g., chlorpromazine, promethazine).	0	absorbent-type anti-diarrhea medicines	kaolin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e1> absorbent-type anti-diarrhea medicines </e1> (e.g., kaolin- <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	absorbent-type anti-diarrhea medicines	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e1> absorbent-type anti-diarrhea medicines </e1> (e.g., kaolin-pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	absorbent-type anti-diarrhea medicines	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e1> absorbent-type anti-diarrhea medicines </e1> (e.g., kaolin-pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	absorbent-type anti-diarrhea medicines	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, <e1> absorbent-type anti-diarrhea medicines </e1> (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	absorbent-type anti-diarrhea medicines	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e1> kaolin </e1> - <e2> pectin </e2> ), phenothiazines (e.g., chlorpromazine, promethazine).	0	kaolin	pectin
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e1> kaolin </e1> -pectin), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	kaolin	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e1> kaolin </e1> -pectin), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	kaolin	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., <e1> kaolin </e1> -pectin), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	kaolin	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e1> pectin </e1> ), <e2> phenothiazines </e2> (e.g., chlorpromazine, promethazine).	0	pectin	phenothiazines
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e1> pectin </e1> ), phenothiazines (e.g., <e2> chlorpromazine </e2> , promethazine).	0	pectin	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin- <e1> pectin </e1> ), phenothiazines (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	pectin	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e1> phenothiazines </e1> (e.g., <e2> chlorpromazine </e2> , promethazine).	0	phenothiazines	chlorpromazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), <e1> phenothiazines </e1> (e.g., chlorpromazine, <e2> promethazine </e2> ).	0	phenothiazines	promethazine
Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., <e1> chlorpromazine </e1> , <e2> promethazine </e2> ).	0	chlorpromazine	promethazine
The concomitant use of <e1> Sanctura </e1> with other <e2> anticholinergic agents </e2> that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.	1	Sanctura	anticholinergic agents
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1> Sanctura </e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e2> digoxin </e2> , procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	0	Sanctura	digoxin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1> Sanctura </e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e2> procainamide </e2> , pancuronium, morphine, vancomycin, metformin and tenofovir).	0	Sanctura	procainamide
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1> Sanctura </e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, <e2> pancuronium </e2> , morphine, vancomycin, metformin and tenofovir).	0	Sanctura	pancuronium
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1> Sanctura </e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, <e2> morphine </e2> , vancomycin, metformin and tenofovir).	0	Sanctura	morphine
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1> Sanctura </e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, <e2> vancomycin </e2> , metformin and tenofovir).	0	Sanctura	vancomycin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1> Sanctura </e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, <e2> metformin </e2> and tenofovir).	0	Sanctura	metformin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with <e1> Sanctura </e1> have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and <e2> tenofovir </e2> ).	0	Sanctura	tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1> Sanctura </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e2> digoxin </e2> , procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir).	1	Sanctura	digoxin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1> Sanctura </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e2> procainamide </e2> , pancuronium, morphine, vancomycin, metformin and tenofovir).	1	Sanctura	procainamide
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1> Sanctura </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, <e2> pancuronium </e2> , morphine, vancomycin, metformin and tenofovir).	1	Sanctura	pancuronium
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1> Sanctura </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, <e2> morphine </e2> , vancomycin, metformin and tenofovir).	1	Sanctura	morphine
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1> Sanctura </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, <e2> vancomycin </e2> , metformin and tenofovir).	1	Sanctura	vancomycin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1> Sanctura </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, <e2> metformin </e2> and tenofovir).	1	Sanctura	metformin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, <e1> Sanctura </e1> has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and <e2> tenofovir </e2> ).	1	Sanctura	tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e1> digoxin </e1> , <e2> procainamide </e2> , pancuronium, morphine, vancomycin, metformin and tenofovir).	0	digoxin	procainamide
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e1> digoxin </e1> , procainamide, <e2> pancuronium </e2> , morphine, vancomycin, metformin and tenofovir).	0	digoxin	pancuronium
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e1> digoxin </e1> , procainamide, pancuronium, <e2> morphine </e2> , vancomycin, metformin and tenofovir).	0	digoxin	morphine
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e1> digoxin </e1> , procainamide, pancuronium, morphine, <e2> vancomycin </e2> , metformin and tenofovir).	0	digoxin	vancomycin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e1> digoxin </e1> , procainamide, pancuronium, morphine, vancomycin, <e2> metformin </e2> and tenofovir).	0	digoxin	metformin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. <e1> digoxin </e1> , procainamide, pancuronium, morphine, vancomycin, metformin and <e2> tenofovir </e2> ).	0	digoxin	tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e1> procainamide </e1> , <e2> pancuronium </e2> , morphine, vancomycin, metformin and tenofovir).	0	procainamide	pancuronium
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e1> procainamide </e1> , pancuronium, <e2> morphine </e2> , vancomycin, metformin and tenofovir).	0	procainamide	morphine
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e1> procainamide </e1> , pancuronium, morphine, <e2> vancomycin </e2> , metformin and tenofovir).	0	procainamide	vancomycin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e1> procainamide </e1> , pancuronium, morphine, vancomycin, <e2> metformin </e2> and tenofovir).	0	procainamide	metformin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, <e1> procainamide </e1> , pancuronium, morphine, vancomycin, metformin and <e2> tenofovir </e2> ).	0	procainamide	tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, <e1> pancuronium </e1> , <e2> morphine </e2> , vancomycin, metformin and tenofovir).	0	pancuronium	morphine
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, <e1> pancuronium </e1> , morphine, <e2> vancomycin </e2> , metformin and tenofovir).	0	pancuronium	vancomycin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, <e1> pancuronium </e1> , morphine, vancomycin, <e2> metformin </e2> and tenofovir).	0	pancuronium	metformin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, <e1> pancuronium </e1> , morphine, vancomycin, metformin and <e2> tenofovir </e2> ).	0	pancuronium	tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, <e1> morphine </e1> , <e2> vancomycin </e2> , metformin and tenofovir).	0	morphine	vancomycin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, <e1> morphine </e1> , vancomycin, <e2> metformin </e2> and tenofovir).	0	morphine	metformin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, <e1> morphine </e1> , vancomycin, metformin and <e2> tenofovir </e2> ).	0	morphine	tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, <e1> vancomycin </e1> , <e2> metformin </e2> and tenofovir).	0	vancomycin	metformin
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, <e1> vancomycin </e1> , metformin and <e2> tenofovir </e2> ).	0	vancomycin	tenofovir
Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, <e1> metformin </e1> and <e2> tenofovir </e2> ).	0	metformin	tenofovir
Preliminary evidence suggests that <e1> cimetidine </e1> inhibits <e2> mebendazole </e2> metabolism and may result in an increase in plasma concentrations of mebendazole.	1	cimetidine	mebendazole
Preliminary evidence suggests that <e1> cimetidine </e1> inhibits mebendazole metabolism and may result in an increase in plasma concentrations of <e2> mebendazole </e2> .	0	cimetidine	mebendazole
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> MYCAMINE </e1> and <e2> mycophenolate mofetil </e2> , cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	0	MYCAMINE	mycophenolate mofetil
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> MYCAMINE </e1> and mycophenolate mofetil, <e2> cyclosporine </e2> , tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	0	MYCAMINE	cyclosporine
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> MYCAMINE </e1> and mycophenolate mofetil, cyclosporine, <e2> tacrolimus </e2> , prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	0	MYCAMINE	tacrolimus
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> MYCAMINE </e1> and mycophenolate mofetil, cyclosporine, tacrolimus, <e2> prednisolone </e2> , sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	0	MYCAMINE	prednisolone
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> MYCAMINE </e1> and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, <e2> sirolimus </e2> , nifedipine, fluconazole, ritonavir, and rifampin.	0	MYCAMINE	sirolimus
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> MYCAMINE </e1> and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, <e2> nifedipine </e2> , fluconazole, ritonavir, and rifampin.	0	MYCAMINE	nifedipine
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> MYCAMINE </e1> and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, <e2> fluconazole </e2> , ritonavir, and rifampin.	0	MYCAMINE	fluconazole
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> MYCAMINE </e1> and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, <e2> ritonavir </e2> , and rifampin.	0	MYCAMINE	ritonavir
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between <e1> MYCAMINE </e1> and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and <e2> rifampin </e2> .	0	MYCAMINE	rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> mycophenolate mofetil </e1> , <e2> cyclosporine </e2> , tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	0	mycophenolate mofetil	cyclosporine
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> mycophenolate mofetil </e1> , cyclosporine, <e2> tacrolimus </e2> , prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	0	mycophenolate mofetil	tacrolimus
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus, <e2> prednisolone </e2> , sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	0	mycophenolate mofetil	prednisolone
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus, prednisolone, <e2> sirolimus </e2> , nifedipine, fluconazole, ritonavir, and rifampin.	0	mycophenolate mofetil	sirolimus
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus, prednisolone, sirolimus, <e2> nifedipine </e2> , fluconazole, ritonavir, and rifampin.	0	mycophenolate mofetil	nifedipine
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, <e2> fluconazole </e2> , ritonavir, and rifampin.	0	mycophenolate mofetil	fluconazole
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, <e2> ritonavir </e2> , and rifampin.	0	mycophenolate mofetil	ritonavir
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and <e2> rifampin </e2> .	0	mycophenolate mofetil	rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1> cyclosporine </e1> , <e2> tacrolimus </e2> , prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	0	cyclosporine	tacrolimus
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1> cyclosporine </e1> , tacrolimus, <e2> prednisolone </e2> , sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	0	cyclosporine	prednisolone
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1> cyclosporine </e1> , tacrolimus, prednisolone, <e2> sirolimus </e2> , nifedipine, fluconazole, ritonavir, and rifampin.	0	cyclosporine	sirolimus
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1> cyclosporine </e1> , tacrolimus, prednisolone, sirolimus, <e2> nifedipine </e2> , fluconazole, ritonavir, and rifampin.	0	cyclosporine	nifedipine
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1> cyclosporine </e1> , tacrolimus, prednisolone, sirolimus, nifedipine, <e2> fluconazole </e2> , ritonavir, and rifampin.	0	cyclosporine	fluconazole
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1> cyclosporine </e1> , tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, <e2> ritonavir </e2> , and rifampin.	0	cyclosporine	ritonavir
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, <e1> cyclosporine </e1> , tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and <e2> rifampin </e2> .	0	cyclosporine	rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, <e1> tacrolimus </e1> , <e2> prednisolone </e2> , sirolimus, nifedipine, fluconazole, ritonavir, and rifampin.	0	tacrolimus	prednisolone
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, <e1> tacrolimus </e1> , prednisolone, <e2> sirolimus </e2> , nifedipine, fluconazole, ritonavir, and rifampin.	0	tacrolimus	sirolimus
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, <e1> tacrolimus </e1> , prednisolone, sirolimus, <e2> nifedipine </e2> , fluconazole, ritonavir, and rifampin.	0	tacrolimus	nifedipine
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, <e1> tacrolimus </e1> , prednisolone, sirolimus, nifedipine, <e2> fluconazole </e2> , ritonavir, and rifampin.	0	tacrolimus	fluconazole
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, <e1> tacrolimus </e1> , prednisolone, sirolimus, nifedipine, fluconazole, <e2> ritonavir </e2> , and rifampin.	0	tacrolimus	ritonavir
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, <e1> tacrolimus </e1> , prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and <e2> rifampin </e2> .	0	tacrolimus	rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, <e1> prednisolone </e1> , <e2> sirolimus </e2> , nifedipine, fluconazole, ritonavir, and rifampin.	0	prednisolone	sirolimus
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, <e1> prednisolone </e1> , sirolimus, <e2> nifedipine </e2> , fluconazole, ritonavir, and rifampin.	0	prednisolone	nifedipine
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, <e1> prednisolone </e1> , sirolimus, nifedipine, <e2> fluconazole </e2> , ritonavir, and rifampin.	0	prednisolone	fluconazole
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, <e1> prednisolone </e1> , sirolimus, nifedipine, fluconazole, <e2> ritonavir </e2> , and rifampin.	0	prednisolone	ritonavir
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, <e1> prednisolone </e1> , sirolimus, nifedipine, fluconazole, ritonavir, and <e2> rifampin </e2> .	0	prednisolone	rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, <e1> sirolimus </e1> , <e2> nifedipine </e2> , fluconazole, ritonavir, and rifampin.	0	sirolimus	nifedipine
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, <e1> sirolimus </e1> , nifedipine, <e2> fluconazole </e2> , ritonavir, and rifampin.	0	sirolimus	fluconazole
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, <e1> sirolimus </e1> , nifedipine, fluconazole, <e2> ritonavir </e2> , and rifampin.	0	sirolimus	ritonavir
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, <e1> sirolimus </e1> , nifedipine, fluconazole, ritonavir, and <e2> rifampin </e2> .	0	sirolimus	rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, <e1> nifedipine </e1> , <e2> fluconazole </e2> , ritonavir, and rifampin.	0	nifedipine	fluconazole
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, <e1> nifedipine </e1> , fluconazole, <e2> ritonavir </e2> , and rifampin.	0	nifedipine	ritonavir
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, <e1> nifedipine </e1> , fluconazole, ritonavir, and <e2> rifampin </e2> .	0	nifedipine	rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, <e1> fluconazole </e1> , <e2> ritonavir </e2> , and rifampin.	0	fluconazole	ritonavir
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, <e1> fluconazole </e1> , ritonavir, and <e2> rifampin </e2> .	0	fluconazole	rifampin
A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, <e1> ritonavir </e1> , and <e2> rifampin </e2> .	0	ritonavir	rifampin
There was no effect of a single dose or multiple doses of <e1> MYCAMINE </e1> on <e2> mycophenolate mofetil </e2> , cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics.	0	MYCAMINE	mycophenolate mofetil
There was no effect of a single dose or multiple doses of <e1> MYCAMINE </e1> on mycophenolate mofetil, <e2> cyclosporine </e2> , tacrolimus, prednisolone, and fluconazole pharmacokinetics.	0	MYCAMINE	cyclosporine
There was no effect of a single dose or multiple doses of <e1> MYCAMINE </e1> on mycophenolate mofetil, cyclosporine, <e2> tacrolimus </e2> , prednisolone, and fluconazole pharmacokinetics.	0	MYCAMINE	tacrolimus
There was no effect of a single dose or multiple doses of <e1> MYCAMINE </e1> on mycophenolate mofetil, cyclosporine, tacrolimus, <e2> prednisolone </e2> , and fluconazole pharmacokinetics.	0	MYCAMINE	prednisolone
There was no effect of a single dose or multiple doses of <e1> MYCAMINE </e1> on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and <e2> fluconazole </e2> pharmacokinetics.	0	MYCAMINE	fluconazole
There was no effect of a single dose or multiple doses of MYCAMINE on <e1> mycophenolate mofetil </e1> , <e2> cyclosporine </e2> , tacrolimus, prednisolone, and fluconazole pharmacokinetics.	0	mycophenolate mofetil	cyclosporine
There was no effect of a single dose or multiple doses of MYCAMINE on <e1> mycophenolate mofetil </e1> , cyclosporine, <e2> tacrolimus </e2> , prednisolone, and fluconazole pharmacokinetics.	0	mycophenolate mofetil	tacrolimus
There was no effect of a single dose or multiple doses of MYCAMINE on <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus, <e2> prednisolone </e2> , and fluconazole pharmacokinetics.	0	mycophenolate mofetil	prednisolone
There was no effect of a single dose or multiple doses of MYCAMINE on <e1> mycophenolate mofetil </e1> , cyclosporine, tacrolimus, prednisolone, and <e2> fluconazole </e2> pharmacokinetics.	0	mycophenolate mofetil	fluconazole
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, <e1> cyclosporine </e1> , <e2> tacrolimus </e2> , prednisolone, and fluconazole pharmacokinetics.	0	cyclosporine	tacrolimus
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, <e1> cyclosporine </e1> , tacrolimus, <e2> prednisolone </e2> , and fluconazole pharmacokinetics.	0	cyclosporine	prednisolone
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, <e1> cyclosporine </e1> , tacrolimus, prednisolone, and <e2> fluconazole </e2> pharmacokinetics.	0	cyclosporine	fluconazole
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, <e1> tacrolimus </e1> , <e2> prednisolone </e2> , and fluconazole pharmacokinetics.	0	tacrolimus	prednisolone
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, <e1> tacrolimus </e1> , prednisolone, and <e2> fluconazole </e2> pharmacokinetics.	0	tacrolimus	fluconazole
There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, <e1> prednisolone </e1> , and <e2> fluconazole </e2> pharmacokinetics.	0	prednisolone	fluconazole
<e1> Sirolimus </e1> AUC was increased by 21% with no effect on Cmax in the presence of steady-state <e2> MYCAMINE </e2> compared with sirolimus alone.	1	Sirolimus	MYCAMINE
Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state <e1> MYCAMINE </e1> compared with <e2> sirolimus </e2> alone.	0	MYCAMINE	sirolimus
<e1> Nifedipine </e1> AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state <e2> MYCAMINE </e2> compared with nifedipine alone.	1	Nifedipine	MYCAMINE
Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state <e1> MYCAMINE </e1> compared with <e2> nifedipine </e2> alone.	0	MYCAMINE	nifedipine
Patients receiving <e1> sirolimus </e1> or <e2> nifedipine </e2> in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	0	sirolimus	nifedipine
Patients receiving <e1> sirolimus </e1> or nifedipine in combination with <e2> MYCAMINE </e2> should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	0	sirolimus	MYCAMINE
Patients receiving <e1> sirolimus </e1> or nifedipine in combination with MYCAMINE should be monitored for sirolimus or <e2> nifedipine </e2> toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	0	sirolimus	nifedipine
Patients receiving <e1> sirolimus </e1> or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or <e2> nifedipine </e2> dosage should be reduced if necessary.	0	sirolimus	nifedipine
Patients receiving sirolimus or <e1> nifedipine </e1> in combination with <e2> MYCAMINE </e2> should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	0	nifedipine	MYCAMINE
Patients receiving sirolimus or <e1> nifedipine </e1> in combination with MYCAMINE should be monitored for <e2> sirolimus </e2> or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	0	nifedipine	sirolimus
Patients receiving sirolimus or <e1> nifedipine </e1> in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and <e2> sirolimus </e2> or nifedipine dosage should be reduced if necessary.	0	nifedipine	sirolimus
Patients receiving sirolimus or nifedipine in combination with <e1> MYCAMINE </e1> should be monitored for <e2> sirolimus </e2> or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	0	MYCAMINE	sirolimus
Patients receiving sirolimus or nifedipine in combination with <e1> MYCAMINE </e1> should be monitored for sirolimus or <e2> nifedipine </e2> toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	0	MYCAMINE	nifedipine
Patients receiving sirolimus or nifedipine in combination with <e1> MYCAMINE </e1> should be monitored for sirolimus or nifedipine toxicity and <e2> sirolimus </e2> or nifedipine dosage should be reduced if necessary.	0	MYCAMINE	sirolimus
Patients receiving sirolimus or nifedipine in combination with <e1> MYCAMINE </e1> should be monitored for sirolimus or nifedipine toxicity and sirolimus or <e2> nifedipine </e2> dosage should be reduced if necessary.	0	MYCAMINE	nifedipine
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for <e1> sirolimus </e1> or <e2> nifedipine </e2> toxicity and sirolimus or nifedipine dosage should be reduced if necessary.	0	sirolimus	nifedipine
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for <e1> sirolimus </e1> or nifedipine toxicity and sirolimus or <e2> nifedipine </e2> dosage should be reduced if necessary.	0	sirolimus	nifedipine
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or <e1> nifedipine </e1> toxicity and <e2> sirolimus </e2> or nifedipine dosage should be reduced if necessary.	0	nifedipine	sirolimus
Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and <e1> sirolimus </e1> or <e2> nifedipine </e2> dosage should be reduced if necessary.	0	sirolimus	nifedipine
Coadministration of <e1> TRITEC </e1> with <e2> clarithromycin </e2> resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).	1	TRITEC	clarithromycin
Coadministration of <e1> TRITEC </e1> with clarithromycin resulted in increased plasma <e2> ranitidine </e2> concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).	0	TRITEC	ranitidine
Coadministration of <e1> TRITEC </e1> with clarithromycin resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased <e2> 14- hydroxy- clarithromycin </e2> plasma concentrations (31%).	0	TRITEC	14- hydroxy- clarithromycin
Coadministration of TRITEC with <e1> clarithromycin </e1> resulted in increased plasma <e2> ranitidine </e2> concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).	0	clarithromycin	ranitidine
Coadministration of TRITEC with <e1> clarithromycin </e1> resulted in increased plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased <e2> 14- hydroxy- clarithromycin </e2> plasma concentrations (31%).	0	clarithromycin	14- hydroxy- clarithromycin
Coadministration of TRITEC with clarithromycin resulted in increased plasma <e1> ranitidine </e1> concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased <e2> 14- hydroxy- clarithromycin </e2> plasma concentrations (31%).	0	ranitidine	14- hydroxy- clarithromycin
Coadministration with <e1> aspirin </e1> results in a slight decrease in the rate of <e2> salicylate </e2> absorption that is clinically unimportant.	0	aspirin	salicylate
Coadministration with a high dose of <e1> antacid </e1> (170 mEq) results in a 28% decrease in plasma concentrations of <e2> ranitidine </e2> and may decrease plasma concentrations of bismuth from TRITEC.	1	antacid	ranitidine
Coadministration with a high dose of <e1> antacid </e1> (170 mEq) results in a 28% decrease in plasma concentrations of ranitidine and may decrease plasma concentrations of bismuth from <e2> TRITEC </e2> .	1	antacid	TRITEC
Coadministration with a high dose of antacid (170 mEq) results in a 28% decrease in plasma concentrations of <e1> ranitidine </e1> and may decrease plasma concentrations of bismuth from <e2> TRITEC </e2> .	0	ranitidine	TRITEC
For information on drug interactions associated with <e1> ranitidine </e1> , refer to the <e2> ZANTAC </e2> package insert.	0	ranitidine	ZANTAC
Pharmacokinetic properties of <e1> abacavir </e1> were not altered by the addition of either <e2> lamivudine </e2> or zidovudine or the combination of lamivudine and zidovudine.	0	abacavir	lamivudine
Pharmacokinetic properties of <e1> abacavir </e1> were not altered by the addition of either lamivudine or <e2> zidovudine </e2> or the combination of lamivudine and zidovudine.	0	abacavir	zidovudine
Pharmacokinetic properties of <e1> abacavir </e1> were not altered by the addition of either lamivudine or zidovudine or the combination of <e2> lamivudine </e2> and zidovudine.	0	abacavir	lamivudine
Pharmacokinetic properties of <e1> abacavir </e1> were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and <e2> zidovudine </e2> .	0	abacavir	zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either <e1> lamivudine </e1> or <e2> zidovudine </e2> or the combination of lamivudine and zidovudine.	0	lamivudine	zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either <e1> lamivudine </e1> or zidovudine or the combination of lamivudine and <e2> zidovudine </e2> .	0	lamivudine	zidovudine
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or <e1> zidovudine </e1> or the combination of <e2> lamivudine </e2> and zidovudine.	0	zidovudine	lamivudine
Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of <e1> lamivudine </e1> and <e2> zidovudine </e2> .	0	lamivudine	zidovudine
No clinically significant changes to <e1> lamivudine </e1> or <e2> zidovudine </e2> pharmacokinetics were observed following concomitant administration of abacavir.	0	lamivudine	zidovudine
No clinically significant changes to <e1> lamivudine </e1> or zidovudine pharmacokinetics were observed following concomitant administration of <e2> abacavir </e2> .	0	lamivudine	abacavir
No clinically significant changes to lamivudine or <e1> zidovudine </e1> pharmacokinetics were observed following concomitant administration of <e2> abacavir </e2> .	0	zidovudine	abacavir
<e1> Abacavir </e1> has no effect on the pharmacokinetic properties of <e2> ethanol </e2> .	0	Abacavir	ethanol
<e1> Ethanol </e1> decreases the elimination of <e2> abacavir </e2> causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir.	1	Ethanol	abacavir
<e1> Ethanol </e1> decreases the elimination of abacavir causing an increase in overall exposure . The addition of <e2> methadone </e2> has no clinically significant effect on the pharmacokinetic properties of abacavir.	0	Ethanol	methadone
<e1> Ethanol </e1> decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of <e2> abacavir </e2> .	0	Ethanol	abacavir
Ethanol decreases the elimination of <e1> abacavir </e1> causing an increase in overall exposure . The addition of <e2> methadone </e2> has no clinically significant effect on the pharmacokinetic properties of abacavir.	0	abacavir	methadone
Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of <e1> methadone </e1> has no clinically significant effect on the pharmacokinetic properties of <e2> abacavir </e2> .	0	methadone	abacavir
In a study of 11 HIV-infected patients receiving <e1> methadone </e1> -maintenance therapy (40 mg and 90 mg daily) with 600 mg of <e2> ZIAGEN </e2> twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%).	1	methadone	ZIAGEN
In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of <e1> ZIAGEN </e1> twice daily (twice the currently recommended dose), oral <e2> methadone </e2> clearance increased 22% (90% CI 6% to 42%).	0	ZIAGEN	methadone
Although <e1> MIVACRON </e1> (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and <e2> succinylcholine </e2> has not been systematically studied.	0	MIVACRON	succinylcholine
Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between <e1> MIVACRON </e1> and <e2> succinylcholine </e2> has not been systematically studied.	0	MIVACRON	succinylcholine
Prior administration of <e1> succinylcholine </e1> can potentiate the neuromuscular blocking effects of <e2> nondepolarizing agents </e2> .	1	succinylcholine	nondepolarizing agents
Evidence of spontaneous recovery from <e1> succinylcholine </e1> should be observed before the administration of <e2> MIVACRON </e2> .	0	succinylcholine	MIVACRON
The use of <e1> MIVACRON </e1> before <e2> succinylcholine </e2> to attenuate some of the side effects of succinylcholine has not been studied.	0	MIVACRON	succinylcholine
The use of <e1> MIVACRON </e1> before succinylcholine to attenuate some of the side effects of <e2> succinylcholine </e2> has not been studied.	0	MIVACRON	succinylcholine
There are no clinical data on the use of <e1> MIVACRON </e1> with other <e2> nondepolarizing neuromuscular blocking agents </e2> .	0	MIVACRON	nondepolarizing neuromuscular blocking agents
<e1> Isoflurane </e1> and <e2> enflurane </e2> (administered with nitrous oxide/oxygen to achieve 1.25 M.C.	0	Isoflurane	enflurane
<e1> Isoflurane </e1> and enflurane (administered with <e2> nitrous oxide </e2> /oxygen to achieve 1.25 M.C.	0	Isoflurane	nitrous oxide
<e1> Isoflurane </e1> and enflurane (administered with nitrous oxide/ <e2> oxygen </e2> to achieve 1.25 M.C.	0	Isoflurane	oxygen
Isoflurane and <e1> enflurane </e1> (administered with <e2> nitrous oxide </e2> /oxygen to achieve 1.25 M.C.	0	enflurane	nitrous oxide
Isoflurane and <e1> enflurane </e1> (administered with nitrous oxide/ <e2> oxygen </e2> to achieve 1.25 M.C.	0	enflurane	oxygen
Isoflurane and enflurane (administered with <e1> nitrous oxide </e1> / <e2> oxygen </e2> to achieve 1.25 M.C.	0	nitrous oxide	oxygen
A greater potentiation of the neuromuscular blocking effects of <e1> MIVACRON </e1> may be expected with higher concentrations of <e2> enflurane </e2> or isoflurane.	0	MIVACRON	enflurane
A greater potentiation of the neuromuscular blocking effects of <e1> MIVACRON </e1> may be expected with higher concentrations of enflurane or <e2> isoflurane </e2> .	0	MIVACRON	isoflurane
A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of <e1> enflurane </e1> or <e2> isoflurane </e2> .	0	enflurane	isoflurane
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as <e2> MIVACRON </e2> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	nondepolarizing agents	MIVACRON
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain <e2> antibiotics </e2> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	nondepolarizing agents	antibiotics
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., <e2> aminoglycosides </e2> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	nondepolarizing agents	aminoglycosides
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e2> tetracyclines </e2> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	nondepolarizing agents	tetracyclines
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	nondepolarizing agents	bacitracin
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	nondepolarizing agents	polymyxins
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	nondepolarizing agents	lincomycin
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	nondepolarizing agents	clindamycin
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	nondepolarizing agents	colistin
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	nondepolarizing agents	sodium colistimethate
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2> magnesium </e2> salts, lithium, local anesthetics, procainamide, and quinidine.	0	nondepolarizing agents	magnesium
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.	0	nondepolarizing agents	lithium
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2> anesthetics </e2> , procainamide, and quinidine.	0	nondepolarizing agents	anesthetics
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2> procainamide </e2> , and quinidine.	0	nondepolarizing agents	procainamide
Other drugs which may enhance the neuromuscular blocking action of <e1> nondepolarizing agents </e1> such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2> quinidine </e2> .	0	nondepolarizing agents	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain <e2> antibiotics </e2> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	MIVACRON	antibiotics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., <e2> aminoglycosides </e2> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	MIVACRON	aminoglycosides
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., aminoglycosides, <e2> tetracyclines </e2> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	MIVACRON	tetracyclines
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	MIVACRON	bacitracin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	MIVACRON	polymyxins
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	MIVACRON	lincomycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	MIVACRON	clindamycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	MIVACRON	colistin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	MIVACRON	sodium colistimethate
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2> magnesium </e2> salts, lithium, local anesthetics, procainamide, and quinidine.	0	MIVACRON	magnesium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.	0	MIVACRON	lithium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2> anesthetics </e2> , procainamide, and quinidine.	0	MIVACRON	anesthetics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2> procainamide </e2> , and quinidine.	0	MIVACRON	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as <e1> MIVACRON </e1> include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2> quinidine </e2> .	0	MIVACRON	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., <e2> aminoglycosides </e2> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	antibiotics	aminoglycosides
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., aminoglycosides, <e2> tetracyclines </e2> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	antibiotics	tetracyclines
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., aminoglycosides, tetracyclines, <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	antibiotics	bacitracin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., aminoglycosides, tetracyclines, bacitracin, <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	antibiotics	polymyxins
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	antibiotics	lincomycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	antibiotics	clindamycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	antibiotics	colistin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	antibiotics	sodium colistimethate
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2> magnesium </e2> salts, lithium, local anesthetics, procainamide, and quinidine.	0	antibiotics	magnesium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.	0	antibiotics	lithium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2> anesthetics </e2> , procainamide, and quinidine.	0	antibiotics	anesthetics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2> procainamide </e2> , and quinidine.	0	antibiotics	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain <e1> antibiotics </e1> (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2> quinidine </e2> .	0	antibiotics	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1> aminoglycosides </e1> , <e2> tetracyclines </e2> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	aminoglycosides	tetracyclines
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1> aminoglycosides </e1> , tetracyclines, <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	aminoglycosides	bacitracin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1> aminoglycosides </e1> , tetracyclines, bacitracin, <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	aminoglycosides	polymyxins
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	aminoglycosides	lincomycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	aminoglycosides	clindamycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	aminoglycosides	colistin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	aminoglycosides	sodium colistimethate
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2> magnesium </e2> salts, lithium, local anesthetics, procainamide, and quinidine.	0	aminoglycosides	magnesium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.	0	aminoglycosides	lithium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2> anesthetics </e2> , procainamide, and quinidine.	0	aminoglycosides	anesthetics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2> procainamide </e2> , and quinidine.	0	aminoglycosides	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., <e1> aminoglycosides </e1> , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2> quinidine </e2> .	0	aminoglycosides	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1> tetracyclines </e1> , <e2> bacitracin </e2> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	tetracyclines	bacitracin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1> tetracyclines </e1> , bacitracin, <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	tetracyclines	polymyxins
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1> tetracyclines </e1> , bacitracin, polymyxins, <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	tetracyclines	lincomycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	tetracyclines	clindamycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	tetracyclines	colistin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	tetracyclines	sodium colistimethate
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2> magnesium </e2> salts, lithium, local anesthetics, procainamide, and quinidine.	0	tetracyclines	magnesium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.	0	tetracyclines	lithium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2> anesthetics </e2> , procainamide, and quinidine.	0	tetracyclines	anesthetics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2> procainamide </e2> , and quinidine.	0	tetracyclines	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, <e1> tetracyclines </e1> , bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2> quinidine </e2> .	0	tetracyclines	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1> bacitracin </e1> , <e2> polymyxins </e2> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	bacitracin	polymyxins
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1> bacitracin </e1> , polymyxins, <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	bacitracin	lincomycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1> bacitracin </e1> , polymyxins, lincomycin, <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	bacitracin	clindamycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	bacitracin	colistin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	bacitracin	sodium colistimethate
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e2> magnesium </e2> salts, lithium, local anesthetics, procainamide, and quinidine.	0	bacitracin	magnesium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.	0	bacitracin	lithium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2> anesthetics </e2> , procainamide, and quinidine.	0	bacitracin	anesthetics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2> procainamide </e2> , and quinidine.	0	bacitracin	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, <e1> bacitracin </e1> , polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2> quinidine </e2> .	0	bacitracin	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1> polymyxins </e1> , <e2> lincomycin </e2> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	polymyxins	lincomycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1> polymyxins </e1> , lincomycin, <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	polymyxins	clindamycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1> polymyxins </e1> , lincomycin, clindamycin, <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	polymyxins	colistin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	polymyxins	sodium colistimethate
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistimethate), <e2> magnesium </e2> salts, lithium, local anesthetics, procainamide, and quinidine.	0	polymyxins	magnesium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.	0	polymyxins	lithium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2> anesthetics </e2> , procainamide, and quinidine.	0	polymyxins	anesthetics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2> procainamide </e2> , and quinidine.	0	polymyxins	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, <e1> polymyxins </e1> , lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2> quinidine </e2> .	0	polymyxins	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1> lincomycin </e1> , <e2> clindamycin </e2> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	lincomycin	clindamycin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1> lincomycin </e1> , clindamycin, <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	lincomycin	colistin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1> lincomycin </e1> , clindamycin, colistin, and <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	lincomycin	sodium colistimethate
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1> lincomycin </e1> , clindamycin, colistin, and sodium colistimethate), <e2> magnesium </e2> salts, lithium, local anesthetics, procainamide, and quinidine.	0	lincomycin	magnesium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1> lincomycin </e1> , clindamycin, colistin, and sodium colistimethate), magnesium salts, <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.	0	lincomycin	lithium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1> lincomycin </e1> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e2> anesthetics </e2> , procainamide, and quinidine.	0	lincomycin	anesthetics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1> lincomycin </e1> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2> procainamide </e2> , and quinidine.	0	lincomycin	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, <e1> lincomycin </e1> , clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2> quinidine </e2> .	0	lincomycin	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1> clindamycin </e1> , <e2> colistin </e2> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	clindamycin	colistin
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1> clindamycin </e1> , colistin, and <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	clindamycin	sodium colistimethate
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1> clindamycin </e1> , colistin, and sodium colistimethate), <e2> magnesium </e2> salts, lithium, local anesthetics, procainamide, and quinidine.	0	clindamycin	magnesium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1> clindamycin </e1> , colistin, and sodium colistimethate), magnesium salts, <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.	0	clindamycin	lithium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1> clindamycin </e1> , colistin, and sodium colistimethate), magnesium salts, lithium, local <e2> anesthetics </e2> , procainamide, and quinidine.	0	clindamycin	anesthetics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1> clindamycin </e1> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2> procainamide </e2> , and quinidine.	0	clindamycin	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, <e1> clindamycin </e1> , colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2> quinidine </e2> .	0	clindamycin	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e1> colistin </e1> , and <e2> sodium colistimethate </e2> ), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	0	colistin	sodium colistimethate
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e1> colistin </e1> , and sodium colistimethate), <e2> magnesium </e2> salts, lithium, local anesthetics, procainamide, and quinidine.	0	colistin	magnesium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e1> colistin </e1> , and sodium colistimethate), magnesium salts, <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.	0	colistin	lithium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e1> colistin </e1> , and sodium colistimethate), magnesium salts, lithium, local <e2> anesthetics </e2> , procainamide, and quinidine.	0	colistin	anesthetics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e1> colistin </e1> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e2> procainamide </e2> , and quinidine.	0	colistin	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, <e1> colistin </e1> , and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and <e2> quinidine </e2> .	0	colistin	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e1> sodium colistimethate </e1> ), <e2> magnesium </e2> salts, lithium, local anesthetics, procainamide, and quinidine.	0	sodium colistimethate	magnesium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e1> sodium colistimethate </e1> ), magnesium salts, <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.	0	sodium colistimethate	lithium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e1> sodium colistimethate </e1> ), magnesium salts, lithium, local <e2> anesthetics </e2> , procainamide, and quinidine.	0	sodium colistimethate	anesthetics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e1> sodium colistimethate </e1> ), magnesium salts, lithium, local anesthetics, <e2> procainamide </e2> , and quinidine.	0	sodium colistimethate	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and <e1> sodium colistimethate </e1> ), magnesium salts, lithium, local anesthetics, procainamide, and <e2> quinidine </e2> .	0	sodium colistimethate	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e1> magnesium </e1> salts, <e2> lithium </e2> , local anesthetics, procainamide, and quinidine.	0	magnesium	lithium
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e1> magnesium </e1> salts, lithium, local <e2> anesthetics </e2> , procainamide, and quinidine.	0	magnesium	anesthetics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e1> magnesium </e1> salts, lithium, local anesthetics, <e2> procainamide </e2> , and quinidine.	0	magnesium	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), <e1> magnesium </e1> salts, lithium, local anesthetics, procainamide, and <e2> quinidine </e2> .	0	magnesium	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e1> lithium </e1> , local <e2> anesthetics </e2> , procainamide, and quinidine.	0	lithium	anesthetics
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e1> lithium </e1> , local anesthetics, <e2> procainamide </e2> , and quinidine.	0	lithium	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, <e1> lithium </e1> , local anesthetics, procainamide, and <e2> quinidine </e2> .	0	lithium	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e1> anesthetics </e1> , <e2> procainamide </e2> , and quinidine.	0	anesthetics	procainamide
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local <e1> anesthetics </e1> , procainamide, and <e2> quinidine </e2> .	0	anesthetics	quinidine
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, <e1> procainamide </e1> , and <e2> quinidine </e2> .	0	procainamide	quinidine
The neuromuscular blocking effect of <e1> MIVACRON </e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e2> contraceptives </e2> , glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	1	MIVACRON	contraceptives
The neuromuscular blocking effect of <e1> MIVACRON </e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, <e2> glucocorticoids </e2> , or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	1	MIVACRON	glucocorticoids
The neuromuscular blocking effect of <e1> MIVACRON </e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain <e2> monoamine oxidase inhibitors </e2> ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	1	MIVACRON	monoamine oxidase inhibitors
The neuromuscular blocking effect of <e1> MIVACRON </e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e2> neuromuscular blocking agents </e2> has been demonstrated in patients chronically administered phenytoin or carbamazepine.	0	MIVACRON	neuromuscular blocking agents
The neuromuscular blocking effect of <e1> MIVACRON </e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered <e2> phenytoin </e2> or carbamazepine.	0	MIVACRON	phenytoin
The neuromuscular blocking effect of <e1> MIVACRON </e1> may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or <e2> carbamazepine </e2> .	0	MIVACRON	carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e1> contraceptives </e1> , <e2> glucocorticoids </e2> , or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	0	contraceptives	glucocorticoids
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e1> contraceptives </e1> , glucocorticoids, or certain <e2> monoamine oxidase inhibitors </e2> ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	0	contraceptives	monoamine oxidase inhibitors
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e1> contraceptives </e1> , glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e2> neuromuscular blocking agents </e2> has been demonstrated in patients chronically administered phenytoin or carbamazepine.	0	contraceptives	neuromuscular blocking agents
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e1> contraceptives </e1> , glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered <e2> phenytoin </e2> or carbamazepine.	0	contraceptives	phenytoin
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral <e1> contraceptives </e1> , glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or <e2> carbamazepine </e2> .	0	contraceptives	carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, <e1> glucocorticoids </e1> , or certain <e2> monoamine oxidase inhibitors </e2> ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine.	0	glucocorticoids	monoamine oxidase inhibitors
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, <e1> glucocorticoids </e1> , or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e2> neuromuscular blocking agents </e2> has been demonstrated in patients chronically administered phenytoin or carbamazepine.	0	glucocorticoids	neuromuscular blocking agents
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, <e1> glucocorticoids </e1> , or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered <e2> phenytoin </e2> or carbamazepine.	0	glucocorticoids	phenytoin
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, <e1> glucocorticoids </e1> , or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or <e2> carbamazepine </e2> .	0	glucocorticoids	carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain <e1> monoamine oxidase inhibitors </e1> ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e2> neuromuscular blocking agents </e2> has been demonstrated in patients chronically administered phenytoin or carbamazepine.	0	monoamine oxidase inhibitors	neuromuscular blocking agents
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain <e1> monoamine oxidase inhibitors </e1> ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered <e2> phenytoin </e2> or carbamazepine.	0	monoamine oxidase inhibitors	phenytoin
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain <e1> monoamine oxidase inhibitors </e1> ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or <e2> carbamazepine </e2> .	0	monoamine oxidase inhibitors	carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e1> neuromuscular blocking agents </e1> has been demonstrated in patients chronically administered <e2> phenytoin </e2> or carbamazepine.	1	neuromuscular blocking agents	phenytoin
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing <e1> neuromuscular blocking agents </e1> has been demonstrated in patients chronically administered phenytoin or <e2> carbamazepine </e2> .	1	neuromuscular blocking agents	carbamazepine
The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered <e1> phenytoin </e1> or <e2> carbamazepine </e2> .	0	phenytoin	carbamazepine
While the effects of chronic <e1> phenytoin </e1> or <e2> carbamazepine </e2> therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.	0	phenytoin	carbamazepine
While the effects of chronic <e1> phenytoin </e1> or carbamazepine therapy on the action of <e2> MIVACRON </e2> are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.	1	phenytoin	MIVACRON
While the effects of chronic phenytoin or <e1> carbamazepine </e1> therapy on the action of <e2> MIVACRON </e2> are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.	1	carbamazepine	MIVACRON
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e2> phenytoin </e2> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	corticosteroids	phenytoin
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e2> carbamazepine </e2> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	corticosteroids	carbamazepine
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e2> antibiotics </e2> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	corticosteroids	antibiotics
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e2> cisplatin </e2> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	corticosteroids	cisplatin
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e2> edrophonium </e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	corticosteroids	edrophonium
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e2> neostigmine </e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	corticosteroids	neostigmine
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e2> polymyxin B </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	corticosteroids	polymyxin B
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e2> bacitracin </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	corticosteroids	bacitracin
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2> anesthetics </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	corticosteroids	anesthetics
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2> procaine </e2> - general anesthetics - succinylcholine or other muscle relaxants	0	corticosteroids	procaine
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> anesthetics </e2> - succinylcholine or other muscle relaxants	0	corticosteroids	anesthetics
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> succinylcholine </e2> or other muscle relaxants	0	corticosteroids	succinylcholine
Some drug interactions are: - birth control pills - <e1> corticosteroids </e1> - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> muscle relaxants </e2>	0	corticosteroids	muscle relaxants
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> phenytoin </e1> or <e2> carbamazepine </e2> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	phenytoin	carbamazepine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> phenytoin </e1> or carbamazepine - certain <e2> antibiotics </e2> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	phenytoin	antibiotics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> phenytoin </e1> or carbamazepine - certain antibiotics given by injection - <e2> cisplatin </e2> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	phenytoin	cisplatin
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> phenytoin </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - <e2> edrophonium </e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	phenytoin	edrophonium
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> phenytoin </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e2> neostigmine </e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	phenytoin	neostigmine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> phenytoin </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e2> polymyxin B </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	phenytoin	polymyxin B
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> phenytoin </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e2> bacitracin </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	phenytoin	bacitracin
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> phenytoin </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2> anesthetics </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	phenytoin	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> phenytoin </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2> procaine </e2> - general anesthetics - succinylcholine or other muscle relaxants	0	phenytoin	procaine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> phenytoin </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> anesthetics </e2> - succinylcholine or other muscle relaxants	0	phenytoin	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> phenytoin </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> succinylcholine </e2> or other muscle relaxants	0	phenytoin	succinylcholine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as <e1> phenytoin </e1> or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> muscle relaxants </e2>	0	phenytoin	muscle relaxants
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> carbamazepine </e1> - certain <e2> antibiotics </e2> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	carbamazepine	antibiotics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> carbamazepine </e1> - certain antibiotics given by injection - <e2> cisplatin </e2> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	carbamazepine	cisplatin
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> carbamazepine </e1> - certain antibiotics given by injection - cisplatin - <e2> edrophonium </e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	carbamazepine	edrophonium
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> carbamazepine </e1> - certain antibiotics given by injection - cisplatin - edrophonium - <e2> neostigmine </e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	carbamazepine	neostigmine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> carbamazepine </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e2> polymyxin B </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	carbamazepine	polymyxin B
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> carbamazepine </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e2> bacitracin </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	carbamazepine	bacitracin
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> carbamazepine </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2> anesthetics </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	carbamazepine	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> carbamazepine </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2> procaine </e2> - general anesthetics - succinylcholine or other muscle relaxants	0	carbamazepine	procaine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> carbamazepine </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> anesthetics </e2> - succinylcholine or other muscle relaxants	0	carbamazepine	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> carbamazepine </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> succinylcholine </e2> or other muscle relaxants	0	carbamazepine	succinylcholine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or <e1> carbamazepine </e1> - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> muscle relaxants </e2>	0	carbamazepine	muscle relaxants
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> antibiotics </e1> given by injection - <e2> cisplatin </e2> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	antibiotics	cisplatin
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> antibiotics </e1> given by injection - cisplatin - <e2> edrophonium </e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	antibiotics	edrophonium
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> antibiotics </e1> given by injection - cisplatin - edrophonium - <e2> neostigmine </e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	antibiotics	neostigmine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> antibiotics </e1> given by injection - cisplatin - edrophonium - neostigmine - <e2> polymyxin B </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	antibiotics	polymyxin B
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> antibiotics </e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e2> bacitracin </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	antibiotics	bacitracin
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> antibiotics </e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2> anesthetics </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	antibiotics	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> antibiotics </e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2> procaine </e2> - general anesthetics - succinylcholine or other muscle relaxants	0	antibiotics	procaine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> antibiotics </e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> anesthetics </e2> - succinylcholine or other muscle relaxants	0	antibiotics	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> antibiotics </e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> succinylcholine </e2> or other muscle relaxants	0	antibiotics	succinylcholine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain <e1> antibiotics </e1> given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> muscle relaxants </e2>	0	antibiotics	muscle relaxants
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> cisplatin </e1> - <e2> edrophonium </e2> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	cisplatin	edrophonium
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> cisplatin </e1> - edrophonium - <e2> neostigmine </e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	cisplatin	neostigmine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> cisplatin </e1> - edrophonium - neostigmine - <e2> polymyxin B </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	cisplatin	polymyxin B
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> cisplatin </e1> - edrophonium - neostigmine - polymyxin B or <e2> bacitracin </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	cisplatin	bacitracin
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> cisplatin </e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local <e2> anesthetics </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	cisplatin	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> cisplatin </e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2> procaine </e2> - general anesthetics - succinylcholine or other muscle relaxants	0	cisplatin	procaine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> cisplatin </e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> anesthetics </e2> - succinylcholine or other muscle relaxants	0	cisplatin	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> cisplatin </e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> succinylcholine </e2> or other muscle relaxants	0	cisplatin	succinylcholine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - <e1> cisplatin </e1> - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> muscle relaxants </e2>	0	cisplatin	muscle relaxants
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> edrophonium </e1> - <e2> neostigmine </e2> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	edrophonium	neostigmine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> edrophonium </e1> - neostigmine - <e2> polymyxin B </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	edrophonium	polymyxin B
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> edrophonium </e1> - neostigmine - polymyxin B or <e2> bacitracin </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	edrophonium	bacitracin
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> edrophonium </e1> - neostigmine - polymyxin B or bacitracin - local <e2> anesthetics </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	edrophonium	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> edrophonium </e1> - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e2> procaine </e2> - general anesthetics - succinylcholine or other muscle relaxants	0	edrophonium	procaine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> edrophonium </e1> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> anesthetics </e2> - succinylcholine or other muscle relaxants	0	edrophonium	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> edrophonium </e1> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> succinylcholine </e2> or other muscle relaxants	0	edrophonium	succinylcholine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - <e1> edrophonium </e1> - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> muscle relaxants </e2>	0	edrophonium	muscle relaxants
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> neostigmine </e1> - <e2> polymyxin B </e2> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	neostigmine	polymyxin B
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> neostigmine </e1> - polymyxin B or <e2> bacitracin </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	neostigmine	bacitracin
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> neostigmine </e1> - polymyxin B or bacitracin - local <e2> anesthetics </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	neostigmine	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> neostigmine </e1> - polymyxin B or bacitracin - local anesthetics such as <e2> procaine </e2> - general anesthetics - succinylcholine or other muscle relaxants	0	neostigmine	procaine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> neostigmine </e1> - polymyxin B or bacitracin - local anesthetics such as procaine - general <e2> anesthetics </e2> - succinylcholine or other muscle relaxants	0	neostigmine	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> neostigmine </e1> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> succinylcholine </e2> or other muscle relaxants	0	neostigmine	succinylcholine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - <e1> neostigmine </e1> - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> muscle relaxants </e2>	0	neostigmine	muscle relaxants
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1> polymyxin B </e1> or <e2> bacitracin </e2> - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	polymyxin B	bacitracin
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1> polymyxin B </e1> or bacitracin - local <e2> anesthetics </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	polymyxin B	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1> polymyxin B </e1> or bacitracin - local anesthetics such as <e2> procaine </e2> - general anesthetics - succinylcholine or other muscle relaxants	0	polymyxin B	procaine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1> polymyxin B </e1> or bacitracin - local anesthetics such as procaine - general <e2> anesthetics </e2> - succinylcholine or other muscle relaxants	0	polymyxin B	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1> polymyxin B </e1> or bacitracin - local anesthetics such as procaine - general anesthetics - <e2> succinylcholine </e2> or other muscle relaxants	0	polymyxin B	succinylcholine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - <e1> polymyxin B </e1> or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> muscle relaxants </e2>	0	polymyxin B	muscle relaxants
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1> bacitracin </e1> - local <e2> anesthetics </e2> such as procaine - general anesthetics - succinylcholine or other muscle relaxants	0	bacitracin	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1> bacitracin </e1> - local anesthetics such as <e2> procaine </e2> - general anesthetics - succinylcholine or other muscle relaxants	0	bacitracin	procaine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1> bacitracin </e1> - local anesthetics such as procaine - general <e2> anesthetics </e2> - succinylcholine or other muscle relaxants	0	bacitracin	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1> bacitracin </e1> - local anesthetics such as procaine - general anesthetics - <e2> succinylcholine </e2> or other muscle relaxants	0	bacitracin	succinylcholine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or <e1> bacitracin </e1> - local anesthetics such as procaine - general anesthetics - succinylcholine or other <e2> muscle relaxants </e2>	0	bacitracin	muscle relaxants
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e1> anesthetics </e1> such as <e2> procaine </e2> - general anesthetics - succinylcholine or other muscle relaxants	0	anesthetics	procaine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e1> anesthetics </e1> such as procaine - general anesthetics - <e2> succinylcholine </e2> or other muscle relaxants	0	anesthetics	succinylcholine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local <e1> anesthetics </e1> such as procaine - general anesthetics - succinylcholine or other <e2> muscle relaxants </e2>	0	anesthetics	muscle relaxants
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e1> procaine </e1> - general <e2> anesthetics </e2> - succinylcholine or other muscle relaxants	0	procaine	anesthetics
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e1> procaine </e1> - general anesthetics - <e2> succinylcholine </e2> or other muscle relaxants	0	procaine	succinylcholine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as <e1> procaine </e1> - general anesthetics - succinylcholine or other <e2> muscle relaxants </e2>	0	procaine	muscle relaxants
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e1> anesthetics </e1> - <e2> succinylcholine </e2> or other muscle relaxants	0	anesthetics	succinylcholine
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general <e1> anesthetics </e1> - succinylcholine or other <e2> muscle relaxants </e2>	0	anesthetics	muscle relaxants
Some drug interactions are: - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - <e1> succinylcholine </e1> or other <e2> muscle relaxants </e2>	0	succinylcholine	muscle relaxants
Administration of <e1> valproic acid </e1> decreases oral clearance of <e2> temozolomide </e2> by about 5%.	1	valproic acid	temozolomide
<e1> Cholestyramine </e1> : Concomitant cholestyramine administration decreased the mean AUC of total <e2> ezetimibe </e2> approximately 55%.	0	Cholestyramine	ezetimibe
Cholestyramine: Concomitant <e1> cholestyramine </e1> administration decreased the mean AUC of total <e2> ezetimibe </e2> approximately 55%.	1	cholestyramine	ezetimibe
The incremental LDL-C reduction due to adding <e1> ezetimibe </e1> to <e2> cholestyramine </e2> may be reduced by this interaction.	1	ezetimibe	cholestyramine
<e1> Fibrates </e1> : The safety and effectiveness of <e2> ezetimibe </e2> administered with fibrates have not been established.	0	Fibrates	ezetimibe
Fibrates: The safety and effectiveness of <e1> ezetimibe </e1> administered with <e2> fibrates </e2> have not been established.	0	ezetimibe	fibrates
Co-administration of <e1> ZETIA </e1> with <e2> fibrates </e2> is not recommended until use in patients is studied.	0	ZETIA	fibrates
<e1> Fenofibrate </e1> : In a pharmacokinetic study, concomitant fenofibrate administration increased total <e2> ezetimibe </e2> concentrations approximately 1.5-fold.	0	Fenofibrate	ezetimibe
Fenofibrate: In a pharmacokinetic study, concomitant <e1> fenofibrate </e1> administration increased total <e2> ezetimibe </e2> concentrations approximately 1.5-fold.	1	fenofibrate	ezetimibe
<e1> Gemfibrozil </e1> : In a pharmacokinetic study, concomitant gemfibrozil administration increased total <e2> ezetimibe </e2> concentrations approximately 1.7-fold.	0	Gemfibrozil	ezetimibe
Gemfibrozil: In a pharmacokinetic study, concomitant <e1> gemfibrozil </e1> administration increased total <e2> ezetimibe </e2> concentrations approximately 1.7-fold.	0	gemfibrozil	ezetimibe
<e1> HMG-CoA reductase inhibitors </e1> : No clinically significant pharmacokinetic interactions were seen when <e2> ezetimibe </e2> was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin.	0	HMG-CoA reductase inhibitors	ezetimibe
<e1> HMG-CoA reductase inhibitors </e1> : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e2> atorvastatin </e2> , simvastatin, pravastatin, lovastatin, or fluvastatin.	0	HMG-CoA reductase inhibitors	atorvastatin
<e1> HMG-CoA reductase inhibitors </e1> : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, <e2> simvastatin </e2> , pravastatin, lovastatin, or fluvastatin.	0	HMG-CoA reductase inhibitors	simvastatin
<e1> HMG-CoA reductase inhibitors </e1> : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, <e2> pravastatin </e2> , lovastatin, or fluvastatin.	0	HMG-CoA reductase inhibitors	pravastatin
<e1> HMG-CoA reductase inhibitors </e1> : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, <e2> lovastatin </e2> , or fluvastatin.	0	HMG-CoA reductase inhibitors	lovastatin
<e1> HMG-CoA reductase inhibitors </e1> : No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or <e2> fluvastatin </e2> .	0	HMG-CoA reductase inhibitors	fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when <e1> ezetimibe </e1> was co-administered with <e2> atorvastatin </e2> , simvastatin, pravastatin, lovastatin, or fluvastatin.	0	ezetimibe	atorvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when <e1> ezetimibe </e1> was co-administered with atorvastatin, <e2> simvastatin </e2> , pravastatin, lovastatin, or fluvastatin.	0	ezetimibe	simvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when <e1> ezetimibe </e1> was co-administered with atorvastatin, simvastatin, <e2> pravastatin </e2> , lovastatin, or fluvastatin.	0	ezetimibe	pravastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when <e1> ezetimibe </e1> was co-administered with atorvastatin, simvastatin, pravastatin, <e2> lovastatin </e2> , or fluvastatin.	0	ezetimibe	lovastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when <e1> ezetimibe </e1> was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or <e2> fluvastatin </e2> .	0	ezetimibe	fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e1> atorvastatin </e1> , <e2> simvastatin </e2> , pravastatin, lovastatin, or fluvastatin.	0	atorvastatin	simvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e1> atorvastatin </e1> , simvastatin, <e2> pravastatin </e2> , lovastatin, or fluvastatin.	0	atorvastatin	pravastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e1> atorvastatin </e1> , simvastatin, pravastatin, <e2> lovastatin </e2> , or fluvastatin.	0	atorvastatin	lovastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with <e1> atorvastatin </e1> , simvastatin, pravastatin, lovastatin, or <e2> fluvastatin </e2> .	0	atorvastatin	fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, <e1> simvastatin </e1> , <e2> pravastatin </e2> , lovastatin, or fluvastatin.	0	simvastatin	pravastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, <e1> simvastatin </e1> , pravastatin, <e2> lovastatin </e2> , or fluvastatin.	0	simvastatin	lovastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, <e1> simvastatin </e1> , pravastatin, lovastatin, or <e2> fluvastatin </e2> .	0	simvastatin	fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, <e1> pravastatin </e1> , <e2> lovastatin </e2> , or fluvastatin.	0	pravastatin	lovastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, <e1> pravastatin </e1> , lovastatin, or <e2> fluvastatin </e2> .	0	pravastatin	fluvastatin
HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, <e1> lovastatin </e1> , or <e2> fluvastatin </e2> .	0	lovastatin	fluvastatin
<e1> Cyclosporine </e1> : The total <e2> ezetimibe </e2> level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine.	0	Cyclosporine	ezetimibe
Cyclosporine: The total <e1> ezetimibe </e1> level increased 12-fold in one renal transplant patient receiving multiple medications, including <e2> cyclosporine </e2> .	1	ezetimibe	cyclosporine
Patients who take both <e1> ezetimibe </e1> and <e2> cyclosporine </e2> should be carefully monitored.	0	ezetimibe	cyclosporine
Multiple dose studies of <e1> ezetimibe </e1> given in combination with <e2> HMG-CoA reductase inhibitors </e2> (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.	0	ezetimibe	HMG-CoA reductase inhibitors
Multiple dose studies of <e1> ezetimibe </e1> given in combination with HMG-CoA reductase inhibitors ( <e2> statins </e2> ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.	0	ezetimibe	statins
Multiple dose studies of ezetimibe given in combination with <e1> HMG-CoA reductase inhibitors </e1> ( <e2> statins </e2> ) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures.	0	HMG-CoA reductase inhibitors	statins
Multiple dose studies of ezetimibe given in combination with <e1> HMG-CoA reductase inhibitors </e1> (statins) in rats and rabbits during organogenesis result in higher <e2> ezetimibe </e2> and statin exposures.	0	HMG-CoA reductase inhibitors	ezetimibe
Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors ( <e1> statins </e1> ) in rats and rabbits during organogenesis result in higher <e2> ezetimibe </e2> and statin exposures.	0	statins	ezetimibe
When <e1> ZETIA </e1> is administered with an <e2> HMG-CoA reductase inhibitor </e2> in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor.	0	ZETIA	HMG-CoA reductase inhibitor
When <e1> ZETIA </e1> is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the <e2> HMG-CoA reductase inhibitor </e2> .	0	ZETIA	HMG-CoA reductase inhibitor
Patients receiving <e1> antibiotics </e1> and <e2> sulfonamides </e2> generally should not be treated with ganglion blockers.	0	antibiotics	sulfonamides
Patients receiving <e1> antibiotics </e1> and sulfonamides generally should not be treated with <e2> ganglion blockers </e2> .	0	antibiotics	ganglion blockers
Patients receiving antibiotics and <e1> sulfonamides </e1> generally should not be treated with <e2> ganglion blockers </e2> .	0	sulfonamides	ganglion blockers
The action of <e1> Mecamylamine </e1> may be potentiated by anesthesia, other <e2> antihypertensive drugs </e2> and alcohol.	1	Mecamylamine	antihypertensive drugs
The action of <e1> Mecamylamine </e1> may be potentiated by anesthesia, other antihypertensive drugs and <e2> alcohol </e2> .	1	Mecamylamine	alcohol
The action of Mecamylamine may be potentiated by anesthesia, other <e1> antihypertensive drugs </e1> and <e2> alcohol </e2> .	0	antihypertensive drugs	alcohol
<e1> ASPIRIN </e1> AND OTHER <e2> SALICYLATE DRUGS </e2> WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.	0	ASPIRIN	SALICYLATE DRUGS
<e1> ASPIRIN </e1> AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO <e2> DISALCID </e2> AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.	1	ASPIRIN	DISALCID
<e1> ASPIRIN </e1> AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF <e2> SALICYLIC ACID </e2> TO TOXIC LEVELS.	0	ASPIRIN	SALICYLIC ACID
ASPIRIN AND OTHER <e1> SALICYLATE DRUGS </e1> WILL BE ADDITIVE TO <e2> DISALCID </e2> AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS.	1	SALICYLATE DRUGS	DISALCID
ASPIRIN AND OTHER <e1> SALICYLATE DRUGS </e1> WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF <e2> SALICYLIC ACID </e2> TO TOXIC LEVELS.	0	SALICYLATE DRUGS	SALICYLIC ACID
ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO <e1> DISALCID </e1> AND MAY INCREASE PLASMA CONCENTRATIONS OF <e2> SALICYLIC ACID </e2> TO TOXIC LEVELS.	0	DISALCID	SALICYLIC ACID
<e1> Salicylates </e1> given concomitantly with <e2> anticoagulant drugs </e2> may predispose to systemic bleeding.	1	Salicylates	anticoagulant drugs
<e1> Salicylates </e1> may enhance the hypoglycemic effect of oral <e2> antidiabetic drugs </e2> of the sulfonylurea class.	1	Salicylates	antidiabetic drugs
<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably <e2> penicillin </e2> , thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	1	Salicylate	penicillin
<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, <e2> thiopental </e2> , thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	1	Salicylate	thiopental
<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e2> thyroxine </e2> , triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	1	Salicylate	thyroxine
<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e2> triiodothyronine </e2> , phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	1	Salicylate	triiodothyronine
<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e2> phenytoin </e2> , sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	1	Salicylate	phenytoin
<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, <e2> sulfinpyrazone </e2> , naproxen, warfarin, methotrexate, and possibly corticosteroids.	1	Salicylate	sulfinpyrazone
<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids.	1	Salicylate	naproxen
<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e2> warfarin </e2> , methotrexate, and possibly corticosteroids.	1	Salicylate	warfarin
<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, <e2> methotrexate </e2> , and possibly corticosteroids.	1	Salicylate	methotrexate
<e1> Salicylate </e1> competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2> corticosteroids </e2> .	1	Salicylate	corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably <e1> penicillin </e1> , <e2> thiopental </e2> , thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	penicillin	thiopental
Salicylate competes with a number of drugs for protein binding sites, notably <e1> penicillin </e1> , thiopental, <e2> thyroxine </e2> , triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	penicillin	thyroxine
Salicylate competes with a number of drugs for protein binding sites, notably <e1> penicillin </e1> , thiopental, thyroxine, <e2> triiodothyronine </e2> , phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	penicillin	triiodothyronine
Salicylate competes with a number of drugs for protein binding sites, notably <e1> penicillin </e1> , thiopental, thyroxine, triiodothyronine, <e2> phenytoin </e2> , sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	penicillin	phenytoin
Salicylate competes with a number of drugs for protein binding sites, notably <e1> penicillin </e1> , thiopental, thyroxine, triiodothyronine, phenytoin, <e2> sulfinpyrazone </e2> , naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	penicillin	sulfinpyrazone
Salicylate competes with a number of drugs for protein binding sites, notably <e1> penicillin </e1> , thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids.	0	penicillin	naproxen
Salicylate competes with a number of drugs for protein binding sites, notably <e1> penicillin </e1> , thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e2> warfarin </e2> , methotrexate, and possibly corticosteroids.	0	penicillin	warfarin
Salicylate competes with a number of drugs for protein binding sites, notably <e1> penicillin </e1> , thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, <e2> methotrexate </e2> , and possibly corticosteroids.	0	penicillin	methotrexate
Salicylate competes with a number of drugs for protein binding sites, notably <e1> penicillin </e1> , thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2> corticosteroids </e2> .	0	penicillin	corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1> thiopental </e1> , <e2> thyroxine </e2> , triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	thiopental	thyroxine
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1> thiopental </e1> , thyroxine, <e2> triiodothyronine </e2> , phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	thiopental	triiodothyronine
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1> thiopental </e1> , thyroxine, triiodothyronine, <e2> phenytoin </e2> , sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	thiopental	phenytoin
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1> thiopental </e1> , thyroxine, triiodothyronine, phenytoin, <e2> sulfinpyrazone </e2> , naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	thiopental	sulfinpyrazone
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1> thiopental </e1> , thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids.	0	thiopental	naproxen
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1> thiopental </e1> , thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e2> warfarin </e2> , methotrexate, and possibly corticosteroids.	0	thiopental	warfarin
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1> thiopental </e1> , thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, <e2> methotrexate </e2> , and possibly corticosteroids.	0	thiopental	methotrexate
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, <e1> thiopental </e1> , thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2> corticosteroids </e2> .	0	thiopental	corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1> thyroxine </e1> , <e2> triiodothyronine </e2> , phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	thyroxine	triiodothyronine
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1> thyroxine </e1> , triiodothyronine, <e2> phenytoin </e2> , sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	thyroxine	phenytoin
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1> thyroxine </e1> , triiodothyronine, phenytoin, <e2> sulfinpyrazone </e2> , naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	thyroxine	sulfinpyrazone
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1> thyroxine </e1> , triiodothyronine, phenytoin, sulfinpyrazone, <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids.	0	thyroxine	naproxen
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1> thyroxine </e1> , triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e2> warfarin </e2> , methotrexate, and possibly corticosteroids.	0	thyroxine	warfarin
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1> thyroxine </e1> , triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, <e2> methotrexate </e2> , and possibly corticosteroids.	0	thyroxine	methotrexate
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, <e1> thyroxine </e1> , triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2> corticosteroids </e2> .	0	thyroxine	corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e1> triiodothyronine </e1> , <e2> phenytoin </e2> , sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	triiodothyronine	phenytoin
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e1> triiodothyronine </e1> , phenytoin, <e2> sulfinpyrazone </e2> , naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	triiodothyronine	sulfinpyrazone
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e1> triiodothyronine </e1> , phenytoin, sulfinpyrazone, <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids.	0	triiodothyronine	naproxen
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e1> triiodothyronine </e1> , phenytoin, sulfinpyrazone, naproxen, <e2> warfarin </e2> , methotrexate, and possibly corticosteroids.	0	triiodothyronine	warfarin
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e1> triiodothyronine </e1> , phenytoin, sulfinpyrazone, naproxen, warfarin, <e2> methotrexate </e2> , and possibly corticosteroids.	0	triiodothyronine	methotrexate
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, <e1> triiodothyronine </e1> , phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2> corticosteroids </e2> .	0	triiodothyronine	corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e1> phenytoin </e1> , <e2> sulfinpyrazone </e2> , naproxen, warfarin, methotrexate, and possibly corticosteroids.	0	phenytoin	sulfinpyrazone
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e1> phenytoin </e1> , sulfinpyrazone, <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids.	0	phenytoin	naproxen
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e1> phenytoin </e1> , sulfinpyrazone, naproxen, <e2> warfarin </e2> , methotrexate, and possibly corticosteroids.	0	phenytoin	warfarin
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e1> phenytoin </e1> , sulfinpyrazone, naproxen, warfarin, <e2> methotrexate </e2> , and possibly corticosteroids.	0	phenytoin	methotrexate
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, <e1> phenytoin </e1> , sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly <e2> corticosteroids </e2> .	0	phenytoin	corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, <e1> sulfinpyrazone </e1> , <e2> naproxen </e2> , warfarin, methotrexate, and possibly corticosteroids.	0	sulfinpyrazone	naproxen
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, <e1> sulfinpyrazone </e1> , naproxen, <e2> warfarin </e2> , methotrexate, and possibly corticosteroids.	0	sulfinpyrazone	warfarin
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, <e1> sulfinpyrazone </e1> , naproxen, warfarin, <e2> methotrexate </e2> , and possibly corticosteroids.	0	sulfinpyrazone	methotrexate
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, <e1> sulfinpyrazone </e1> , naproxen, warfarin, methotrexate, and possibly <e2> corticosteroids </e2> .	0	sulfinpyrazone	corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e1> naproxen </e1> , <e2> warfarin </e2> , methotrexate, and possibly corticosteroids.	0	naproxen	warfarin
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e1> naproxen </e1> , warfarin, <e2> methotrexate </e2> , and possibly corticosteroids.	0	naproxen	methotrexate
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, <e1> naproxen </e1> , warfarin, methotrexate, and possibly <e2> corticosteroids </e2> .	0	naproxen	corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e1> warfarin </e1> , <e2> methotrexate </e2> , and possibly corticosteroids.	0	warfarin	methotrexate
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, <e1> warfarin </e1> , methotrexate, and possibly <e2> corticosteroids </e2> .	0	warfarin	corticosteroids
Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, <e1> methotrexate </e1> , and possibly <e2> corticosteroids </e2> .	0	methotrexate	corticosteroids
patients receiving <e1> lithium </e1> and <e2> Neulasta </e2> should have more frequent monitoring of neutrophil counts.	0	lithium	Neulasta
<e1> Triprolidine </e1> may enhance the sedative effects of <e2> central nervous system depressants </e2> including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	1	Triprolidine	central nervous system depressants
<e1> Triprolidine </e1> may enhance the sedative effects of central nervous system depressants including <e2> alcohol </e2> , barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	1	Triprolidine	alcohol
<e1> Triprolidine </e1> may enhance the sedative effects of central nervous system depressants including alcohol, <e2> barbiturates </e2> , hypnotics, narcotic analgesics, sedatives, and tranquillisers.	1	Triprolidine	barbiturates
<e1> Triprolidine </e1> may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, <e2> hypnotics </e2> , narcotic analgesics, sedatives, and tranquillisers.	1	Triprolidine	hypnotics
<e1> Triprolidine </e1> may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, <e2> narcotic analgesics </e2> , sedatives, and tranquillisers.	1	Triprolidine	narcotic analgesics
<e1> Triprolidine </e1> may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, <e2> sedatives </e2> , and tranquillisers.	1	Triprolidine	sedatives
<e1> Triprolidine </e1> may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and <e2> tranquillisers </e2> .	1	Triprolidine	tranquillisers
Triprolidine may enhance the sedative effects of <e1> central nervous system depressants </e1> including <e2> alcohol </e2> , barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.	0	central nervous system depressants	alcohol
Triprolidine may enhance the sedative effects of <e1> central nervous system depressants </e1> including alcohol, <e2> barbiturates </e2> , hypnotics, narcotic analgesics, sedatives, and tranquillisers.	0	central nervous system depressants	barbiturates
Triprolidine may enhance the sedative effects of <e1> central nervous system depressants </e1> including alcohol, barbiturates, <e2> hypnotics </e2> , narcotic analgesics, sedatives, and tranquillisers.	0	central nervous system depressants	hypnotics
Triprolidine may enhance the sedative effects of <e1> central nervous system depressants </e1> including alcohol, barbiturates, hypnotics, <e2> narcotic analgesics </e2> , sedatives, and tranquillisers.	0	central nervous system depressants	narcotic analgesics
Triprolidine may enhance the sedative effects of <e1> central nervous system depressants </e1> including alcohol, barbiturates, hypnotics, narcotic analgesics, <e2> sedatives </e2> , and tranquillisers.	0	central nervous system depressants	sedatives
Triprolidine may enhance the sedative effects of <e1> central nervous system depressants </e1> including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and <e2> tranquillisers </e2> .	0	central nervous system depressants	tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including <e1> alcohol </e1> , <e2> barbiturates </e2> , hypnotics, narcotic analgesics, sedatives, and tranquillisers.	0	alcohol	barbiturates
Triprolidine may enhance the sedative effects of central nervous system depressants including <e1> alcohol </e1> , barbiturates, <e2> hypnotics </e2> , narcotic analgesics, sedatives, and tranquillisers.	0	alcohol	hypnotics
Triprolidine may enhance the sedative effects of central nervous system depressants including <e1> alcohol </e1> , barbiturates, hypnotics, <e2> narcotic analgesics </e2> , sedatives, and tranquillisers.	0	alcohol	narcotic analgesics
Triprolidine may enhance the sedative effects of central nervous system depressants including <e1> alcohol </e1> , barbiturates, hypnotics, narcotic analgesics, <e2> sedatives </e2> , and tranquillisers.	0	alcohol	sedatives
Triprolidine may enhance the sedative effects of central nervous system depressants including <e1> alcohol </e1> , barbiturates, hypnotics, narcotic analgesics, sedatives, and <e2> tranquillisers </e2> .	0	alcohol	tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, <e1> barbiturates </e1> , <e2> hypnotics </e2> , narcotic analgesics, sedatives, and tranquillisers.	0	barbiturates	hypnotics
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, <e1> barbiturates </e1> , hypnotics, <e2> narcotic analgesics </e2> , sedatives, and tranquillisers.	0	barbiturates	narcotic analgesics
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, <e1> barbiturates </e1> , hypnotics, narcotic analgesics, <e2> sedatives </e2> , and tranquillisers.	0	barbiturates	sedatives
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, <e1> barbiturates </e1> , hypnotics, narcotic analgesics, sedatives, and <e2> tranquillisers </e2> .	0	barbiturates	tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, <e1> hypnotics </e1> , <e2> narcotic analgesics </e2> , sedatives, and tranquillisers.	0	hypnotics	narcotic analgesics
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, <e1> hypnotics </e1> , narcotic analgesics, <e2> sedatives </e2> , and tranquillisers.	0	hypnotics	sedatives
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, <e1> hypnotics </e1> , narcotic analgesics, sedatives, and <e2> tranquillisers </e2> .	0	hypnotics	tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, <e1> narcotic analgesics </e1> , <e2> sedatives </e2> , and tranquillisers.	0	narcotic analgesics	sedatives
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, <e1> narcotic analgesics </e1> , sedatives, and <e2> tranquillisers </e2> .	0	narcotic analgesics	tranquillisers
Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, <e1> sedatives </e1> , and <e2> tranquillisers </e2> .	0	sedatives	tranquillisers
The effects of <e1> anticholinergic drugs </e1> , such as <e2> atropine </e2> and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine.	0	anticholinergic drugs	atropine
The effects of <e1> anticholinergic drugs </e1> , such as atropine and <e2> tricyclic antidepressants </e2> may be enhanced by the concomitant administration of triprolidine.	0	anticholinergic drugs	tricyclic antidepressants
The effects of <e1> anticholinergic drugs </e1> , such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of <e2> triprolidine </e2> .	1	anticholinergic drugs	triprolidine
The effects of anticholinergic drugs, such as <e1> atropine </e1> and <e2> tricyclic antidepressants </e2> may be enhanced by the concomitant administration of triprolidine.	0	atropine	tricyclic antidepressants
The effects of anticholinergic drugs, such as <e1> atropine </e1> and tricyclic antidepressants may be enhanced by the concomitant administration of <e2> triprolidine </e2> .	1	atropine	triprolidine
The effects of anticholinergic drugs, such as atropine and <e1> tricyclic antidepressants </e1> may be enhanced by the concomitant administration of <e2> triprolidine </e2> .	1	tricyclic antidepressants	triprolidine
<e1> AGGRASTAT </e1> has been studied on a background of <e2> aspirin </e2> and heparin.	0	AGGRASTAT	aspirin
<e1> AGGRASTAT </e1> has been studied on a background of aspirin and <e2> heparin </e2> .	0	AGGRASTAT	heparin
AGGRASTAT has been studied on a background of <e1> aspirin </e1> and <e2> heparin </e2> .	0	aspirin	heparin
The use of <e1> AGGRASTAT </e1> , in combination with <e2> heparin </e2> and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see	1	AGGRASTAT	heparin
The use of <e1> AGGRASTAT </e1> , in combination with heparin and <e2> aspirin </e2> , has been associated with an increase in bleeding compared to heparin and aspirin alone (see	1	AGGRASTAT	aspirin
The use of <e1> AGGRASTAT </e1> , in combination with heparin and aspirin, has been associated with an increase in bleeding compared to <e2> heparin </e2> and aspirin alone (see	0	AGGRASTAT	heparin
The use of <e1> AGGRASTAT </e1> , in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and <e2> aspirin </e2> alone (see	0	AGGRASTAT	aspirin
The use of AGGRASTAT, in combination with <e1> heparin </e1> and <e2> aspirin </e2> , has been associated with an increase in bleeding compared to heparin and aspirin alone (see	0	heparin	aspirin
The use of AGGRASTAT, in combination with <e1> heparin </e1> and aspirin, has been associated with an increase in bleeding compared to heparin and <e2> aspirin </e2> alone (see	0	heparin	aspirin
The use of AGGRASTAT, in combination with heparin and <e1> aspirin </e1> , has been associated with an increase in bleeding compared to <e2> heparin </e2> and aspirin alone (see	0	aspirin	heparin
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to <e1> heparin </e1> and <e2> aspirin </e2> alone (see	0	heparin	aspirin
In clinical studies of <e1> TOBI </e1> , patients taking TOBI concomitantly with <e2> dornase alfa </e2> (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	TOBI	dornase alfa
In clinical studies of <e1> TOBI </e1> , patients taking TOBI concomitantly with dornase alfa ( <e2> PULMOZYME </e2> , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	TOBI	PULMOZYME
In clinical studies of <e1> TOBI </e1> , patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), <e2> (beta)-agonists </e2> , inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	TOBI	(beta)-agonists
In clinical studies of <e1> TOBI </e1> , patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled <e2> corticosteroids </e2> , other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	TOBI	corticosteroids
In clinical studies of <e1> TOBI </e1> , patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other <e2> anti-pseudomonal antibiotics </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	TOBI	anti-pseudomonal antibiotics
In clinical studies of <e1> TOBI </e1> , patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral <e2> aminoglycosides </e2> demonstrated adverse experience profiles similar to the study population as a whole.	0	TOBI	aminoglycosides
In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with <e2> dornase alfa </e2> (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	1	TOBI	dornase alfa
In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with dornase alfa ( <e2> PULMOZYME </e2> , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	1	TOBI	PULMOZYME
In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with dornase alfa (PULMOZYME , Genentech), <e2> (beta)-agonists </e2> , inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	1	TOBI	(beta)-agonists
In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled <e2> corticosteroids </e2> , other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	1	TOBI	corticosteroids
In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other <e2> anti-pseudomonal antibiotics </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	1	TOBI	anti-pseudomonal antibiotics
In clinical studies of TOBI, patients taking <e1> TOBI </e1> concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral <e2> aminoglycosides </e2> demonstrated adverse experience profiles similar to the study population as a whole.	1	TOBI	aminoglycosides
In clinical studies of TOBI, patients taking TOBI concomitantly with <e1> dornase alfa </e1> ( <e2> PULMOZYME </e2> , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	dornase alfa	PULMOZYME
In clinical studies of TOBI, patients taking TOBI concomitantly with <e1> dornase alfa </e1> (PULMOZYME , Genentech), <e2> (beta)-agonists </e2> , inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	dornase alfa	(beta)-agonists
In clinical studies of TOBI, patients taking TOBI concomitantly with <e1> dornase alfa </e1> (PULMOZYME , Genentech), (beta)-agonists, inhaled <e2> corticosteroids </e2> , other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	dornase alfa	corticosteroids
In clinical studies of TOBI, patients taking TOBI concomitantly with <e1> dornase alfa </e1> (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other <e2> anti-pseudomonal antibiotics </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	dornase alfa	anti-pseudomonal antibiotics
In clinical studies of TOBI, patients taking TOBI concomitantly with <e1> dornase alfa </e1> (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral <e2> aminoglycosides </e2> demonstrated adverse experience profiles similar to the study population as a whole.	0	dornase alfa	aminoglycosides
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa ( <e1> PULMOZYME </e1> , Genentech), <e2> (beta)-agonists </e2> , inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	PULMOZYME	(beta)-agonists
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa ( <e1> PULMOZYME </e1> , Genentech), (beta)-agonists, inhaled <e2> corticosteroids </e2> , other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	PULMOZYME	corticosteroids
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa ( <e1> PULMOZYME </e1> , Genentech), (beta)-agonists, inhaled corticosteroids, other <e2> anti-pseudomonal antibiotics </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	PULMOZYME	anti-pseudomonal antibiotics
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa ( <e1> PULMOZYME </e1> , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral <e2> aminoglycosides </e2> demonstrated adverse experience profiles similar to the study population as a whole.	0	PULMOZYME	aminoglycosides
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), <e1> (beta)-agonists </e1> , inhaled <e2> corticosteroids </e2> , other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	(beta)-agonists	corticosteroids
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), <e1> (beta)-agonists </e1> , inhaled corticosteroids, other <e2> anti-pseudomonal antibiotics </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	(beta)-agonists	anti-pseudomonal antibiotics
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), <e1> (beta)-agonists </e1> , inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral <e2> aminoglycosides </e2> demonstrated adverse experience profiles similar to the study population as a whole.	0	(beta)-agonists	aminoglycosides
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled <e1> corticosteroids </e1> , other <e2> anti-pseudomonal antibiotics </e2> , or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole.	0	corticosteroids	anti-pseudomonal antibiotics
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled <e1> corticosteroids </e1> , other anti-pseudomonal antibiotics, or parenteral <e2> aminoglycosides </e2> demonstrated adverse experience profiles similar to the study population as a whole.	0	corticosteroids	aminoglycosides
In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME , Genentech), (beta)-agonists, inhaled corticosteroids, other <e1> anti-pseudomonal antibiotics </e1> , or parenteral <e2> aminoglycosides </e2> demonstrated adverse experience profiles similar to the study population as a whole.	0	anti-pseudomonal antibiotics	aminoglycosides
Some <e1> diuretics </e1> can enhance <e2> aminoglycoside </e2> toxicity by altering antibiotic concentrations in serum and tissue.	1	diuretics	aminoglycoside
Some <e1> diuretics </e1> can enhance aminoglycoside toxicity by altering <e2> antibiotic </e2> concentrations in serum and tissue.	0	diuretics	antibiotic
Some diuretics can enhance <e1> aminoglycoside </e1> toxicity by altering <e2> antibiotic </e2> concentrations in serum and tissue.	0	aminoglycoside	antibiotic
<e1> TOBI </e1> should not be administered concomitantly with <e2> ethacrynic acid </e2> , furosemide, urea, or mannitol.	0	TOBI	ethacrynic acid
<e1> TOBI </e1> should not be administered concomitantly with ethacrynic acid, <e2> furosemide </e2> , urea, or mannitol.	0	TOBI	furosemide
<e1> TOBI </e1> should not be administered concomitantly with ethacrynic acid, furosemide, <e2> urea </e2> , or mannitol.	0	TOBI	urea
<e1> TOBI </e1> should not be administered concomitantly with ethacrynic acid, furosemide, urea, or <e2> mannitol </e2> .	0	TOBI	mannitol
TOBI should not be administered concomitantly with <e1> ethacrynic acid </e1> , <e2> furosemide </e2> , urea, or mannitol.	0	ethacrynic acid	furosemide
TOBI should not be administered concomitantly with <e1> ethacrynic acid </e1> , furosemide, <e2> urea </e2> , or mannitol.	0	ethacrynic acid	urea
TOBI should not be administered concomitantly with <e1> ethacrynic acid </e1> , furosemide, urea, or <e2> mannitol </e2> .	0	ethacrynic acid	mannitol
TOBI should not be administered concomitantly with ethacrynic acid, <e1> furosemide </e1> , <e2> urea </e2> , or mannitol.	0	furosemide	urea
TOBI should not be administered concomitantly with ethacrynic acid, <e1> furosemide </e1> , urea, or <e2> mannitol </e2> .	0	furosemide	mannitol
TOBI should not be administered concomitantly with ethacrynic acid, furosemide, <e1> urea </e1> , or <e2> mannitol </e2> .	0	urea	mannitol
<e1> Phenothiazines </e1> are capable of potentiating <e2> CNS depressants </e2> (e.g., barbiturates, anesthetics, opiates, alcohol, etc.)	1	Phenothiazines	CNS depressants
<e1> Phenothiazines </e1> are capable of potentiating CNS depressants (e.g., <e2> barbiturates </e2> , anesthetics, opiates, alcohol, etc.)	1	Phenothiazines	barbiturates
<e1> Phenothiazines </e1> are capable of potentiating CNS depressants (e.g., barbiturates, <e2> anesthetics </e2> , opiates, alcohol, etc.)	1	Phenothiazines	anesthetics
<e1> Phenothiazines </e1> are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, <e2> opiates </e2> , alcohol, etc.)	1	Phenothiazines	opiates
<e1> Phenothiazines </e1> are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, <e2> alcohol </e2> , etc.)	1	Phenothiazines	alcohol
Phenothiazines are capable of potentiating <e1> CNS depressants </e1> (e.g., <e2> barbiturates </e2> , anesthetics, opiates, alcohol, etc.)	0	CNS depressants	barbiturates
Phenothiazines are capable of potentiating <e1> CNS depressants </e1> (e.g., barbiturates, <e2> anesthetics </e2> , opiates, alcohol, etc.)	0	CNS depressants	anesthetics
Phenothiazines are capable of potentiating <e1> CNS depressants </e1> (e.g., barbiturates, anesthetics, <e2> opiates </e2> , alcohol, etc.)	0	CNS depressants	opiates
Phenothiazines are capable of potentiating <e1> CNS depressants </e1> (e.g., barbiturates, anesthetics, opiates, <e2> alcohol </e2> , etc.)	0	CNS depressants	alcohol
Phenothiazines are capable of potentiating CNS depressants (e.g., <e1> barbiturates </e1> , <e2> anesthetics </e2> , opiates, alcohol, etc.)	0	barbiturates	anesthetics
Phenothiazines are capable of potentiating CNS depressants (e.g., <e1> barbiturates </e1> , anesthetics, <e2> opiates </e2> , alcohol, etc.)	0	barbiturates	opiates
Phenothiazines are capable of potentiating CNS depressants (e.g., <e1> barbiturates </e1> , anesthetics, opiates, <e2> alcohol </e2> , etc.)	0	barbiturates	alcohol
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, <e1> anesthetics </e1> , <e2> opiates </e2> , alcohol, etc.)	0	anesthetics	opiates
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, <e1> anesthetics </e1> , opiates, <e2> alcohol </e2> , etc.)	0	anesthetics	alcohol
Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, <e1> opiates </e1> , <e2> alcohol </e2> , etc.)	0	opiates	alcohol
as well as <e1> atropine </e1> and <e2> phosphorous insecticides </e2> .	0	atropine	phosphorous insecticides
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , <e2> Coumarin-type anticoagulants </e2> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	hypoglycemics	Coumarin-type anticoagulants
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, <e2> Phenytoin </e2> , Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	hypoglycemics	Phenytoin
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, <e2> Cyclosporine </e2> , Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	hypoglycemics	Cyclosporine
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e2> Rifampin </e2> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	hypoglycemics	Rifampin
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e2> Theophylline </e2> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	hypoglycemics	Theophylline
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e2> Terfenadine </e2> , Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	hypoglycemics	Terfenadine
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e2> Cisapride </e2> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	hypoglycemics	Cisapride
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e2> Astemizole </e2> , Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	hypoglycemics	Astemizole
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	hypoglycemics	Rifabutin
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e2> Tacrolimus </e2> , Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	hypoglycemics	Tacrolimus
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2> Short-acting benzodiazepines </e2> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	hypoglycemics	Short-acting benzodiazepines
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	hypoglycemics	DIFLUCAN
These are described in greater detail below: Oral <e1> hypoglycemics </e1> , Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	hypoglycemics	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , <e2> Phenytoin </e2> , Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Coumarin-type anticoagulants	Phenytoin
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , Phenytoin, <e2> Cyclosporine </e2> , Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Coumarin-type anticoagulants	Cyclosporine
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, <e2> Rifampin </e2> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Coumarin-type anticoagulants	Rifampin
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, <e2> Theophylline </e2> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Coumarin-type anticoagulants	Theophylline
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, <e2> Terfenadine </e2> , Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Coumarin-type anticoagulants	Terfenadine
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e2> Cisapride </e2> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Coumarin-type anticoagulants	Cisapride
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e2> Astemizole </e2> , Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Coumarin-type anticoagulants	Astemizole
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Coumarin-type anticoagulants	Rifabutin
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e2> Tacrolimus </e2> , Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Coumarin-type anticoagulants	Tacrolimus
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2> Short-acting benzodiazepines </e2> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Coumarin-type anticoagulants	Short-acting benzodiazepines
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Coumarin-type anticoagulants	hypoglycemics
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	Coumarin-type anticoagulants	DIFLUCAN
These are described in greater detail below: Oral hypoglycemics, <e1> Coumarin-type anticoagulants </e1> , Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	Coumarin-type anticoagulants	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, <e1> Phenytoin </e1> , <e2> Cyclosporine </e2> , Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Phenytoin	Cyclosporine
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, <e1> Phenytoin </e1> , Cyclosporine, <e2> Rifampin </e2> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Phenytoin	Rifampin
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, <e1> Phenytoin </e1> , Cyclosporine, Rifampin, <e2> Theophylline </e2> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Phenytoin	Theophylline
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, <e1> Phenytoin </e1> , Cyclosporine, Rifampin, Theophylline, <e2> Terfenadine </e2> , Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Phenytoin	Terfenadine
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, <e1> Phenytoin </e1> , Cyclosporine, Rifampin, Theophylline, Terfenadine, <e2> Cisapride </e2> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Phenytoin	Cisapride
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, <e1> Phenytoin </e1> , Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e2> Astemizole </e2> , Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Phenytoin	Astemizole
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, <e1> Phenytoin </e1> , Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Phenytoin	Rifabutin
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, <e1> Phenytoin </e1> , Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e2> Tacrolimus </e2> , Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Phenytoin	Tacrolimus
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, <e1> Phenytoin </e1> , Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2> Short-acting benzodiazepines </e2> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Phenytoin	Short-acting benzodiazepines
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, <e1> Phenytoin </e1> , Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Phenytoin	hypoglycemics
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, <e1> Phenytoin </e1> , Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	Phenytoin	DIFLUCAN
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, <e1> Phenytoin </e1> , Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	Phenytoin	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1> Cyclosporine </e1> , <e2> Rifampin </e2> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cyclosporine	Rifampin
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1> Cyclosporine </e1> , Rifampin, <e2> Theophylline </e2> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cyclosporine	Theophylline
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1> Cyclosporine </e1> , Rifampin, Theophylline, <e2> Terfenadine </e2> , Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cyclosporine	Terfenadine
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine, <e2> Cisapride </e2> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cyclosporine	Cisapride
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine, Cisapride, <e2> Astemizole </e2> , Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cyclosporine	Astemizole
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cyclosporine	Rifabutin
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e2> Tacrolimus </e2> , Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cyclosporine	Tacrolimus
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2> Short-acting benzodiazepines </e2> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cyclosporine	Short-acting benzodiazepines
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cyclosporine	hypoglycemics
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	Cyclosporine	DIFLUCAN
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, <e1> Cyclosporine </e1> , Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	Cyclosporine	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1> Rifampin </e1> , <e2> Theophylline </e2> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Rifampin	Theophylline
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1> Rifampin </e1> , Theophylline, <e2> Terfenadine </e2> , Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Rifampin	Terfenadine
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1> Rifampin </e1> , Theophylline, Terfenadine, <e2> Cisapride </e2> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Rifampin	Cisapride
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1> Rifampin </e1> , Theophylline, Terfenadine, Cisapride, <e2> Astemizole </e2> , Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Rifampin	Astemizole
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1> Rifampin </e1> , Theophylline, Terfenadine, Cisapride, Astemizole, <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Rifampin	Rifabutin
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1> Rifampin </e1> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e2> Tacrolimus </e2> , Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Rifampin	Tacrolimus
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1> Rifampin </e1> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2> Short-acting benzodiazepines </e2> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Rifampin	Short-acting benzodiazepines
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1> Rifampin </e1> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Rifampin	hypoglycemics
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1> Rifampin </e1> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	Rifampin	DIFLUCAN
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, <e1> Rifampin </e1> , Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	Rifampin	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1> Theophylline </e1> , <e2> Terfenadine </e2> , Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Theophylline	Terfenadine
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1> Theophylline </e1> , Terfenadine, <e2> Cisapride </e2> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Theophylline	Cisapride
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1> Theophylline </e1> , Terfenadine, Cisapride, <e2> Astemizole </e2> , Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Theophylline	Astemizole
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1> Theophylline </e1> , Terfenadine, Cisapride, Astemizole, <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Theophylline	Rifabutin
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1> Theophylline </e1> , Terfenadine, Cisapride, Astemizole, Rifabutin, <e2> Tacrolimus </e2> , Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Theophylline	Tacrolimus
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1> Theophylline </e1> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2> Short-acting benzodiazepines </e2> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Theophylline	Short-acting benzodiazepines
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1> Theophylline </e1> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Theophylline	hypoglycemics
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1> Theophylline </e1> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	Theophylline	DIFLUCAN
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, <e1> Theophylline </e1> , Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	Theophylline	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1> Terfenadine </e1> , <e2> Cisapride </e2> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Terfenadine	Cisapride
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1> Terfenadine </e1> , Cisapride, <e2> Astemizole </e2> , Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Terfenadine	Astemizole
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1> Terfenadine </e1> , Cisapride, Astemizole, <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Terfenadine	Rifabutin
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1> Terfenadine </e1> , Cisapride, Astemizole, Rifabutin, <e2> Tacrolimus </e2> , Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Terfenadine	Tacrolimus
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1> Terfenadine </e1> , Cisapride, Astemizole, Rifabutin, Tacrolimus, <e2> Short-acting benzodiazepines </e2> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Terfenadine	Short-acting benzodiazepines
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1> Terfenadine </e1> , Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Terfenadine	hypoglycemics
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1> Terfenadine </e1> , Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	Terfenadine	DIFLUCAN
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, <e1> Terfenadine </e1> , Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	Terfenadine	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1> Cisapride </e1> , <e2> Astemizole </e2> , Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cisapride	Astemizole
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1> Cisapride </e1> , Astemizole, <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cisapride	Rifabutin
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1> Cisapride </e1> , Astemizole, Rifabutin, <e2> Tacrolimus </e2> , Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cisapride	Tacrolimus
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1> Cisapride </e1> , Astemizole, Rifabutin, Tacrolimus, <e2> Short-acting benzodiazepines </e2> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cisapride	Short-acting benzodiazepines
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1> Cisapride </e1> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Cisapride	hypoglycemics
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1> Cisapride </e1> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	Cisapride	DIFLUCAN
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, <e1> Cisapride </e1> , Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	Cisapride	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e1> Astemizole </e1> , <e2> Rifabutin </e2> , Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Astemizole	Rifabutin
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e1> Astemizole </e1> , Rifabutin, <e2> Tacrolimus </e2> , Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Astemizole	Tacrolimus
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e1> Astemizole </e1> , Rifabutin, Tacrolimus, <e2> Short-acting benzodiazepines </e2> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Astemizole	Short-acting benzodiazepines
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e1> Astemizole </e1> , Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Astemizole	hypoglycemics
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e1> Astemizole </e1> , Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	Astemizole	DIFLUCAN
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, <e1> Astemizole </e1> , Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	Astemizole	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e1> Rifabutin </e1> , <e2> Tacrolimus </e2> , Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Rifabutin	Tacrolimus
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e1> Rifabutin </e1> , Tacrolimus, <e2> Short-acting benzodiazepines </e2> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Rifabutin	Short-acting benzodiazepines
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e1> Rifabutin </e1> , Tacrolimus, Short-acting benzodiazepines, Oral <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Rifabutin	hypoglycemics
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e1> Rifabutin </e1> , Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	Rifabutin	DIFLUCAN
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, <e1> Rifabutin </e1> , Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	Rifabutin	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e1> Tacrolimus </e1> , <e2> Short-acting benzodiazepines </e2> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Tacrolimus	Short-acting benzodiazepines
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e1> Tacrolimus </e1> , Short-acting benzodiazepines, Oral <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Tacrolimus	hypoglycemics
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e1> Tacrolimus </e1> , Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	Tacrolimus	DIFLUCAN
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, <e1> Tacrolimus </e1> , Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	Tacrolimus	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e1> Short-acting benzodiazepines </e1> , Oral <e2> hypoglycemics </e2> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents;	0	Short-acting benzodiazepines	hypoglycemics
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e1> Short-acting benzodiazepines </e1> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	Short-acting benzodiazepines	DIFLUCAN
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, <e1> Short-acting benzodiazepines </e1> , Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	Short-acting benzodiazepines	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral <e1> hypoglycemics </e1> : Clinically significant hypoglycemia may be precipitated by the use of <e2> DIFLUCAN </e2> with oral hypoglycemic agents;	0	hypoglycemics	DIFLUCAN
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral <e1> hypoglycemics </e1> : Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral <e2> hypoglycemic agents </e2> ;	0	hypoglycemics	hypoglycemic agents
These are described in greater detail below: Oral hypoglycemics, Coumarin-type anticoagulants, Phenytoin, Cyclosporine, Rifampin, Theophylline, Terfenadine, Cisapride, Astemizole, Rifabutin, Tacrolimus, Short-acting benzodiazepines, Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of <e1> DIFLUCAN </e1> with oral <e2> hypoglycemic agents </e2> ;	1	DIFLUCAN	hypoglycemic agents
one fatality has been reported from hypoglycemia in association with combined <e1> DIFLUCAN </e1> and <e2> glyburide </e2> use.	1	DIFLUCAN	glyburide
<e1> DIFLUCAN </e1> reduces the metabolism of <e2> tolbutamide </e2> , glyburide, and glipizide and increases the plasma concentration of these agents.	1	DIFLUCAN	tolbutamide
<e1> DIFLUCAN </e1> reduces the metabolism of tolbutamide, <e2> glyburide </e2> , and glipizide and increases the plasma concentration of these agents.	1	DIFLUCAN	glyburide
<e1> DIFLUCAN </e1> reduces the metabolism of tolbutamide, glyburide, and <e2> glipizide </e2> and increases the plasma concentration of these agents.	1	DIFLUCAN	glipizide
DIFLUCAN reduces the metabolism of <e1> tolbutamide </e1> , <e2> glyburide </e2> , and glipizide and increases the plasma concentration of these agents.	0	tolbutamide	glyburide
DIFLUCAN reduces the metabolism of <e1> tolbutamide </e1> , glyburide, and <e2> glipizide </e2> and increases the plasma concentration of these agents.	0	tolbutamide	glipizide
DIFLUCAN reduces the metabolism of tolbutamide, <e1> glyburide </e1> , and <e2> glipizide </e2> and increases the plasma concentration of these agents.	0	glyburide	glipizide
When <e1> DIFLUCAN </e1> is used concomitantly with these or other <e2> sulfonylurea oral hypoglycemic agents </e2> , blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.	0	DIFLUCAN	sulfonylurea oral hypoglycemic agents
When <e1> DIFLUCAN </e1> is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the <e2> sulfonylurea </e2> should be adjusted as necessary.	0	DIFLUCAN	sulfonylurea
When DIFLUCAN is used concomitantly with these or other <e1> sulfonylurea oral hypoglycemic agents </e1> , blood glucose concentrations should be carefully monitored and the dose of the <e2> sulfonylurea </e2> should be adjusted as necessary.	0	sulfonylurea oral hypoglycemic agents	sulfonylurea
<e1> Coumarin-type anticoagulants </e1> : Prothrombin time may be increased in patients receiving concomitant <e2> DIFLUCAN </e2> and coumarin-type anticoagulants.	0	Coumarin-type anticoagulants	DIFLUCAN
Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant <e1> DIFLUCAN </e1> and <e2> coumarin-type anticoagulants </e2> .	1	DIFLUCAN	coumarin-type anticoagulants
In post-marketing experience, as with other <e1> azole antifungals </e1> , bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving <e2> fluconazole </e2> concurrently with warfarin.	0	azole antifungals	fluconazole
In post-marketing experience, as with other <e1> azole antifungals </e1> , bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with <e2> warfarin </e2> .	0	azole antifungals	warfarin
In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving <e1> fluconazole </e1> concurrently with <e2> warfarin </e2> .	1	fluconazole	warfarin
Careful monitoring of prothrombin time in patients receiving <e1> DIFLUCAN </e1> and <e2> coumarin-type anticoagulants </e2> is recommended.	0	DIFLUCAN	coumarin-type anticoagulants
<e1> Phenytoin </e1> : <e2> DIFLUCAN </e2> increases the plasma concentrations of phenytoin.	0	Phenytoin	DIFLUCAN
Phenytoin: <e1> DIFLUCAN </e1> increases the plasma concentrations of <e2> phenytoin </e2> .	1	DIFLUCAN	phenytoin
Careful monitoring of <e1> phenytoin </e1> concentrations in patients receiving <e2> DIFLUCAN </e2> and phenytoin is recommended.	0	phenytoin	DIFLUCAN
Careful monitoring of phenytoin concentrations in patients receiving <e1> DIFLUCAN </e1> and <e2> phenytoin </e2> is recommended.	0	DIFLUCAN	phenytoin
<e1> Cyclosporine </e1> : <e2> DIFLUCAN </e2> may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment.	0	Cyclosporine	DIFLUCAN
Cyclosporine: <e1> DIFLUCAN </e1> may significantly increase <e2> cyclosporine </e2> levels in renal transplant patients with or without renal impairment.	1	DIFLUCAN	cyclosporine
Careful monitoring of <e1> cyclosporine </e1> concentrations and serum creatinine is recommended in patients receiving <e2> DIFLUCAN </e2> and cyclosporine.	0	cyclosporine	DIFLUCAN
Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving <e1> DIFLUCAN </e1> and <e2> cyclosporine </e2> .	0	DIFLUCAN	cyclosporine
<e1> Rifampin </e1> : Rifampin enhances the metabolism of concurrently administered <e2> DIFLUCAN </e2> .	0	Rifampin	DIFLUCAN
Rifampin: <e1> Rifampin </e1> enhances the metabolism of concurrently administered <e2> DIFLUCAN </e2> .	1	Rifampin	DIFLUCAN
Depending on clinical circumstances, consideration should be given to increasing the dose of <e1> DIFLUCAN </e1> when it is administered with <e2> rifampin </e2> .	0	DIFLUCAN	rifampin
<e1> Theophylline </e1> : <e2> DIFLUCAN </e2> increases the serum concentrations of theophylline.	0	Theophylline	DIFLUCAN
Theophylline: <e1> DIFLUCAN </e1> increases the serum concentrations of <e2> theophylline </e2> .	1	DIFLUCAN	theophylline
Careful monitoring of serum <e1> theophylline </e1> concentrations in patients receiving <e2> DIFLUCAN </e2> and theophylline is recommended.	0	theophylline	DIFLUCAN
Careful monitoring of serum theophylline concentrations in patients receiving <e1> DIFLUCAN </e1> and <e2> theophylline </e2> is recommended.	0	DIFLUCAN	theophylline
<e1> Terfenadine </e1> : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving <e2> azole antifungals </e2> in conjunction with terfenadine, interaction studies have been performed.	0	Terfenadine	azole antifungals
Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving <e1> azole antifungals </e1> in conjunction with <e2> terfenadine </e2> , interaction studies have been performed.	1	azole antifungals	terfenadine
Another study at a 400-mg and 800-mg daily dose of <e1> fluconazole </e1> demonstrated that <e2> DIFLUCAN </e2> taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly.	0	fluconazole	DIFLUCAN
Another study at a 400-mg and 800-mg daily dose of <e1> fluconazole </e1> demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of <e2> terfenadine </e2> when taken concomitantly.	0	fluconazole	terfenadine
Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that <e1> DIFLUCAN </e1> taken in doses of 400 mg per day or greater significantly increases plasma levels of <e2> terfenadine </e2> when taken concomitantly.	1	DIFLUCAN	terfenadine
The combined use of <e1> fluconazole </e1> at doses of 400 mg or greater with <e2> terfenadine </e2> is contraindicated.	0	fluconazole	terfenadine
The coadministration of <e1> fluconazole </e1> at doses lower than 400 mg/day with <e2> terfenadine </e2> should be carefully monitored.	0	fluconazole	terfenadine
<e1> Cisapride </e1> : There have been reports of cardiac events, including torsade de pointes in patients to whom <e2> fluconazole </e2> and cisapride were coadministered.	0	Cisapride	fluconazole
Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom <e1> fluconazole </e1> and <e2> cisapride </e2> were coadministered.	1	fluconazole	cisapride
A controlled study found that concomitant <e1> fluconazole </e1> 200 mg once daily and <e2> cisapride </e2> 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.	1	fluconazole	cisapride
A controlled study found that concomitant <e1> fluconazole </e1> 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in <e2> cisapride </e2> plasma levels and prolongation of QTc interval.	0	fluconazole	cisapride
The combined use of <e1> fluconazole </e1> with <e2> cisapride </e2> is contraindicated.	0	fluconazole	cisapride
<e1> Astemizole </e1> : The use of <e2> fluconazole </e2> in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.	0	Astemizole	fluconazole
Astemizole: The use of <e1> fluconazole </e1> in patients concurrently taking <e2> astemizole </e2> or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.	1	fluconazole	astemizole
<e1> Rifabutin </e1> : There have been reports of uveitis in patients to whom <e2> fluconazole </e2> and rifabutin were coadministered.	0	Rifabutin	fluconazole
Rifabutin: There have been reports of uveitis in patients to whom <e1> fluconazole </e1> and <e2> rifabutin </e2> were coadministered.	1	fluconazole	rifabutin
Patients receiving <e1> rifabutin </e1> and <e2> fluconazole </e2> concomitantly should be carefully monitored.	0	rifabutin	fluconazole
<e1> Tacrolimus </e1> : There have been reports of nephrotoxicity in patients to whom <e2> fluconazole </e2> and tacrolimus were coadministered.	0	Tacrolimus	fluconazole
Tacrolimus: There have been reports of nephrotoxicity in patients to whom <e1> fluconazole </e1> and <e2> tacrolimus </e2> were coadministered.	1	fluconazole	tacrolimus
Patients receiving <e1> tacrolimus </e1> and <e2> fluconazole </e2> concomitantly should be carefully monitored.	0	tacrolimus	fluconazole
<e1> Short-acting Benzodiazepines </e1> : Following oral administration of <e2> midazolam </e2> , fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects.	0	Short-acting Benzodiazepines	midazolam
<e1> Short-acting Benzodiazepines </e1> : Following oral administration of midazolam, <e2> fluconazole </e2> resulted in substantial increases in midazolam concentrations and psychomotor effects.	0	Short-acting Benzodiazepines	fluconazole
<e1> Short-acting Benzodiazepines </e1> : Following oral administration of midazolam, fluconazole resulted in substantial increases in <e2> midazolam </e2> concentrations and psychomotor effects.	0	Short-acting Benzodiazepines	midazolam
Short-acting Benzodiazepines: Following oral administration of <e1> midazolam </e1> , <e2> fluconazole </e2> resulted in substantial increases in midazolam concentrations and psychomotor effects.	1	midazolam	fluconazole
Short-acting Benzodiazepines: Following oral administration of midazolam, <e1> fluconazole </e1> resulted in substantial increases in <e2> midazolam </e2> concentrations and psychomotor effects.	0	fluconazole	midazolam
This effect on <e1> midazolam </e1> appears to be more pronounced following oral administration of <e2> fluconazole </e2> than with fluconazole administered intravenously.	1	midazolam	fluconazole
This effect on <e1> midazolam </e1> appears to be more pronounced following oral administration of fluconazole than with <e2> fluconazole </e2> administered intravenously.	0	midazolam	fluconazole
If <e1> short-acting benzodiazepines </e1> , which are metabolized by the cytochrome P450 system, are concomitantly administered with <e2> fluconazole </e2> , consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.	0	short-acting benzodiazepines	fluconazole
If <e1> short-acting benzodiazepines </e1> , which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the <e2> benzodiazepine </e2> dosage, and the patients should be appropriately monitored.	0	short-acting benzodiazepines	benzodiazepine
If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with <e1> fluconazole </e1> , consideration should be given to decreasing the <e2> benzodiazepine </e2> dosage, and the patients should be appropriately monitored.	0	fluconazole	benzodiazepine
<e1> Fluconazole </e1> tablets coadministered with <e2> ethinyl estradiol </e2> - and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	1	Fluconazole	ethinyl estradiol
<e1> Fluconazole </e1> tablets coadministered with ethinyl estradiol- and <e2> levonorgestrel </e2> -containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	1	Fluconazole	levonorgestrel
<e1> Fluconazole </e1> tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral <e2> contraceptives </e2> produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	0	Fluconazole	contraceptives
<e1> Fluconazole </e1> tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in <e2> ethinyl estradiol </e2> and levonorgestrel levels;	0	Fluconazole	ethinyl estradiol
<e1> Fluconazole </e1> tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and <e2> levonorgestrel </e2> levels;	0	Fluconazole	levonorgestrel
Fluconazole tablets coadministered with <e1> ethinyl estradiol </e1> - and <e2> levonorgestrel </e2> -containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	0	ethinyl estradiol	levonorgestrel
Fluconazole tablets coadministered with <e1> ethinyl estradiol </e1> - and levonorgestrel-containing oral <e2> contraceptives </e2> produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	0	ethinyl estradiol	contraceptives
Fluconazole tablets coadministered with <e1> ethinyl estradiol </e1> - and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and <e2> levonorgestrel </e2> levels;	0	ethinyl estradiol	levonorgestrel
Fluconazole tablets coadministered with ethinyl estradiol- and <e1> levonorgestrel </e1> -containing oral <e2> contraceptives </e2> produced an overall mean increase in ethinyl estradiol and levonorgestrel levels;	0	levonorgestrel	contraceptives
Fluconazole tablets coadministered with ethinyl estradiol- and <e1> levonorgestrel </e1> -containing oral contraceptives produced an overall mean increase in <e2> ethinyl estradiol </e2> and levonorgestrel levels;	0	levonorgestrel	ethinyl estradiol
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral <e1> contraceptives </e1> produced an overall mean increase in <e2> ethinyl estradiol </e2> and levonorgestrel levels;	0	contraceptives	ethinyl estradiol
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral <e1> contraceptives </e1> produced an overall mean increase in ethinyl estradiol and <e2> levonorgestrel </e2> levels;	0	contraceptives	levonorgestrel
Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in <e1> ethinyl estradiol </e1> and <e2> levonorgestrel </e2> levels;	0	ethinyl estradiol	levonorgestrel
however, in some patients there were decreases up to 47% and 33% of <e1> ethinyl estradiol </e1> and <e2> levonorgestrel </e2> levels.	0	ethinyl estradiol	levonorgestrel
The data presently available indicate that the decreases in some individual <e1> ethinyl estradiol </e1> and <e2> levonorgestrel </e2> AUC values with fluconazole treatment are likely the result of random variation.	0	ethinyl estradiol	levonorgestrel
The data presently available indicate that the decreases in some individual <e1> ethinyl estradiol </e1> and levonorgestrel AUC values with <e2> fluconazole </e2> treatment are likely the result of random variation.	0	ethinyl estradiol	fluconazole
The data presently available indicate that the decreases in some individual ethinyl estradiol and <e1> levonorgestrel </e1> AUC values with <e2> fluconazole </e2> treatment are likely the result of random variation.	0	levonorgestrel	fluconazole
While there is evidence that <e1> fluconazole </e1> can inhibit the metabolism of <e2> ethinyl estradiol </e2> and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	1	fluconazole	ethinyl estradiol
While there is evidence that <e1> fluconazole </e1> can inhibit the metabolism of ethinyl estradiol and <e2> levonorgestrel </e2> , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	1	fluconazole	levonorgestrel
While there is evidence that <e1> fluconazole </e1> can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of <e2> ethinyl estradiol </e2> or levonorgestrel metabolism.	0	fluconazole	ethinyl estradiol
While there is evidence that <e1> fluconazole </e1> can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or <e2> levonorgestrel </e2> metabolism.	0	fluconazole	levonorgestrel
While there is evidence that fluconazole can inhibit the metabolism of <e1> ethinyl estradiol </e1> and <e2> levonorgestrel </e2> , there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	0	ethinyl estradiol	levonorgestrel
While there is evidence that fluconazole can inhibit the metabolism of <e1> ethinyl estradiol </e1> and levonorgestrel, there is no evidence that <e2> fluconazole </e2> is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	0	ethinyl estradiol	fluconazole
While there is evidence that fluconazole can inhibit the metabolism of <e1> ethinyl estradiol </e1> and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or <e2> levonorgestrel </e2> metabolism.	0	ethinyl estradiol	levonorgestrel
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and <e1> levonorgestrel </e1> , there is no evidence that <e2> fluconazole </e2> is a net inducer of ethinyl estradiol or levonorgestrel metabolism.	0	levonorgestrel	fluconazole
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and <e1> levonorgestrel </e1> , there is no evidence that fluconazole is a net inducer of <e2> ethinyl estradiol </e2> or levonorgestrel metabolism.	0	levonorgestrel	ethinyl estradiol
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that <e1> fluconazole </e1> is a net inducer of <e2> ethinyl estradiol </e2> or levonorgestrel metabolism.	0	fluconazole	ethinyl estradiol
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that <e1> fluconazole </e1> is a net inducer of ethinyl estradiol or <e2> levonorgestrel </e2> metabolism.	0	fluconazole	levonorgestrel
While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of <e1> ethinyl estradiol </e1> or <e2> levonorgestrel </e2> metabolism.	0	ethinyl estradiol	levonorgestrel
Prothrombin time or other suitable anticoagulation test should be monitored if <e1> tigecycline </e1> is administered with <e2> warfarin </e2> .	0	tigecycline	warfarin
Concurrent use of <e1> antibacterial drugs </e1> with oral <e2> contraceptives </e2> may render oral contraceptives less effective.	1	antibacterial drugs	contraceptives
Concurrent use of <e1> antibacterial drugs </e1> with oral contraceptives may render oral <e2> contraceptives </e2> less effective.	0	antibacterial drugs	contraceptives
The in vitro binding of <e1> warfarin </e1> to human plasma proteins is unaffected by <e2> tolmetin </e2> , and tolmetin does not alter the prothrombin time of normal volunteers.	0	warfarin	tolmetin
The in vitro binding of <e1> warfarin </e1> to human plasma proteins is unaffected by tolmetin, and <e2> tolmetin </e2> does not alter the prothrombin time of normal volunteers.	0	warfarin	tolmetin
However, increased prothrombin time and bleeding have been reported in patients on concomitant <e1> TOLECTIN </e1> and <e2> warfarin </e2> therapy.	1	TOLECTIN	warfarin
Therefore, caution should be exercised when administering <e1> TOLECTIN </e1> to patients on <e2> anticoagulants </e2> .	0	TOLECTIN	anticoagulants
In adult diabetic patients under treatment with either <e1> sulfonylureas </e1> or <e2> insulin </e2> there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents.	0	sulfonylureas	insulin
In adult diabetic patients under treatment with either <e1> sulfonylureas </e1> or insulin there is no change in the clinical effects of either <e2> TOLECTIN </e2> or the hypoglycemic agents.	0	sulfonylureas	TOLECTIN
In adult diabetic patients under treatment with either <e1> sulfonylureas </e1> or insulin there is no change in the clinical effects of either TOLECTIN or the <e2> hypoglycemic agents </e2> .	0	sulfonylureas	hypoglycemic agents
In adult diabetic patients under treatment with either sulfonylureas or <e1> insulin </e1> there is no change in the clinical effects of either <e2> TOLECTIN </e2> or the hypoglycemic agents.	0	insulin	TOLECTIN
In adult diabetic patients under treatment with either sulfonylureas or <e1> insulin </e1> there is no change in the clinical effects of either TOLECTIN or the <e2> hypoglycemic agents </e2> .	0	insulin	hypoglycemic agents
In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either <e1> TOLECTIN </e1> or the <e2> hypoglycemic agents </e2> .	0	TOLECTIN	hypoglycemic agents
Caution should be used if <e1> TOLECTIN </e1> is administered concomitantly with <e2> methotrexate </e2> .	0	TOLECTIN	methotrexate
<e1> TOLECTIN </e1> and other <e2> nonsteroidal anti-inflammatory drugs </e2> have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate.	0	TOLECTIN	nonsteroidal anti-inflammatory drugs
<e1> TOLECTIN </e1> and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of <e2> methotrexate </e2> in an animal model, possibly enhancing the toxicity of methotrexate.	1	TOLECTIN	methotrexate
<e1> TOLECTIN </e1> and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of <e2> methotrexate </e2> .	0	TOLECTIN	methotrexate
TOLECTIN and other <e1> nonsteroidal anti-inflammatory drugs </e1> have been reported to reduce the tubular secretion of <e2> methotrexate </e2> in an animal model, possibly enhancing the toxicity of methotrexate.	1	nonsteroidal anti-inflammatory drugs	methotrexate
TOLECTIN and other <e1> nonsteroidal anti-inflammatory drugs </e1> have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of <e2> methotrexate </e2> .	0	nonsteroidal anti-inflammatory drugs	methotrexate
<e1> Trimethoprim </e1> may inhibit the hepatic metabolism of <e2> phenytoin </e2> .	1	Trimethoprim	phenytoin
<e1> Trimethoprim </e1> , given at a common clinical dosage, increased the <e2> phenytoin </e2> half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%.	1	Trimethoprim	phenytoin
<e1> Trimethoprim </e1> , given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the <e2> phenytoin </e2> metabolic clearance rate by 30%.	1	Trimethoprim	phenytoin
Concomitant use of <e1> alcohol </e1> with <e2> phentermine hydrochloride </e2> may result in an adverse drug interaction.	0	alcohol	phentermine hydrochloride
<e1> Phenytoin </e1> , <e2> Carbamazepine </e2> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	0	Phenytoin	Carbamazepine
<e1> Phenytoin </e1> , Carbamazepine, and <e2> Rifampicin </e2> : In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	0	Phenytoin	Rifampicin
<e1> Phenytoin </e1> , Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, <e2> carbamazepine </e2> , and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	0	Phenytoin	carbamazepine
<e1> Phenytoin </e1> , Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	0	Phenytoin	rifampicin
<e1> Phenytoin </e1> , Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of <e2> ondansetron </e2> was significantly increased and ondansetron blood concentrations were decreased.	0	Phenytoin	ondansetron
<e1> Phenytoin </e1> , Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and <e2> ondansetron </e2> blood concentrations were decreased.	0	Phenytoin	ondansetron
Phenytoin, <e1> Carbamazepine </e1> , and <e2> Rifampicin </e2> : In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	0	Carbamazepine	Rifampicin
Phenytoin, <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., <e2> phenytoin </e2> , carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	0	Carbamazepine	phenytoin
Phenytoin, <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	0	Carbamazepine	rifampicin
Phenytoin, <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of <e2> ondansetron </e2> was significantly increased and ondansetron blood concentrations were decreased.	0	Carbamazepine	ondansetron
Phenytoin, <e1> Carbamazepine </e1> , and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and <e2> ondansetron </e2> blood concentrations were decreased.	0	Carbamazepine	ondansetron
Phenytoin, Carbamazepine, and <e1> Rifampicin </e1> : In patients treated with potent inducers of CYP3A4 (i.e., <e2> phenytoin </e2> , carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	0	Rifampicin	phenytoin
Phenytoin, Carbamazepine, and <e1> Rifampicin </e1> : In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, <e2> carbamazepine </e2> , and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	0	Rifampicin	carbamazepine
Phenytoin, Carbamazepine, and <e1> Rifampicin </e1> : In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of <e2> ondansetron </e2> was significantly increased and ondansetron blood concentrations were decreased.	0	Rifampicin	ondansetron
Phenytoin, Carbamazepine, and <e1> Rifampicin </e1> : In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and <e2> ondansetron </e2> blood concentrations were decreased.	0	Rifampicin	ondansetron
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., <e1> phenytoin </e1> , <e2> carbamazepine </e2> , and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	0	phenytoin	carbamazepine
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., <e1> phenytoin </e1> , carbamazepine, and <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	0	phenytoin	rifampicin
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., <e1> phenytoin </e1> , carbamazepine, and rifampicin), the clearance of <e2> ondansetron </e2> was significantly increased and ondansetron blood concentrations were decreased.	1	phenytoin	ondansetron
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., <e1> phenytoin </e1> , carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and <e2> ondansetron </e2> blood concentrations were decreased.	1	phenytoin	ondansetron
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, <e1> carbamazepine </e1> , and <e2> rifampicin </e2> ), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.	0	carbamazepine	rifampicin
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, <e1> carbamazepine </e1> , and rifampicin), the clearance of <e2> ondansetron </e2> was significantly increased and ondansetron blood concentrations were decreased.	1	carbamazepine	ondansetron
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, <e1> carbamazepine </e1> , and rifampicin), the clearance of ondansetron was significantly increased and <e2> ondansetron </e2> blood concentrations were decreased.	1	carbamazepine	ondansetron
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and <e1> rifampicin </e1> ), the clearance of <e2> ondansetron </e2> was significantly increased and ondansetron blood concentrations were decreased.	1	rifampicin	ondansetron
Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and <e1> rifampicin </e1> ), the clearance of ondansetron was significantly increased and <e2> ondansetron </e2> blood concentrations were decreased.	1	rifampicin	ondansetron
However, on the basis of available data, no dosage adjustment for <e1> ondansetron </e1> is recommended for patients on these drugs.1,3 <e2> Tramadol </e2> : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	0	ondansetron	Tramadol
However, on the basis of available data, no dosage adjustment for <e1> ondansetron </e1> is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and <e2> tramadol </e2> has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	0	ondansetron	tramadol
However, on the basis of available data, no dosage adjustment for <e1> ondansetron </e1> is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of <e2> tramadol </e2> .4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	0	ondansetron	tramadol
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 <e1> Tramadol </e1> : Although no pharmacokinetic drug interaction between <e2> ondansetron </e2> and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	0	Tramadol	ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 <e1> Tramadol </e1> : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that <e2> ondansetron </e2> may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	0	Tramadol	ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 <e1> Tramadol </e1> : Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2> ondansetron </e2> .	0	Tramadol	ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between <e1> ondansetron </e1> and <e2> tramadol </e2> has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	0	ondansetron	tramadol
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between <e1> ondansetron </e1> and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of <e2> tramadol </e2> .4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	0	ondansetron	tramadol
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and <e1> tramadol </e1> has been observed, data from 2 small studies indicate that <e2> ondansetron </e2> may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	0	tramadol	ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and <e1> tramadol </e1> has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2> ondansetron </e2> .	0	tramadol	ondansetron
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that <e1> ondansetron </e1> may be associated with an increase in patient controlled administration of <e2> tramadol </e2> .4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron.	1	ondansetron	tramadol
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3 Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of <e1> tramadol </e1> .4,5 Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by <e2> ondansetron </e2> .	0	tramadol	ondansetron
In humans, <e1> carmustine </e1> , <e2> etoposide </e2> , and cisplatin do not affect the pharmacokinetics of ondansetron.	0	carmustine	etoposide
In humans, <e1> carmustine </e1> , etoposide, and <e2> cisplatin </e2> do not affect the pharmacokinetics of ondansetron.	0	carmustine	cisplatin
In humans, <e1> carmustine </e1> , etoposide, and cisplatin do not affect the pharmacokinetics of <e2> ondansetron </e2> .	0	carmustine	ondansetron
In humans, carmustine, <e1> etoposide </e1> , and <e2> cisplatin </e2> do not affect the pharmacokinetics of ondansetron.	0	etoposide	cisplatin
In humans, carmustine, <e1> etoposide </e1> , and cisplatin do not affect the pharmacokinetics of <e2> ondansetron </e2> .	0	etoposide	ondansetron
In humans, carmustine, etoposide, and <e1> cisplatin </e1> do not affect the pharmacokinetics of <e2> ondansetron </e2> .	0	cisplatin	ondansetron
<e1> ondansetron </e1> did not increase blood levels of high-dose <e2> methotrexate </e2> .	0	ondansetron	methotrexate
<e1> norepinephrine </e1> and <e2> dobutamine </e2> are incompatible with sodium bicarbonate solution.	0	norepinephrine	dobutamine
<e1> norepinephrine </e1> and dobutamine are incompatible with <e2> sodium bicarbonate </e2> solution.	0	norepinephrine	sodium bicarbonate
norepinephrine and <e1> dobutamine </e1> are incompatible with <e2> sodium bicarbonate </e2> solution.	0	dobutamine	sodium bicarbonate
The addition of <e1> sodium bicarbonate </e1> to parenteral solutions containing <e2> calcium </e2> should be avoided, except where compatibility has been previously established.	0	sodium bicarbonate	calcium
<e1> Vasopressors </e1> , particularly <e2> metaraminol </e2> , may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all.	0	Vasopressors	metaraminol
<e1> Vasopressors </e1> , particularly metaraminol, may cause serious cardiac arrhythmias during <e2> halothane </e2> anesthesia and therefore should be used only with great caution or not at all.	1	Vasopressors	halothane
Vasopressors, particularly <e1> metaraminol </e1> , may cause serious cardiac arrhythmias during <e2> halothane </e2> anesthesia and therefore should be used only with great caution or not at all.	1	metaraminol	halothane
<e1> MAO Inhibitors </e1> - The pressor effect of <e2> sympathomimetic pressor amines </e2> is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI).	0	MAO Inhibitors	sympathomimetic pressor amines
<e1> MAO Inhibitors </e1> - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving <e2> monoamine oxidase inhibitors </e2> (MAOI).	0	MAO Inhibitors	monoamine oxidase inhibitors
<e1> MAO Inhibitors </e1> - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors ( <e2> MAOI </e2> ).	0	MAO Inhibitors	MAOI
MAO Inhibitors - The pressor effect of <e1> sympathomimetic pressor amines </e1> is markedly potentiated in patients receiving <e2> monoamine oxidase inhibitors </e2> (MAOI).	1	sympathomimetic pressor amines	monoamine oxidase inhibitors
MAO Inhibitors - The pressor effect of <e1> sympathomimetic pressor amines </e1> is markedly potentiated in patients receiving monoamine oxidase inhibitors ( <e2> MAOI </e2> ).	1	sympathomimetic pressor amines	MAOI
MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving <e1> monoamine oxidase inhibitors </e1> ( <e2> MAOI </e2> ).	0	monoamine oxidase inhibitors	MAOI
The pressor response of <e1> adrenergic agents </e1> may also be potentiated by <e2> tricyclic antidepressants </e2> .	1	adrenergic agents	tricyclic antidepressants
Agents that might be coadministered with <e1> trimetrexate </e1> in AIDS patients for other indications that could elicit this activity include <e2> erythromycin </e2> , rifampin, rifabutin, ketoconazole, and fluconazole.	1	trimetrexate	erythromycin
Agents that might be coadministered with <e1> trimetrexate </e1> in AIDS patients for other indications that could elicit this activity include erythromycin, <e2> rifampin </e2> , rifabutin, ketoconazole, and fluconazole.	1	trimetrexate	rifampin
Agents that might be coadministered with <e1> trimetrexate </e1> in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, <e2> rifabutin </e2> , ketoconazole, and fluconazole.	1	trimetrexate	rifabutin
Agents that might be coadministered with <e1> trimetrexate </e1> in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, <e2> ketoconazole </e2> , and fluconazole.	1	trimetrexate	ketoconazole
Agents that might be coadministered with <e1> trimetrexate </e1> in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, ketoconazole, and <e2> fluconazole </e2> .	1	trimetrexate	fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include <e1> erythromycin </e1> , <e2> rifampin </e2> , rifabutin, ketoconazole, and fluconazole.	0	erythromycin	rifampin
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include <e1> erythromycin </e1> , rifampin, <e2> rifabutin </e2> , ketoconazole, and fluconazole.	0	erythromycin	rifabutin
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include <e1> erythromycin </e1> , rifampin, rifabutin, <e2> ketoconazole </e2> , and fluconazole.	0	erythromycin	ketoconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include <e1> erythromycin </e1> , rifampin, rifabutin, ketoconazole, and <e2> fluconazole </e2> .	0	erythromycin	fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, <e1> rifampin </e1> , <e2> rifabutin </e2> , ketoconazole, and fluconazole.	0	rifampin	rifabutin
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, <e1> rifampin </e1> , rifabutin, <e2> ketoconazole </e2> , and fluconazole.	0	rifampin	ketoconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, <e1> rifampin </e1> , rifabutin, ketoconazole, and <e2> fluconazole </e2> .	0	rifampin	fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, <e1> rifabutin </e1> , <e2> ketoconazole </e2> , and fluconazole.	0	rifabutin	ketoconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, <e1> rifabutin </e1> , ketoconazole, and <e2> fluconazole </e2> .	0	rifabutin	fluconazole
Agents that might be coadministered with trimetrexate in AIDS patients for other indications that could elicit this activity include erythromycin, rifampin, rifabutin, <e1> ketoconazole </e1> , and <e2> fluconazole </e2> .	0	ketoconazole	fluconazole
In vitro perfusion of isolated rat liver has shown that <e1> cimetidine </e1> caused a significant reduction in <e2> trimetrexate </e2> metabolism and that acetaminophen altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.	1	cimetidine	trimetrexate
In vitro perfusion of isolated rat liver has shown that <e1> cimetidine </e1> caused a significant reduction in trimetrexate metabolism and that <e2> acetaminophen </e2> altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.	0	cimetidine	acetaminophen
In vitro perfusion of isolated rat liver has shown that cimetidine caused a significant reduction in <e1> trimetrexate </e1> metabolism and that <e2> acetaminophen </e2> altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.	0	trimetrexate	acetaminophen
Based on an in vitro rat liver model, nitrogen substituted <e1> imidazole drugs </e1> ( <e2> clotrimazole </e2> , ketoconazole, miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	0	imidazole drugs	clotrimazole
Based on an in vitro rat liver model, nitrogen substituted <e1> imidazole drugs </e1> (clotrimazole, <e2> ketoconazole </e2> , miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	0	imidazole drugs	ketoconazole
Based on an in vitro rat liver model, nitrogen substituted <e1> imidazole drugs </e1> (clotrimazole, ketoconazole, <e2> miconazole </e2> ) were potent, non-competitive inhibitors of trimetrexate metabolism.	0	imidazole drugs	miconazole
Based on an in vitro rat liver model, nitrogen substituted <e1> imidazole drugs </e1> (clotrimazole, ketoconazole, miconazole) were potent, non-competitive inhibitors of <e2> trimetrexate </e2> metabolism.	1	imidazole drugs	trimetrexate
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs ( <e1> clotrimazole </e1> , <e2> ketoconazole </e2> , miconazole) were potent, non-competitive inhibitors of trimetrexate metabolism.	0	clotrimazole	ketoconazole
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs ( <e1> clotrimazole </e1> , ketoconazole, <e2> miconazole </e2> ) were potent, non-competitive inhibitors of trimetrexate metabolism.	0	clotrimazole	miconazole
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs ( <e1> clotrimazole </e1> , ketoconazole, miconazole) were potent, non-competitive inhibitors of <e2> trimetrexate </e2> metabolism.	1	clotrimazole	trimetrexate
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, <e1> ketoconazole </e1> , <e2> miconazole </e2> ) were potent, non-competitive inhibitors of trimetrexate metabolism.	0	ketoconazole	miconazole
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, <e1> ketoconazole </e1> , miconazole) were potent, non-competitive inhibitors of <e2> trimetrexate </e2> metabolism.	1	ketoconazole	trimetrexate
Based on an in vitro rat liver model, nitrogen substituted imidazole drugs (clotrimazole, ketoconazole, <e1> miconazole </e1> ) were potent, non-competitive inhibitors of <e2> trimetrexate </e2> metabolism.	1	miconazole	trimetrexate
CYP 3A4 Inhibitors (e.g. <e1> Macrolide Antibiotics </e1> and <e2> Protease Inhibitors </e2> ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	0	Macrolide Antibiotics	Protease Inhibitors
CYP 3A4 Inhibitors (e.g. <e1> Macrolide Antibiotics </e1> and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain <e2> ergot alkaloid drugs </e2> (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	0	Macrolide Antibiotics	ergot alkaloid drugs
CYP 3A4 Inhibitors (e.g. <e1> Macrolide Antibiotics </e1> and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. <e2> dihydroergotamine </e2> and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	0	Macrolide Antibiotics	dihydroergotamine
CYP 3A4 Inhibitors (e.g. <e1> Macrolide Antibiotics </e1> and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and <e2> ergotamine </e2> ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	0	Macrolide Antibiotics	ergotamine
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and <e1> Protease Inhibitors </e1> ) There have been rare reports of serious adverse events in connection with the coadministration of certain <e2> ergot alkaloid drugs </e2> (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	0	Protease Inhibitors	ergot alkaloid drugs
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and <e1> Protease Inhibitors </e1> ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. <e2> dihydroergotamine </e2> and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	0	Protease Inhibitors	dihydroergotamine
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and <e1> Protease Inhibitors </e1> ) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and <e2> ergotamine </e2> ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	0	Protease Inhibitors	ergotamine
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain <e1> ergot alkaloid drugs </e1> (e.g. <e2> dihydroergotamine </e2> and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	0	ergot alkaloid drugs	dihydroergotamine
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain <e1> ergot alkaloid drugs </e1> (e.g. dihydroergotamine and <e2> ergotamine </e2> ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	0	ergot alkaloid drugs	ergotamine
CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. <e1> dihydroergotamine </e1> and <e2> ergotamine </e2> ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.	0	dihydroergotamine	ergotamine
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., <e2> erythromycin </e2> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	macrolide antibiotics	erythromycin
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., erythromycin, <e2> troleandomycin </e2> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	macrolide antibiotics	troleandomycin
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., erythromycin, troleandomycin, <e2> clarithromycin </e2> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	macrolide antibiotics	clarithromycin
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., erythromycin, troleandomycin, clarithromycin), <e2> HIV protease inhibitors </e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	macrolide antibiotics	HIV protease inhibitors
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e2> reverse transcriptase inhibitors </e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	macrolide antibiotics	reverse transcriptase inhibitors
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e2> ritonavir </e2> , indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	macrolide antibiotics	ritonavir
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	macrolide antibiotics	indinavir
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e2> nelfinavir </e2> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	macrolide antibiotics	nelfinavir
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e2> delavirdine </e2> ) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	macrolide antibiotics	delavirdine
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e2> azole antifungals </e2> (e.g., ketoconazole, itraconazole, voriconazole).	0	macrolide antibiotics	azole antifungals
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2> ketoconazole </e2> , itraconazole, voriconazole).	0	macrolide antibiotics	ketoconazole
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2> itraconazole </e2> , voriconazole).	0	macrolide antibiotics	itraconazole
Examples of some of the more potent CYP 3A4 inhibitors include <e1> macrolide antibiotics </e1> (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2> voriconazole </e2> ).	0	macrolide antibiotics	voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1> erythromycin </e1> , <e2> troleandomycin </e2> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	erythromycin	troleandomycin
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1> erythromycin </e1> , troleandomycin, <e2> clarithromycin </e2> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	erythromycin	clarithromycin
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1> erythromycin </e1> , troleandomycin, clarithromycin), <e2> HIV protease inhibitors </e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	erythromycin	HIV protease inhibitors
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or <e2> reverse transcriptase inhibitors </e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	erythromycin	reverse transcriptase inhibitors
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e2> ritonavir </e2> , indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	erythromycin	ritonavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	erythromycin	indinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e2> nelfinavir </e2> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	erythromycin	nelfinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e2> delavirdine </e2> ) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	erythromycin	delavirdine
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e2> azole antifungals </e2> (e.g., ketoconazole, itraconazole, voriconazole).	0	erythromycin	azole antifungals
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2> ketoconazole </e2> , itraconazole, voriconazole).	0	erythromycin	ketoconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2> itraconazole </e2> , voriconazole).	0	erythromycin	itraconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., <e1> erythromycin </e1> , troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2> voriconazole </e2> ).	0	erythromycin	voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1> troleandomycin </e1> , <e2> clarithromycin </e2> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	troleandomycin	clarithromycin
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1> troleandomycin </e1> , clarithromycin), <e2> HIV protease inhibitors </e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	troleandomycin	HIV protease inhibitors
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1> troleandomycin </e1> , clarithromycin), HIV protease or <e2> reverse transcriptase inhibitors </e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	troleandomycin	reverse transcriptase inhibitors
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e2> ritonavir </e2> , indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	troleandomycin	ritonavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	troleandomycin	indinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e2> nelfinavir </e2> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	troleandomycin	nelfinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e2> delavirdine </e2> ) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	troleandomycin	delavirdine
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e2> azole antifungals </e2> (e.g., ketoconazole, itraconazole, voriconazole).	0	troleandomycin	azole antifungals
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2> ketoconazole </e2> , itraconazole, voriconazole).	0	troleandomycin	ketoconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2> itraconazole </e2> , voriconazole).	0	troleandomycin	itraconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, <e1> troleandomycin </e1> , clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2> voriconazole </e2> ).	0	troleandomycin	voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1> clarithromycin </e1> ), <e2> HIV protease inhibitors </e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	clarithromycin	HIV protease inhibitors
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1> clarithromycin </e1> ), HIV protease or <e2> reverse transcriptase inhibitors </e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	clarithromycin	reverse transcriptase inhibitors
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase inhibitors (e.g., <e2> ritonavir </e2> , indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	clarithromycin	ritonavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	clarithromycin	indinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e2> nelfinavir </e2> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	clarithromycin	nelfinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e2> delavirdine </e2> ) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	clarithromycin	delavirdine
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e2> azole antifungals </e2> (e.g., ketoconazole, itraconazole, voriconazole).	0	clarithromycin	azole antifungals
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2> ketoconazole </e2> , itraconazole, voriconazole).	0	clarithromycin	ketoconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2> itraconazole </e2> , voriconazole).	0	clarithromycin	itraconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, <e1> clarithromycin </e1> ), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2> voriconazole </e2> ).	0	clarithromycin	voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1> HIV protease inhibitors </e1> - <e2> reverse transcriptase inhibitors </e2> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	HIV protease inhibitors	reverse transcriptase inhibitors
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1> HIV protease inhibitors </e1> (e.g., <e2> ritonavir </e2> , indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	HIV protease inhibitors	ritonavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1> HIV protease inhibitors </e1> (e.g., ritonavir, <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	HIV protease inhibitors	indinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1> HIV protease inhibitors </e1> (e.g., ritonavir, indinavir, <e2> nelfinavir </e2> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	HIV protease inhibitors	nelfinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1> HIV protease inhibitors </e1> (e.g., ritonavir, indinavir, nelfinavir, <e2> delavirdine </e2> ) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	HIV protease inhibitors	delavirdine
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1> HIV protease inhibitors </e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e2> azole antifungals </e2> (e.g., ketoconazole, itraconazole, voriconazole).	0	HIV protease inhibitors	azole antifungals
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1> HIV protease inhibitors </e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2> ketoconazole </e2> , itraconazole, voriconazole).	0	HIV protease inhibitors	ketoconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1> HIV protease inhibitors </e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2> itraconazole </e2> , voriconazole).	0	HIV protease inhibitors	itraconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), <e1> HIV protease inhibitors </e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2> voriconazole </e2> ).	0	HIV protease inhibitors	voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1> reverse transcriptase inhibitors </e1> (e.g., <e2> ritonavir </e2> , indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	reverse transcriptase inhibitors	ritonavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1> reverse transcriptase inhibitors </e1> (e.g., ritonavir, <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	reverse transcriptase inhibitors	indinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1> reverse transcriptase inhibitors </e1> (e.g., ritonavir, indinavir, <e2> nelfinavir </e2> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	reverse transcriptase inhibitors	nelfinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1> reverse transcriptase inhibitors </e1> (e.g., ritonavir, indinavir, nelfinavir, <e2> delavirdine </e2> ) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	reverse transcriptase inhibitors	delavirdine
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1> reverse transcriptase inhibitors </e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e2> azole antifungals </e2> (e.g., ketoconazole, itraconazole, voriconazole).	0	reverse transcriptase inhibitors	azole antifungals
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1> reverse transcriptase inhibitors </e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2> ketoconazole </e2> , itraconazole, voriconazole).	0	reverse transcriptase inhibitors	ketoconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1> reverse transcriptase inhibitors </e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2> itraconazole </e2> , voriconazole).	0	reverse transcriptase inhibitors	itraconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or <e1> reverse transcriptase inhibitors </e1> (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2> voriconazole </e2> ).	0	reverse transcriptase inhibitors	voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1> ritonavir </e1> , <e2> indinavir </e2> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	ritonavir	indinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1> ritonavir </e1> , indinavir, <e2> nelfinavir </e2> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	ritonavir	nelfinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1> ritonavir </e1> , indinavir, nelfinavir, <e2> delavirdine </e2> ) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	ritonavir	delavirdine
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1> ritonavir </e1> , indinavir, nelfinavir, delavirdine) or <e2> azole antifungals </e2> (e.g., ketoconazole, itraconazole, voriconazole).	0	ritonavir	azole antifungals
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1> ritonavir </e1> , indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e2> ketoconazole </e2> , itraconazole, voriconazole).	0	ritonavir	ketoconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1> ritonavir </e1> , indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2> itraconazole </e2> , voriconazole).	0	ritonavir	itraconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., <e1> ritonavir </e1> , indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2> voriconazole </e2> ).	0	ritonavir	voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e1> indinavir </e1> , <e2> nelfinavir </e2> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	indinavir	nelfinavir
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e1> indinavir </e1> , nelfinavir, <e2> delavirdine </e2> ) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	indinavir	delavirdine
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e1> indinavir </e1> , nelfinavir, delavirdine) or <e2> azole antifungals </e2> (e.g., ketoconazole, itraconazole, voriconazole).	0	indinavir	azole antifungals
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e1> indinavir </e1> , nelfinavir, delavirdine) or azole antifungals (e.g., <e2> ketoconazole </e2> , itraconazole, voriconazole).	0	indinavir	ketoconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e1> indinavir </e1> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e2> itraconazole </e2> , voriconazole).	0	indinavir	itraconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, <e1> indinavir </e1> , nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2> voriconazole </e2> ).	0	indinavir	voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e1> nelfinavir </e1> , <e2> delavirdine </e2> ) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).	0	nelfinavir	delavirdine
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e1> nelfinavir </e1> , delavirdine) or <e2> azole antifungals </e2> (e.g., ketoconazole, itraconazole, voriconazole).	0	nelfinavir	azole antifungals
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e1> nelfinavir </e1> , delavirdine) or azole antifungals (e.g., <e2> ketoconazole </e2> , itraconazole, voriconazole).	0	nelfinavir	ketoconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e1> nelfinavir </e1> , delavirdine) or azole antifungals (e.g., ketoconazole, <e2> itraconazole </e2> , voriconazole).	0	nelfinavir	itraconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, <e1> nelfinavir </e1> , delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, <e2> voriconazole </e2> ).	0	nelfinavir	voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e1> delavirdine </e1> ) or <e2> azole antifungals </e2> (e.g., ketoconazole, itraconazole, voriconazole).	0	delavirdine	azole antifungals
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e1> delavirdine </e1> ) or azole antifungals (e.g., <e2> ketoconazole </e2> , itraconazole, voriconazole).	0	delavirdine	ketoconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e1> delavirdine </e1> ) or azole antifungals (e.g., ketoconazole, <e2> itraconazole </e2> , voriconazole).	0	delavirdine	itraconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, <e1> delavirdine </e1> ) or azole antifungals (e.g., ketoconazole, itraconazole, <e2> voriconazole </e2> ).	0	delavirdine	voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e1> azole antifungals </e1> (e.g., <e2> ketoconazole </e2> , itraconazole, voriconazole).	0	azole antifungals	ketoconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e1> azole antifungals </e1> (e.g., ketoconazole, <e2> itraconazole </e2> , voriconazole).	0	azole antifungals	itraconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or <e1> azole antifungals </e1> (e.g., ketoconazole, itraconazole, <e2> voriconazole </e2> ).	0	azole antifungals	voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e1> ketoconazole </e1> , <e2> itraconazole </e2> , voriconazole).	0	ketoconazole	itraconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., <e1> ketoconazole </e1> , itraconazole, <e2> voriconazole </e2> ).	0	ketoconazole	voriconazole
Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, <e1> itraconazole </e1> , <e2> voriconazole </e2> ).	0	itraconazole	voriconazole
Less potent inhibitors include <e1> saquinavir </e1> , <e2> nefazodone </e2> , fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	0	saquinavir	nefazodone
Less potent inhibitors include <e1> saquinavir </e1> , nefazodone, <e2> fluconazole </e2> , grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	0	saquinavir	fluconazole
Less potent inhibitors include <e1> saquinavir </e1> , nefazodone, fluconazole, grapefruit juice, <e2> fluoxetine </e2> , fluvoxamine, zileuton, and clotrimazole.	0	saquinavir	fluoxetine
Less potent inhibitors include <e1> saquinavir </e1> , nefazodone, fluconazole, grapefruit juice, fluoxetine, <e2> fluvoxamine </e2> , zileuton, and clotrimazole.	0	saquinavir	fluvoxamine
Less potent inhibitors include <e1> saquinavir </e1> , nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, <e2> zileuton </e2> , and clotrimazole.	0	saquinavir	zileuton
Less potent inhibitors include <e1> saquinavir </e1> , nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and <e2> clotrimazole </e2> .	0	saquinavir	clotrimazole
Less potent inhibitors include saquinavir, <e1> nefazodone </e1> , <e2> fluconazole </e2> , grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.	0	nefazodone	fluconazole
Less potent inhibitors include saquinavir, <e1> nefazodone </e1> , fluconazole, grapefruit juice, <e2> fluoxetine </e2> , fluvoxamine, zileuton, and clotrimazole.	0	nefazodone	fluoxetine
Less potent inhibitors include saquinavir, <e1> nefazodone </e1> , fluconazole, grapefruit juice, fluoxetine, <e2> fluvoxamine </e2> , zileuton, and clotrimazole.	0	nefazodone	fluvoxamine
Less potent inhibitors include saquinavir, <e1> nefazodone </e1> , fluconazole, grapefruit juice, fluoxetine, fluvoxamine, <e2> zileuton </e2> , and clotrimazole.	0	nefazodone	zileuton
Less potent inhibitors include saquinavir, <e1> nefazodone </e1> , fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and <e2> clotrimazole </e2> .	0	nefazodone	clotrimazole
Less potent inhibitors include saquinavir, nefazodone, <e1> fluconazole </e1> , grapefruit juice, <e2> fluoxetine </e2> , fluvoxamine, zileuton, and clotrimazole.	0	fluconazole	fluoxetine
Less potent inhibitors include saquinavir, nefazodone, <e1> fluconazole </e1> , grapefruit juice, fluoxetine, <e2> fluvoxamine </e2> , zileuton, and clotrimazole.	0	fluconazole	fluvoxamine
Less potent inhibitors include saquinavir, nefazodone, <e1> fluconazole </e1> , grapefruit juice, fluoxetine, fluvoxamine, <e2> zileuton </e2> , and clotrimazole.	0	fluconazole	zileuton
Less potent inhibitors include saquinavir, nefazodone, <e1> fluconazole </e1> , grapefruit juice, fluoxetine, fluvoxamine, zileuton, and <e2> clotrimazole </e2> .	0	fluconazole	clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, <e1> fluoxetine </e1> , <e2> fluvoxamine </e2> , zileuton, and clotrimazole.	0	fluoxetine	fluvoxamine
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, <e1> fluoxetine </e1> , fluvoxamine, <e2> zileuton </e2> , and clotrimazole.	0	fluoxetine	zileuton
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, <e1> fluoxetine </e1> , fluvoxamine, zileuton, and <e2> clotrimazole </e2> .	0	fluoxetine	clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, <e1> fluvoxamine </e1> , <e2> zileuton </e2> , and clotrimazole.	0	fluvoxamine	zileuton
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, <e1> fluvoxamine </e1> , zileuton, and <e2> clotrimazole </e2> .	0	fluvoxamine	clotrimazole
Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, <e1> zileuton </e1> , and <e2> clotrimazole </e2> .	0	zileuton	clotrimazole
Caution should be exercised when <e1> Methergine </e1> ( <e2> methylergonovine maleate </e2> ) is used concurrently with other vasoconstrictors or ergot alkaloids.	0	Methergine	methylergonovine maleate
Caution should be exercised when <e1> Methergine </e1> (methylergonovine maleate) is used concurrently with other <e2> vasoconstrictors </e2> or ergot alkaloids.	0	Methergine	vasoconstrictors
Caution should be exercised when <e1> Methergine </e1> (methylergonovine maleate) is used concurrently with other vasoconstrictors or <e2> ergot alkaloids </e2> .	0	Methergine	ergot alkaloids
Caution should be exercised when Methergine ( <e1> methylergonovine maleate </e1> ) is used concurrently with other <e2> vasoconstrictors </e2> or ergot alkaloids.	0	methylergonovine maleate	vasoconstrictors
Caution should be exercised when Methergine ( <e1> methylergonovine maleate </e1> ) is used concurrently with other vasoconstrictors or <e2> ergot alkaloids </e2> .	0	methylergonovine maleate	ergot alkaloids
Caution should be exercised when Methergine (methylergonovine maleate) is used concurrently with other <e1> vasoconstrictors </e1> or <e2> ergot alkaloids </e2> .	0	vasoconstrictors	ergot alkaloids
Concomitant administration of substances that are also tubularly secreted (e.g., <e1> probenecid </e1> ) could potentially result in delayed clearance of <e2> ALIMTA </e2> .	1	probenecid	ALIMTA
Although <e1> ibuprofen </e1> (400 mg qid) can be administered with <e2> ALIMTA </e2> in patients with normal renal function (creatinine clearance 80 mL/min), caution should be used when administering ibuprofen concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).	0	ibuprofen	ALIMTA
Although <e1> ibuprofen </e1> (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance 80 mL/min), caution should be used when administering ibuprofen concurrently with <e2> ALIMTA </e2> to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).	0	ibuprofen	ALIMTA
Although ibuprofen (400 mg qid) can be administered with <e1> ALIMTA </e1> in patients with normal renal function (creatinine clearance 80 mL/min), caution should be used when administering <e2> ibuprofen </e2> concurrently with ALIMTA to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).	0	ALIMTA	ibuprofen
Although ibuprofen (400 mg qid) can be administered with ALIMTA in patients with normal renal function (creatinine clearance 80 mL/min), caution should be used when administering <e1> ibuprofen </e1> concurrently with <e2> ALIMTA </e2> to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).	0	ibuprofen	ALIMTA
Patients with mild to moderate renal insufficiency should avoid taking <e1> NSAIDs </e1> with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of <e2> ALIMTA </e2> .	0	NSAIDs	ALIMTA
In the absence of data regarding potential interaction between <e1> ALIMTA </e1> and <e2> NSAIDs </e2> with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.	0	ALIMTA	NSAIDs
In the absence of data regarding potential interaction between <e1> ALIMTA </e1> and NSAIDs with longer half-lives, all patients taking these <e2> NSAIDs </e2> should interrupt dosing for at least 5 days before, the day of, and 2 days following ALIMTA administration.	0	ALIMTA	NSAIDs
In the absence of data regarding potential interaction between ALIMTA and <e1> NSAIDs </e1> with longer half-lives, all patients taking these NSAIDs should interrupt dosing for at least 5 days before, the day of, and 2 days following <e2> ALIMTA </e2> administration.	0	NSAIDs	ALIMTA
In the absence of data regarding potential interaction between ALIMTA and NSAIDs with longer half-lives, all patients taking these <e1> NSAIDs </e1> should interrupt dosing for at least 5 days before, the day of, and 2 days following <e2> ALIMTA </e2> administration.	0	NSAIDs	ALIMTA
<e1> Carbidopa </e1> / <e2> Levodopa </e2> : Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).	0	Carbidopa	Levodopa
<e1> Carbidopa </e1> /Levodopa: Carbidopa/ <e2> Levodopa </e2> does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).	0	Carbidopa	Levodopa
<e1> Carbidopa </e1> /Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of <e2> pramipexole </e2> in healthy volunteers (N= 10).	0	Carbidopa	pramipexole
Carbidopa/ <e1> Levodopa </e1> : <e2> Carbidopa </e2> /Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).	0	Levodopa	Carbidopa
Carbidopa/ <e1> Levodopa </e1> : Carbidopa/Levodopa does not influence the pharmacokinetics of <e2> pramipexole </e2> in healthy volunteers (N= 10).	0	Levodopa	pramipexole
Carbidopa/Levodopa: <e1> Carbidopa </e1> / <e2> Levodopa </e2> does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10).	0	Carbidopa	Levodopa
Carbidopa/Levodopa: <e1> Carbidopa </e1> /Levodopa does not influence the pharmacokinetics of <e2> pramipexole </e2> in healthy volunteers (N= 10).	0	Carbidopa	pramipexole
Carbidopa/Levodopa: Carbidopa/ <e1> Levodopa </e1> does not influence the pharmacokinetics of <e2> pramipexole </e2> in healthy volunteers (N= 10).	0	Levodopa	pramipexole
<e1> Selegiline </e1> : In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of <e2> pramipexole </e2> .	0	Selegiline	pramipexole
Selegiline: In healthy volunteers (N= 11), <e1> selegiline </e1> did not influence the pharmacokinetics of <e2> pramipexole </e2> .	0	selegiline	pramipexole
<e1> Amantadine </e1> : Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of <e2> pramipexole </e2> (N= 54).	0	Amantadine	pramipexole
Amantadine: Population pharmacokinetic analysis suggests that <e1> amantadine </e1> is unlikely to alter the oral clearance of <e2> pramipexole </e2> (N= 54).	0	amantadine	pramipexole
<e1> Cimetidine </e1> : Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in <e2> pramipexole </e2> AUC and a 40% increase in half-life (N= 12).	0	Cimetidine	pramipexole
Cimetidine: <e1> Cimetidine </e1> , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in <e2> pramipexole </e2> AUC and a 40% increase in half-life (N= 12).	1	Cimetidine	pramipexole
<e1> Probenecid </e1> : Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence <e2> pramipexole </e2> pharmacokinetics (N= 12).	0	Probenecid	pramipexole
Probenecid: <e1> Probenecid </e1> , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence <e2> pramipexole </e2> pharmacokinetics (N= 12).	0	Probenecid	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , <e2> ranitidine </e2> , diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cimetidine	ranitidine
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , ranitidine, <e2> diltiazem </e2> , triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cimetidine	diltiazem
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , ranitidine, diltiazem, <e2> triamterene </e2> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cimetidine	triamterene
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , ranitidine, diltiazem, triamterene, <e2> verapamil </e2> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cimetidine	verapamil
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , ranitidine, diltiazem, triamterene, verapamil, <e2> quinidine </e2> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cimetidine	quinidine
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e2> quinine </e2> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cimetidine	quinine
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e2> pramipexole </e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	1	cimetidine	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2> cephalosporins </e2> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cimetidine	cephalosporins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cimetidine	penicillins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2> indomethacin </e2> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cimetidine	indomethacin
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cimetidine	hydrochlorothiazide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole.	0	cimetidine	chlorpropamide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., <e1> cimetidine </e1> , ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2> pramipexole </e2> .	0	cimetidine	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1> ranitidine </e1> , <e2> diltiazem </e2> , triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	ranitidine	diltiazem
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1> ranitidine </e1> , diltiazem, <e2> triamterene </e2> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	ranitidine	triamterene
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1> ranitidine </e1> , diltiazem, triamterene, <e2> verapamil </e2> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	ranitidine	verapamil
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1> ranitidine </e1> , diltiazem, triamterene, verapamil, <e2> quinidine </e2> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	ranitidine	quinidine
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1> ranitidine </e1> , diltiazem, triamterene, verapamil, quinidine, and <e2> quinine </e2> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	ranitidine	quinine
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1> ranitidine </e1> , diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e2> pramipexole </e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	1	ranitidine	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1> ranitidine </e1> , diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2> cephalosporins </e2> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	ranitidine	cephalosporins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1> ranitidine </e1> , diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	ranitidine	penicillins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1> ranitidine </e1> , diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2> indomethacin </e2> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	ranitidine	indomethacin
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1> ranitidine </e1> , diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	ranitidine	hydrochlorothiazide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1> ranitidine </e1> , diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole.	0	ranitidine	chlorpropamide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, <e1> ranitidine </e1> , diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2> pramipexole </e2> .	0	ranitidine	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1> diltiazem </e1> , <e2> triamterene </e2> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	diltiazem	triamterene
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1> diltiazem </e1> , triamterene, <e2> verapamil </e2> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	diltiazem	verapamil
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1> diltiazem </e1> , triamterene, verapamil, <e2> quinidine </e2> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	diltiazem	quinidine
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1> diltiazem </e1> , triamterene, verapamil, quinidine, and <e2> quinine </e2> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	diltiazem	quinine
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1> diltiazem </e1> , triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e2> pramipexole </e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	1	diltiazem	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1> diltiazem </e1> , triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2> cephalosporins </e2> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	diltiazem	cephalosporins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1> diltiazem </e1> , triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	diltiazem	penicillins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1> diltiazem </e1> , triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2> indomethacin </e2> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	diltiazem	indomethacin
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1> diltiazem </e1> , triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	diltiazem	hydrochlorothiazide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1> diltiazem </e1> , triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole.	0	diltiazem	chlorpropamide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, <e1> diltiazem </e1> , triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2> pramipexole </e2> .	0	diltiazem	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1> triamterene </e1> , <e2> verapamil </e2> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	triamterene	verapamil
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1> triamterene </e1> , verapamil, <e2> quinidine </e2> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	triamterene	quinidine
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1> triamterene </e1> , verapamil, quinidine, and <e2> quinine </e2> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	triamterene	quinine
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1> triamterene </e1> , verapamil, quinidine, and quinine) decreases the oral clearance of <e2> pramipexole </e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	1	triamterene	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1> triamterene </e1> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2> cephalosporins </e2> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	triamterene	cephalosporins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1> triamterene </e1> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	triamterene	penicillins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1> triamterene </e1> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2> indomethacin </e2> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	triamterene	indomethacin
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1> triamterene </e1> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	triamterene	hydrochlorothiazide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1> triamterene </e1> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole.	0	triamterene	chlorpropamide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, <e1> triamterene </e1> , verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2> pramipexole </e2> .	0	triamterene	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1> verapamil </e1> , <e2> quinidine </e2> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	verapamil	quinidine
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1> verapamil </e1> , quinidine, and <e2> quinine </e2> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	verapamil	quinine
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of <e2> pramipexole </e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	1	verapamil	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2> cephalosporins </e2> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	verapamil	cephalosporins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	verapamil	penicillins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2> indomethacin </e2> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	verapamil	indomethacin
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	verapamil	hydrochlorothiazide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole.	0	verapamil	chlorpropamide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, <e1> verapamil </e1> , quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2> pramipexole </e2> .	0	verapamil	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1> quinidine </e1> , and <e2> quinine </e2> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	quinidine	quinine
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1> quinidine </e1> , and quinine) decreases the oral clearance of <e2> pramipexole </e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	1	quinidine	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1> quinidine </e1> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2> cephalosporins </e2> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	quinidine	cephalosporins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1> quinidine </e1> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	quinidine	penicillins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1> quinidine </e1> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2> indomethacin </e2> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	quinidine	indomethacin
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1> quinidine </e1> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	quinidine	hydrochlorothiazide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1> quinidine </e1> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole.	0	quinidine	chlorpropamide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, <e1> quinidine </e1> , and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2> pramipexole </e2> .	0	quinidine	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1> quinine </e1> ) decreases the oral clearance of <e2> pramipexole </e2> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	1	quinine	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1> quinine </e1> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e2> cephalosporins </e2> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	quinine	cephalosporins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1> quinine </e1> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	quinine	penicillins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1> quinine </e1> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2> indomethacin </e2> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	quinine	indomethacin
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1> quinine </e1> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	quinine	hydrochlorothiazide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1> quinine </e1> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole.	0	quinine	chlorpropamide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and <e1> quinine </e1> ) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2> pramipexole </e2> .	0	quinine	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e1> pramipexole </e1> by about 20%, while those secreted by the anionic transport system (e.g., <e2> cephalosporins </e2> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	pramipexole	cephalosporins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e1> pramipexole </e1> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	pramipexole	penicillins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e1> pramipexole </e1> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e2> indomethacin </e2> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	pramipexole	indomethacin
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e1> pramipexole </e1> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	pramipexole	hydrochlorothiazide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of <e1> pramipexole </e1> by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole.	0	pramipexole	chlorpropamide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e1> cephalosporins </e1> , <e2> penicillins </e2> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cephalosporins	penicillins
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e1> cephalosporins </e1> , penicillins, <e2> indomethacin </e2> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cephalosporins	indomethacin
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e1> cephalosporins </e1> , penicillins, indomethacin, <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	cephalosporins	hydrochlorothiazide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e1> cephalosporins </e1> , penicillins, indomethacin, hydrochlorothiazide, and <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole.	0	cephalosporins	chlorpropamide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., <e1> cephalosporins </e1> , penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2> pramipexole </e2> .	1	cephalosporins	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e1> penicillins </e1> , <e2> indomethacin </e2> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	penicillins	indomethacin
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e1> penicillins </e1> , indomethacin, <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	penicillins	hydrochlorothiazide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e1> penicillins </e1> , indomethacin, hydrochlorothiazide, and <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole.	0	penicillins	chlorpropamide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, <e1> penicillins </e1> , indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2> pramipexole </e2> .	1	penicillins	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e1> indomethacin </e1> , <e2> hydrochlorothiazide </e2> , and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole.	0	indomethacin	hydrochlorothiazide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e1> indomethacin </e1> , hydrochlorothiazide, and <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole.	0	indomethacin	chlorpropamide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, <e1> indomethacin </e1> , hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of <e2> pramipexole </e2> .	1	indomethacin	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e1> hydrochlorothiazide </e1> , and <e2> chlorpropamide </e2> ) are likely to have little effect on the oral clearance of pramipexole.	0	hydrochlorothiazide	chlorpropamide
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, <e1> hydrochlorothiazide </e1> , and chlorpropamide) are likely to have little effect on the oral clearance of <e2> pramipexole </e2> .	1	hydrochlorothiazide	pramipexole
Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and <e1> chlorpropamide </e1> ) are likely to have little effect on the oral clearance of <e2> pramipexole </e2> .	1	chlorpropamide	pramipexole
<e1> Dopamine antagonists </e1> : Since <e2> pramipexole </e2> is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	Dopamine antagonists	pramipexole
<e1> Dopamine antagonists </e1> : Since pramipexole is a <e2> dopamine agonist </e2> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	Dopamine antagonists	dopamine agonist
<e1> Dopamine antagonists </e1> : Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e2> neuroleptics </e2> (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	Dopamine antagonists	neuroleptics
<e1> Dopamine antagonists </e1> : Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e2> phenothiazines </e2> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	Dopamine antagonists	phenothiazines
<e1> Dopamine antagonists </e1> : Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, <e2> butyrophenones </e2> , thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	Dopamine antagonists	butyrophenones
<e1> Dopamine antagonists </e1> : Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e2> thioxanthenes </e2> ) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	Dopamine antagonists	thioxanthenes
<e1> Dopamine antagonists </e1> : Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or <e2> metoclopramide </e2> , may diminish the effectiveness of MIRAPEX.	0	Dopamine antagonists	metoclopramide
<e1> Dopamine antagonists </e1> : Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2> MIRAPEX </e2> .	0	Dopamine antagonists	MIRAPEX
Dopamine antagonists: Since <e1> pramipexole </e1> is a <e2> dopamine agonist </e2> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	pramipexole	dopamine agonist
Dopamine antagonists: Since <e1> pramipexole </e1> is a dopamine agonist, it is possible that <e2> dopamine antagonists </e2> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	pramipexole	dopamine antagonists
Dopamine antagonists: Since <e1> pramipexole </e1> is a dopamine agonist, it is possible that dopamine antagonists, such as the <e2> neuroleptics </e2> (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	pramipexole	neuroleptics
Dopamine antagonists: Since <e1> pramipexole </e1> is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e2> phenothiazines </e2> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	pramipexole	phenothiazines
Dopamine antagonists: Since <e1> pramipexole </e1> is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, <e2> butyrophenones </e2> , thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	pramipexole	butyrophenones
Dopamine antagonists: Since <e1> pramipexole </e1> is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e2> thioxanthenes </e2> ) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	pramipexole	thioxanthenes
Dopamine antagonists: Since <e1> pramipexole </e1> is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or <e2> metoclopramide </e2> , may diminish the effectiveness of MIRAPEX.	0	pramipexole	metoclopramide
Dopamine antagonists: Since <e1> pramipexole </e1> is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2> MIRAPEX </e2> .	0	pramipexole	MIRAPEX
Dopamine antagonists: Since pramipexole is a <e1> dopamine agonist </e1> , it is possible that <e2> dopamine antagonists </e2> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	dopamine agonist	dopamine antagonists
Dopamine antagonists: Since pramipexole is a <e1> dopamine agonist </e1> , it is possible that dopamine antagonists, such as the <e2> neuroleptics </e2> (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	dopamine agonist	neuroleptics
Dopamine antagonists: Since pramipexole is a <e1> dopamine agonist </e1> , it is possible that dopamine antagonists, such as the neuroleptics ( <e2> phenothiazines </e2> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	dopamine agonist	phenothiazines
Dopamine antagonists: Since pramipexole is a <e1> dopamine agonist </e1> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, <e2> butyrophenones </e2> , thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	dopamine agonist	butyrophenones
Dopamine antagonists: Since pramipexole is a <e1> dopamine agonist </e1> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e2> thioxanthenes </e2> ) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	dopamine agonist	thioxanthenes
Dopamine antagonists: Since pramipexole is a <e1> dopamine agonist </e1> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or <e2> metoclopramide </e2> , may diminish the effectiveness of MIRAPEX.	0	dopamine agonist	metoclopramide
Dopamine antagonists: Since pramipexole is a <e1> dopamine agonist </e1> , it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2> MIRAPEX </e2> .	0	dopamine agonist	MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1> dopamine antagonists </e1> , such as the <e2> neuroleptics </e2> (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	dopamine antagonists	neuroleptics
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1> dopamine antagonists </e1> , such as the neuroleptics ( <e2> phenothiazines </e2> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	dopamine antagonists	phenothiazines
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1> dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, <e2> butyrophenones </e2> , thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	dopamine antagonists	butyrophenones
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1> dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones, <e2> thioxanthenes </e2> ) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	dopamine antagonists	thioxanthenes
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1> dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or <e2> metoclopramide </e2> , may diminish the effectiveness of MIRAPEX.	0	dopamine antagonists	metoclopramide
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that <e1> dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2> MIRAPEX </e2> .	1	dopamine antagonists	MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e1> neuroleptics </e1> ( <e2> phenothiazines </e2> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	neuroleptics	phenothiazines
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e1> neuroleptics </e1> (phenothiazines, <e2> butyrophenones </e2> , thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	neuroleptics	butyrophenones
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e1> neuroleptics </e1> (phenothiazines, butyrophenones, <e2> thioxanthenes </e2> ) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	neuroleptics	thioxanthenes
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e1> neuroleptics </e1> (phenothiazines, butyrophenones, thioxanthenes) or <e2> metoclopramide </e2> , may diminish the effectiveness of MIRAPEX.	0	neuroleptics	metoclopramide
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the <e1> neuroleptics </e1> (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2> MIRAPEX </e2> .	1	neuroleptics	MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , <e2> butyrophenones </e2> , thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	phenothiazines	butyrophenones
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , butyrophenones, <e2> thioxanthenes </e2> ) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	phenothiazines	thioxanthenes
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , butyrophenones, thioxanthenes) or <e2> metoclopramide </e2> , may diminish the effectiveness of MIRAPEX.	0	phenothiazines	metoclopramide
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2> MIRAPEX </e2> .	1	phenothiazines	MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, <e1> butyrophenones </e1> , <e2> thioxanthenes </e2> ) or metoclopramide, may diminish the effectiveness of MIRAPEX.	0	butyrophenones	thioxanthenes
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, <e1> butyrophenones </e1> , thioxanthenes) or <e2> metoclopramide </e2> , may diminish the effectiveness of MIRAPEX.	0	butyrophenones	metoclopramide
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, <e1> butyrophenones </e1> , thioxanthenes) or metoclopramide, may diminish the effectiveness of <e2> MIRAPEX </e2> .	1	butyrophenones	MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e1> thioxanthenes </e1> ) or <e2> metoclopramide </e2> , may diminish the effectiveness of MIRAPEX.	0	thioxanthenes	metoclopramide
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e1> thioxanthenes </e1> ) or metoclopramide, may diminish the effectiveness of <e2> MIRAPEX </e2> .	1	thioxanthenes	MIRAPEX
Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or <e1> metoclopramide </e1> , may diminish the effectiveness of <e2> MIRAPEX </e2> .	1	metoclopramide	MIRAPEX
<e1> Mitotane </e1> has been reported to accelerate the metabolism of <e2> warfarin </e2> by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin.	1	Mitotane	warfarin
<e1> Mitotane </e1> has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for <e2> warfarin </e2> .	0	Mitotane	warfarin
Therefore, physicians should closely monitor patients for a change in <e1> anticoagulant </e1> dosage requirements when administering <e2> Mitotane </e2> to patients on coumarin-type anticoagulants.	0	anticoagulant	Mitotane
Therefore, physicians should closely monitor patients for a change in <e1> anticoagulant </e1> dosage requirements when administering Mitotane to patients on <e2> coumarin-type anticoagulants </e2> .	0	anticoagulant	coumarin-type anticoagulants
Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering <e1> Mitotane </e1> to patients on <e2> coumarin-type anticoagulants </e2> .	0	Mitotane	coumarin-type anticoagulants
Caution should be observed in administering <e1> DEMSER </e1> to patients receiving <e2> phenothiazines </e2> or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.	0	DEMSER	phenothiazines
Caution should be observed in administering <e1> DEMSER </e1> to patients receiving phenothiazines or <e2> haloperidol </e2> because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.	0	DEMSER	haloperidol
Caution should be observed in administering DEMSER to patients receiving <e1> phenothiazines </e1> or <e2> haloperidol </e2> because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.	0	phenothiazines	haloperidol
Concurrent use of <e1> DEMSER </e1> with <e2> alcohol </e2> or other CNS depressants can increase their sedative effects.	1	DEMSER	alcohol
Concurrent use of <e1> DEMSER </e1> with alcohol or other <e2> CNS depressants </e2> can increase their sedative effects.	1	DEMSER	CNS depressants
Concurrent use of DEMSER with <e1> alcohol </e1> or other <e2> CNS depressants </e2> can increase their sedative effects.	0	alcohol	CNS depressants
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e1> midazolam </e1> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of <e2> azole antimycotics </e2> , protease inhibitors, calcium channel antagonists, and macrolide antibiotics).	0	midazolam	azole antimycotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e1> midazolam </e1> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, <e2> protease inhibitors </e2> , calcium channel antagonists, and macrolide antibiotics).	0	midazolam	protease inhibitors
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e1> midazolam </e1> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, <e2> calcium channel antagonists </e2> , and macrolide antibiotics).	0	midazolam	calcium channel antagonists
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when <e1> midazolam </e1> is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and <e2> macrolide antibiotics </e2> ).	0	midazolam	macrolide antibiotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of <e1> azole antimycotics </e1> , <e2> protease inhibitors </e2> , calcium channel antagonists, and macrolide antibiotics).	0	azole antimycotics	protease inhibitors
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of <e1> azole antimycotics </e1> , protease inhibitors, <e2> calcium channel antagonists </e2> , and macrolide antibiotics).	0	azole antimycotics	calcium channel antagonists
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of <e1> azole antimycotics </e1> , protease inhibitors, calcium channel antagonists, and <e2> macrolide antibiotics </e2> ).	0	azole antimycotics	macrolide antibiotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, <e1> protease inhibitors </e1> , <e2> calcium channel antagonists </e2> , and macrolide antibiotics).	0	protease inhibitors	calcium channel antagonists
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, <e1> protease inhibitors </e1> , calcium channel antagonists, and <e2> macrolide antibiotics </e2> ).	0	protease inhibitors	macrolide antibiotics
Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, <e1> calcium channel antagonists </e1> , and <e2> macrolide antibiotics </e2> ).	0	calcium channel antagonists	macrolide antibiotics
Drugs such as <e1> erythromycin </e1> , <e2> diltiazem </e2> , verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	0	erythromycin	diltiazem
Drugs such as <e1> erythromycin </e1> , diltiazem, <e2> verapamil </e2> , ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	0	erythromycin	verapamil
Drugs such as <e1> erythromycin </e1> , diltiazem, verapamil, <e2> ketoconazole </e2> , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	0	erythromycin	ketoconazole
Drugs such as <e1> erythromycin </e1> , diltiazem, verapamil, ketoconazole, <e2> fluconazole </e2> and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	0	erythromycin	fluconazole
Drugs such as <e1> erythromycin </e1> , diltiazem, verapamil, ketoconazole, fluconazole and <e2> itraconazole </e2> were shown to significantly increase the C max and AUC of orally administered midazolam.	0	erythromycin	itraconazole
Drugs such as <e1> erythromycin </e1> , diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2> midazolam </e2> .	1	erythromycin	midazolam
Drugs such as erythromycin, <e1> diltiazem </e1> , <e2> verapamil </e2> , ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	0	diltiazem	verapamil
Drugs such as erythromycin, <e1> diltiazem </e1> , verapamil, <e2> ketoconazole </e2> , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	0	diltiazem	ketoconazole
Drugs such as erythromycin, <e1> diltiazem </e1> , verapamil, ketoconazole, <e2> fluconazole </e2> and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	0	diltiazem	fluconazole
Drugs such as erythromycin, <e1> diltiazem </e1> , verapamil, ketoconazole, fluconazole and <e2> itraconazole </e2> were shown to significantly increase the C max and AUC of orally administered midazolam.	0	diltiazem	itraconazole
Drugs such as erythromycin, <e1> diltiazem </e1> , verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2> midazolam </e2> .	1	diltiazem	midazolam
Drugs such as erythromycin, diltiazem, <e1> verapamil </e1> , <e2> ketoconazole </e2> , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	0	verapamil	ketoconazole
Drugs such as erythromycin, diltiazem, <e1> verapamil </e1> , ketoconazole, <e2> fluconazole </e2> and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	0	verapamil	fluconazole
Drugs such as erythromycin, diltiazem, <e1> verapamil </e1> , ketoconazole, fluconazole and <e2> itraconazole </e2> were shown to significantly increase the C max and AUC of orally administered midazolam.	0	verapamil	itraconazole
Drugs such as erythromycin, diltiazem, <e1> verapamil </e1> , ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2> midazolam </e2> .	1	verapamil	midazolam
Drugs such as erythromycin, diltiazem, verapamil, <e1> ketoconazole </e1> , <e2> fluconazole </e2> and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam.	0	ketoconazole	fluconazole
Drugs such as erythromycin, diltiazem, verapamil, <e1> ketoconazole </e1> , fluconazole and <e2> itraconazole </e2> were shown to significantly increase the C max and AUC of orally administered midazolam.	0	ketoconazole	itraconazole
Drugs such as erythromycin, diltiazem, verapamil, <e1> ketoconazole </e1> , fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2> midazolam </e2> .	1	ketoconazole	midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, <e1> fluconazole </e1> and <e2> itraconazole </e2> were shown to significantly increase the C max and AUC of orally administered midazolam.	0	fluconazole	itraconazole
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, <e1> fluconazole </e1> and itraconazole were shown to significantly increase the C max and AUC of orally administered <e2> midazolam </e2> .	1	fluconazole	midazolam
Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and <e1> itraconazole </e1> were shown to significantly increase the C max and AUC of orally administered <e2> midazolam </e2> .	1	itraconazole	midazolam
Although not studied, the potent cytochrome P450 3A4 inhibitors <e1> ritonavir </e1> and <e2> nelfinavir </e2> may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam.	0	ritonavir	nelfinavir
Although not studied, the potent cytochrome P450 3A4 inhibitors <e1> ritonavir </e1> and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of <e2> midazolam </e2> .	1	ritonavir	midazolam
Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and <e1> nelfinavir </e1> may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of <e2> midazolam </e2> .	1	nelfinavir	midazolam
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as <e1> rifampin </e1> , <e2> carbamazepine </e2> , and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.	0	rifampin	carbamazepine
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as <e1> rifampin </e1> , carbamazepine, and <e2> phenytoin </e2> , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.	0	rifampin	phenytoin
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as <e1> rifampin </e1> , carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral <e2> midazolam </e2> in adult studies.	1	rifampin	midazolam
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, <e1> carbamazepine </e1> , and <e2> phenytoin </e2> , induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies.	0	carbamazepine	phenytoin
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, <e1> carbamazepine </e1> , and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral <e2> midazolam </e2> in adult studies.	1	carbamazepine	midazolam
Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and <e1> phenytoin </e1> , induce metabolism and caused a markedly decreased C max and AUC of oral <e2> midazolam </e2> in adult studies.	1	phenytoin	midazolam
The difficulty in achieving adequate sedation may have been the result of decreased absorption of the <e1> sedatives </e1> due to both the gastrointestinal effects and stimulant effects of <e2> methylphenidate </e2> .	0	sedatives	methylphenidate
The sedative effect of <e1> VERSED Syrup </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e2> narcotics </e2> (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	1	VERSED Syrup	narcotics
The sedative effect of <e1> VERSED Syrup </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e2> morphine </e2> , meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	1	VERSED Syrup	morphine
The sedative effect of <e1> VERSED Syrup </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e2> meperidine </e2> and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	1	VERSED Syrup	meperidine
The sedative effect of <e1> VERSED Syrup </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and <e2> fentanyl </e2> ), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	1	VERSED Syrup	fentanyl
The sedative effect of <e1> VERSED Syrup </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), <e2> propofol </e2> , ketamine, nitrous oxide, secobarbital and droperidol.	1	VERSED Syrup	propofol
The sedative effect of <e1> VERSED Syrup </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, <e2> ketamine </e2> , nitrous oxide, secobarbital and droperidol.	1	VERSED Syrup	ketamine
The sedative effect of <e1> VERSED Syrup </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, <e2> nitrous oxide </e2> , secobarbital and droperidol.	1	VERSED Syrup	nitrous oxide
The sedative effect of <e1> VERSED Syrup </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, <e2> secobarbital </e2> and droperidol.	1	VERSED Syrup	secobarbital
The sedative effect of <e1> VERSED Syrup </e1> is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and <e2> droperidol </e2> .	1	VERSED Syrup	droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1> narcotics </e1> (eg, <e2> morphine </e2> , meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	0	narcotics	morphine
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1> narcotics </e1> (eg, morphine, <e2> meperidine </e2> and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	0	narcotics	meperidine
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1> narcotics </e1> (eg, morphine, meperidine and <e2> fentanyl </e2> ), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	0	narcotics	fentanyl
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1> narcotics </e1> (eg, morphine, meperidine and fentanyl), <e2> propofol </e2> , ketamine, nitrous oxide, secobarbital and droperidol.	0	narcotics	propofol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1> narcotics </e1> (eg, morphine, meperidine and fentanyl), propofol, <e2> ketamine </e2> , nitrous oxide, secobarbital and droperidol.	0	narcotics	ketamine
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1> narcotics </e1> (eg, morphine, meperidine and fentanyl), propofol, ketamine, <e2> nitrous oxide </e2> , secobarbital and droperidol.	0	narcotics	nitrous oxide
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1> narcotics </e1> (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, <e2> secobarbital </e2> and droperidol.	0	narcotics	secobarbital
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly <e1> narcotics </e1> (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and <e2> droperidol </e2> .	0	narcotics	droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1> morphine </e1> , <e2> meperidine </e2> and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	0	morphine	meperidine
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1> morphine </e1> , meperidine and <e2> fentanyl </e2> ), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	0	morphine	fentanyl
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1> morphine </e1> , meperidine and fentanyl), <e2> propofol </e2> , ketamine, nitrous oxide, secobarbital and droperidol.	0	morphine	propofol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1> morphine </e1> , meperidine and fentanyl), propofol, <e2> ketamine </e2> , nitrous oxide, secobarbital and droperidol.	0	morphine	ketamine
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1> morphine </e1> , meperidine and fentanyl), propofol, ketamine, <e2> nitrous oxide </e2> , secobarbital and droperidol.	0	morphine	nitrous oxide
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1> morphine </e1> , meperidine and fentanyl), propofol, ketamine, nitrous oxide, <e2> secobarbital </e2> and droperidol.	0	morphine	secobarbital
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, <e1> morphine </e1> , meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and <e2> droperidol </e2> .	0	morphine	droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e1> meperidine </e1> and <e2> fentanyl </e2> ), propofol, ketamine, nitrous oxide, secobarbital and droperidol.	0	meperidine	fentanyl
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e1> meperidine </e1> and fentanyl), <e2> propofol </e2> , ketamine, nitrous oxide, secobarbital and droperidol.	0	meperidine	propofol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e1> meperidine </e1> and fentanyl), propofol, <e2> ketamine </e2> , nitrous oxide, secobarbital and droperidol.	0	meperidine	ketamine
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e1> meperidine </e1> and fentanyl), propofol, ketamine, <e2> nitrous oxide </e2> , secobarbital and droperidol.	0	meperidine	nitrous oxide
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e1> meperidine </e1> and fentanyl), propofol, ketamine, nitrous oxide, <e2> secobarbital </e2> and droperidol.	0	meperidine	secobarbital
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, <e1> meperidine </e1> and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and <e2> droperidol </e2> .	0	meperidine	droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and <e1> fentanyl </e1> ), <e2> propofol </e2> , ketamine, nitrous oxide, secobarbital and droperidol.	0	fentanyl	propofol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and <e1> fentanyl </e1> ), propofol, <e2> ketamine </e2> , nitrous oxide, secobarbital and droperidol.	0	fentanyl	ketamine
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and <e1> fentanyl </e1> ), propofol, ketamine, <e2> nitrous oxide </e2> , secobarbital and droperidol.	0	fentanyl	nitrous oxide
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and <e1> fentanyl </e1> ), propofol, ketamine, nitrous oxide, <e2> secobarbital </e2> and droperidol.	0	fentanyl	secobarbital
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and <e1> fentanyl </e1> ), propofol, ketamine, nitrous oxide, secobarbital and <e2> droperidol </e2> .	0	fentanyl	droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), <e1> propofol </e1> , <e2> ketamine </e2> , nitrous oxide, secobarbital and droperidol.	0	propofol	ketamine
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), <e1> propofol </e1> , ketamine, <e2> nitrous oxide </e2> , secobarbital and droperidol.	0	propofol	nitrous oxide
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), <e1> propofol </e1> , ketamine, nitrous oxide, <e2> secobarbital </e2> and droperidol.	0	propofol	secobarbital
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), <e1> propofol </e1> , ketamine, nitrous oxide, secobarbital and <e2> droperidol </e2> .	0	propofol	droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, <e1> ketamine </e1> , <e2> nitrous oxide </e2> , secobarbital and droperidol.	0	ketamine	nitrous oxide
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, <e1> ketamine </e1> , nitrous oxide, <e2> secobarbital </e2> and droperidol.	0	ketamine	secobarbital
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, <e1> ketamine </e1> , nitrous oxide, secobarbital and <e2> droperidol </e2> .	0	ketamine	droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, <e1> nitrous oxide </e1> , <e2> secobarbital </e2> and droperidol.	0	nitrous oxide	secobarbital
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, <e1> nitrous oxide </e1> , secobarbital and <e2> droperidol </e2> .	0	nitrous oxide	droperidol
The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, <e1> secobarbital </e1> and <e2> droperidol </e2> .	0	secobarbital	droperidol
No significant adverse interactions with common premedications (such as <e1> atropine </e1> , <e2> scopolamine </e2> , glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	0	atropine	scopolamine
No significant adverse interactions with common premedications (such as <e1> atropine </e1> , scopolamine, <e2> glycopyrrolate </e2> , diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	0	atropine	glycopyrrolate
No significant adverse interactions with common premedications (such as <e1> atropine </e1> , scopolamine, glycopyrrolate, <e2> diazepam </e2> , hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	0	atropine	diazepam
No significant adverse interactions with common premedications (such as <e1> atropine </e1> , scopolamine, glycopyrrolate, diazepam, <e2> hydroxyzine </e2> , and other muscle relaxants) or local anesthetics have been observed.	0	atropine	hydroxyzine
No significant adverse interactions with common premedications (such as <e1> atropine </e1> , scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other <e2> muscle relaxants </e2> ) or local anesthetics have been observed.	0	atropine	muscle relaxants
No significant adverse interactions with common premedications (such as <e1> atropine </e1> , scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local <e2> anesthetics </e2> have been observed.	0	atropine	anesthetics
No significant adverse interactions with common premedications (such as atropine, <e1> scopolamine </e1> , <e2> glycopyrrolate </e2> , diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	0	scopolamine	glycopyrrolate
No significant adverse interactions with common premedications (such as atropine, <e1> scopolamine </e1> , glycopyrrolate, <e2> diazepam </e2> , hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	0	scopolamine	diazepam
No significant adverse interactions with common premedications (such as atropine, <e1> scopolamine </e1> , glycopyrrolate, diazepam, <e2> hydroxyzine </e2> , and other muscle relaxants) or local anesthetics have been observed.	0	scopolamine	hydroxyzine
No significant adverse interactions with common premedications (such as atropine, <e1> scopolamine </e1> , glycopyrrolate, diazepam, hydroxyzine, and other <e2> muscle relaxants </e2> ) or local anesthetics have been observed.	0	scopolamine	muscle relaxants
No significant adverse interactions with common premedications (such as atropine, <e1> scopolamine </e1> , glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local <e2> anesthetics </e2> have been observed.	0	scopolamine	anesthetics
No significant adverse interactions with common premedications (such as atropine, scopolamine, <e1> glycopyrrolate </e1> , <e2> diazepam </e2> , hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.	0	glycopyrrolate	diazepam
No significant adverse interactions with common premedications (such as atropine, scopolamine, <e1> glycopyrrolate </e1> , diazepam, <e2> hydroxyzine </e2> , and other muscle relaxants) or local anesthetics have been observed.	0	glycopyrrolate	hydroxyzine
No significant adverse interactions with common premedications (such as atropine, scopolamine, <e1> glycopyrrolate </e1> , diazepam, hydroxyzine, and other <e2> muscle relaxants </e2> ) or local anesthetics have been observed.	0	glycopyrrolate	muscle relaxants
No significant adverse interactions with common premedications (such as atropine, scopolamine, <e1> glycopyrrolate </e1> , diazepam, hydroxyzine, and other muscle relaxants) or local <e2> anesthetics </e2> have been observed.	0	glycopyrrolate	anesthetics
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, <e1> diazepam </e1> , <e2> hydroxyzine </e2> , and other muscle relaxants) or local anesthetics have been observed.	0	diazepam	hydroxyzine
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, <e1> diazepam </e1> , hydroxyzine, and other <e2> muscle relaxants </e2> ) or local anesthetics have been observed.	0	diazepam	muscle relaxants
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, <e1> diazepam </e1> , hydroxyzine, and other muscle relaxants) or local <e2> anesthetics </e2> have been observed.	0	diazepam	anesthetics
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, <e1> hydroxyzine </e1> , and other <e2> muscle relaxants </e2> ) or local anesthetics have been observed.	0	hydroxyzine	muscle relaxants
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, <e1> hydroxyzine </e1> , and other muscle relaxants) or local <e2> anesthetics </e2> have been observed.	0	hydroxyzine	anesthetics
No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other <e1> muscle relaxants </e1> ) or local <e2> anesthetics </e2> have been observed.	0	muscle relaxants	anesthetics
The metabolism of <e1> Metopirone </e1> is accelerated by <e2> phenytoin </e2> ;	1	Metopirone	phenytoin
<e1> Metopirone </e1> inhibits the glucuronidation of <e2> acetaminophen </e2> and could possibly potentiate acetaminophen toxicity.	1	Metopirone	acetaminophen
<e1> Metopirone </e1> inhibits the glucuronidation of acetaminophen and could possibly potentiate <e2> acetaminophen </e2> toxicity.	1	Metopirone	acetaminophen
Some <e1> anticonvulsants </e1> may interact with <e2> Mephenytoin </e2> .	0	anticonvulsants	Mephenytoin
Those <e1> anticonvulsants </e1> include <e2> divalproex sodium </e2> , valproic acid, and phenobarbital.	0	anticonvulsants	divalproex sodium
Those <e1> anticonvulsants </e1> include divalproex sodium, <e2> valproic acid </e2> , and phenobarbital.	0	anticonvulsants	valproic acid
Those <e1> anticonvulsants </e1> include divalproex sodium, valproic acid, and <e2> phenobarbital </e2> .	0	anticonvulsants	phenobarbital
Those anticonvulsants include <e1> divalproex sodium </e1> , <e2> valproic acid </e2> , and phenobarbital.	0	divalproex sodium	valproic acid
Those anticonvulsants include <e1> divalproex sodium </e1> , valproic acid, and <e2> phenobarbital </e2> .	0	divalproex sodium	phenobarbital
Those anticonvulsants include divalproex sodium, <e1> valproic acid </e1> , and <e2> phenobarbital </e2> .	0	valproic acid	phenobarbital
<e1> Mephenytoin </e1> may also affect the effects of other drugs, which include some <e2> steroid medications </e2> , warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	1	Mephenytoin	steroid medications
<e1> Mephenytoin </e1> may also affect the effects of other drugs, which include some steroid medications, <e2> warfarin </e2> , certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	1	Mephenytoin	warfarin
<e1> Mephenytoin </e1> may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, <e2> anti-infective medicines </e2> , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	1	Mephenytoin	anti-infective medicines
<e1> Mephenytoin </e1> may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, <e2> furosemide </e2> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	1	Mephenytoin	furosemide
<e1> Mephenytoin </e1> may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and <e2> theophylline </e2> Please note that Mephenytoin may interact with other drugs that are not listed here.	1	Mephenytoin	theophylline
Mephenytoin may also affect the effects of other drugs, which include some <e1> steroid medications </e1> , <e2> warfarin </e2> , certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	0	steroid medications	warfarin
Mephenytoin may also affect the effects of other drugs, which include some <e1> steroid medications </e1> , warfarin, certain heart medicines, birth control pills, <e2> anti-infective medicines </e2> , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	0	steroid medications	anti-infective medicines
Mephenytoin may also affect the effects of other drugs, which include some <e1> steroid medications </e1> , warfarin, certain heart medicines, birth control pills, anti-infective medicines, <e2> furosemide </e2> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	0	steroid medications	furosemide
Mephenytoin may also affect the effects of other drugs, which include some <e1> steroid medications </e1> , warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and <e2> theophylline </e2> Please note that Mephenytoin may interact with other drugs that are not listed here.	0	steroid medications	theophylline
Mephenytoin may also affect the effects of other drugs, which include some <e1> steroid medications </e1> , warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that <e2> Mephenytoin </e2> may interact with other drugs that are not listed here.	0	steroid medications	Mephenytoin
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, <e1> warfarin </e1> , certain heart medicines, birth control pills, <e2> anti-infective medicines </e2> , furosemide and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	0	warfarin	anti-infective medicines
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, <e1> warfarin </e1> , certain heart medicines, birth control pills, anti-infective medicines, <e2> furosemide </e2> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	0	warfarin	furosemide
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, <e1> warfarin </e1> , certain heart medicines, birth control pills, anti-infective medicines, furosemide and <e2> theophylline </e2> Please note that Mephenytoin may interact with other drugs that are not listed here.	0	warfarin	theophylline
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, <e1> warfarin </e1> , certain heart medicines, birth control pills, anti-infective medicines, furosemide and theophylline Please note that <e2> Mephenytoin </e2> may interact with other drugs that are not listed here.	0	warfarin	Mephenytoin
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, <e1> anti-infective medicines </e1> , <e2> furosemide </e2> and theophylline Please note that Mephenytoin may interact with other drugs that are not listed here.	0	anti-infective medicines	furosemide
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, <e1> anti-infective medicines </e1> , furosemide and <e2> theophylline </e2> Please note that Mephenytoin may interact with other drugs that are not listed here.	0	anti-infective medicines	theophylline
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, <e1> anti-infective medicines </e1> , furosemide and theophylline Please note that <e2> Mephenytoin </e2> may interact with other drugs that are not listed here.	0	anti-infective medicines	Mephenytoin
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, <e1> furosemide </e1> and <e2> theophylline </e2> Please note that Mephenytoin may interact with other drugs that are not listed here.	0	furosemide	theophylline
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, <e1> furosemide </e1> and theophylline Please note that <e2> Mephenytoin </e2> may interact with other drugs that are not listed here.	0	furosemide	Mephenytoin
Mephenytoin may also affect the effects of other drugs, which include some steroid medications, warfarin, certain heart medicines, birth control pills, anti-infective medicines, furosemide and <e1> theophylline </e1> Please note that <e2> Mephenytoin </e2> may interact with other drugs that are not listed here.	0	theophylline	Mephenytoin
<e1> Thalidomide </e1> has been reported to enhance the sedative activity of <e2> barbiturates </e2> , alcohol, chlorpromazine, and reserpine.	1	Thalidomide	barbiturates
<e1> Thalidomide </e1> has been reported to enhance the sedative activity of barbiturates, <e2> alcohol </e2> , chlorpromazine, and reserpine.	0	Thalidomide	alcohol
<e1> Thalidomide </e1> has been reported to enhance the sedative activity of barbiturates, alcohol, <e2> chlorpromazine </e2> , and reserpine.	0	Thalidomide	chlorpromazine
<e1> Thalidomide </e1> has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and <e2> reserpine </e2> .	0	Thalidomide	reserpine
Thalidomide has been reported to enhance the sedative activity of <e1> barbiturates </e1> , <e2> alcohol </e2> , chlorpromazine, and reserpine.	0	barbiturates	alcohol
Thalidomide has been reported to enhance the sedative activity of <e1> barbiturates </e1> , alcohol, <e2> chlorpromazine </e2> , and reserpine.	0	barbiturates	chlorpromazine
Thalidomide has been reported to enhance the sedative activity of <e1> barbiturates </e1> , alcohol, chlorpromazine, and <e2> reserpine </e2> .	0	barbiturates	reserpine
Thalidomide has been reported to enhance the sedative activity of barbiturates, <e1> alcohol </e1> , <e2> chlorpromazine </e2> , and reserpine.	0	alcohol	chlorpromazine
Thalidomide has been reported to enhance the sedative activity of barbiturates, <e1> alcohol </e1> , chlorpromazine, and <e2> reserpine </e2> .	0	alcohol	reserpine
Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, <e1> chlorpromazine </e1> , and <e2> reserpine </e2> .	0	chlorpromazine	reserpine
Oral <e1> Contraceptives </e1> : In 10 healthy women, the pharmacokinetic profiles of <e2> norethindrone </e2> and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied.	0	Contraceptives	norethindrone
Oral <e1> Contraceptives </e1> : In 10 healthy women, the pharmacokinetic profiles of norethindrone and <e2> ethinyl estradiol </e2> following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied.	0	Contraceptives	ethinyl estradiol
Oral <e1> Contraceptives </e1> : In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of <e2> norethindrone acetate </e2> and 75 g of ethinyl estradiol were studied.	0	Contraceptives	norethindrone acetate
Oral <e1> Contraceptives </e1> : In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of <e2> ethinyl estradiol </e2> were studied.	0	Contraceptives	ethinyl estradiol
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of <e1> norethindrone </e1> and <e2> ethinyl estradiol </e2> following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of ethinyl estradiol were studied.	0	norethindrone	ethinyl estradiol
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of <e1> norethindrone </e1> and ethinyl estradiol following administration of a single dose containing 1.0 mg of <e2> norethindrone acetate </e2> and 75 g of ethinyl estradiol were studied.	0	norethindrone	norethindrone acetate
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of <e1> norethindrone </e1> and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75 g of <e2> ethinyl estradiol </e2> were studied.	0	norethindrone	ethinyl estradiol
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and <e1> ethinyl estradiol </e1> following administration of a single dose containing 1.0 mg of <e2> norethindrone acetate </e2> and 75 g of ethinyl estradiol were studied.	0	ethinyl estradiol	norethindrone acetate
Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of <e1> norethindrone acetate </e1> and 75 g of <e2> ethinyl estradiol </e2> were studied.	0	norethindrone acetate	ethinyl estradiol
Important Non- <e1> Thalidomide </e1> Drug Interactions Drugs That Interfere with <e2> Hormonal Contraceptives </e2> : Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Thalidomide	Hormonal Contraceptives
Important Non- <e1> Thalidomide </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e2> HIV-protease inhibitors </e2> , griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Thalidomide	HIV-protease inhibitors
Important Non- <e1> Thalidomide </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e2> griseofulvin </e2> , modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Thalidomide	griseofulvin
Important Non- <e1> Thalidomide </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, <e2> modafinil </e2> , penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Thalidomide	modafinil
Important Non- <e1> Thalidomide </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, <e2> penicillins </e2> , rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Thalidomide	penicillins
Important Non- <e1> Thalidomide </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Thalidomide	rifampin
Important Non- <e1> Thalidomide </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, <e2> rifabutin </e2> , phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Thalidomide	rifabutin
Important Non- <e1> Thalidomide </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, <e2> phenytoin </e2> , carbamazepine, or certain herbal supplements such as St.	0	Thalidomide	phenytoin
Important Non- <e1> Thalidomide </e1> Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, <e2> carbamazepine </e2> , or certain herbal supplements such as St.	0	Thalidomide	carbamazepine
Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1> Hormonal Contraceptives </e1> : Concomitant use of <e2> HIV-protease inhibitors </e2> , griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Hormonal Contraceptives	HIV-protease inhibitors
Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1> Hormonal Contraceptives </e1> : Concomitant use of HIV-protease inhibitors, <e2> griseofulvin </e2> , modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Hormonal Contraceptives	griseofulvin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1> Hormonal Contraceptives </e1> : Concomitant use of HIV-protease inhibitors, griseofulvin, <e2> modafinil </e2> , penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Hormonal Contraceptives	modafinil
Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1> Hormonal Contraceptives </e1> : Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, <e2> penicillins </e2> , rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Hormonal Contraceptives	penicillins
Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1> Hormonal Contraceptives </e1> : Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Hormonal Contraceptives	rifampin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1> Hormonal Contraceptives </e1> : Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, <e2> rifabutin </e2> , phenytoin, carbamazepine, or certain herbal supplements such as St.	0	Hormonal Contraceptives	rifabutin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1> Hormonal Contraceptives </e1> : Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, <e2> phenytoin </e2> , carbamazepine, or certain herbal supplements such as St.	0	Hormonal Contraceptives	phenytoin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with <e1> Hormonal Contraceptives </e1> : Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, <e2> carbamazepine </e2> , or certain herbal supplements such as St.	0	Hormonal Contraceptives	carbamazepine
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1> HIV-protease inhibitors </e1> , <e2> griseofulvin </e2> , modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	HIV-protease inhibitors	griseofulvin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1> HIV-protease inhibitors </e1> , griseofulvin, <e2> modafinil </e2> , penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	HIV-protease inhibitors	modafinil
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1> HIV-protease inhibitors </e1> , griseofulvin, modafinil, <e2> penicillins </e2> , rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	HIV-protease inhibitors	penicillins
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1> HIV-protease inhibitors </e1> , griseofulvin, modafinil, penicillins, <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	HIV-protease inhibitors	rifampin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1> HIV-protease inhibitors </e1> , griseofulvin, modafinil, penicillins, rifampin, <e2> rifabutin </e2> , phenytoin, carbamazepine, or certain herbal supplements such as St.	0	HIV-protease inhibitors	rifabutin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1> HIV-protease inhibitors </e1> , griseofulvin, modafinil, penicillins, rifampin, rifabutin, <e2> phenytoin </e2> , carbamazepine, or certain herbal supplements such as St.	0	HIV-protease inhibitors	phenytoin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of <e1> HIV-protease inhibitors </e1> , griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, <e2> carbamazepine </e2> , or certain herbal supplements such as St.	0	HIV-protease inhibitors	carbamazepine
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e1> griseofulvin </e1> , <e2> modafinil </e2> , penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	griseofulvin	modafinil
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e1> griseofulvin </e1> , modafinil, <e2> penicillins </e2> , rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	griseofulvin	penicillins
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e1> griseofulvin </e1> , modafinil, penicillins, <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	griseofulvin	rifampin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e1> griseofulvin </e1> , modafinil, penicillins, rifampin, <e2> rifabutin </e2> , phenytoin, carbamazepine, or certain herbal supplements such as St.	0	griseofulvin	rifabutin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e1> griseofulvin </e1> , modafinil, penicillins, rifampin, rifabutin, <e2> phenytoin </e2> , carbamazepine, or certain herbal supplements such as St.	0	griseofulvin	phenytoin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, <e1> griseofulvin </e1> , modafinil, penicillins, rifampin, rifabutin, phenytoin, <e2> carbamazepine </e2> , or certain herbal supplements such as St.	0	griseofulvin	carbamazepine
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, <e1> modafinil </e1> , <e2> penicillins </e2> , rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	modafinil	penicillins
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, <e1> modafinil </e1> , penicillins, <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	modafinil	rifampin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, <e1> modafinil </e1> , penicillins, rifampin, <e2> rifabutin </e2> , phenytoin, carbamazepine, or certain herbal supplements such as St.	0	modafinil	rifabutin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, <e1> modafinil </e1> , penicillins, rifampin, rifabutin, <e2> phenytoin </e2> , carbamazepine, or certain herbal supplements such as St.	0	modafinil	phenytoin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, <e1> modafinil </e1> , penicillins, rifampin, rifabutin, phenytoin, <e2> carbamazepine </e2> , or certain herbal supplements such as St.	0	modafinil	carbamazepine
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, <e1> penicillins </e1> , <e2> rifampin </e2> , rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St.	0	penicillins	rifampin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, <e1> penicillins </e1> , rifampin, <e2> rifabutin </e2> , phenytoin, carbamazepine, or certain herbal supplements such as St.	0	penicillins	rifabutin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, <e1> penicillins </e1> , rifampin, rifabutin, <e2> phenytoin </e2> , carbamazepine, or certain herbal supplements such as St.	0	penicillins	phenytoin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, <e1> penicillins </e1> , rifampin, rifabutin, phenytoin, <e2> carbamazepine </e2> , or certain herbal supplements such as St.	0	penicillins	carbamazepine
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, <e1> rifampin </e1> , <e2> rifabutin </e2> , phenytoin, carbamazepine, or certain herbal supplements such as St.	0	rifampin	rifabutin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, <e1> rifampin </e1> , rifabutin, <e2> phenytoin </e2> , carbamazepine, or certain herbal supplements such as St.	0	rifampin	phenytoin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, <e1> rifampin </e1> , rifabutin, phenytoin, <e2> carbamazepine </e2> , or certain herbal supplements such as St.	0	rifampin	carbamazepine
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, <e1> rifabutin </e1> , <e2> phenytoin </e2> , carbamazepine, or certain herbal supplements such as St.	0	rifabutin	phenytoin
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, <e1> rifabutin </e1> , phenytoin, <e2> carbamazepine </e2> , or certain herbal supplements such as St.	0	rifabutin	carbamazepine
Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, <e1> phenytoin </e1> , <e2> carbamazepine </e2> , or certain herbal supplements such as St.	0	phenytoin	carbamazepine
<e1> John's Wort </e1> with <e2> hormonal contraceptive agents </e2> may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies.	1	John's Wort	hormonal contraceptive agents
Concurrent administration of <e1> bacteriostatic antibiotics </e1> (e.g., <e2> erythromycin </e2> , tetracycline) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.	0	bacteriostatic antibiotics	erythromycin
Concurrent administration of <e1> bacteriostatic antibiotics </e1> (e.g., erythromycin, <e2> tetracycline </e2> ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.	0	bacteriostatic antibiotics	tetracycline
Concurrent administration of <e1> bacteriostatic antibiotics </e1> (e.g., erythromycin, tetracycline) may diminish the bactericidal effects of <e2> penicillins </e2> by slowing the rate of bacterial growth.	1	bacteriostatic antibiotics	penicillins
Concurrent administration of bacteriostatic antibiotics (e.g., <e1> erythromycin </e1> , <e2> tetracycline </e2> ) may diminish the bactericidal effects of penicillins by slowing the rate of bacterial growth.	0	erythromycin	tetracycline
Concurrent administration of bacteriostatic antibiotics (e.g., <e1> erythromycin </e1> , tetracycline) may diminish the bactericidal effects of <e2> penicillins </e2> by slowing the rate of bacterial growth.	1	erythromycin	penicillins
Concurrent administration of bacteriostatic antibiotics (e.g., erythromycin, <e1> tetracycline </e1> ) may diminish the bactericidal effects of <e2> penicillins </e2> by slowing the rate of bacterial growth.	1	tetracycline	penicillins
<e1> Penicillin </e1> blood levels may be prolonged by concurrent administration of <e2> probenecid </e2> which blocks the renal tubular secretion of penicillins.	1	Penicillin	probenecid
<e1> Penicillin </e1> blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of <e2> penicillins </e2> .	0	Penicillin	penicillins
Penicillin blood levels may be prolonged by concurrent administration of <e1> probenecid </e1> which blocks the renal tubular secretion of <e2> penicillins </e2> .	0	probenecid	penicillins
<e1> Probenecid </e1> competes with <e2> meropenem </e2> for active tubular secretion and thus inhibits the renal excretion of meropenem.	1	Probenecid	meropenem
<e1> Probenecid </e1> competes with meropenem for active tubular secretion and thus inhibits the renal excretion of <e2> meropenem </e2> .	0	Probenecid	meropenem
Therefore, the coadministration of <e1> probenecid </e1> with <e2> meropenem </e2> is not recommended.	0	probenecid	meropenem
There is evidence that <e1> meropenem </e1> may reduce serum levels of <e2> valproic acid </e2> to subtherapeutic levels (therapeutic range considered to be 50 to 100 g/mL total valproate).	1	meropenem	valproic acid
There is evidence that <e1> meropenem </e1> may reduce serum levels of valproic acid to subtherapeutic levels (therapeutic range considered to be 50 to 100 g/mL total <e2> valproate </e2> ).	0	meropenem	valproate
There is evidence that meropenem may reduce serum levels of <e1> valproic acid </e1> to subtherapeutic levels (therapeutic range considered to be 50 to 100 g/mL total <e2> valproate </e2> ).	0	valproic acid	valproate
Co-administration of oral <e1> ketoconazole </e1> 200 mg twice daily increased <e2> retapamulin </e2> geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment, 1% on the abraded skin of healthy adult males.	0	ketoconazole	retapamulin
Co-administration of oral <e1> ketoconazole </e1> 200 mg twice daily increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of <e2> retapamulin </e2> ointment, 1% on the abraded skin of healthy adult males.	1	ketoconazole	retapamulin
Due to low systemic exposure to <e1> retapamulin </e1> following topical application in patients, dosage adjustments for retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as <e2> ketoconazole </e2> .	0	retapamulin	ketoconazole
Due to low systemic exposure to retapamulin following topical application in patients, dosage adjustments for <e1> retapamulin </e1> are unnecessary when co-administered with CYP3A4 inhibitors, such as <e2> ketoconazole </e2> .	0	retapamulin	ketoconazole
Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of <e1> ALTABAX </e1> , <e2> retapamulin </e2> is unlikely to affect the metabolism of other P450 substrates.	0	ALTABAX	retapamulin
<e1> Dopamine antagonists </e1> , such as the <e2> neuroleptics </e2> (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	Dopamine antagonists	neuroleptics
<e1> Dopamine antagonists </e1> , such as the neuroleptics ( <e2> phenothiazines </e2> , butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	Dopamine antagonists	phenothiazines
<e1> Dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, <e2> butyrophenones </e2> , thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	Dopamine antagonists	butyrophenones
<e1> Dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones, <e2> thioxanthines </e2> ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	Dopamine antagonists	thioxanthines
<e1> Dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or <e2> metoclopramide </e2> , ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	Dopamine antagonists	metoclopramide
<e1> Dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with <e2> Permax </e2> (a dopamine agonist);	0	Dopamine antagonists	Permax
<e1> Dopamine antagonists </e1> , such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a <e2> dopamine agonist </e2> );	0	Dopamine antagonists	dopamine agonist
Dopamine antagonists, such as the <e1> neuroleptics </e1> ( <e2> phenothiazines </e2> , butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	neuroleptics	phenothiazines
Dopamine antagonists, such as the <e1> neuroleptics </e1> (phenothiazines, <e2> butyrophenones </e2> , thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	neuroleptics	butyrophenones
Dopamine antagonists, such as the <e1> neuroleptics </e1> (phenothiazines, butyrophenones, <e2> thioxanthines </e2> ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	neuroleptics	thioxanthines
Dopamine antagonists, such as the <e1> neuroleptics </e1> (phenothiazines, butyrophenones, thioxanthines ) or <e2> metoclopramide </e2> , ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	neuroleptics	metoclopramide
Dopamine antagonists, such as the <e1> neuroleptics </e1> (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with <e2> Permax </e2> (a dopamine agonist);	0	neuroleptics	Permax
Dopamine antagonists, such as the <e1> neuroleptics </e1> (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a <e2> dopamine agonist </e2> );	0	neuroleptics	dopamine agonist
Dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , <e2> butyrophenones </e2> , thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	phenothiazines	butyrophenones
Dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , butyrophenones, <e2> thioxanthines </e2> ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	phenothiazines	thioxanthines
Dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , butyrophenones, thioxanthines ) or <e2> metoclopramide </e2> , ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	phenothiazines	metoclopramide
Dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with <e2> Permax </e2> (a dopamine agonist);	0	phenothiazines	Permax
Dopamine antagonists, such as the neuroleptics ( <e1> phenothiazines </e1> , butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a <e2> dopamine agonist </e2> );	0	phenothiazines	dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, <e1> butyrophenones </e1> , <e2> thioxanthines </e2> ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	butyrophenones	thioxanthines
Dopamine antagonists, such as the neuroleptics (phenothiazines, <e1> butyrophenones </e1> , thioxanthines ) or <e2> metoclopramide </e2> , ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	butyrophenones	metoclopramide
Dopamine antagonists, such as the neuroleptics (phenothiazines, <e1> butyrophenones </e1> , thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with <e2> Permax </e2> (a dopamine agonist);	0	butyrophenones	Permax
Dopamine antagonists, such as the neuroleptics (phenothiazines, <e1> butyrophenones </e1> , thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a <e2> dopamine agonist </e2> );	0	butyrophenones	dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e1> thioxanthines </e1> ) or <e2> metoclopramide </e2> , ordinarily should not be administered concurrently with Permax (a dopamine agonist);	0	thioxanthines	metoclopramide
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e1> thioxanthines </e1> ) or metoclopramide, ordinarily should not be administered concurrently with <e2> Permax </e2> (a dopamine agonist);	0	thioxanthines	Permax
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, <e1> thioxanthines </e1> ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a <e2> dopamine agonist </e2> );	0	thioxanthines	dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or <e1> metoclopramide </e1> , ordinarily should not be administered concurrently with <e2> Permax </e2> (a dopamine agonist);	0	metoclopramide	Permax
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or <e1> metoclopramide </e1> , ordinarily should not be administered concurrently with Permax (a <e2> dopamine agonist </e2> );	0	metoclopramide	dopamine agonist
Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with <e1> Permax </e1> (a <e2> dopamine agonist </e2> );	0	Permax	dopamine agonist
The CNS-depressant effect of <e1> propoxyphene </e1> is additive with that of other <e2> CNS depressants </e2> , including alcohol.	1	propoxyphene	CNS depressants
The CNS-depressant effect of <e1> propoxyphene </e1> is additive with that of other CNS depressants, including <e2> alcohol </e2> .	1	propoxyphene	alcohol
The CNS-depressant effect of propoxyphene is additive with that of other <e1> CNS depressants </e1> , including <e2> alcohol </e2> .	0	CNS depressants	alcohol
Such occurrences have been reported when <e1> propoxyphene </e1> was administered to patients on <e2> antidepressants </e2> , anticonvulsants, or warfarin-like drugs.	0	propoxyphene	antidepressants
Such occurrences have been reported when <e1> propoxyphene </e1> was administered to patients on antidepressants, <e2> anticonvulsants </e2> , or warfarin-like drugs.	0	propoxyphene	anticonvulsants
Such occurrences have been reported when <e1> propoxyphene </e1> was administered to patients on antidepressants, anticonvulsants, or <e2> warfarin </e2> -like drugs.	0	propoxyphene	warfarin
Such occurrences have been reported when propoxyphene was administered to patients on <e1> antidepressants </e1> , <e2> anticonvulsants </e2> , or warfarin-like drugs.	0	antidepressants	anticonvulsants
Such occurrences have been reported when propoxyphene was administered to patients on <e1> antidepressants </e1> , anticonvulsants, or <e2> warfarin </e2> -like drugs.	0	antidepressants	warfarin
Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, <e1> anticonvulsants </e1> , or <e2> warfarin </e2> -like drugs.	0	anticonvulsants	warfarin
Due to its effects on gastric emptying, <e1> SYMLIN </e1> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., <e2> anticholinergic agents </e2> such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).	0	SYMLIN	anticholinergic agents
Due to its effects on gastric emptying, <e1> SYMLIN </e1> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as <e2> atropine </e2> ) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).	0	SYMLIN	atropine
Due to its effects on gastric emptying, <e1> SYMLIN </e1> therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., <e2> alpha glucosidase inhibitors </e2> ).	0	SYMLIN	alpha glucosidase inhibitors
Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., <e1> anticholinergic agents </e1> such as <e2> atropine </e2> ) and agents that slow the intestinal absorption of nutrients (e.g., alpha glucosidase inhibitors).	0	anticholinergic agents	atropine
Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., <e1> anticholinergic agents </e1> such as atropine) and agents that slow the intestinal absorption of nutrients (e.g., <e2> alpha glucosidase inhibitors </e2> ).	0	anticholinergic agents	alpha glucosidase inhibitors
Due to its effects on gastric emptying, SYMLIN therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g., anticholinergic agents such as <e1> atropine </e1> ) and agents that slow the intestinal absorption of nutrients (e.g., <e2> alpha glucosidase inhibitors </e2> ).	0	atropine	alpha glucosidase inhibitors
When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as <e1> analgesics </e1> ), the agent should be administered at least 1 hour prior to or 2 hours after <e2> SYMLIN </e2> injection.	0	analgesics	SYMLIN
In clinical trials, the concomitant use of <e1> sulfonylureas </e1> or <e2> biguanides </e2> did not alter the adverse event profile of SYMLIN.	0	sulfonylureas	biguanides
In clinical trials, the concomitant use of <e1> sulfonylureas </e1> or biguanides did not alter the adverse event profile of <e2> SYMLIN </e2> .	0	sulfonylureas	SYMLIN
In clinical trials, the concomitant use of sulfonylureas or <e1> biguanides </e1> did not alter the adverse event profile of <e2> SYMLIN </e2> .	0	biguanides	SYMLIN
No formal interaction studies have been performed to assess the effect of <e1> SYMLIN </e1> on the kinetics of oral <e2> antidiabetic agents </e2> .	0	SYMLIN	antidiabetic agents
Mixing <e1> SYMLIN </e1> and <e2> Insulin </e2> The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.	0	SYMLIN	Insulin
Mixing <e1> SYMLIN </e1> and Insulin The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant <e2> human insulin </e2> immediately prior to injection.	0	SYMLIN	human insulin
Mixing SYMLIN and <e1> Insulin </e1> The pharmacokinetic parameters of <e2> SYMLIN </e2> were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant human insulin immediately prior to injection.	0	Insulin	SYMLIN
Mixing SYMLIN and <e1> Insulin </e1> The pharmacokinetic parameters of SYMLIN were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant <e2> human insulin </e2> immediately prior to injection.	0	Insulin	human insulin
Mixing SYMLIN and Insulin The pharmacokinetic parameters of <e1> SYMLIN </e1> were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant <e2> human insulin </e2> immediately prior to injection.	1	SYMLIN	human insulin
Thus, <e1> SYMLIN </e1> and <e2> insulin </e2> should not be mixed and must be administered separately.	0	SYMLIN	insulin
<e1> Barbiturates </e1> may decrease the effectiveness of oral <e2> contraceptives </e2> , certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	0	Barbiturates	contraceptives
<e1> Barbiturates </e1> may decrease the effectiveness of oral contraceptives, certain <e2> antibiotics </e2> , quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	0	Barbiturates	antibiotics
<e1> Barbiturates </e1> may decrease the effectiveness of oral contraceptives, certain antibiotics, <e2> quinidine </e2> , theophylline, corticosteroids, anticoagulants, and beta blockers.	0	Barbiturates	quinidine
<e1> Barbiturates </e1> may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, <e2> theophylline </e2> , corticosteroids, anticoagulants, and beta blockers.	0	Barbiturates	theophylline
<e1> Barbiturates </e1> may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, <e2> corticosteroids </e2> , anticoagulants, and beta blockers.	0	Barbiturates	corticosteroids
<e1> Barbiturates </e1> may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, <e2> anticoagulants </e2> , and beta blockers.	0	Barbiturates	anticoagulants
<e1> Barbiturates </e1> may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and <e2> beta blockers </e2> .	0	Barbiturates	beta blockers
Barbiturates may decrease the effectiveness of oral <e1> contraceptives </e1> , certain <e2> antibiotics </e2> , quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	0	contraceptives	antibiotics
Barbiturates may decrease the effectiveness of oral <e1> contraceptives </e1> , certain antibiotics, <e2> quinidine </e2> , theophylline, corticosteroids, anticoagulants, and beta blockers.	0	contraceptives	quinidine
Barbiturates may decrease the effectiveness of oral <e1> contraceptives </e1> , certain antibiotics, quinidine, <e2> theophylline </e2> , corticosteroids, anticoagulants, and beta blockers.	0	contraceptives	theophylline
Barbiturates may decrease the effectiveness of oral <e1> contraceptives </e1> , certain antibiotics, quinidine, theophylline, <e2> corticosteroids </e2> , anticoagulants, and beta blockers.	0	contraceptives	corticosteroids
Barbiturates may decrease the effectiveness of oral <e1> contraceptives </e1> , certain antibiotics, quinidine, theophylline, corticosteroids, <e2> anticoagulants </e2> , and beta blockers.	0	contraceptives	anticoagulants
Barbiturates may decrease the effectiveness of oral <e1> contraceptives </e1> , certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and <e2> beta blockers </e2> .	0	contraceptives	beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain <e1> antibiotics </e1> , <e2> quinidine </e2> , theophylline, corticosteroids, anticoagulants, and beta blockers.	0	antibiotics	quinidine
Barbiturates may decrease the effectiveness of oral contraceptives, certain <e1> antibiotics </e1> , quinidine, <e2> theophylline </e2> , corticosteroids, anticoagulants, and beta blockers.	0	antibiotics	theophylline
Barbiturates may decrease the effectiveness of oral contraceptives, certain <e1> antibiotics </e1> , quinidine, theophylline, <e2> corticosteroids </e2> , anticoagulants, and beta blockers.	0	antibiotics	corticosteroids
Barbiturates may decrease the effectiveness of oral contraceptives, certain <e1> antibiotics </e1> , quinidine, theophylline, corticosteroids, <e2> anticoagulants </e2> , and beta blockers.	0	antibiotics	anticoagulants
Barbiturates may decrease the effectiveness of oral contraceptives, certain <e1> antibiotics </e1> , quinidine, theophylline, corticosteroids, anticoagulants, and <e2> beta blockers </e2> .	0	antibiotics	beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, <e1> quinidine </e1> , <e2> theophylline </e2> , corticosteroids, anticoagulants, and beta blockers.	0	quinidine	theophylline
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, <e1> quinidine </e1> , theophylline, <e2> corticosteroids </e2> , anticoagulants, and beta blockers.	0	quinidine	corticosteroids
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, <e1> quinidine </e1> , theophylline, corticosteroids, <e2> anticoagulants </e2> , and beta blockers.	0	quinidine	anticoagulants
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, <e1> quinidine </e1> , theophylline, corticosteroids, anticoagulants, and <e2> beta blockers </e2> .	0	quinidine	beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, <e1> theophylline </e1> , <e2> corticosteroids </e2> , anticoagulants, and beta blockers.	0	theophylline	corticosteroids
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, <e1> theophylline </e1> , corticosteroids, <e2> anticoagulants </e2> , and beta blockers.	0	theophylline	anticoagulants
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, <e1> theophylline </e1> , corticosteroids, anticoagulants, and <e2> beta blockers </e2> .	0	theophylline	beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, <e1> corticosteroids </e1> , <e2> anticoagulants </e2> , and beta blockers.	0	corticosteroids	anticoagulants
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, <e1> corticosteroids </e1> , anticoagulants, and <e2> beta blockers </e2> .	0	corticosteroids	beta blockers
Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, <e1> anticoagulants </e1> , and <e2> beta blockers </e2> .	0	anticoagulants	beta blockers
Acromegalic patients with diabetes mellitus being treated with <e1> insulin </e1> and/or oral <e2> hypoglycemic </e2> agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT.	0	insulin	hypoglycemic
Acromegalic patients with diabetes mellitus being treated with <e1> insulin </e1> and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with <e2> SOMAVERT </e2> .	0	insulin	SOMAVERT
Acromegalic patients with diabetes mellitus being treated with insulin and/or oral <e1> hypoglycemic </e1> agents may require dose reductions of these therapeutic agents after the initiation of therapy with <e2> SOMAVERT </e2> .	0	hypoglycemic	SOMAVERT
In clinical studies, patients on <e1> opioids </e1> often needed higher serum <e2> pegvisomant </e2> concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids.	1	opioids	pegvisomant
In clinical studies, patients on opioids often needed higher serum <e1> pegvisomant </e1> concentrations to achieve appropriate IGF-I suppression compared with patients not receiving <e2> opioids </e2> .	0	pegvisomant	opioids
In elderly patients concurrently receiving certain <e1> diuretics </e1> , primarily <e2> thiazides </e2> , an increased incidence of thrombopenia with purpura has been reported.	0	diuretics	thiazides
It has been reported that <e1> sulfamethoxazole </e1> may prolong the prothrombin time in patients who are receiving the <e2> anticoagulant </e2> warfarin.	0	sulfamethoxazole	anticoagulant
It has been reported that <e1> sulfamethoxazole </e1> may prolong the prothrombin time in patients who are receiving the anticoagulant <e2> warfarin </e2> .	1	sulfamethoxazole	warfarin
It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the <e1> anticoagulant </e1> <e2> warfarin </e2> .	0	anticoagulant	warfarin
<e1> Sulfamethoxazole </e1> may inhibit the hepatic metabolism of <e2> phenytoin </e2> .	1	Sulfamethoxazole	phenytoin
At a 1.6-g dose, <e1> sulfamethoxazole </e1> produced a slight but significant increase in the half-life of <e2> phenytoin </e2> but did not produce a corresponding decrease in the metabolic clearance rate.	1	sulfamethoxazole	phenytoin
<e1> Sulfonamides </e1> can also displace <e2> methotrexate </e2> from plasma protein-binding sites, thus increasing free methotrexate concentrations.	1	Sulfonamides	methotrexate
<e1> Sulfonamides </e1> can also displace methotrexate from plasma protein-binding sites, thus increasing free <e2> methotrexate </e2> concentrations.	0	Sulfonamides	methotrexate
<e1> Thiabendazole </e1> may compete with other drugs, such as <e2> theophylline </e2> , for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.	1	Thiabendazole	theophylline
Therefore, when concomitant use of <e1> thiabendazole </e1> and <e2> xanthine derivatives </e2> is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.	0	thiabendazole	xanthine derivatives
In vitro studies with human liver microsomes showed that <e1> terbinafine </e1> does not inhibit the metabolism of <e2> tolbutamide </e2> , ethinylestradiol, ethoxycoumarin, and cyclosporine.	0	terbinafine	tolbutamide
In vitro studies with human liver microsomes showed that <e1> terbinafine </e1> does not inhibit the metabolism of tolbutamide, <e2> ethinylestradiol </e2> , ethoxycoumarin, and cyclosporine.	0	terbinafine	ethinylestradiol
In vitro studies with human liver microsomes showed that <e1> terbinafine </e1> does not inhibit the metabolism of tolbutamide, ethinylestradiol, <e2> ethoxycoumarin </e2> , and cyclosporine.	0	terbinafine	ethoxycoumarin
In vitro studies with human liver microsomes showed that <e1> terbinafine </e1> does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and <e2> cyclosporine </e2> .	0	terbinafine	cyclosporine
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of <e1> tolbutamide </e1> , <e2> ethinylestradiol </e2> , ethoxycoumarin, and cyclosporine.	0	tolbutamide	ethinylestradiol
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of <e1> tolbutamide </e1> , ethinylestradiol, <e2> ethoxycoumarin </e2> , and cyclosporine.	0	tolbutamide	ethoxycoumarin
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of <e1> tolbutamide </e1> , ethinylestradiol, ethoxycoumarin, and <e2> cyclosporine </e2> .	0	tolbutamide	cyclosporine
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, <e1> ethinylestradiol </e1> , <e2> ethoxycoumarin </e2> , and cyclosporine.	0	ethinylestradiol	ethoxycoumarin
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, <e1> ethinylestradiol </e1> , ethoxycoumarin, and <e2> cyclosporine </e2> .	0	ethinylestradiol	cyclosporine
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, <e1> ethoxycoumarin </e1> , and <e2> cyclosporine </e2> .	0	ethoxycoumarin	cyclosporine
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as <e1> tricyclic antidepressants </e1> , -blockers, <e2> selective serotonin reuptake inhibitors </e2> (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.	0	tricyclic antidepressants	selective serotonin reuptake inhibitors
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as <e1> tricyclic antidepressants </e1> , -blockers, selective serotonin reuptake inhibitors ( <e2> SSRIs </e2> ), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.	0	tricyclic antidepressants	SSRIs
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as <e1> tricyclic antidepressants </e1> , -blockers, selective serotonin reuptake inhibitors (SSRIs), and <e2> monoamine oxidase inhibitors (MAO-Is) Type B </e2> , if they have a narrow therapeutic window.	0	tricyclic antidepressants	monoamine oxidase inhibitors (MAO-Is) Type B
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants, -blockers, <e1> selective serotonin reuptake inhibitors </e1> ( <e2> SSRIs </e2> ), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window.	0	selective serotonin reuptake inhibitors	SSRIs
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants, -blockers, <e1> selective serotonin reuptake inhibitors </e1> (SSRIs), and <e2> monoamine oxidase inhibitors (MAO-Is) Type B </e2> , if they have a narrow therapeutic window.	0	selective serotonin reuptake inhibitors	monoamine oxidase inhibitors (MAO-Is) Type B
This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants, -blockers, selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ), and <e2> monoamine oxidase inhibitors (MAO-Is) Type B </e2> , if they have a narrow therapeutic window.	0	SSRIs	monoamine oxidase inhibitors (MAO-Is) Type B
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that <e1> terbinafine </e1> does not affect the clearance of <e2> antipyrine </e2> or digoxin.	0	terbinafine	antipyrine
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that <e1> terbinafine </e1> does not affect the clearance of antipyrine or <e2> digoxin </e2> .	0	terbinafine	digoxin
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of <e1> antipyrine </e1> or <e2> digoxin </e2> .	0	antipyrine	digoxin
<e1> Terbinafine </e1> decreases the clearance of <e2> caffeine </e2> by 19%.	1	Terbinafine	caffeine
<e1> Terbinafine </e1> increases the clearance of <e2> cyclosporine </e2> by 15%.	1	Terbinafine	cyclosporine
There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral <e1> terbinafine </e1> and <e2> warfarin </e2> , however, a causal relationship between LAMISIL Tablets and these changes has not been established.	1	terbinafine	warfarin
There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral <e1> terbinafine </e1> and warfarin, however, a causal relationship between <e2> LAMISIL </e2> Tablets and these changes has not been established.	0	terbinafine	LAMISIL
There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and <e1> warfarin </e1> , however, a causal relationship between <e2> LAMISIL </e2> Tablets and these changes has not been established.	0	warfarin	LAMISIL
<e1> Terbinafine </e1> clearance is increased 100% by <e2> rifampin </e2> , a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor.	1	Terbinafine	rifampin
<e1> Terbinafine </e1> clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by <e2> cimetidine </e2> , a CyP450 enzyme inhibitor.	1	Terbinafine	cimetidine
Terbinafine clearance is increased 100% by <e1> rifampin </e1> , a CyP450 enzyme inducer, and decreased 33% by <e2> cimetidine </e2> , a CyP450 enzyme inhibitor.	0	rifampin	cimetidine
<e1> Terbinafine </e1> clearance is unaffected by <e2> cyclosporine </e2> .	0	Terbinafine	cyclosporine
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e1> contraceptives </e1> , hormone replacement therapies, <e2> hypoglycemics </e2> , theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	0	contraceptives	hypoglycemics
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e1> contraceptives </e1> , hormone replacement therapies, hypoglycemics, <e2> theophyllines </e2> , phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	0	contraceptives	theophyllines
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e1> contraceptives </e1> , hormone replacement therapies, hypoglycemics, theophyllines, <e2> phenytoins </e2> , thiazide diuretics, beta blockers, and calcium channel blockers.	0	contraceptives	phenytoins
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e1> contraceptives </e1> , hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, <e2> thiazide diuretics </e2> , beta blockers, and calcium channel blockers.	0	contraceptives	thiazide diuretics
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e1> contraceptives </e1> , hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, <e2> beta blockers </e2> , and calcium channel blockers.	0	contraceptives	beta blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral <e1> contraceptives </e1> , hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and <e2> calcium channel blockers </e2> .	0	contraceptives	calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, <e1> hypoglycemics </e1> , <e2> theophyllines </e2> , phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.	0	hypoglycemics	theophyllines
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, <e1> hypoglycemics </e1> , theophyllines, <e2> phenytoins </e2> , thiazide diuretics, beta blockers, and calcium channel blockers.	0	hypoglycemics	phenytoins
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, <e1> hypoglycemics </e1> , theophyllines, phenytoins, <e2> thiazide diuretics </e2> , beta blockers, and calcium channel blockers.	0	hypoglycemics	thiazide diuretics
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, <e1> hypoglycemics </e1> , theophyllines, phenytoins, thiazide diuretics, <e2> beta blockers </e2> , and calcium channel blockers.	0	hypoglycemics	beta blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, <e1> hypoglycemics </e1> , theophyllines, phenytoins, thiazide diuretics, beta blockers, and <e2> calcium channel blockers </e2> .	0	hypoglycemics	calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, <e1> theophyllines </e1> , <e2> phenytoins </e2> , thiazide diuretics, beta blockers, and calcium channel blockers.	0	theophyllines	phenytoins
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, <e1> theophyllines </e1> , phenytoins, <e2> thiazide diuretics </e2> , beta blockers, and calcium channel blockers.	0	theophyllines	thiazide diuretics
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, <e1> theophyllines </e1> , phenytoins, thiazide diuretics, <e2> beta blockers </e2> , and calcium channel blockers.	0	theophyllines	beta blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, <e1> theophyllines </e1> , phenytoins, thiazide diuretics, beta blockers, and <e2> calcium channel blockers </e2> .	0	theophyllines	calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, <e1> phenytoins </e1> , <e2> thiazide diuretics </e2> , beta blockers, and calcium channel blockers.	0	phenytoins	thiazide diuretics
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, <e1> phenytoins </e1> , thiazide diuretics, <e2> beta blockers </e2> , and calcium channel blockers.	0	phenytoins	beta blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, <e1> phenytoins </e1> , thiazide diuretics, beta blockers, and <e2> calcium channel blockers </e2> .	0	phenytoins	calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, <e1> thiazide diuretics </e1> , <e2> beta blockers </e2> , and calcium channel blockers.	0	thiazide diuretics	beta blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, <e1> thiazide diuretics </e1> , beta blockers, and <e2> calcium channel blockers </e2> .	0	thiazide diuretics	calcium channel blockers
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, <e1> beta blockers </e1> , and <e2> calcium channel blockers </e2> .	0	beta blockers	calcium channel blockers
Interactions for <e1> Vitamin B2 </e1> ( <e2> Riboflavin </e2> ): Alcohol - impairs the intestinal absorption of riboflavin	0	Vitamin B2	Riboflavin
Interactions for <e1> Vitamin B2 </e1> (Riboflavin): <e2> Alcohol </e2> - impairs the intestinal absorption of riboflavin	0	Vitamin B2	Alcohol
Interactions for <e1> Vitamin B2 </e1> (Riboflavin): Alcohol - impairs the intestinal absorption of <e2> riboflavin </e2>	0	Vitamin B2	riboflavin
Interactions for Vitamin B2 ( <e1> Riboflavin </e1> ): <e2> Alcohol </e2> - impairs the intestinal absorption of riboflavin	0	Riboflavin	Alcohol
Interactions for Vitamin B2 (Riboflavin): <e1> Alcohol </e1> - impairs the intestinal absorption of <e2> riboflavin </e2>	1	Alcohol	riboflavin
<e1> Probenecid </e1> - concurrent use decreases gastrointestinal absorption of <e2> riboflavin </e2> ;	1	Probenecid	riboflavin
requirements for <e1> riboflavin </e1> may be increased in patients receiving <e2> probenecid </e2> .	1	riboflavin	probenecid
Interaction with Other <e1> Central Nervous System Depressants </e1> : <e2> MEPERIDINE </e2> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	Central Nervous System Depressants	MEPERIDINE
Interaction with Other <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e2> NARCOTIC ANALGESICS </e2> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	Central Nervous System Depressants	NARCOTIC ANALGESICS
Interaction with Other <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e2> ANESTHETICS </e2> , PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	Central Nervous System Depressants	ANESTHETICS
Interaction with Other <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e2> PHENOTHIAZINES </e2> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	Central Nervous System Depressants	PHENOTHIAZINES
Interaction with Other <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e2> TRANQUILIZERS </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	Central Nervous System Depressants	TRANQUILIZERS
Interaction with Other <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e2> SEDATIVE-HYPNOTICS </e2> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	Central Nervous System Depressants	SEDATIVE-HYPNOTICS
Interaction with Other <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e2> BARBITURATES </e2> ), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	Central Nervous System Depressants	BARBITURATES
Interaction with Other <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e2> TRICYCLIC ANTIDEPRESSANTS </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	Central Nervous System Depressants	TRICYCLIC ANTIDEPRESSANTS
Interaction with Other <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> CNS DEPRESSANTS </e2> (INCLUDING ALCOHOL).	0	Central Nervous System Depressants	CNS DEPRESSANTS
Interaction with Other <e1> Central Nervous System Depressants </e1> : MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> ALCOHOL </e2> ).	0	Central Nervous System Depressants	ALCOHOL
Interaction with Other Central Nervous System Depressants: <e1> MEPERIDINE </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e2> NARCOTIC ANALGESICS </e2> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	MEPERIDINE	NARCOTIC ANALGESICS
Interaction with Other Central Nervous System Depressants: <e1> MEPERIDINE </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e2> ANESTHETICS </e2> , PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	MEPERIDINE	ANESTHETICS
Interaction with Other Central Nervous System Depressants: <e1> MEPERIDINE </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e2> PHENOTHIAZINES </e2> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	MEPERIDINE	PHENOTHIAZINES
Interaction with Other Central Nervous System Depressants: <e1> MEPERIDINE </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e2> TRANQUILIZERS </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	MEPERIDINE	TRANQUILIZERS
Interaction with Other Central Nervous System Depressants: <e1> MEPERIDINE </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e2> SEDATIVE-HYPNOTICS </e2> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	MEPERIDINE	SEDATIVE-HYPNOTICS
Interaction with Other Central Nervous System Depressants: <e1> MEPERIDINE </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e2> BARBITURATES </e2> ), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	MEPERIDINE	BARBITURATES
Interaction with Other Central Nervous System Depressants: <e1> MEPERIDINE </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e2> TRICYCLIC ANTIDEPRESSANTS </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	MEPERIDINE	TRICYCLIC ANTIDEPRESSANTS
Interaction with Other Central Nervous System Depressants: <e1> MEPERIDINE </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> CNS DEPRESSANTS </e2> (INCLUDING ALCOHOL).	0	MEPERIDINE	CNS DEPRESSANTS
Interaction with Other Central Nervous System Depressants: <e1> MEPERIDINE </e1> SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> ALCOHOL </e2> ).	0	MEPERIDINE	ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> NARCOTIC ANALGESICS </e1> , GENERAL <e2> ANESTHETICS </e2> , PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	NARCOTIC ANALGESICS	ANESTHETICS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> NARCOTIC ANALGESICS </e1> , GENERAL ANESTHETICS, <e2> PHENOTHIAZINES </e2> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	NARCOTIC ANALGESICS	PHENOTHIAZINES
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> NARCOTIC ANALGESICS </e1> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e2> TRANQUILIZERS </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	NARCOTIC ANALGESICS	TRANQUILIZERS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> NARCOTIC ANALGESICS </e1> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e2> SEDATIVE-HYPNOTICS </e2> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	NARCOTIC ANALGESICS	SEDATIVE-HYPNOTICS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> NARCOTIC ANALGESICS </e1> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e2> BARBITURATES </e2> ), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	NARCOTIC ANALGESICS	BARBITURATES
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> NARCOTIC ANALGESICS </e1> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e2> TRICYCLIC ANTIDEPRESSANTS </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	NARCOTIC ANALGESICS	TRICYCLIC ANTIDEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> NARCOTIC ANALGESICS </e1> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> CNS DEPRESSANTS </e2> (INCLUDING ALCOHOL).	0	NARCOTIC ANALGESICS	CNS DEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER <e1> NARCOTIC ANALGESICS </e1> , GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> ALCOHOL </e2> ).	0	NARCOTIC ANALGESICS	ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1> ANESTHETICS </e1> , <e2> PHENOTHIAZINES </e2> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	ANESTHETICS	PHENOTHIAZINES
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1> ANESTHETICS </e1> , PHENOTHIAZINES, OTHER <e2> TRANQUILIZERS </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	ANESTHETICS	TRANQUILIZERS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1> ANESTHETICS </e1> , PHENOTHIAZINES, OTHER TRANQUILIZERS, <e2> SEDATIVE-HYPNOTICS </e2> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	ANESTHETICS	SEDATIVE-HYPNOTICS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1> ANESTHETICS </e1> , PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e2> BARBITURATES </e2> ), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	ANESTHETICS	BARBITURATES
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1> ANESTHETICS </e1> , PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e2> TRICYCLIC ANTIDEPRESSANTS </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	ANESTHETICS	TRICYCLIC ANTIDEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1> ANESTHETICS </e1> , PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> CNS DEPRESSANTS </e2> (INCLUDING ALCOHOL).	0	ANESTHETICS	CNS DEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL <e1> ANESTHETICS </e1> , PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> ALCOHOL </e2> ).	0	ANESTHETICS	ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e1> PHENOTHIAZINES </e1> , OTHER <e2> TRANQUILIZERS </e2> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	PHENOTHIAZINES	TRANQUILIZERS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e1> PHENOTHIAZINES </e1> , OTHER TRANQUILIZERS, <e2> SEDATIVE-HYPNOTICS </e2> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	PHENOTHIAZINES	SEDATIVE-HYPNOTICS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e1> PHENOTHIAZINES </e1> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e2> BARBITURATES </e2> ), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	PHENOTHIAZINES	BARBITURATES
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e1> PHENOTHIAZINES </e1> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e2> TRICYCLIC ANTIDEPRESSANTS </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	PHENOTHIAZINES	TRICYCLIC ANTIDEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e1> PHENOTHIAZINES </e1> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> CNS DEPRESSANTS </e2> (INCLUDING ALCOHOL).	0	PHENOTHIAZINES	CNS DEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, <e1> PHENOTHIAZINES </e1> , OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> ALCOHOL </e2> ).	0	PHENOTHIAZINES	ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e1> TRANQUILIZERS </e1> , <e2> SEDATIVE-HYPNOTICS </e2> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	TRANQUILIZERS	SEDATIVE-HYPNOTICS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e1> TRANQUILIZERS </e1> , SEDATIVE-HYPNOTICS (INCLUDING <e2> BARBITURATES </e2> ), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	TRANQUILIZERS	BARBITURATES
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e1> TRANQUILIZERS </e1> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e2> TRICYCLIC ANTIDEPRESSANTS </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	TRANQUILIZERS	TRICYCLIC ANTIDEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e1> TRANQUILIZERS </e1> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> CNS DEPRESSANTS </e2> (INCLUDING ALCOHOL).	0	TRANQUILIZERS	CNS DEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER <e1> TRANQUILIZERS </e1> , SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> ALCOHOL </e2> ).	0	TRANQUILIZERS	ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e1> SEDATIVE-HYPNOTICS </e1> (INCLUDING <e2> BARBITURATES </e2> ), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	SEDATIVE-HYPNOTICS	BARBITURATES
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e1> SEDATIVE-HYPNOTICS </e1> (INCLUDING BARBITURATES), <e2> TRICYCLIC ANTIDEPRESSANTS </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	SEDATIVE-HYPNOTICS	TRICYCLIC ANTIDEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e1> SEDATIVE-HYPNOTICS </e1> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> CNS DEPRESSANTS </e2> (INCLUDING ALCOHOL).	0	SEDATIVE-HYPNOTICS	CNS DEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, <e1> SEDATIVE-HYPNOTICS </e1> (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> ALCOHOL </e2> ).	0	SEDATIVE-HYPNOTICS	ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e1> BARBITURATES </e1> ), <e2> TRICYCLIC ANTIDEPRESSANTS </e2> AND OTHER CNS DEPRESSANTS (INCLUDING ALCOHOL).	0	BARBITURATES	TRICYCLIC ANTIDEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e1> BARBITURATES </e1> ), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e2> CNS DEPRESSANTS </e2> (INCLUDING ALCOHOL).	0	BARBITURATES	CNS DEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING <e1> BARBITURATES </e1> ), TRICYCLIC ANTIDEPRESSANTS AND OTHER CNS DEPRESSANTS (INCLUDING <e2> ALCOHOL </e2> ).	0	BARBITURATES	ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e1> TRICYCLIC ANTIDEPRESSANTS </e1> AND OTHER <e2> CNS DEPRESSANTS </e2> (INCLUDING ALCOHOL).	0	TRICYCLIC ANTIDEPRESSANTS	CNS DEPRESSANTS
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), <e1> TRICYCLIC ANTIDEPRESSANTS </e1> AND OTHER CNS DEPRESSANTS (INCLUDING <e2> ALCOHOL </e2> ).	0	TRICYCLIC ANTIDEPRESSANTS	ALCOHOL
Interaction with Other Central Nervous System Depressants: MEPERIDINE SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER NARCOTIC ANALGESICS, GENERAL ANESTHETICS, PHENOTHIAZINES, OTHER TRANQUILIZERS, SEDATIVE-HYPNOTICS (INCLUDING BARBITURATES), TRICYCLIC ANTIDEPRESSANTS AND OTHER <e1> CNS DEPRESSANTS </e1> (INCLUDING <e2> ALCOHOL </e2> ).	0	CNS DEPRESSANTS	ALCOHOL
Catecholamine-depleting drugs (e.g., <e1> reserpine </e1> ) may have an additive effect when given with <e2> beta-blocking agents </e2> .	1	reserpine	beta-blocking agents
<e1> Pindolol </e1> has been used with a variety of <e2> antihypertensive agents </e2> , including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions.	0	Pindolol	antihypertensive agents
<e1> Pindolol </e1> has been used with a variety of antihypertensive agents, including <e2> hydrochlorothiazide </e2> , hydralazine, and guanethidine without unexpected adverse interactions.	0	Pindolol	hydrochlorothiazide
<e1> Pindolol </e1> has been used with a variety of antihypertensive agents, including hydrochlorothiazide, <e2> hydralazine </e2> , and guanethidine without unexpected adverse interactions.	0	Pindolol	hydralazine
<e1> Pindolol </e1> has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and <e2> guanethidine </e2> without unexpected adverse interactions.	0	Pindolol	guanethidine
Pindolol has been used with a variety of <e1> antihypertensive agents </e1> , including <e2> hydrochlorothiazide </e2> , hydralazine, and guanethidine without unexpected adverse interactions.	0	antihypertensive agents	hydrochlorothiazide
Pindolol has been used with a variety of <e1> antihypertensive agents </e1> , including hydrochlorothiazide, <e2> hydralazine </e2> , and guanethidine without unexpected adverse interactions.	0	antihypertensive agents	hydralazine
Pindolol has been used with a variety of <e1> antihypertensive agents </e1> , including hydrochlorothiazide, hydralazine, and <e2> guanethidine </e2> without unexpected adverse interactions.	0	antihypertensive agents	guanethidine
Pindolol has been used with a variety of antihypertensive agents, including <e1> hydrochlorothiazide </e1> , <e2> hydralazine </e2> , and guanethidine without unexpected adverse interactions.	0	hydrochlorothiazide	hydralazine
Pindolol has been used with a variety of antihypertensive agents, including <e1> hydrochlorothiazide </e1> , hydralazine, and <e2> guanethidine </e2> without unexpected adverse interactions.	0	hydrochlorothiazide	guanethidine
Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, <e1> hydralazine </e1> , and <e2> guanethidine </e2> without unexpected adverse interactions.	0	hydralazine	guanethidine
<e1> Pindolol </e1> has been shown to increase serum <e2> thioridazine </e2> levels when both drugs are co-administered.	1	Pindolol	thioridazine
Other <e1> beta adrenergic aerosol bronchodilators </e1> should not be used concomitantly with <e2> Alupent </e2> (metaproterenol sulfate USP) because they may have additive effects.	0	beta adrenergic aerosol bronchodilators	Alupent
Other <e1> beta adrenergic aerosol bronchodilators </e1> should not be used concomitantly with Alupent ( <e2> metaproterenol sulfate </e2> USP) because they may have additive effects.	0	beta adrenergic aerosol bronchodilators	metaproterenol sulfate
Other beta adrenergic aerosol bronchodilators should not be used concomitantly with <e1> Alupent </e1> ( <e2> metaproterenol sulfate </e2> USP) because they may have additive effects.	0	Alupent	metaproterenol sulfate
<e1> Beta adrenergic agonists </e1> should be administered with caution to patients being treated with <e2> monoamine oxidase inhibitors </e2> or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.	0	Beta adrenergic agonists	monoamine oxidase inhibitors
<e1> Beta adrenergic agonists </e1> should be administered with caution to patients being treated with monoamine oxidase inhibitors or <e2> tricyclic antidepressants </e2> , since the action of beta adrenergic agonists on the vascular system may be potentiated.	0	Beta adrenergic agonists	tricyclic antidepressants
Beta adrenergic agonists should be administered with caution to patients being treated with <e1> monoamine oxidase inhibitors </e1> or <e2> tricyclic antidepressants </e2> , since the action of beta adrenergic agonists on the vascular system may be potentiated.	0	monoamine oxidase inhibitors	tricyclic antidepressants
Beta adrenergic agonists should be administered with caution to patients being treated with <e1> monoamine oxidase inhibitors </e1> or tricyclic antidepressants, since the action of <e2> beta adrenergic agonists </e2> on the vascular system may be potentiated.	0	monoamine oxidase inhibitors	beta adrenergic agonists
Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or <e1> tricyclic antidepressants </e1> , since the action of <e2> beta adrenergic agonists </e2> on the vascular system may be potentiated.	0	tricyclic antidepressants	beta adrenergic agonists
Interactions for <e1> Vitamin B1 </e1> ( <e2> Thiamine </e2> ): Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants	0	Vitamin B1	Thiamine
Interactions for <e1> Vitamin B1 </e1> (Thiamine): <e2> Loop Diuretics </e2> , Oral Contraceptives, Stavudine, Tricyclic Antidepressants	0	Vitamin B1	Loop Diuretics
Interactions for <e1> Vitamin B1 </e1> (Thiamine): Loop Diuretics, Oral <e2> Contraceptives </e2> , Stavudine, Tricyclic Antidepressants	0	Vitamin B1	Contraceptives
Interactions for <e1> Vitamin B1 </e1> (Thiamine): Loop Diuretics, Oral Contraceptives, <e2> Stavudine </e2> , Tricyclic Antidepressants	0	Vitamin B1	Stavudine
Interactions for <e1> Vitamin B1 </e1> (Thiamine): Loop Diuretics, Oral Contraceptives, Stavudine, <e2> Tricyclic Antidepressants </e2>	0	Vitamin B1	Tricyclic Antidepressants
Interactions for Vitamin B1 ( <e1> Thiamine </e1> ): <e2> Loop Diuretics </e2> , Oral Contraceptives, Stavudine, Tricyclic Antidepressants	0	Thiamine	Loop Diuretics
Interactions for Vitamin B1 ( <e1> Thiamine </e1> ): Loop Diuretics, Oral <e2> Contraceptives </e2> , Stavudine, Tricyclic Antidepressants	0	Thiamine	Contraceptives
Interactions for Vitamin B1 ( <e1> Thiamine </e1> ): Loop Diuretics, Oral Contraceptives, <e2> Stavudine </e2> , Tricyclic Antidepressants	0	Thiamine	Stavudine
Interactions for Vitamin B1 ( <e1> Thiamine </e1> ): Loop Diuretics, Oral Contraceptives, Stavudine, <e2> Tricyclic Antidepressants </e2>	0	Thiamine	Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine): <e1> Loop Diuretics </e1> , Oral <e2> Contraceptives </e2> , Stavudine, Tricyclic Antidepressants	0	Loop Diuretics	Contraceptives
Interactions for Vitamin B1 (Thiamine): <e1> Loop Diuretics </e1> , Oral Contraceptives, <e2> Stavudine </e2> , Tricyclic Antidepressants	0	Loop Diuretics	Stavudine
Interactions for Vitamin B1 (Thiamine): <e1> Loop Diuretics </e1> , Oral Contraceptives, Stavudine, <e2> Tricyclic Antidepressants </e2>	0	Loop Diuretics	Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine): Loop Diuretics, Oral <e1> Contraceptives </e1> , <e2> Stavudine </e2> , Tricyclic Antidepressants	0	Contraceptives	Stavudine
Interactions for Vitamin B1 (Thiamine): Loop Diuretics, Oral <e1> Contraceptives </e1> , Stavudine, <e2> Tricyclic Antidepressants </e2>	0	Contraceptives	Tricyclic Antidepressants
Interactions for Vitamin B1 (Thiamine): Loop Diuretics, Oral Contraceptives, <e1> Stavudine </e1> , <e2> Tricyclic Antidepressants </e2>	0	Stavudine	Tricyclic Antidepressants
<e1> ACE inhibitors </e1> Reports suggest that <e2> NSAIDs </e2> may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors.	0	ACE inhibitors	NSAIDs
<e1> ACE inhibitors </e1> Reports suggest that NSAIDs may diminish the antihypertensive effect of <e2> angiotensin-converting enzyme (ACE) inhibitors </e2> .	0	ACE inhibitors	angiotensin-converting enzyme (ACE) inhibitors
ACE inhibitors Reports suggest that <e1> NSAIDs </e1> may diminish the antihypertensive effect of <e2> angiotensin-converting enzyme (ACE) inhibitors </e2> .	1	NSAIDs	angiotensin-converting enzyme (ACE) inhibitors
This interaction should be given consideration in patients taking <e1> NSAIDs </e1> concomitantly with <e2> ACE inhibitors </e2> .	0	NSAIDs	ACE inhibitors
<e1> Aspirin </e1> : Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of <e2> meloxicam </e2> .	0	Aspirin	meloxicam
Aspirin: Concomitant administration of <e1> aspirin </e1> (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of <e2> meloxicam </e2> .	1	aspirin	meloxicam
however, as with other <e1> NSAIDs </e1> , concomitant administration of <e2> meloxicam </e2> and aspirin is not generally recommended because of the potential for increased adverse effects.	0	NSAIDs	meloxicam
however, as with other <e1> NSAIDs </e1> , concomitant administration of meloxicam and <e2> aspirin </e2> is not generally recommended because of the potential for increased adverse effects.	0	NSAIDs	aspirin
however, as with other NSAIDs, concomitant administration of <e1> meloxicam </e1> and <e2> aspirin </e2> is not generally recommended because of the potential for increased adverse effects.	0	meloxicam	aspirin
Concomitant administration of low-dose <e1> aspirin </e1> with <e2> MOBIC </e2> may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone.	1	aspirin	MOBIC
Concomitant administration of low-dose <e1> aspirin </e1> with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of <e2> MOBIC </e2> alone.	0	aspirin	MOBIC
<e1> MOBIC </e1> is not a substitute for <e2> aspirin </e2> for cardiovascular prophylaxis.	0	MOBIC	aspirin
<e1> Cholestyramine </e1> : Pretreatment for four days with cholestyramine significantly increased the clearance of <e2> meloxicam </e2> by 50%.	0	Cholestyramine	meloxicam
Cholestyramine: Pretreatment for four days with <e1> cholestyramine </e1> significantly increased the clearance of <e2> meloxicam </e2> by 50%.	1	cholestyramine	meloxicam
<e1> Cimetidine </e1> : Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg <e2> meloxicam </e2> .	0	Cimetidine	meloxicam
Cimetidine: Concomitant administration of 200 mg <e1> cimetidine </e1> QID did not alter the single-dose pharmacokinetics of 30 mg <e2> meloxicam </e2> .	0	cimetidine	meloxicam
<e1> Digoxin </e1> : <e2> Meloxicam </e2> 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses.	0	Digoxin	Meloxicam
Digoxin: <e1> Meloxicam </e1> 15 mg once daily for 7 days did not alter the plasma concentration profile of <e2> digoxin </e2> after b-acetyldigoxin administration for 7 days at clinical doses.	0	Meloxicam	digoxin
In vitro testing found no protein binding drug interaction between <e1> digoxin </e1> and <e2> meloxicam </e2> .	0	digoxin	meloxicam
<e1> Furosemide </e1> : Clinical studies, as well as post-marketing observations, have shown that <e2> NSAIDs </e2> can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients.	0	Furosemide	NSAIDs
<e1> Furosemide </e1> : Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and <e2> thiazide diuretics </e2> in some patients.	0	Furosemide	thiazide diuretics
Furosemide: Clinical studies, as well as post-marketing observations, have shown that <e1> NSAIDs </e1> can reduce the natriuretic effect of <e2> furosemide </e2> and thiazide diuretics in some patients.	1	NSAIDs	furosemide
Furosemide: Clinical studies, as well as post-marketing observations, have shown that <e1> NSAIDs </e1> can reduce the natriuretic effect of furosemide and <e2> thiazide diuretics </e2> in some patients.	1	NSAIDs	thiazide diuretics
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of <e1> furosemide </e1> and <e2> thiazide diuretics </e2> in some patients.	0	furosemide	thiazide diuretics
Studies with <e1> furosemide </e1> agents and <e2> meloxicam </e2> have not demonstrated a reduction in natriuretic effect.	0	furosemide	meloxicam
<e1> Furosemide </e1> : single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of <e2> meloxicam </e2> .	0	Furosemide	meloxicam
Nevertheless, during concomitant therapy with <e1> furosemide </e1> and <e2> MOBIC </e2> , patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.	0	furosemide	MOBIC
<e1> Lithium </e1> : In clinical trials, <e2> NSAIDs </e2> have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	0	Lithium	NSAIDs
Lithium: In clinical trials, <e1> NSAIDs </e1> have produced an elevation of plasma <e2> lithium </e2> levels and a reduction in renal lithium clearance.	1	NSAIDs	lithium
Lithium: In clinical trials, <e1> NSAIDs </e1> have produced an elevation of plasma lithium levels and a reduction in renal <e2> lithium </e2> clearance.	0	NSAIDs	lithium
In a study conducted in healthy subjects, mean pre-dose <e1> lithium </e1> concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with <e2> meloxicam </e2> 15 mg QD as compared to subjects receiving lithium alone.	0	lithium	meloxicam
In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving <e1> lithium </e1> doses ranging from 804 to 1072 mg BID with <e2> meloxicam </e2> 15 mg QD as compared to subjects receiving lithium alone.	1	lithium	meloxicam
In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with <e1> meloxicam </e1> 15 mg QD as compared to subjects receiving <e2> lithium </e2> alone.	0	meloxicam	lithium
Patients on <e1> lithium </e1> treatment should be closely monitored when <e2> MOBIC </e2> is introduced or withdrawn.	0	lithium	MOBIC
<e1> Methotrexate </e1> : A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of <e2> meloxicam </e2> on the pharmacokinetics of methotrexate taken once weekly.	0	Methotrexate	meloxicam
Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of <e1> meloxicam </e1> on the pharmacokinetics of <e2> methotrexate </e2> taken once weekly.	0	meloxicam	methotrexate
<e1> Meloxicam </e1> did not have a significant effect on the pharmacokinetics of single doses of <e2> methotrexate </e2> .	0	Meloxicam	methotrexate
In vitro, <e1> methotrexate </e1> did not displace <e2> meloxicam </e2> from its human serum binding sites.	0	methotrexate	meloxicam
<e1> Warfarin </e1> : Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing <e2> MOBIC </e2> therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding.	0	Warfarin	MOBIC
Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing <e1> MOBIC </e1> therapy in patients receiving <e2> warfarin </e2> or similar agents, since these patients are at an increased risk of bleeding.	0	MOBIC	warfarin
The effect of <e1> meloxicam </e1> on the anticoagulant effect of <e2> warfarin </e2> was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8.	0	meloxicam	warfarin
The effect of <e1> meloxicam </e1> on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of <e2> warfarin </e2> that produced an INR (International Normalized Ratio) between 1.2 and 1.8.	0	meloxicam	warfarin
In these subjects, <e1> meloxicam </e1> did not alter <e2> warfarin </e2> pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time.	0	meloxicam	warfarin
In these subjects, <e1> meloxicam </e1> did not alter warfarin pharmacokinetics and the average anticoagulant effect of <e2> warfarin </e2> as determined by prothrombin time.	0	meloxicam	warfarin
Caution should be used when administering <e1> MOBIC </e1> with <e2> warfarin </e2> since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.	0	MOBIC	warfarin
Caution should be used when administering <e1> MOBIC </e1> with warfarin since patients on <e2> warfarin </e2> may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.	0	MOBIC	warfarin
Drugs that induce hepatic enzymes such as <e1> phenobarbital </e1> , <e2> phenytoin </e2> and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	0	phenobarbital	phenytoin
Drugs that induce hepatic enzymes such as <e1> phenobarbital </e1> , phenytoin and <e2> rifampin </e2> may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	0	phenobarbital	rifampin
Drugs that induce hepatic enzymes such as <e1> phenobarbital </e1> , phenytoin and rifampin may increase the clearance of <e2> corticosteroids </e2> and may require increases in corticosteroid dose to achieve the desired response.	1	phenobarbital	corticosteroids
Drugs that induce hepatic enzymes such as <e1> phenobarbital </e1> , phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in <e2> corticosteroid </e2> dose to achieve the desired response.	1	phenobarbital	corticosteroid
Drugs that induce hepatic enzymes such as phenobarbital, <e1> phenytoin </e1> and <e2> rifampin </e2> may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	0	phenytoin	rifampin
Drugs that induce hepatic enzymes such as phenobarbital, <e1> phenytoin </e1> and rifampin may increase the clearance of <e2> corticosteroids </e2> and may require increases in corticosteroid dose to achieve the desired response.	1	phenytoin	corticosteroids
Drugs that induce hepatic enzymes such as phenobarbital, <e1> phenytoin </e1> and rifampin may increase the clearance of corticosteroids and may require increases in <e2> corticosteroid </e2> dose to achieve the desired response.	1	phenytoin	corticosteroid
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and <e1> rifampin </e1> may increase the clearance of <e2> corticosteroids </e2> and may require increases in corticosteroid dose to achieve the desired response.	1	rifampin	corticosteroids
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and <e1> rifampin </e1> may increase the clearance of corticosteroids and may require increases in <e2> corticosteroid </e2> dose to achieve the desired response.	1	rifampin	corticosteroid
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of <e1> corticosteroids </e1> and may require increases in <e2> corticosteroid </e2> dose to achieve the desired response.	0	corticosteroids	corticosteroid
Drugs such as <e1> troleandomycin </e1> and <e2> ketoconazole </e2> may inhibit the metabolism of corticosteroids and thus decrease their clearance.	0	troleandomycin	ketoconazole
Drugs such as <e1> troleandomycin </e1> and ketoconazole may inhibit the metabolism of <e2> corticosteroids </e2> and thus decrease their clearance.	1	troleandomycin	corticosteroids
Drugs such as troleandomycin and <e1> ketoconazole </e1> may inhibit the metabolism of <e2> corticosteroids </e2> and thus decrease their clearance.	1	ketoconazole	corticosteroids
<e1> Corticosteroids </e1> may increase the clearance of chronic high dose <e2> aspirin </e2> .	1	Corticosteroids	aspirin
This could lead to decreased <e1> salicylate </e1> serum levels or increase the risk of salicylate toxicity when <e2> corticosteroid </e2> is withdrawn.	0	salicylate	corticosteroid
This could lead to decreased salicylate serum levels or increase the risk of <e1> salicylate </e1> toxicity when <e2> corticosteroid </e2> is withdrawn.	1	salicylate	corticosteroid
<e1> Aspirin </e1> should be used cautiously in conjunction with <e2> corticosteroids </e2> in patients suffering from hypoprothrombinemia.	0	Aspirin	corticosteroids
The effect of <e1> corticosteroids </e1> on oral <e2> anticoagulants </e2> is variable.	1	corticosteroids	anticoagulants
There are reports of enhanced as well as diminished effects of <e1> anticoagulants </e1> when given concurrently with <e2> corticosteroids </e2> .	1	anticoagulants	corticosteroids
<e1> Ropivacaine </e1> should be used with caution in patients receiving other local <e2> anesthetics </e2> or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive.	0	Ropivacaine	anesthetics
<e1> Ropivacaine </e1> should be used with caution in patients receiving other local anesthetics or agents structurally related to <e2> amide-type local anesthetics </e2> , since the toxic effects of these drugs are additive.	0	Ropivacaine	amide-type local anesthetics
Ropivacaine should be used with caution in patients receiving other local <e1> anesthetics </e1> or agents structurally related to <e2> amide-type local anesthetics </e2> , since the toxic effects of these drugs are additive.	0	anesthetics	amide-type local anesthetics
In vivo, the plasma clearance of <e1> ropivacaine </e1> was reduced by 70% during coadministration of <e2> fluvoxamine </e2> (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor.	1	ropivacaine	fluvoxamine
Thus strong inhibitors of cytochrome P4501A2, such as <e1> fluvoxamine </e1> , given concomitantly during administration of <e2> Ropivacaine </e2> , can interact with Ropivacaine leading to increased ropivacaine plasma levels.	0	fluvoxamine	Ropivacaine
Thus strong inhibitors of cytochrome P4501A2, such as <e1> fluvoxamine </e1> , given concomitantly during administration of Ropivacaine, can interact with <e2> Ropivacaine </e2> leading to increased ropivacaine plasma levels.	0	fluvoxamine	Ropivacaine
Thus strong inhibitors of cytochrome P4501A2, such as <e1> fluvoxamine </e1> , given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased <e2> ropivacaine </e2> plasma levels.	0	fluvoxamine	ropivacaine
Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as <e1> theophylline </e1> and <e2> imipramine </e2> may also occur.	0	theophylline	imipramine
Coadministration of a selective and potent inhibitor of CYP3A4, <e1> ketoconazole </e1> (100 mg bid for 2 days with <e2> ropivacaine </e2> infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	0	ketoconazole	ropivacaine
Coadministration of a selective and potent inhibitor of CYP3A4, <e1> ketoconazole </e1> (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of <e2> ropivacaine </e2> .	1	ketoconazole	ropivacaine
Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with <e1> ropivacaine </e1> infusion administered 1 hour after <e2> ketoconazole </e2> ) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.	0	ropivacaine	ketoconazole
Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after <e1> ketoconazole </e1> ) caused a 15% reduction in in-vivo plasma clearance of <e2> ropivacaine </e2> .	0	ketoconazole	ropivacaine
Catecholamine-depleting drugs (e.g., <e1> reserpine </e1> ) may have an additive effect when given with <e2> beta-blocking agents </e2> .	1	reserpine	beta-blocking agents
You cannot take <e1> mazindol </e1> if you have taken a <e2> monoamine oxidase inhibitor </e2> (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	0	mazindol	monoamine oxidase inhibitor
You cannot take <e1> mazindol </e1> if you have taken a monoamine oxidase inhibitor ( <e2> MAOI </e2> ) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	0	mazindol	MAOI
You cannot take <e1> mazindol </e1> if you have taken a monoamine oxidase inhibitor (MAOI) such as <e2> isocarboxazid </e2> (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	0	mazindol	isocarboxazid
You cannot take <e1> mazindol </e1> if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid ( <e2> Marplan </e2> ), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	0	mazindol	Marplan
You cannot take <e1> mazindol </e1> if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), <e2> tranylcypromine </e2> (Parnate), or phenelzine (Nardil) in the last 14 days.	0	mazindol	tranylcypromine
You cannot take <e1> mazindol </e1> if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine ( <e2> Parnate </e2> ), or phenelzine (Nardil) in the last 14 days.	0	mazindol	Parnate
You cannot take <e1> mazindol </e1> if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or <e2> phenelzine </e2> (Nardil) in the last 14 days.	0	mazindol	phenelzine
You cannot take <e1> mazindol </e1> if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine ( <e2> Nardil </e2> ) in the last 14 days.	0	mazindol	Nardil
You cannot take mazindol if you have taken a <e1> monoamine oxidase inhibitor </e1> ( <e2> MAOI </e2> ) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	0	monoamine oxidase inhibitor	MAOI
You cannot take mazindol if you have taken a <e1> monoamine oxidase inhibitor </e1> (MAOI) such as <e2> isocarboxazid </e2> (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	0	monoamine oxidase inhibitor	isocarboxazid
You cannot take mazindol if you have taken a <e1> monoamine oxidase inhibitor </e1> (MAOI) such as isocarboxazid ( <e2> Marplan </e2> ), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	0	monoamine oxidase inhibitor	Marplan
You cannot take mazindol if you have taken a <e1> monoamine oxidase inhibitor </e1> (MAOI) such as isocarboxazid (Marplan), <e2> tranylcypromine </e2> (Parnate), or phenelzine (Nardil) in the last 14 days.	0	monoamine oxidase inhibitor	tranylcypromine
You cannot take mazindol if you have taken a <e1> monoamine oxidase inhibitor </e1> (MAOI) such as isocarboxazid (Marplan), tranylcypromine ( <e2> Parnate </e2> ), or phenelzine (Nardil) in the last 14 days.	0	monoamine oxidase inhibitor	Parnate
You cannot take mazindol if you have taken a <e1> monoamine oxidase inhibitor </e1> (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or <e2> phenelzine </e2> (Nardil) in the last 14 days.	0	monoamine oxidase inhibitor	phenelzine
You cannot take mazindol if you have taken a <e1> monoamine oxidase inhibitor </e1> (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine ( <e2> Nardil </e2> ) in the last 14 days.	0	monoamine oxidase inhibitor	Nardil
You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> MAOI </e1> ) such as <e2> isocarboxazid </e2> (Marplan), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	0	MAOI	isocarboxazid
You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> MAOI </e1> ) such as isocarboxazid ( <e2> Marplan </e2> ), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	0	MAOI	Marplan
You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> MAOI </e1> ) such as isocarboxazid (Marplan), <e2> tranylcypromine </e2> (Parnate), or phenelzine (Nardil) in the last 14 days.	0	MAOI	tranylcypromine
You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> MAOI </e1> ) such as isocarboxazid (Marplan), tranylcypromine ( <e2> Parnate </e2> ), or phenelzine (Nardil) in the last 14 days.	0	MAOI	Parnate
You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> MAOI </e1> ) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or <e2> phenelzine </e2> (Nardil) in the last 14 days.	0	MAOI	phenelzine
You cannot take mazindol if you have taken a monoamine oxidase inhibitor ( <e1> MAOI </e1> ) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or phenelzine ( <e2> Nardil </e2> ) in the last 14 days.	0	MAOI	Nardil
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as <e1> isocarboxazid </e1> ( <e2> Marplan </e2> ), tranylcypromine (Parnate), or phenelzine (Nardil) in the last 14 days.	0	isocarboxazid	Marplan
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as <e1> isocarboxazid </e1> (Marplan), <e2> tranylcypromine </e2> (Parnate), or phenelzine (Nardil) in the last 14 days.	0	isocarboxazid	tranylcypromine
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as <e1> isocarboxazid </e1> (Marplan), tranylcypromine ( <e2> Parnate </e2> ), or phenelzine (Nardil) in the last 14 days.	0	isocarboxazid	Parnate
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as <e1> isocarboxazid </e1> (Marplan), tranylcypromine (Parnate), or <e2> phenelzine </e2> (Nardil) in the last 14 days.	0	isocarboxazid	phenelzine
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as <e1> isocarboxazid </e1> (Marplan), tranylcypromine (Parnate), or phenelzine ( <e2> Nardil </e2> ) in the last 14 days.	0	isocarboxazid	Nardil
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid ( <e1> Marplan </e1> ), <e2> tranylcypromine </e2> (Parnate), or phenelzine (Nardil) in the last 14 days.	0	Marplan	tranylcypromine
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid ( <e1> Marplan </e1> ), tranylcypromine ( <e2> Parnate </e2> ), or phenelzine (Nardil) in the last 14 days.	0	Marplan	Parnate
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid ( <e1> Marplan </e1> ), tranylcypromine (Parnate), or <e2> phenelzine </e2> (Nardil) in the last 14 days.	0	Marplan	phenelzine
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid ( <e1> Marplan </e1> ), tranylcypromine (Parnate), or phenelzine ( <e2> Nardil </e2> ) in the last 14 days.	0	Marplan	Nardil
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), <e1> tranylcypromine </e1> ( <e2> Parnate </e2> ), or phenelzine (Nardil) in the last 14 days.	0	tranylcypromine	Parnate
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), <e1> tranylcypromine </e1> (Parnate), or <e2> phenelzine </e2> (Nardil) in the last 14 days.	0	tranylcypromine	phenelzine
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), <e1> tranylcypromine </e1> (Parnate), or phenelzine ( <e2> Nardil </e2> ) in the last 14 days.	0	tranylcypromine	Nardil
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine ( <e1> Parnate </e1> ), or <e2> phenelzine </e2> (Nardil) in the last 14 days.	0	Parnate	phenelzine
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine ( <e1> Parnate </e1> ), or phenelzine ( <e2> Nardil </e2> ) in the last 14 days.	0	Parnate	Nardil
You cannot take mazindol if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), tranylcypromine (Parnate), or <e1> phenelzine </e1> ( <e2> Nardil </e2> ) in the last 14 days.	0	phenelzine	Nardil
Changes in <e1> insulin </e1> and other diabetes drug therapies may be necessary during treatment with <e2> mazindol </e2> .	0	insulin	mazindol
<e1> Mazindol </e1> may reduce the effects of <e2> guanethidine </e2> (Ismelin).	1	Mazindol	guanethidine
<e1> Mazindol </e1> may reduce the effects of guanethidine ( <e2> Ismelin </e2> ).	1	Mazindol	Ismelin
Mazindol may reduce the effects of <e1> guanethidine </e1> ( <e2> Ismelin </e2> ).	0	guanethidine	Ismelin
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as <e2> amitriptyline </e2> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	amitriptyline
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline ( <e2> Elavil </e2> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	Elavil
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), <e2> amoxapine </e2> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	amoxapine
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine ( <e2> Asendin </e2> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	Asendin
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine (Asendin), <e2> doxepin </e2> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	doxepin
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e2> Sinequan </e2> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	Sinequan
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e2> nortriptyline </e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	nortriptyline
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	Pamelor
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e2> imipramine </e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	imipramine
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	Tofranil
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e2> clomipramine </e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	clomipramine
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	Anafranil
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	tricyclic antidepressant	protriptyline
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	tricyclic antidepressant	Vivactil
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	tricyclic antidepressant	desipramine
Before taking this medication, tell your doctor if you are taking a <e1> tricyclic antidepressant </e1> such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	tricyclic antidepressant	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> ( <e2> Elavil </e2> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amitriptyline	Elavil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), <e2> amoxapine </e2> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amitriptyline	amoxapine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine ( <e2> Asendin </e2> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amitriptyline	Asendin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine (Asendin), <e2> doxepin </e2> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amitriptyline	doxepin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine (Asendin), doxepin ( <e2> Sinequan </e2> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amitriptyline	Sinequan
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e2> nortriptyline </e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amitriptyline	nortriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amitriptyline	Pamelor
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e2> imipramine </e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amitriptyline	imipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amitriptyline	Tofranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e2> clomipramine </e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amitriptyline	clomipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin).	0	amitriptyline	Anafranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	amitriptyline	protriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	amitriptyline	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	amitriptyline	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as <e1> amitriptyline </e1> (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	amitriptyline	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), <e2> amoxapine </e2> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Elavil	amoxapine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine ( <e2> Asendin </e2> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Elavil	Asendin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), <e2> doxepin </e2> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Elavil	doxepin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin ( <e2> Sinequan </e2> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Elavil	Sinequan
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), <e2> nortriptyline </e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Elavil	nortriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Elavil	Pamelor
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e2> imipramine </e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Elavil	imipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Elavil	Tofranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e2> clomipramine </e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Elavil	clomipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin).	0	Elavil	Anafranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	Elavil	protriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	Elavil	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	Elavil	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline ( <e1> Elavil </e1> ), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	Elavil	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> ( <e2> Asendin </e2> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amoxapine	Asendin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> (Asendin), <e2> doxepin </e2> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amoxapine	doxepin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> (Asendin), doxepin ( <e2> Sinequan </e2> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amoxapine	Sinequan
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> (Asendin), doxepin (Sinequan), <e2> nortriptyline </e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amoxapine	nortriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> (Asendin), doxepin (Sinequan), nortriptyline ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amoxapine	Pamelor
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e2> imipramine </e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amoxapine	imipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amoxapine	Tofranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e2> clomipramine </e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	amoxapine	clomipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin).	0	amoxapine	Anafranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	amoxapine	protriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	amoxapine	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	amoxapine	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), <e1> amoxapine </e1> (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	amoxapine	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), <e2> doxepin </e2> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Asendin	doxepin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin ( <e2> Sinequan </e2> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Asendin	Sinequan
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), <e2> nortriptyline </e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Asendin	nortriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Asendin	Pamelor
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), <e2> imipramine </e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Asendin	imipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Asendin	Tofranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e2> clomipramine </e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Asendin	clomipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin).	0	Asendin	Anafranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	Asendin	protriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	Asendin	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	Asendin	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine ( <e1> Asendin </e1> ), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	Asendin	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1> doxepin </e1> ( <e2> Sinequan </e2> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	doxepin	Sinequan
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1> doxepin </e1> (Sinequan), <e2> nortriptyline </e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	doxepin	nortriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1> doxepin </e1> (Sinequan), nortriptyline ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	doxepin	Pamelor
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1> doxepin </e1> (Sinequan), nortriptyline (Pamelor), <e2> imipramine </e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	doxepin	imipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1> doxepin </e1> (Sinequan), nortriptyline (Pamelor), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	doxepin	Tofranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1> doxepin </e1> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e2> clomipramine </e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	doxepin	clomipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1> doxepin </e1> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin).	0	doxepin	Anafranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1> doxepin </e1> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	doxepin	protriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1> doxepin </e1> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	doxepin	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1> doxepin </e1> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	doxepin	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), <e1> doxepin </e1> (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	doxepin	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), <e2> nortriptyline </e2> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Sinequan	nortriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Sinequan	Pamelor
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor), <e2> imipramine </e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Sinequan	imipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Sinequan	Tofranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor), imipramine (Tofranil), <e2> clomipramine </e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Sinequan	clomipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin).	0	Sinequan	Anafranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	Sinequan	protriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	Sinequan	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	Sinequan	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin ( <e1> Sinequan </e1> ), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	Sinequan	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1> nortriptyline </e1> ( <e2> Pamelor </e2> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	nortriptyline	Pamelor
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1> nortriptyline </e1> (Pamelor), <e2> imipramine </e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	nortriptyline	imipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1> nortriptyline </e1> (Pamelor), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	nortriptyline	Tofranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1> nortriptyline </e1> (Pamelor), imipramine (Tofranil), <e2> clomipramine </e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	nortriptyline	clomipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1> nortriptyline </e1> (Pamelor), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin).	0	nortriptyline	Anafranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1> nortriptyline </e1> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	nortriptyline	protriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1> nortriptyline </e1> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	nortriptyline	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1> nortriptyline </e1> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	nortriptyline	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), <e1> nortriptyline </e1> (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	nortriptyline	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), <e2> imipramine </e2> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Pamelor	imipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Pamelor	Tofranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine (Tofranil), <e2> clomipramine </e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Pamelor	clomipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin).	0	Pamelor	Anafranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine (Tofranil), clomipramine (Anafranil), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	Pamelor	protriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	Pamelor	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	Pamelor	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline ( <e1> Pamelor </e1> ), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	Pamelor	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1> imipramine </e1> ( <e2> Tofranil </e2> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	imipramine	Tofranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1> imipramine </e1> (Tofranil), <e2> clomipramine </e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	imipramine	clomipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1> imipramine </e1> (Tofranil), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin).	0	imipramine	Anafranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1> imipramine </e1> (Tofranil), clomipramine (Anafranil), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	imipramine	protriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1> imipramine </e1> (Tofranil), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	imipramine	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1> imipramine </e1> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	imipramine	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), <e1> imipramine </e1> (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	imipramine	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e1> Tofranil </e1> ), <e2> clomipramine </e2> (Anafranil), protriptyline (Vivactil), or desipramine (Norpramin).	0	Tofranil	clomipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e1> Tofranil </e1> ), clomipramine ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin).	0	Tofranil	Anafranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e1> Tofranil </e1> ), clomipramine (Anafranil), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	Tofranil	protriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e1> Tofranil </e1> ), clomipramine (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	Tofranil	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e1> Tofranil </e1> ), clomipramine (Anafranil), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	Tofranil	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine ( <e1> Tofranil </e1> ), clomipramine (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	Tofranil	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e1> clomipramine </e1> ( <e2> Anafranil </e2> ), protriptyline (Vivactil), or desipramine (Norpramin).	0	clomipramine	Anafranil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e1> clomipramine </e1> (Anafranil), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	clomipramine	protriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e1> clomipramine </e1> (Anafranil), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	clomipramine	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e1> clomipramine </e1> (Anafranil), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	clomipramine	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), <e1> clomipramine </e1> (Anafranil), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	clomipramine	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e1> Anafranil </e1> ), <e2> protriptyline </e2> (Vivactil), or desipramine (Norpramin).	0	Anafranil	protriptyline
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e1> Anafranil </e1> ), protriptyline ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	Anafranil	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e1> Anafranil </e1> ), protriptyline (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	Anafranil	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine ( <e1> Anafranil </e1> ), protriptyline (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	Anafranil	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e1> protriptyline </e1> ( <e2> Vivactil </e2> ), or desipramine (Norpramin).	0	protriptyline	Vivactil
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e1> protriptyline </e1> (Vivactil), or <e2> desipramine </e2> (Norpramin).	0	protriptyline	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), <e1> protriptyline </e1> (Vivactil), or desipramine ( <e2> Norpramin </e2> ).	0	protriptyline	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e1> Vivactil </e1> ), or <e2> desipramine </e2> (Norpramin).	0	Vivactil	desipramine
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline ( <e1> Vivactil </e1> ), or desipramine ( <e2> Norpramin </e2> ).	0	Vivactil	Norpramin
Before taking this medication, tell your doctor if you are taking a tricyclic antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), doxepin (Sinequan), nortriptyline (Pamelor), imipramine (Tofranil), clomipramine (Anafranil), protriptyline (Vivactil), or <e1> desipramine </e1> ( <e2> Norpramin </e2> ).	0	desipramine	Norpramin
<e1> Sulfamethizole </e1> may increase the effects of <e2> barbiturates </e2> , tolbutamide, and uricosurics.	1	Sulfamethizole	barbiturates
<e1> Sulfamethizole </e1> may increase the effects of barbiturates, <e2> tolbutamide </e2> , and uricosurics.	1	Sulfamethizole	tolbutamide
<e1> Sulfamethizole </e1> may increase the effects of barbiturates, tolbutamide, and <e2> uricosurics </e2> .	1	Sulfamethizole	uricosurics
Sulfamethizole may increase the effects of <e1> barbiturates </e1> , <e2> tolbutamide </e2> , and uricosurics.	0	barbiturates	tolbutamide
Sulfamethizole may increase the effects of <e1> barbiturates </e1> , tolbutamide, and <e2> uricosurics </e2> .	0	barbiturates	uricosurics
Sulfamethizole may increase the effects of barbiturates, <e1> tolbutamide </e1> , and <e2> uricosurics </e2> .	0	tolbutamide	uricosurics
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), <e2> cyclosporine </e2> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	thiazides	cyclosporine
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e2> sulfonylurea agents </e2> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	thiazides	sulfonylurea agents
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e2> warfarin </e2> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	thiazides	warfarin
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e2> methotrexate </e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	thiazides	methotrexate
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).	0	thiazides	methotrexate
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2> phenytoin </e2> (decreased hepatic clearance of phenytoin).	0	thiazides	phenytoin
It may also interact with <e1> thiazides </e1> (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2> phenytoin </e2> ).	0	thiazides	phenytoin
It may also interact with thiazides (increased thrombocytopenia), <e1> cyclosporine </e1> (increased nephrotoxicity), <e2> sulfonylurea agents </e2> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	cyclosporine	sulfonylurea agents
It may also interact with thiazides (increased thrombocytopenia), <e1> cyclosporine </e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e2> warfarin </e2> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	cyclosporine	warfarin
It may also interact with thiazides (increased thrombocytopenia), <e1> cyclosporine </e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e2> methotrexate </e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	cyclosporine	methotrexate
It may also interact with thiazides (increased thrombocytopenia), <e1> cyclosporine </e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).	0	cyclosporine	methotrexate
It may also interact with thiazides (increased thrombocytopenia), <e1> cyclosporine </e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2> phenytoin </e2> (decreased hepatic clearance of phenytoin).	0	cyclosporine	phenytoin
It may also interact with thiazides (increased thrombocytopenia), <e1> cyclosporine </e1> (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2> phenytoin </e2> ).	0	cyclosporine	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1> sulfonylurea agents </e1> (increased hypoglycemic response), <e2> warfarin </e2> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	sulfonylurea agents	warfarin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1> sulfonylurea agents </e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e2> methotrexate </e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	sulfonylurea agents	methotrexate
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1> sulfonylurea agents </e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).	0	sulfonylurea agents	methotrexate
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1> sulfonylurea agents </e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2> phenytoin </e2> (decreased hepatic clearance of phenytoin).	0	sulfonylurea agents	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), <e1> sulfonylurea agents </e1> (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2> phenytoin </e2> ).	0	sulfonylurea agents	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1> warfarin </e1> (increased anticoagulant effect), <e2> methotrexate </e2> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).	0	warfarin	methotrexate
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1> warfarin </e1> (increased anticoagulant effect), methotrexate (decreased renal excretion of <e2> methotrexate </e2> ), phenytoin (decreased hepatic clearance of phenytoin).	0	warfarin	methotrexate
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1> warfarin </e1> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), <e2> phenytoin </e2> (decreased hepatic clearance of phenytoin).	0	warfarin	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), <e1> warfarin </e1> (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2> phenytoin </e2> ).	0	warfarin	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e1> methotrexate </e1> (decreased renal excretion of methotrexate), <e2> phenytoin </e2> (decreased hepatic clearance of phenytoin).	0	methotrexate	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), <e1> methotrexate </e1> (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of <e2> phenytoin </e2> ).	0	methotrexate	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e1> methotrexate </e1> ), <e2> phenytoin </e2> (decreased hepatic clearance of phenytoin).	0	methotrexate	phenytoin
It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of <e1> methotrexate </e1> ), phenytoin (decreased hepatic clearance of <e2> phenytoin </e2> ).	0	methotrexate	phenytoin
The interaction of <e1> CYLERT </e1> ( <e2> pemoline </e2> ) with other drugs has not been studied in humans.	0	CYLERT	pemoline
Decreased seizure threshold has been reported in patients receiving <e1> CYLERT </e1> concomitantly with <e2> antiepileptic medications </e2> .	1	CYLERT	antiepileptic medications
When <e1> atropine </e1> and <e2> pralidoxime </e2> are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone.	1	atropine	pralidoxime
When atropine and <e1> pralidoxime </e1> are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when <e2> atropine </e2> is used alone.	0	pralidoxime	atropine
This is especially true if the total dose of <e1> atropine </e1> has been large and the administration of <e2> pralidoxime </e2> has been delayed.	0	atropine	pralidoxime
2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of <e1> pralidoxime </e1> : since <e2> barbiturates </e2> are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions;	0	pralidoxime	barbiturates
2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of <e1> pralidoxime </e1> : since barbiturates are potentiated by the <e2> anticholinesterases </e2> , they should be used cautiously in the treatment of convulsions;	0	pralidoxime	anticholinesterases
2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since <e1> barbiturates </e1> are potentiated by the <e2> anticholinesterases </e2> , they should be used cautiously in the treatment of convulsions;	1	barbiturates	anticholinesterases
<e1> morphine </e1> , <e2> theophylline </e2> , aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	0	morphine	theophylline
<e1> morphine </e1> , theophylline, <e2> aminophylline </e2> , succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	0	morphine	aminophylline
<e1> morphine </e1> , theophylline, aminophylline, <e2> succinylcholine </e2> , reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	0	morphine	succinylcholine
<e1> morphine </e1> , theophylline, aminophylline, succinylcholine, <e2> reserpine </e2> , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	0	morphine	reserpine
<e1> morphine </e1> , theophylline, aminophylline, succinylcholine, reserpine, and <e2> phenothiazine-type tranquilizers </e2> should be avoided in patients with organophosphate poisoning.	0	morphine	phenothiazine-type tranquilizers
morphine, <e1> theophylline </e1> , <e2> aminophylline </e2> , succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	0	theophylline	aminophylline
morphine, <e1> theophylline </e1> , aminophylline, <e2> succinylcholine </e2> , reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	0	theophylline	succinylcholine
morphine, <e1> theophylline </e1> , aminophylline, succinylcholine, <e2> reserpine </e2> , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	0	theophylline	reserpine
morphine, <e1> theophylline </e1> , aminophylline, succinylcholine, reserpine, and <e2> phenothiazine-type tranquilizers </e2> should be avoided in patients with organophosphate poisoning.	0	theophylline	phenothiazine-type tranquilizers
morphine, theophylline, <e1> aminophylline </e1> , <e2> succinylcholine </e2> , reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	0	aminophylline	succinylcholine
morphine, theophylline, <e1> aminophylline </e1> , succinylcholine, <e2> reserpine </e2> , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	0	aminophylline	reserpine
morphine, theophylline, <e1> aminophylline </e1> , succinylcholine, reserpine, and <e2> phenothiazine-type tranquilizers </e2> should be avoided in patients with organophosphate poisoning.	0	aminophylline	phenothiazine-type tranquilizers
morphine, theophylline, aminophylline, <e1> succinylcholine </e1> , <e2> reserpine </e2> , and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.	0	succinylcholine	reserpine
morphine, theophylline, aminophylline, <e1> succinylcholine </e1> , reserpine, and <e2> phenothiazine-type tranquilizers </e2> should be avoided in patients with organophosphate poisoning.	0	succinylcholine	phenothiazine-type tranquilizers
morphine, theophylline, aminophylline, succinylcholine, <e1> reserpine </e1> , and <e2> phenothiazine-type tranquilizers </e2> should be avoided in patients with organophosphate poisoning.	0	reserpine	phenothiazine-type tranquilizers
Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., <e2> ketoconazole </e2> , itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	1	SUTENT	ketoconazole
Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e2> itraconazole </e2> , clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	1	SUTENT	itraconazole
Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e2> clarithromycin </e2> , atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	1	SUTENT	clarithromycin
Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e2> atazanavir </e2> , indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	1	SUTENT	atazanavir
Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e2> indinavir </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	1	SUTENT	indinavir
Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	1	SUTENT	nefazodone
Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	1	SUTENT	nelfinavir
Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	1	SUTENT	ritonavir
Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations.	1	SUTENT	saquinavir
Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations.	1	SUTENT	telithromycin
Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e2> voriconizole </e2> ) may increases sunitinib concentrations.	1	SUTENT	voriconizole
Co-administration of <e1> SUTENT </e1> with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2> sunitinib </e2> concentrations.	0	SUTENT	sunitinib
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1> ketoconazole </e1> , <e2> itraconazole </e2> , clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	ketoconazole	itraconazole
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1> ketoconazole </e1> , itraconazole, <e2> clarithromycin </e2> , atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	ketoconazole	clarithromycin
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1> ketoconazole </e1> , itraconazole, clarithromycin, <e2> atazanavir </e2> , indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	ketoconazole	atazanavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1> ketoconazole </e1> , itraconazole, clarithromycin, atazanavir, <e2> indinavir </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	ketoconazole	indinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1> ketoconazole </e1> , itraconazole, clarithromycin, atazanavir, indinavir, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	ketoconazole	nefazodone
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1> ketoconazole </e1> , itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	ketoconazole	nelfinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1> ketoconazole </e1> , itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	ketoconazole	ritonavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1> ketoconazole </e1> , itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations.	0	ketoconazole	saquinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1> ketoconazole </e1> , itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations.	0	ketoconazole	telithromycin
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1> ketoconazole </e1> , itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e2> voriconizole </e2> ) may increases sunitinib concentrations.	0	ketoconazole	voriconizole
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., <e1> ketoconazole </e1> , itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2> sunitinib </e2> concentrations.	0	ketoconazole	sunitinib
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1> itraconazole </e1> , <e2> clarithromycin </e2> , atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	itraconazole	clarithromycin
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1> itraconazole </e1> , clarithromycin, <e2> atazanavir </e2> , indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	itraconazole	atazanavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1> itraconazole </e1> , clarithromycin, atazanavir, <e2> indinavir </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	itraconazole	indinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1> itraconazole </e1> , clarithromycin, atazanavir, indinavir, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	itraconazole	nefazodone
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1> itraconazole </e1> , clarithromycin, atazanavir, indinavir, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	itraconazole	nelfinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1> itraconazole </e1> , clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	itraconazole	ritonavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1> itraconazole </e1> , clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations.	0	itraconazole	saquinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1> itraconazole </e1> , clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations.	0	itraconazole	telithromycin
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1> itraconazole </e1> , clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e2> voriconizole </e2> ) may increases sunitinib concentrations.	0	itraconazole	voriconizole
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, <e1> itraconazole </e1> , clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2> sunitinib </e2> concentrations.	0	itraconazole	sunitinib
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1> clarithromycin </e1> , <e2> atazanavir </e2> , indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	clarithromycin	atazanavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1> clarithromycin </e1> , atazanavir, <e2> indinavir </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	clarithromycin	indinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1> clarithromycin </e1> , atazanavir, indinavir, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	clarithromycin	nefazodone
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1> clarithromycin </e1> , atazanavir, indinavir, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	clarithromycin	nelfinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1> clarithromycin </e1> , atazanavir, indinavir, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	clarithromycin	ritonavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1> clarithromycin </e1> , atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations.	0	clarithromycin	saquinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1> clarithromycin </e1> , atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations.	0	clarithromycin	telithromycin
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1> clarithromycin </e1> , atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e2> voriconizole </e2> ) may increases sunitinib concentrations.	0	clarithromycin	voriconizole
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, <e1> clarithromycin </e1> , atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2> sunitinib </e2> concentrations.	0	clarithromycin	sunitinib
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1> atazanavir </e1> , <e2> indinavir </e2> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	atazanavir	indinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1> atazanavir </e1> , indinavir, <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	atazanavir	nefazodone
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1> atazanavir </e1> , indinavir, nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	atazanavir	nelfinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1> atazanavir </e1> , indinavir, nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	atazanavir	ritonavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1> atazanavir </e1> , indinavir, nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations.	0	atazanavir	saquinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1> atazanavir </e1> , indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations.	0	atazanavir	telithromycin
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1> atazanavir </e1> , indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e2> voriconizole </e2> ) may increases sunitinib concentrations.	0	atazanavir	voriconizole
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, <e1> atazanavir </e1> , indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2> sunitinib </e2> concentrations.	0	atazanavir	sunitinib
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1> indinavir </e1> , <e2> nefazodone </e2> , nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	indinavir	nefazodone
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1> indinavir </e1> , nefazodone, <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	indinavir	nelfinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1> indinavir </e1> , nefazodone, nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	indinavir	ritonavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1> indinavir </e1> , nefazodone, nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations.	0	indinavir	saquinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1> indinavir </e1> , nefazodone, nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations.	0	indinavir	telithromycin
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1> indinavir </e1> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e2> voriconizole </e2> ) may increases sunitinib concentrations.	0	indinavir	voriconizole
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, <e1> indinavir </e1> , nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2> sunitinib </e2> concentrations.	0	indinavir	sunitinib
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e1> nefazodone </e1> , <e2> nelfinavir </e2> , ritonavir, saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	nefazodone	nelfinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e1> nefazodone </e1> , nelfinavir, <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	nefazodone	ritonavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e1> nefazodone </e1> , nelfinavir, ritonavir, <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations.	0	nefazodone	saquinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e1> nefazodone </e1> , nelfinavir, ritonavir, saquinavir, <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations.	0	nefazodone	telithromycin
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e1> nefazodone </e1> , nelfinavir, ritonavir, saquinavir, telithromycin, <e2> voriconizole </e2> ) may increases sunitinib concentrations.	0	nefazodone	voriconizole
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, <e1> nefazodone </e1> , nelfinavir, ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2> sunitinib </e2> concentrations.	0	nefazodone	sunitinib
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e1> nelfinavir </e1> , <e2> ritonavir </e2> , saquinavir, telithromycin, voriconizole) may increases sunitinib concentrations.	0	nelfinavir	ritonavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e1> nelfinavir </e1> , ritonavir, <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations.	0	nelfinavir	saquinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e1> nelfinavir </e1> , ritonavir, saquinavir, <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations.	0	nelfinavir	telithromycin
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e1> nelfinavir </e1> , ritonavir, saquinavir, telithromycin, <e2> voriconizole </e2> ) may increases sunitinib concentrations.	0	nelfinavir	voriconizole
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, <e1> nelfinavir </e1> , ritonavir, saquinavir, telithromycin, voriconizole) may increases <e2> sunitinib </e2> concentrations.	0	nelfinavir	sunitinib
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e1> ritonavir </e1> , <e2> saquinavir </e2> , telithromycin, voriconizole) may increases sunitinib concentrations.	0	ritonavir	saquinavir
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e1> ritonavir </e1> , saquinavir, <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations.	0	ritonavir	telithromycin
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e1> ritonavir </e1> , saquinavir, telithromycin, <e2> voriconizole </e2> ) may increases sunitinib concentrations.	0	ritonavir	voriconizole
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, <e1> ritonavir </e1> , saquinavir, telithromycin, voriconizole) may increases <e2> sunitinib </e2> concentrations.	0	ritonavir	sunitinib
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e1> saquinavir </e1> , <e2> telithromycin </e2> , voriconizole) may increases sunitinib concentrations.	0	saquinavir	telithromycin
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e1> saquinavir </e1> , telithromycin, <e2> voriconizole </e2> ) may increases sunitinib concentrations.	0	saquinavir	voriconizole
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, <e1> saquinavir </e1> , telithromycin, voriconizole) may increases <e2> sunitinib </e2> concentrations.	0	saquinavir	sunitinib
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e1> telithromycin </e1> , <e2> voriconizole </e2> ) may increases sunitinib concentrations.	0	telithromycin	voriconizole
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, <e1> telithromycin </e1> , voriconizole) may increases <e2> sunitinib </e2> concentrations.	0	telithromycin	sunitinib
Co-administration of SUTENT with strong inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, <e1> voriconizole </e1> ) may increases <e2> sunitinib </e2> concentrations.	0	voriconizole	sunitinib
Co-administration of <e1> SUTENT </e1> with inducers of the CYP3A4 family (e.g., <e2> dexamethasone </e2> , phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	1	SUTENT	dexamethasone
Co-administration of <e1> SUTENT </e1> with inducers of the CYP3A4 family (e.g., dexamethasone, <e2> phenytoin </e2> , carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	1	SUTENT	phenytoin
Co-administration of <e1> SUTENT </e1> with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, <e2> carbamazepine </e2> , rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	1	SUTENT	carbamazepine
Co-administration of <e1> SUTENT </e1> with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, <e2> rifampin </e2> , rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	1	SUTENT	rifampin
Co-administration of <e1> SUTENT </e1> with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, <e2> rifabutin </e2> , rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	1	SUTENT	rifabutin
Co-administration of <e1> SUTENT </e1> with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, <e2> rifapentin </e2> , phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	1	SUTENT	rifapentin
Co-administration of <e1> SUTENT </e1> with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, <e2> phenobarbital </e2> , St. Johns Wort) may decrease sunitinib concentrations.	1	SUTENT	phenobarbital
Co-administration of <e1> SUTENT </e1> with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease <e2> sunitinib </e2> concentrations.	0	SUTENT	sunitinib
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1> dexamethasone </e1> , <e2> phenytoin </e2> , carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	dexamethasone	phenytoin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1> dexamethasone </e1> , phenytoin, <e2> carbamazepine </e2> , rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	dexamethasone	carbamazepine
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1> dexamethasone </e1> , phenytoin, carbamazepine, <e2> rifampin </e2> , rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	dexamethasone	rifampin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1> dexamethasone </e1> , phenytoin, carbamazepine, rifampin, <e2> rifabutin </e2> , rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	dexamethasone	rifabutin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1> dexamethasone </e1> , phenytoin, carbamazepine, rifampin, rifabutin, <e2> rifapentin </e2> , phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	dexamethasone	rifapentin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1> dexamethasone </e1> , phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, <e2> phenobarbital </e2> , St. Johns Wort) may decrease sunitinib concentrations.	0	dexamethasone	phenobarbital
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., <e1> dexamethasone </e1> , phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease <e2> sunitinib </e2> concentrations.	0	dexamethasone	sunitinib
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, <e1> phenytoin </e1> , <e2> carbamazepine </e2> , rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	phenytoin	carbamazepine
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, <e1> phenytoin </e1> , carbamazepine, <e2> rifampin </e2> , rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	phenytoin	rifampin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, <e1> phenytoin </e1> , carbamazepine, rifampin, <e2> rifabutin </e2> , rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	phenytoin	rifabutin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, <e1> phenytoin </e1> , carbamazepine, rifampin, rifabutin, <e2> rifapentin </e2> , phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	phenytoin	rifapentin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, <e1> phenytoin </e1> , carbamazepine, rifampin, rifabutin, rifapentin, <e2> phenobarbital </e2> , St. Johns Wort) may decrease sunitinib concentrations.	0	phenytoin	phenobarbital
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, <e1> phenytoin </e1> , carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease <e2> sunitinib </e2> concentrations.	0	phenytoin	sunitinib
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, <e1> carbamazepine </e1> , <e2> rifampin </e2> , rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	carbamazepine	rifampin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, <e1> carbamazepine </e1> , rifampin, <e2> rifabutin </e2> , rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	carbamazepine	rifabutin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, <e1> carbamazepine </e1> , rifampin, rifabutin, <e2> rifapentin </e2> , phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	carbamazepine	rifapentin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, <e1> carbamazepine </e1> , rifampin, rifabutin, rifapentin, <e2> phenobarbital </e2> , St. Johns Wort) may decrease sunitinib concentrations.	0	carbamazepine	phenobarbital
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, <e1> carbamazepine </e1> , rifampin, rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease <e2> sunitinib </e2> concentrations.	0	carbamazepine	sunitinib
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, <e1> rifampin </e1> , <e2> rifabutin </e2> , rifapentin, phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	rifampin	rifabutin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, <e1> rifampin </e1> , rifabutin, <e2> rifapentin </e2> , phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	rifampin	rifapentin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, <e1> rifampin </e1> , rifabutin, rifapentin, <e2> phenobarbital </e2> , St. Johns Wort) may decrease sunitinib concentrations.	0	rifampin	phenobarbital
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, <e1> rifampin </e1> , rifabutin, rifapentin, phenobarbital, St. Johns Wort) may decrease <e2> sunitinib </e2> concentrations.	0	rifampin	sunitinib
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, <e1> rifabutin </e1> , <e2> rifapentin </e2> , phenobarbital, St. Johns Wort) may decrease sunitinib concentrations.	0	rifabutin	rifapentin
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, <e1> rifabutin </e1> , rifapentin, <e2> phenobarbital </e2> , St. Johns Wort) may decrease sunitinib concentrations.	0	rifabutin	phenobarbital
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, <e1> rifabutin </e1> , rifapentin, phenobarbital, St. Johns Wort) may decrease <e2> sunitinib </e2> concentrations.	0	rifabutin	sunitinib
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, <e1> rifapentin </e1> , <e2> phenobarbital </e2> , St. Johns Wort) may decrease sunitinib concentrations.	0	rifapentin	phenobarbital
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, <e1> rifapentin </e1> , phenobarbital, St. Johns Wort) may decrease <e2> sunitinib </e2> concentrations.	0	rifapentin	sunitinib
Co-administration of SUTENT with inducers of the CYP3A4 family (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, <e1> phenobarbital </e1> , St. Johns Wort) may decrease <e2> sunitinib </e2> concentrations.	0	phenobarbital	sunitinib
Since <e1> Celontin </e1> ( <e2> methsuximide </e2> ) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	0	Celontin	methsuximide
Since <e1> Celontin </e1> (methsuximide) may interact with concurrently administered <e2> antiepileptic drugs </e2> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	0	Celontin	antiepileptic drugs
Since <e1> Celontin </e1> (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg <e2> methsuximide </e2> may increase the plasma concentrations of phenytoin and phenobarbital).	0	Celontin	methsuximide
Since <e1> Celontin </e1> (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e2> phenytoin </e2> and phenobarbital).	0	Celontin	phenytoin
Since <e1> Celontin </e1> (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and <e2> phenobarbital </e2> ).	0	Celontin	phenobarbital
Since Celontin ( <e1> methsuximide </e1> ) may interact with concurrently administered <e2> antiepileptic drugs </e2> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).	0	methsuximide	antiepileptic drugs
Since Celontin ( <e1> methsuximide </e1> ) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e2> phenytoin </e2> and phenobarbital).	0	methsuximide	phenytoin
Since Celontin ( <e1> methsuximide </e1> ) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and <e2> phenobarbital </e2> ).	0	methsuximide	phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered <e1> antiepileptic drugs </e1> , periodic serum level determinations of these drugs may be necessary (eg <e2> methsuximide </e2> may increase the plasma concentrations of phenytoin and phenobarbital).	0	antiepileptic drugs	methsuximide
Since Celontin (methsuximide) may interact with concurrently administered <e1> antiepileptic drugs </e1> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e2> phenytoin </e2> and phenobarbital).	0	antiepileptic drugs	phenytoin
Since Celontin (methsuximide) may interact with concurrently administered <e1> antiepileptic drugs </e1> , periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and <e2> phenobarbital </e2> ).	0	antiepileptic drugs	phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg <e1> methsuximide </e1> may increase the plasma concentrations of <e2> phenytoin </e2> and phenobarbital).	1	methsuximide	phenytoin
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg <e1> methsuximide </e1> may increase the plasma concentrations of phenytoin and <e2> phenobarbital </e2> ).	1	methsuximide	phenobarbital
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of <e1> phenytoin </e1> and <e2> phenobarbital </e2> ).	0	phenytoin	phenobarbital
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of <e1> zidovudine </e1> or <e2> rifabutin </e2> to warrant dosage adjustment when megestrol acetate is administered with these drugs.	0	zidovudine	rifabutin
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of <e1> zidovudine </e1> or rifabutin to warrant dosage adjustment when <e2> megestrol acetate </e2> is administered with these drugs.	0	zidovudine	megestrol acetate
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or <e1> rifabutin </e1> to warrant dosage adjustment when <e2> megestrol acetate </e2> is administered with these drugs.	0	rifabutin	megestrol acetate
A pharmacokinetic study demonstrated that coadministration of <e1> megestrol acetate </e1> and <e2> indinavir </e2> results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir.	1	megestrol acetate	indinavir
A pharmacokinetic study demonstrated that coadministration of <e1> megestrol acetate </e1> and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of <e2> indinavir </e2> .	0	megestrol acetate	indinavir
Administration of a higher dose of <e1> indinavir </e1> should be considered when coadministering with <e2> megestrol acetate </e2> .	0	indinavir	megestrol acetate
The effects of <e1> indinavir </e1> , <e2> zidovudine </e2> or rifabutin on the pharmacokinetics of megestrol acetate were not studied.	0	indinavir	zidovudine
The effects of <e1> indinavir </e1> , zidovudine or <e2> rifabutin </e2> on the pharmacokinetics of megestrol acetate were not studied.	0	indinavir	rifabutin
The effects of <e1> indinavir </e1> , zidovudine or rifabutin on the pharmacokinetics of <e2> megestrol acetate </e2> were not studied.	0	indinavir	megestrol acetate
The effects of indinavir, <e1> zidovudine </e1> or <e2> rifabutin </e2> on the pharmacokinetics of megestrol acetate were not studied.	0	zidovudine	rifabutin
The effects of indinavir, <e1> zidovudine </e1> or rifabutin on the pharmacokinetics of <e2> megestrol acetate </e2> were not studied.	0	zidovudine	megestrol acetate
The effects of indinavir, zidovudine or <e1> rifabutin </e1> on the pharmacokinetics of <e2> megestrol acetate </e2> were not studied.	0	rifabutin	megestrol acetate
<e1> Diuretics </e1> : Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of <e2> ACEON </e2> Tablets therapy.	0	Diuretics	ACEON
Diuretics: Patients on <e1> diuretics </e1> , and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of <e2> ACEON </e2> Tablets therapy.	1	diuretics	ACEON
The possibility of hypotensive effects can be minimized by either discontinuing the <e1> diuretic </e1> or increasing the salt intake prior to initiation of treatment with <e2> perindopril </e2> .	1	diuretic	perindopril
If <e1> diuretics </e1> cannot be interrupted, close medical supervision should be provided with the first dose of <e2> ACEON </e2> Tablets, for at least two hours and until blood pressure has stabilized for another hour.	0	diuretics	ACEON
The rate and extent of <e1> perindopril </e1> absorption and elimination are not affected by concomitant <e2> diuretics </e2> .	0	perindopril	diuretics
The bioavailability of <e1> perindoprilat </e1> was reduced by <e2> diuretics </e2> , however, and this was associated with a decrease in plasma ACE inhibition.	0	perindoprilat	diuretics
<e1> Potassium </e1> Supplements and <e2> Potassium-Sparing Diuretics </e2> : ACEON Tablets may increase serum potassium because of its potential to decrease aldosterone production.	0	Potassium	Potassium-Sparing Diuretics
<e1> Potassium </e1> Supplements and Potassium-Sparing Diuretics: <e2> ACEON </e2> Tablets may increase serum potassium because of its potential to decrease aldosterone production.	0	Potassium	ACEON
Potassium Supplements and <e1> Potassium-Sparing Diuretics </e1> : <e2> ACEON </e2> Tablets may increase serum potassium because of its potential to decrease aldosterone production.	0	Potassium-Sparing Diuretics	ACEON
Use of <e1> potassium-sparing diuretics </e1> ( <e2> spironolactone </e2> , amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	potassium-sparing diuretics	spironolactone
Use of <e1> potassium-sparing diuretics </e1> (spironolactone, <e2> amiloride </e2> , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	potassium-sparing diuretics	amiloride
Use of <e1> potassium-sparing diuretics </e1> (spironolactone, amiloride, <e2> triamterene </e2> and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	potassium-sparing diuretics	triamterene
Use of <e1> potassium-sparing diuretics </e1> (spironolactone, amiloride, triamterene and others), <e2> potassium </e2> supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	potassium-sparing diuretics	potassium
Use of <e1> potassium-sparing diuretics </e1> (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( <e2> indomethacin </e2> , heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	potassium-sparing diuretics	indomethacin
Use of <e1> potassium-sparing diuretics </e1> (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, <e2> heparin </e2> , cyclosporine and others) can increase the risk of hyperkalemia.	0	potassium-sparing diuretics	heparin
Use of <e1> potassium-sparing diuretics </e1> (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, <e2> cyclosporine </e2> and others) can increase the risk of hyperkalemia.	0	potassium-sparing diuretics	cyclosporine
Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , <e2> amiloride </e2> , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	spironolactone	amiloride
Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , amiloride, <e2> triamterene </e2> and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	spironolactone	triamterene
Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , amiloride, triamterene and others), <e2> potassium </e2> supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	spironolactone	potassium
Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( <e2> indomethacin </e2> , heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	spironolactone	indomethacin
Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, <e2> heparin </e2> , cyclosporine and others) can increase the risk of hyperkalemia.	0	spironolactone	heparin
Use of potassium-sparing diuretics ( <e1> spironolactone </e1> , amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, <e2> cyclosporine </e2> and others) can increase the risk of hyperkalemia.	0	spironolactone	cyclosporine
Use of potassium-sparing diuretics (spironolactone, <e1> amiloride </e1> , <e2> triamterene </e2> and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	amiloride	triamterene
Use of potassium-sparing diuretics (spironolactone, <e1> amiloride </e1> , triamterene and others), <e2> potassium </e2> supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	amiloride	potassium
Use of potassium-sparing diuretics (spironolactone, <e1> amiloride </e1> , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( <e2> indomethacin </e2> , heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	amiloride	indomethacin
Use of potassium-sparing diuretics (spironolactone, <e1> amiloride </e1> , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, <e2> heparin </e2> , cyclosporine and others) can increase the risk of hyperkalemia.	0	amiloride	heparin
Use of potassium-sparing diuretics (spironolactone, <e1> amiloride </e1> , triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, <e2> cyclosporine </e2> and others) can increase the risk of hyperkalemia.	0	amiloride	cyclosporine
Use of potassium-sparing diuretics (spironolactone, amiloride, <e1> triamterene </e1> and others), <e2> potassium </e2> supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	triamterene	potassium
Use of potassium-sparing diuretics (spironolactone, amiloride, <e1> triamterene </e1> and others), potassium supplements or other drugs capable of increasing serum potassium ( <e2> indomethacin </e2> , heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	triamterene	indomethacin
Use of potassium-sparing diuretics (spironolactone, amiloride, <e1> triamterene </e1> and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, <e2> heparin </e2> , cyclosporine and others) can increase the risk of hyperkalemia.	0	triamterene	heparin
Use of potassium-sparing diuretics (spironolactone, amiloride, <e1> triamterene </e1> and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, <e2> cyclosporine </e2> and others) can increase the risk of hyperkalemia.	0	triamterene	cyclosporine
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), <e1> potassium </e1> supplements or other drugs capable of increasing serum potassium ( <e2> indomethacin </e2> , heparin, cyclosporine and others) can increase the risk of hyperkalemia.	0	potassium	indomethacin
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), <e1> potassium </e1> supplements or other drugs capable of increasing serum potassium (indomethacin, <e2> heparin </e2> , cyclosporine and others) can increase the risk of hyperkalemia.	0	potassium	heparin
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), <e1> potassium </e1> supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, <e2> cyclosporine </e2> and others) can increase the risk of hyperkalemia.	0	potassium	cyclosporine
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( <e1> indomethacin </e1> , <e2> heparin </e2> , cyclosporine and others) can increase the risk of hyperkalemia.	0	indomethacin	heparin
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium ( <e1> indomethacin </e1> , heparin, <e2> cyclosporine </e2> and others) can increase the risk of hyperkalemia.	0	indomethacin	cyclosporine
Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, <e1> heparin </e1> , <e2> cyclosporine </e2> and others) can increase the risk of hyperkalemia.	0	heparin	cyclosporine
Use of a <e1> diuretic </e1> may further increase the risk of <e2> lithium </e2> toxicity.	0	diuretic	lithium
<e1> Digoxin </e1> : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with <e2> ACEON </e2> Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	0	Digoxin	ACEON
<e1> Digoxin </e1> : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets, but an effect of digoxin on the plasma concentration of <e2> perindopril </e2> /perindoprilat has not been excluded.	0	Digoxin	perindopril
<e1> Digoxin </e1> : A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets, but an effect of digoxin on the plasma concentration of perindopril/ <e2> perindoprilat </e2> has not been excluded.	0	Digoxin	perindoprilat
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma <e1> digoxin </e1> concentrations when coadministered with <e2> ACEON </e2> Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded.	0	digoxin	ACEON
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma <e1> digoxin </e1> concentrations when coadministered with ACEON Tablets, but an effect of digoxin on the plasma concentration of <e2> perindopril </e2> /perindoprilat has not been excluded.	0	digoxin	perindopril
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma <e1> digoxin </e1> concentrations when coadministered with ACEON Tablets, but an effect of digoxin on the plasma concentration of perindopril/ <e2> perindoprilat </e2> has not been excluded.	0	digoxin	perindoprilat
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with <e1> ACEON </e1> Tablets, but an effect of <e2> digoxin </e2> on the plasma concentration of perindopril/perindoprilat has not been excluded.	0	ACEON	digoxin
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with <e1> ACEON </e1> Tablets, but an effect of digoxin on the plasma concentration of <e2> perindopril </e2> /perindoprilat has not been excluded.	0	ACEON	perindopril
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with <e1> ACEON </e1> Tablets, but an effect of digoxin on the plasma concentration of perindopril/ <e2> perindoprilat </e2> has not been excluded.	0	ACEON	perindoprilat
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets, but an effect of <e1> digoxin </e1> on the plasma concentration of <e2> perindopril </e2> /perindoprilat has not been excluded.	1	digoxin	perindopril
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets, but an effect of <e1> digoxin </e1> on the plasma concentration of perindopril/ <e2> perindoprilat </e2> has not been excluded.	1	digoxin	perindoprilat
Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON Tablets, but an effect of digoxin on the plasma concentration of <e1> perindopril </e1> / <e2> perindoprilat </e2> has not been excluded.	0	perindopril	perindoprilat
<e1> Gentamicin </e1> : Animal data have suggested the possibility of interaction between <e2> perindopril </e2> and gentamicin.	0	Gentamicin	perindopril
Gentamicin: Animal data have suggested the possibility of interaction between <e1> perindopril </e1> and <e2> gentamicin </e2> .	0	perindopril	gentamicin
Food Interaction: Oral administration of <e1> ACEON </e1> Tablets with food does not significantly lower the rate or extent of <e2> perindopril </e2> absorption relative to the fasted state.	0	ACEON	perindopril
However, the extent of biotransformation of <e1> perindopril </e1> to the active metabolite, <e2> perindoprilat </e2> , is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant.	0	perindopril	perindoprilat
Drug-Drug Interactions Effect of <e1> Exelon </e1> ( <e2> rivastigmine tartrate </e2> ) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases.	0	Exelon	rivastigmine tartrate
Drug-Drug Interactions Effect of <e1> Exelon </e1> (rivastigmine tartrate) on the Metabolism of Other Drugs: <e2> Rivastigmine </e2> is primarily metabolized through hydrolysis by esterases.	0	Exelon	Rivastigmine
Drug-Drug Interactions Effect of Exelon ( <e1> rivastigmine tartrate </e1> ) on the Metabolism of Other Drugs: <e2> Rivastigmine </e2> is primarily metabolized through hydrolysis by esterases.	0	rivastigmine tartrate	Rivastigmine
No pharmacokinetic interaction was observed between <e1> rivastigmine </e1> and <e2> digoxin </e2> , warfarin, diazepam, or fluoxetine in studies in healthy volunteers.	0	rivastigmine	digoxin
No pharmacokinetic interaction was observed between <e1> rivastigmine </e1> and digoxin, <e2> warfarin </e2> , diazepam, or fluoxetine in studies in healthy volunteers.	0	rivastigmine	warfarin
No pharmacokinetic interaction was observed between <e1> rivastigmine </e1> and digoxin, warfarin, <e2> diazepam </e2> , or fluoxetine in studies in healthy volunteers.	0	rivastigmine	diazepam
No pharmacokinetic interaction was observed between <e1> rivastigmine </e1> and digoxin, warfarin, diazepam, or <e2> fluoxetine </e2> in studies in healthy volunteers.	0	rivastigmine	fluoxetine
No pharmacokinetic interaction was observed between rivastigmine and <e1> digoxin </e1> , <e2> warfarin </e2> , diazepam, or fluoxetine in studies in healthy volunteers.	0	digoxin	warfarin
No pharmacokinetic interaction was observed between rivastigmine and <e1> digoxin </e1> , warfarin, <e2> diazepam </e2> , or fluoxetine in studies in healthy volunteers.	0	digoxin	diazepam
No pharmacokinetic interaction was observed between rivastigmine and <e1> digoxin </e1> , warfarin, diazepam, or <e2> fluoxetine </e2> in studies in healthy volunteers.	0	digoxin	fluoxetine
No pharmacokinetic interaction was observed between rivastigmine and digoxin, <e1> warfarin </e1> , <e2> diazepam </e2> , or fluoxetine in studies in healthy volunteers.	0	warfarin	diazepam
No pharmacokinetic interaction was observed between rivastigmine and digoxin, <e1> warfarin </e1> , diazepam, or <e2> fluoxetine </e2> in studies in healthy volunteers.	0	warfarin	fluoxetine
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, <e1> diazepam </e1> , or <e2> fluoxetine </e2> in studies in healthy volunteers.	0	diazepam	fluoxetine
The elevation of prothrombin time induced by <e1> warfarin </e1> is not affected by administration of <e2> Exelon </e2> .	0	warfarin	Exelon
Effect of Other Drugs on the Metabolism of <e1> Exelon </e1> : Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of <e2> rivastigmine </e2> .	0	Exelon	rivastigmine
Single dose pharmacokinetic studies demonstrated that the metabolism of <e1> rivastigmine </e1> is not significantly affected by concurrent administration of <e2> digoxin </e2> , warfarin, diazepam, or fluoxetine.	0	rivastigmine	digoxin
Single dose pharmacokinetic studies demonstrated that the metabolism of <e1> rivastigmine </e1> is not significantly affected by concurrent administration of digoxin, <e2> warfarin </e2> , diazepam, or fluoxetine.	0	rivastigmine	warfarin
Single dose pharmacokinetic studies demonstrated that the metabolism of <e1> rivastigmine </e1> is not significantly affected by concurrent administration of digoxin, warfarin, <e2> diazepam </e2> , or fluoxetine.	0	rivastigmine	diazepam
Single dose pharmacokinetic studies demonstrated that the metabolism of <e1> rivastigmine </e1> is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or <e2> fluoxetine </e2> .	0	rivastigmine	fluoxetine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of <e1> digoxin </e1> , <e2> warfarin </e2> , diazepam, or fluoxetine.	0	digoxin	warfarin
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of <e1> digoxin </e1> , warfarin, <e2> diazepam </e2> , or fluoxetine.	0	digoxin	diazepam
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of <e1> digoxin </e1> , warfarin, diazepam, or <e2> fluoxetine </e2> .	0	digoxin	fluoxetine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, <e1> warfarin </e1> , <e2> diazepam </e2> , or fluoxetine.	0	warfarin	diazepam
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, <e1> warfarin </e1> , diazepam, or <e2> fluoxetine </e2> .	0	warfarin	fluoxetine
Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, <e1> diazepam </e1> , or <e2> fluoxetine </e2> .	0	diazepam	fluoxetine
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> rivastigmine </e1> were not influenced by commonly prescribed medications such as <e2> antacids </e2> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	rivastigmine	antacids
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> rivastigmine </e1> were not influenced by commonly prescribed medications such as antacids (n=77), <e2> antihypertensives </e2> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	rivastigmine	antihypertensives
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> rivastigmine </e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e2> calcium channel blockers </e2> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	rivastigmine	calcium channel blockers
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> rivastigmine </e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e2> antidiabetics </e2> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	rivastigmine	antidiabetics
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> rivastigmine </e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e2> nonsteroidal anti-inflammatory drugs </e2> (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	rivastigmine	nonsteroidal anti-inflammatory drugs
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> rivastigmine </e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e2> estrogens </e2> (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	rivastigmine	estrogens
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> rivastigmine </e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e2> salicylate analgesics </e2> (n=177), antianginals (n=35), and antihistamines (n=15).	0	rivastigmine	salicylate analgesics
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> rivastigmine </e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), <e2> antianginals </e2> (n=35), and antihistamines (n=15).	0	rivastigmine	antianginals
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of <e1> rivastigmine </e1> were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2> antihistamines </e2> (n=15).	0	rivastigmine	antihistamines
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> antacids </e1> (n=77), <e2> antihypertensives </e2> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	antacids	antihypertensives
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> antacids </e1> (n=77), antihypertensives (n=72), <e2> calcium channel blockers </e2> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	antacids	calcium channel blockers
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> antacids </e1> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e2> antidiabetics </e2> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	antacids	antidiabetics
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> antacids </e1> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e2> nonsteroidal anti-inflammatory drugs </e2> (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	antacids	nonsteroidal anti-inflammatory drugs
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> antacids </e1> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e2> estrogens </e2> (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	antacids	estrogens
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> antacids </e1> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e2> salicylate analgesics </e2> (n=177), antianginals (n=35), and antihistamines (n=15).	0	antacids	salicylate analgesics
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> antacids </e1> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), <e2> antianginals </e2> (n=35), and antihistamines (n=15).	0	antacids	antianginals
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as <e1> antacids </e1> (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2> antihistamines </e2> (n=15).	0	antacids	antihistamines
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1> antihypertensives </e1> (n=72), <e2> calcium channel blockers </e2> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	antihypertensives	calcium channel blockers
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1> antihypertensives </e1> (n=72), calcium channel blockers (n=75), <e2> antidiabetics </e2> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	antihypertensives	antidiabetics
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1> antihypertensives </e1> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e2> nonsteroidal anti-inflammatory drugs </e2> (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	antihypertensives	nonsteroidal anti-inflammatory drugs
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1> antihypertensives </e1> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e2> estrogens </e2> (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	antihypertensives	estrogens
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1> antihypertensives </e1> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e2> salicylate analgesics </e2> (n=177), antianginals (n=35), and antihistamines (n=15).	0	antihypertensives	salicylate analgesics
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1> antihypertensives </e1> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), <e2> antianginals </e2> (n=35), and antihistamines (n=15).	0	antihypertensives	antianginals
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), <e1> antihypertensives </e1> (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2> antihistamines </e2> (n=15).	0	antihypertensives	antihistamines
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e1> calcium channel blockers </e1> (n=75), <e2> antidiabetics </e2> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	calcium channel blockers	antidiabetics
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e1> calcium channel blockers </e1> (n=75), antidiabetics (n=21), <e2> nonsteroidal anti-inflammatory drugs </e2> (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	calcium channel blockers	nonsteroidal anti-inflammatory drugs
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e1> calcium channel blockers </e1> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e2> estrogens </e2> (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	calcium channel blockers	estrogens
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e1> calcium channel blockers </e1> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e2> salicylate analgesics </e2> (n=177), antianginals (n=35), and antihistamines (n=15).	0	calcium channel blockers	salicylate analgesics
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e1> calcium channel blockers </e1> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), <e2> antianginals </e2> (n=35), and antihistamines (n=15).	0	calcium channel blockers	antianginals
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), <e1> calcium channel blockers </e1> (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2> antihistamines </e2> (n=15).	0	calcium channel blockers	antihistamines
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e1> antidiabetics </e1> (n=21), <e2> nonsteroidal anti-inflammatory drugs </e2> (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	antidiabetics	nonsteroidal anti-inflammatory drugs
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e1> antidiabetics </e1> (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e2> estrogens </e2> (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	antidiabetics	estrogens
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e1> antidiabetics </e1> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e2> salicylate analgesics </e2> (n=177), antianginals (n=35), and antihistamines (n=15).	0	antidiabetics	salicylate analgesics
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e1> antidiabetics </e1> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), <e2> antianginals </e2> (n=35), and antihistamines (n=15).	0	antidiabetics	antianginals
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), <e1> antidiabetics </e1> (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2> antihistamines </e2> (n=15).	0	antidiabetics	antihistamines
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e1> nonsteroidal anti-inflammatory drugs </e1> (n=79), <e2> estrogens </e2> (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15).	0	nonsteroidal anti-inflammatory drugs	estrogens
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e1> nonsteroidal anti-inflammatory drugs </e1> (n=79), estrogens (n=70), <e2> salicylate analgesics </e2> (n=177), antianginals (n=35), and antihistamines (n=15).	0	nonsteroidal anti-inflammatory drugs	salicylate analgesics
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e1> nonsteroidal anti-inflammatory drugs </e1> (n=79), estrogens (n=70), salicylate analgesics (n=177), <e2> antianginals </e2> (n=35), and antihistamines (n=15).	0	nonsteroidal anti-inflammatory drugs	antianginals
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), <e1> nonsteroidal anti-inflammatory drugs </e1> (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2> antihistamines </e2> (n=15).	0	nonsteroidal anti-inflammatory drugs	antihistamines
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e1> estrogens </e1> (n=70), <e2> salicylate analgesics </e2> (n=177), antianginals (n=35), and antihistamines (n=15).	0	estrogens	salicylate analgesics
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e1> estrogens </e1> (n=70), salicylate analgesics (n=177), <e2> antianginals </e2> (n=35), and antihistamines (n=15).	0	estrogens	antianginals
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), <e1> estrogens </e1> (n=70), salicylate analgesics (n=177), antianginals (n=35), and <e2> antihistamines </e2> (n=15).	0	estrogens	antihistamines
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e1> salicylate analgesics </e1> (n=177), <e2> antianginals </e2> (n=35), and antihistamines (n=15).	0	salicylate analgesics	antianginals
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), <e1> salicylate analgesics </e1> (n=177), antianginals (n=35), and <e2> antihistamines </e2> (n=15).	0	salicylate analgesics	antihistamines
Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), <e1> antianginals </e1> (n=35), and <e2> antihistamines </e2> (n=15).	0	antianginals	antihistamines
Use with <e1> Anticholinergics </e1> : Because of their mechanism of action, <e2> cholinesterase inhibitors </e2> have the potential to interfere with the activity of anticholinergic medications.	0	Anticholinergics	cholinesterase inhibitors
Use with <e1> Anticholinergics </e1> : Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of <e2> anticholinergic medications </e2> .	0	Anticholinergics	anticholinergic medications
Use with Anticholinergics: Because of their mechanism of action, <e1> cholinesterase inhibitors </e1> have the potential to interfere with the activity of <e2> anticholinergic medications </e2> .	0	cholinesterase inhibitors	anticholinergic medications
Use with <e1> Cholinomimetics </e1> and Other <e2> Cholinesterase Inhibitors </e2> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	0	Cholinomimetics	Cholinesterase Inhibitors
Use with <e1> Cholinomimetics </e1> and Other Cholinesterase Inhibitors: A synergistic effect may be expected when <e2> cholinesterase inhibitors </e2> are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	0	Cholinomimetics	cholinesterase inhibitors
Use with <e1> Cholinomimetics </e1> and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e2> succinylcholine </e2> , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	0	Cholinomimetics	succinylcholine
Use with <e1> Cholinomimetics </e1> and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar <e2> neuromuscular blocking agents </e2> or cholinergic agonists such as bethanechol.	0	Cholinomimetics	neuromuscular blocking agents
Use with <e1> Cholinomimetics </e1> and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or <e2> cholinergic agonists </e2> such as bethanechol.	0	Cholinomimetics	cholinergic agonists
Use with <e1> Cholinomimetics </e1> and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as <e2> bethanechol </e2> .	0	Cholinomimetics	bethanechol
Use with Cholinomimetics and Other <e1> Cholinesterase Inhibitors </e1> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e2> succinylcholine </e2> , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	0	Cholinesterase Inhibitors	succinylcholine
Use with Cholinomimetics and Other <e1> Cholinesterase Inhibitors </e1> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar <e2> neuromuscular blocking agents </e2> or cholinergic agonists such as bethanechol.	0	Cholinesterase Inhibitors	neuromuscular blocking agents
Use with Cholinomimetics and Other <e1> Cholinesterase Inhibitors </e1> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or <e2> cholinergic agonists </e2> such as bethanechol.	0	Cholinesterase Inhibitors	cholinergic agonists
Use with Cholinomimetics and Other <e1> Cholinesterase Inhibitors </e1> : A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as <e2> bethanechol </e2> .	0	Cholinesterase Inhibitors	bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when <e1> cholinesterase inhibitors </e1> are given concurrently with <e2> succinylcholine </e2> , similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.	1	cholinesterase inhibitors	succinylcholine
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when <e1> cholinesterase inhibitors </e1> are given concurrently with succinylcholine, similar <e2> neuromuscular blocking agents </e2> or cholinergic agonists such as bethanechol.	1	cholinesterase inhibitors	neuromuscular blocking agents
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when <e1> cholinesterase inhibitors </e1> are given concurrently with succinylcholine, similar neuromuscular blocking agents or <e2> cholinergic agonists </e2> such as bethanechol.	1	cholinesterase inhibitors	cholinergic agonists
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when <e1> cholinesterase inhibitors </e1> are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as <e2> bethanechol </e2> .	1	cholinesterase inhibitors	bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e1> succinylcholine </e1> , similar <e2> neuromuscular blocking agents </e2> or cholinergic agonists such as bethanechol.	0	succinylcholine	neuromuscular blocking agents
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e1> succinylcholine </e1> , similar neuromuscular blocking agents or <e2> cholinergic agonists </e2> such as bethanechol.	0	succinylcholine	cholinergic agonists
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with <e1> succinylcholine </e1> , similar neuromuscular blocking agents or cholinergic agonists such as <e2> bethanechol </e2> .	0	succinylcholine	bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar <e1> neuromuscular blocking agents </e1> or <e2> cholinergic agonists </e2> such as bethanechol.	0	neuromuscular blocking agents	cholinergic agonists
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar <e1> neuromuscular blocking agents </e1> or cholinergic agonists such as <e2> bethanechol </e2> .	0	neuromuscular blocking agents	bethanechol
Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or <e1> cholinergic agonists </e1> such as <e2> bethanechol </e2> .	0	cholinergic agonists	bethanechol
<e1> Pilocarpine </e1> should be administered with caution to patients taking <e2> beta adrenergic antagonists </e2> because of the possibility of conduction disturbances.	0	Pilocarpine	beta adrenergic antagonists
These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., <e1> atropine </e1> , inhaled <e2> ipratropium </e2> ).	0	atropine	ipratropium
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e1> acetylsalicylic acid </e1> , artificial tears, <e2> calcium </e2> , conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	acetylsalicylic acid	calcium
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e1> acetylsalicylic acid </e1> , artificial tears, calcium, <e2> conjugated estrogens </e2> , hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	acetylsalicylic acid	conjugated estrogens
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, <e2> hydroxychloroquine sulfate </e2> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	acetylsalicylic acid	hydroxychloroquine sulfate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e2> ibuprofen </e2> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	acetylsalicylic acid	ibuprofen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e2> levothyroxine sodium </e2> , medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	acetylsalicylic acid	levothyroxine sodium
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e2> medroxyprogesterone acetate </e2> , methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	acetylsalicylic acid	medroxyprogesterone acetate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e2> methotrexate </e2> , multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	acetylsalicylic acid	methotrexate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.	0	acetylsalicylic acid	multivitamins
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.	0	acetylsalicylic acid	naproxen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e2> omeprazole </e2> , paracetamol, and prednisone.	0	acetylsalicylic acid	omeprazole
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e2> paracetamol </e2> , and prednisone.	0	acetylsalicylic acid	paracetamol
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: <e1> acetylsalicylic acid </e1> , artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2> prednisone </e2> .	0	acetylsalicylic acid	prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, <e1> calcium </e1> , <e2> conjugated estrogens </e2> , hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	calcium	conjugated estrogens
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, <e1> calcium </e1> , conjugated estrogens, <e2> hydroxychloroquine sulfate </e2> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	calcium	hydroxychloroquine sulfate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, <e1> calcium </e1> , conjugated estrogens, hydroxychloroquine sulfate, <e2> ibuprofen </e2> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	calcium	ibuprofen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, <e1> calcium </e1> , conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e2> levothyroxine sodium </e2> , medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	calcium	levothyroxine sodium
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, <e1> calcium </e1> , conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e2> medroxyprogesterone acetate </e2> , methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	calcium	medroxyprogesterone acetate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, <e1> calcium </e1> , conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e2> methotrexate </e2> , multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	calcium	methotrexate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, <e1> calcium </e1> , conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.	0	calcium	multivitamins
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, <e1> calcium </e1> , conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.	0	calcium	naproxen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, <e1> calcium </e1> , conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e2> omeprazole </e2> , paracetamol, and prednisone.	0	calcium	omeprazole
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, <e1> calcium </e1> , conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e2> paracetamol </e2> , and prednisone.	0	calcium	paracetamol
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, <e1> calcium </e1> , conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2> prednisone </e2> .	0	calcium	prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1> conjugated estrogens </e1> , <e2> hydroxychloroquine sulfate </e2> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	conjugated estrogens	hydroxychloroquine sulfate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1> conjugated estrogens </e1> , hydroxychloroquine sulfate, <e2> ibuprofen </e2> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	conjugated estrogens	ibuprofen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1> conjugated estrogens </e1> , hydroxychloroquine sulfate, ibuprofen, <e2> levothyroxine sodium </e2> , medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	conjugated estrogens	levothyroxine sodium
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1> conjugated estrogens </e1> , hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e2> medroxyprogesterone acetate </e2> , methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	conjugated estrogens	medroxyprogesterone acetate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1> conjugated estrogens </e1> , hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e2> methotrexate </e2> , multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	conjugated estrogens	methotrexate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1> conjugated estrogens </e1> , hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.	0	conjugated estrogens	multivitamins
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1> conjugated estrogens </e1> , hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.	0	conjugated estrogens	naproxen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1> conjugated estrogens </e1> , hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e2> omeprazole </e2> , paracetamol, and prednisone.	0	conjugated estrogens	omeprazole
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1> conjugated estrogens </e1> , hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e2> paracetamol </e2> , and prednisone.	0	conjugated estrogens	paracetamol
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, <e1> conjugated estrogens </e1> , hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2> prednisone </e2> .	0	conjugated estrogens	prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1> hydroxychloroquine sulfate </e1> , <e2> ibuprofen </e2> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	hydroxychloroquine sulfate	ibuprofen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1> hydroxychloroquine sulfate </e1> , ibuprofen, <e2> levothyroxine sodium </e2> , medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	hydroxychloroquine sulfate	levothyroxine sodium
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1> hydroxychloroquine sulfate </e1> , ibuprofen, levothyroxine sodium, <e2> medroxyprogesterone acetate </e2> , methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	hydroxychloroquine sulfate	medroxyprogesterone acetate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1> hydroxychloroquine sulfate </e1> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e2> methotrexate </e2> , multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	hydroxychloroquine sulfate	methotrexate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1> hydroxychloroquine sulfate </e1> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.	0	hydroxychloroquine sulfate	multivitamins
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1> hydroxychloroquine sulfate </e1> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.	0	hydroxychloroquine sulfate	naproxen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1> hydroxychloroquine sulfate </e1> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e2> omeprazole </e2> , paracetamol, and prednisone.	0	hydroxychloroquine sulfate	omeprazole
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1> hydroxychloroquine sulfate </e1> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e2> paracetamol </e2> , and prednisone.	0	hydroxychloroquine sulfate	paracetamol
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, <e1> hydroxychloroquine sulfate </e1> , ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2> prednisone </e2> .	0	hydroxychloroquine sulfate	prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1> ibuprofen </e1> , <e2> levothyroxine sodium </e2> , medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	ibuprofen	levothyroxine sodium
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1> ibuprofen </e1> , levothyroxine sodium, <e2> medroxyprogesterone acetate </e2> , methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	ibuprofen	medroxyprogesterone acetate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1> ibuprofen </e1> , levothyroxine sodium, medroxyprogesterone acetate, <e2> methotrexate </e2> , multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	ibuprofen	methotrexate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1> ibuprofen </e1> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.	0	ibuprofen	multivitamins
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1> ibuprofen </e1> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.	0	ibuprofen	naproxen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1> ibuprofen </e1> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e2> omeprazole </e2> , paracetamol, and prednisone.	0	ibuprofen	omeprazole
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1> ibuprofen </e1> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e2> paracetamol </e2> , and prednisone.	0	ibuprofen	paracetamol
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, <e1> ibuprofen </e1> , levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2> prednisone </e2> .	0	ibuprofen	prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1> levothyroxine sodium </e1> , <e2> medroxyprogesterone acetate </e2> , methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	levothyroxine sodium	medroxyprogesterone acetate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1> levothyroxine sodium </e1> , medroxyprogesterone acetate, <e2> methotrexate </e2> , multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	levothyroxine sodium	methotrexate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1> levothyroxine sodium </e1> , medroxyprogesterone acetate, methotrexate, <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.	0	levothyroxine sodium	multivitamins
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1> levothyroxine sodium </e1> , medroxyprogesterone acetate, methotrexate, multivitamins, <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.	0	levothyroxine sodium	naproxen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1> levothyroxine sodium </e1> , medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e2> omeprazole </e2> , paracetamol, and prednisone.	0	levothyroxine sodium	omeprazole
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1> levothyroxine sodium </e1> , medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e2> paracetamol </e2> , and prednisone.	0	levothyroxine sodium	paracetamol
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, <e1> levothyroxine sodium </e1> , medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2> prednisone </e2> .	0	levothyroxine sodium	prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e1> medroxyprogesterone acetate </e1> , <e2> methotrexate </e2> , multivitamins, naproxen, omeprazole, paracetamol, and prednisone.	0	medroxyprogesterone acetate	methotrexate
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e1> medroxyprogesterone acetate </e1> , methotrexate, <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.	0	medroxyprogesterone acetate	multivitamins
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e1> medroxyprogesterone acetate </e1> , methotrexate, multivitamins, <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.	0	medroxyprogesterone acetate	naproxen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e1> medroxyprogesterone acetate </e1> , methotrexate, multivitamins, naproxen, <e2> omeprazole </e2> , paracetamol, and prednisone.	0	medroxyprogesterone acetate	omeprazole
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e1> medroxyprogesterone acetate </e1> , methotrexate, multivitamins, naproxen, omeprazole, <e2> paracetamol </e2> , and prednisone.	0	medroxyprogesterone acetate	paracetamol
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, <e1> medroxyprogesterone acetate </e1> , methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and <e2> prednisone </e2> .	0	medroxyprogesterone acetate	prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e1> methotrexate </e1> , <e2> multivitamins </e2> , naproxen, omeprazole, paracetamol, and prednisone.	0	methotrexate	multivitamins
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e1> methotrexate </e1> , multivitamins, <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.	0	methotrexate	naproxen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e1> methotrexate </e1> , multivitamins, naproxen, <e2> omeprazole </e2> , paracetamol, and prednisone.	0	methotrexate	omeprazole
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e1> methotrexate </e1> , multivitamins, naproxen, omeprazole, <e2> paracetamol </e2> , and prednisone.	0	methotrexate	paracetamol
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, <e1> methotrexate </e1> , multivitamins, naproxen, omeprazole, paracetamol, and <e2> prednisone </e2> .	0	methotrexate	prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e1> multivitamins </e1> , <e2> naproxen </e2> , omeprazole, paracetamol, and prednisone.	0	multivitamins	naproxen
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e1> multivitamins </e1> , naproxen, <e2> omeprazole </e2> , paracetamol, and prednisone.	0	multivitamins	omeprazole
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e1> multivitamins </e1> , naproxen, omeprazole, <e2> paracetamol </e2> , and prednisone.	0	multivitamins	paracetamol
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, <e1> multivitamins </e1> , naproxen, omeprazole, paracetamol, and <e2> prednisone </e2> .	0	multivitamins	prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e1> naproxen </e1> , <e2> omeprazole </e2> , paracetamol, and prednisone.	0	naproxen	omeprazole
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e1> naproxen </e1> , omeprazole, <e2> paracetamol </e2> , and prednisone.	0	naproxen	paracetamol
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, <e1> naproxen </e1> , omeprazole, paracetamol, and <e2> prednisone </e2> .	0	naproxen	prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e1> omeprazole </e1> , <e2> paracetamol </e2> , and prednisone.	0	omeprazole	paracetamol
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, <e1> omeprazole </e1> , paracetamol, and <e2> prednisone </e2> .	0	omeprazole	prednisone
While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, <e1> paracetamol </e1> , and <e2> prednisone </e2> .	0	paracetamol	prednisone
<e1> Ritalin </e1> may decrease the hypotensive effect of <e2> guanethidine </e2> .	1	Ritalin	guanethidine
Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of <e2> coumarin anticoagulants </e2> , anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	1	Ritalin	coumarin anticoagulants
Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of coumarin anticoagulants, <e2> anticonvulsants </e2> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	1	Ritalin	anticonvulsants
Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e2> phenobarbital </e2> , diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	1	Ritalin	phenobarbital
Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e2> diphenylhydantoin </e2> , primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	1	Ritalin	diphenylhydantoin
Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, <e2> primidone </e2> ), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	1	Ritalin	primidone
Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), <e2> phenylbutazone </e2> , and tricyclic drugs (imipramine, clomipramine, desipramine).	1	Ritalin	phenylbutazone
Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e2> tricyclic drugs </e2> (imipramine, clomipramine, desipramine).	1	Ritalin	tricyclic drugs
Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs ( <e2> imipramine </e2> , clomipramine, desipramine).	1	Ritalin	imipramine
Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, <e2> clomipramine </e2> , desipramine).	1	Ritalin	clomipramine
Human pharmacologic studies have shown that <e1> Ritalin </e1> may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, <e2> desipramine </e2> ).	1	Ritalin	desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> coumarin anticoagulants </e1> , <e2> anticonvulsants </e2> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	0	coumarin anticoagulants	anticonvulsants
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> coumarin anticoagulants </e1> , anticonvulsants ( <e2> phenobarbital </e2> , diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	0	coumarin anticoagulants	phenobarbital
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> coumarin anticoagulants </e1> , anticonvulsants (phenobarbital, <e2> diphenylhydantoin </e2> , primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	0	coumarin anticoagulants	diphenylhydantoin
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> coumarin anticoagulants </e1> , anticonvulsants (phenobarbital, diphenylhydantoin, <e2> primidone </e2> ), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	0	coumarin anticoagulants	primidone
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> coumarin anticoagulants </e1> , anticonvulsants (phenobarbital, diphenylhydantoin, primidone), <e2> phenylbutazone </e2> , and tricyclic drugs (imipramine, clomipramine, desipramine).	0	coumarin anticoagulants	phenylbutazone
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> coumarin anticoagulants </e1> , anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e2> tricyclic drugs </e2> (imipramine, clomipramine, desipramine).	0	coumarin anticoagulants	tricyclic drugs
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> coumarin anticoagulants </e1> , anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs ( <e2> imipramine </e2> , clomipramine, desipramine).	0	coumarin anticoagulants	imipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> coumarin anticoagulants </e1> , anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, <e2> clomipramine </e2> , desipramine).	0	coumarin anticoagulants	clomipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of <e1> coumarin anticoagulants </e1> , anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, <e2> desipramine </e2> ).	0	coumarin anticoagulants	desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1> anticonvulsants </e1> ( <e2> phenobarbital </e2> , diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	0	anticonvulsants	phenobarbital
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1> anticonvulsants </e1> (phenobarbital, <e2> diphenylhydantoin </e2> , primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	0	anticonvulsants	diphenylhydantoin
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1> anticonvulsants </e1> (phenobarbital, diphenylhydantoin, <e2> primidone </e2> ), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	0	anticonvulsants	primidone
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1> anticonvulsants </e1> (phenobarbital, diphenylhydantoin, primidone), <e2> phenylbutazone </e2> , and tricyclic drugs (imipramine, clomipramine, desipramine).	0	anticonvulsants	phenylbutazone
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1> anticonvulsants </e1> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e2> tricyclic drugs </e2> (imipramine, clomipramine, desipramine).	0	anticonvulsants	tricyclic drugs
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1> anticonvulsants </e1> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs ( <e2> imipramine </e2> , clomipramine, desipramine).	0	anticonvulsants	imipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1> anticonvulsants </e1> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, <e2> clomipramine </e2> , desipramine).	0	anticonvulsants	clomipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, <e1> anticonvulsants </e1> (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, <e2> desipramine </e2> ).	0	anticonvulsants	desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e1> phenobarbital </e1> , <e2> diphenylhydantoin </e2> , primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	0	phenobarbital	diphenylhydantoin
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e1> phenobarbital </e1> , diphenylhydantoin, <e2> primidone </e2> ), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	0	phenobarbital	primidone
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e1> phenobarbital </e1> , diphenylhydantoin, primidone), <e2> phenylbutazone </e2> , and tricyclic drugs (imipramine, clomipramine, desipramine).	0	phenobarbital	phenylbutazone
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e1> phenobarbital </e1> , diphenylhydantoin, primidone), phenylbutazone, and <e2> tricyclic drugs </e2> (imipramine, clomipramine, desipramine).	0	phenobarbital	tricyclic drugs
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e1> phenobarbital </e1> , diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs ( <e2> imipramine </e2> , clomipramine, desipramine).	0	phenobarbital	imipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e1> phenobarbital </e1> , diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, <e2> clomipramine </e2> , desipramine).	0	phenobarbital	clomipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants ( <e1> phenobarbital </e1> , diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, <e2> desipramine </e2> ).	0	phenobarbital	desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e1> diphenylhydantoin </e1> , <e2> primidone </e2> ), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine).	0	diphenylhydantoin	primidone
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e1> diphenylhydantoin </e1> , primidone), <e2> phenylbutazone </e2> , and tricyclic drugs (imipramine, clomipramine, desipramine).	0	diphenylhydantoin	phenylbutazone
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e1> diphenylhydantoin </e1> , primidone), phenylbutazone, and <e2> tricyclic drugs </e2> (imipramine, clomipramine, desipramine).	0	diphenylhydantoin	tricyclic drugs
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e1> diphenylhydantoin </e1> , primidone), phenylbutazone, and tricyclic drugs ( <e2> imipramine </e2> , clomipramine, desipramine).	0	diphenylhydantoin	imipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e1> diphenylhydantoin </e1> , primidone), phenylbutazone, and tricyclic drugs (imipramine, <e2> clomipramine </e2> , desipramine).	0	diphenylhydantoin	clomipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, <e1> diphenylhydantoin </e1> , primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, <e2> desipramine </e2> ).	0	diphenylhydantoin	desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, <e1> primidone </e1> ), <e2> phenylbutazone </e2> , and tricyclic drugs (imipramine, clomipramine, desipramine).	0	primidone	phenylbutazone
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, <e1> primidone </e1> ), phenylbutazone, and <e2> tricyclic drugs </e2> (imipramine, clomipramine, desipramine).	0	primidone	tricyclic drugs
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, <e1> primidone </e1> ), phenylbutazone, and tricyclic drugs ( <e2> imipramine </e2> , clomipramine, desipramine).	0	primidone	imipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, <e1> primidone </e1> ), phenylbutazone, and tricyclic drugs (imipramine, <e2> clomipramine </e2> , desipramine).	0	primidone	clomipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, <e1> primidone </e1> ), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, <e2> desipramine </e2> ).	0	primidone	desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), <e1> phenylbutazone </e1> , and <e2> tricyclic drugs </e2> (imipramine, clomipramine, desipramine).	0	phenylbutazone	tricyclic drugs
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), <e1> phenylbutazone </e1> , and tricyclic drugs ( <e2> imipramine </e2> , clomipramine, desipramine).	0	phenylbutazone	imipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), <e1> phenylbutazone </e1> , and tricyclic drugs (imipramine, <e2> clomipramine </e2> , desipramine).	0	phenylbutazone	clomipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), <e1> phenylbutazone </e1> , and tricyclic drugs (imipramine, clomipramine, <e2> desipramine </e2> ).	0	phenylbutazone	desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e1> tricyclic drugs </e1> ( <e2> imipramine </e2> , clomipramine, desipramine).	0	tricyclic drugs	imipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e1> tricyclic drugs </e1> (imipramine, <e2> clomipramine </e2> , desipramine).	0	tricyclic drugs	clomipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and <e1> tricyclic drugs </e1> (imipramine, clomipramine, <e2> desipramine </e2> ).	0	tricyclic drugs	desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs ( <e1> imipramine </e1> , <e2> clomipramine </e2> , desipramine).	0	imipramine	clomipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs ( <e1> imipramine </e1> , clomipramine, <e2> desipramine </e2> ).	0	imipramine	desipramine
Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, <e1> clomipramine </e1> , <e2> desipramine </e2> ).	0	clomipramine	desipramine
The safety of using <e1> methylphenidate </e1> in combination with <e2> clonidine </e2> or other centrally acting alpha-2 agonists has not been systemically evaluated.	0	methylphenidate	clonidine
The safety of using <e1> methylphenidate </e1> in combination with clonidine or other centrally acting <e2> alpha-2 agonists </e2> has not been systemically evaluated.	0	methylphenidate	alpha-2 agonists
The safety of using methylphenidate in combination with <e1> clonidine </e1> or other centrally acting <e2> alpha-2 agonists </e2> has not been systemically evaluated.	0	clonidine	alpha-2 agonists
Because <e1> tetracyclines </e1> have been shown to depress plasma prothrombin activity, patients who are on <e2> anticoagulant </e2> therapy may require downward adjustment of their anticoagulant dosage.	0	tetracyclines	anticoagulant
Because <e1> tetracyclines </e1> have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their <e2> anticoagulant </e2> dosage.	0	tetracyclines	anticoagulant
Since bacteriostatic drugs may interfere with the bactericidal action of <e1> penicillin </e1> , it is advisable to avoid giving <e2> tetracycline class drugs </e2> in conjunction with penicillin.	0	penicillin	tetracycline class drugs
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving <e1> tetracycline class drugs </e1> in conjunction with <e2> penicillin </e2> .	0	tetracycline class drugs	penicillin
Absorption of <e1> tetracyclines </e1> is impaired by <e2> antacids </e2> containing aluminum, calcium or magnesium, and iron-containing preparations.	0	tetracyclines	antacids
Absorption of <e1> tetracyclines </e1> is impaired by antacids containing <e2> aluminum </e2> , calcium or magnesium, and iron-containing preparations.	1	tetracyclines	aluminum
Absorption of <e1> tetracyclines </e1> is impaired by antacids containing aluminum, <e2> calcium </e2> or magnesium, and iron-containing preparations.	1	tetracyclines	calcium
Absorption of <e1> tetracyclines </e1> is impaired by antacids containing aluminum, calcium or <e2> magnesium </e2> , and iron-containing preparations.	1	tetracyclines	magnesium
Absorption of <e1> tetracyclines </e1> is impaired by antacids containing aluminum, calcium or magnesium, and <e2> iron </e2> -containing preparations.	1	tetracyclines	iron
Absorption of tetracyclines is impaired by <e1> antacids </e1> containing <e2> aluminum </e2> , calcium or magnesium, and iron-containing preparations.	0	antacids	aluminum
Absorption of tetracyclines is impaired by <e1> antacids </e1> containing aluminum, <e2> calcium </e2> or magnesium, and iron-containing preparations.	0	antacids	calcium
Absorption of tetracyclines is impaired by <e1> antacids </e1> containing aluminum, calcium or <e2> magnesium </e2> , and iron-containing preparations.	0	antacids	magnesium
Absorption of tetracyclines is impaired by <e1> antacids </e1> containing aluminum, calcium or magnesium, and <e2> iron </e2> -containing preparations.	0	antacids	iron
Absorption of tetracyclines is impaired by antacids containing <e1> aluminum </e1> , <e2> calcium </e2> or magnesium, and iron-containing preparations.	0	aluminum	calcium
Absorption of tetracyclines is impaired by antacids containing <e1> aluminum </e1> , calcium or <e2> magnesium </e2> , and iron-containing preparations.	0	aluminum	magnesium
Absorption of tetracyclines is impaired by antacids containing <e1> aluminum </e1> , calcium or magnesium, and <e2> iron </e2> -containing preparations.	0	aluminum	iron
Absorption of tetracyclines is impaired by antacids containing aluminum, <e1> calcium </e1> or <e2> magnesium </e2> , and iron-containing preparations.	0	calcium	magnesium
Absorption of tetracyclines is impaired by antacids containing aluminum, <e1> calcium </e1> or magnesium, and <e2> iron </e2> -containing preparations.	0	calcium	iron
Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or <e1> magnesium </e1> , and <e2> iron </e2> -containing preparations.	0	magnesium	iron
The concurrent use of <e1> tetracycline </e1> and <e2> methoxyflurane </e2> has been reported to result in fatal renal toxicity.	1	tetracycline	methoxyflurane
Concurrent use of <e1> tetracyclines </e1> with oral <e2> contraceptives </e2> may render oral contraceptives less effective.	1	tetracyclines	contraceptives
Concurrent use of <e1> tetracyclines </e1> with oral contraceptives may render oral <e2> contraceptives </e2> less effective.	0	tetracyclines	contraceptives
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of <e1> tolbutamide </e1> , <e2> sodium salicylate </e2> and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent.	0	tolbutamide	sodium salicylate
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of <e1> tolbutamide </e1> , sodium salicylate and <e2> sulfamethizole </e2> displaced protein-bound teniposide in fresh human serum to a small but significant extent.	0	tolbutamide	sulfamethizole
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of <e1> tolbutamide </e1> , sodium salicylate and sulfamethizole displaced protein-bound <e2> teniposide </e2> in fresh human serum to a small but significant extent.	1	tolbutamide	teniposide
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, <e1> sodium salicylate </e1> and <e2> sulfamethizole </e2> displaced protein-bound teniposide in fresh human serum to a small but significant extent.	0	sodium salicylate	sulfamethizole
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, <e1> sodium salicylate </e1> and sulfamethizole displaced protein-bound <e2> teniposide </e2> in fresh human serum to a small but significant extent.	1	sodium salicylate	teniposide
In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and <e1> sulfamethizole </e1> displaced protein-bound <e2> teniposide </e2> in fresh human serum to a small but significant extent.	1	sulfamethizole	teniposide
Therefore, caution should be used in administering <e1> VUMON </e1> ( <e2> teniposide </e2> injection) to patients receiving these other agents.	0	VUMON	teniposide
There was no change in the plasma kinetics of <e1> teniposide </e1> when coadministered with <e2> methotrexate </e2> .	0	teniposide	methotrexate
An increase in intracellular levels of <e1> methotrexate </e1> was observed in vitro in the presence of <e2> teniposide </e2> .	1	methotrexate	teniposide
Although this has not occurred in in vitro studies with <e1> coumarin-type anticoagulants </e1> , interactions with coumarin-type anticoagulants have been reported with <e2> FELDENE </e2> since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	0	coumarin-type anticoagulants	FELDENE
Although this has not occurred in in vitro studies with <e1> coumarin-type anticoagulants </e1> , interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering <e2> FELDENE </e2> to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	0	coumarin-type anticoagulants	FELDENE
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with <e1> coumarin-type anticoagulants </e1> have been reported with <e2> FELDENE </e2> since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	0	coumarin-type anticoagulants	FELDENE
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with <e1> coumarin-type anticoagulants </e1> have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering <e2> FELDENE </e2> to patients on coumarin-type anticoagulants and other highly protein-bound drugs.	0	coumarin-type anticoagulants	FELDENE
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with <e1> FELDENE </e1> since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on <e2> coumarin-type anticoagulants </e2> and other highly protein-bound drugs.	0	FELDENE	coumarin-type anticoagulants
Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering <e1> FELDENE </e1> to patients on <e2> coumarin-type anticoagulants </e2> and other highly protein-bound drugs.	0	FELDENE	coumarin-type anticoagulants
Plasma levels of <e1> piroxicam </e1> are depressed to approximately 80% of their normal values when <e2> FELDENE </e2> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	0	piroxicam	FELDENE
Plasma levels of <e1> piroxicam </e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e2> aspirin </e2> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	0	piroxicam	aspirin
Plasma levels of <e1> piroxicam </e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e2> antacids </e2> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	0	piroxicam	antacids
Plasma levels of <e1> piroxicam </e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . <e2> Nonsteroidal anti-inflammatory agents </e2> , including FELDENE, have been reported to increase steady state plasma lithium levels.	0	piroxicam	Nonsteroidal anti-inflammatory agents
Plasma levels of <e1> piroxicam </e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including <e2> FELDENE </e2> , have been reported to increase steady state plasma lithium levels.	0	piroxicam	FELDENE
Plasma levels of <e1> piroxicam </e1> are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma <e2> lithium </e2> levels.	0	piroxicam	lithium
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1> FELDENE </e1> is administered in conjunction with <e2> aspirin </e2> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	1	FELDENE	aspirin
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1> FELDENE </e1> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e2> antacids </e2> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	0	FELDENE	antacids
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1> FELDENE </e1> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e2> piroxicam </e2> plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	0	FELDENE	piroxicam
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1> FELDENE </e1> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . <e2> Nonsteroidal anti-inflammatory agents </e2> , including FELDENE, have been reported to increase steady state plasma lithium levels.	0	FELDENE	Nonsteroidal anti-inflammatory agents
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when <e1> FELDENE </e1> is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma <e2> lithium </e2> levels.	0	FELDENE	lithium
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e1> aspirin </e1> (3900 mg/day), but concomitant administration of <e2> antacids </e2> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	0	aspirin	antacids
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e1> aspirin </e1> (3900 mg/day), but concomitant administration of antacids has no effect on <e2> piroxicam </e2> plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	0	aspirin	piroxicam
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e1> aspirin </e1> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . <e2> Nonsteroidal anti-inflammatory agents </e2> , including FELDENE, have been reported to increase steady state plasma lithium levels.	0	aspirin	Nonsteroidal anti-inflammatory agents
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e1> aspirin </e1> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including <e2> FELDENE </e2> , have been reported to increase steady state plasma lithium levels.	0	aspirin	FELDENE
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with <e1> aspirin </e1> (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma <e2> lithium </e2> levels.	0	aspirin	lithium
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e1> antacids </e1> has no effect on <e2> piroxicam </e2> plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels.	0	antacids	piroxicam
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e1> antacids </e1> has no effect on piroxicam plasma levels . <e2> Nonsteroidal anti-inflammatory agents </e2> , including FELDENE, have been reported to increase steady state plasma lithium levels.	0	antacids	Nonsteroidal anti-inflammatory agents
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e1> antacids </e1> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including <e2> FELDENE </e2> , have been reported to increase steady state plasma lithium levels.	0	antacids	FELDENE
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of <e1> antacids </e1> has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma <e2> lithium </e2> levels.	0	antacids	lithium
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e1> piroxicam </e1> plasma levels . <e2> Nonsteroidal anti-inflammatory agents </e2> , including FELDENE, have been reported to increase steady state plasma lithium levels.	0	piroxicam	Nonsteroidal anti-inflammatory agents
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e1> piroxicam </e1> plasma levels . Nonsteroidal anti-inflammatory agents, including <e2> FELDENE </e2> , have been reported to increase steady state plasma lithium levels.	0	piroxicam	FELDENE
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on <e1> piroxicam </e1> plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma <e2> lithium </e2> levels.	0	piroxicam	lithium
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . <e1> Nonsteroidal anti-inflammatory agents </e1> , including <e2> FELDENE </e2> , have been reported to increase steady state plasma lithium levels.	0	Nonsteroidal anti-inflammatory agents	FELDENE
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . <e1> Nonsteroidal anti-inflammatory agents </e1> , including FELDENE, have been reported to increase steady state plasma <e2> lithium </e2> levels.	1	Nonsteroidal anti-inflammatory agents	lithium
Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including <e1> FELDENE </e1> , have been reported to increase steady state plasma <e2> lithium </e2> levels.	1	FELDENE	lithium
It is recommended that plasma <e1> lithium </e1> levels be monitored when initiating, adjusting and discontinuing <e2> FELDENE </e2> .	0	lithium	FELDENE
Other eye drops or medications such as <e1> acetylcholine chloride </e1> ( <e2> Miochol </e2> ) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	0	acetylcholine chloride	Miochol
Other eye drops or medications such as <e1> acetylcholine chloride </e1> (Miochol) and <e2> carbachol </e2> (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	0	acetylcholine chloride	carbachol
Other eye drops or medications such as <e1> acetylcholine chloride </e1> (Miochol) and carbachol ( <e2> Carboptic </e2> , Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	0	acetylcholine chloride	Carboptic
Other eye drops or medications such as <e1> acetylcholine chloride </e1> (Miochol) and carbachol (Carboptic, <e2> Isopto Carbachol </e2> ) may decrease the effects of suprofen ophthalmic.	0	acetylcholine chloride	Isopto Carbachol
Other eye drops or medications such as <e1> acetylcholine chloride </e1> (Miochol) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of <e2> suprofen </e2> ophthalmic.	1	acetylcholine chloride	suprofen
Other eye drops or medications such as acetylcholine chloride ( <e1> Miochol </e1> ) and <e2> carbachol </e2> (Carboptic, Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	0	Miochol	carbachol
Other eye drops or medications such as acetylcholine chloride ( <e1> Miochol </e1> ) and carbachol ( <e2> Carboptic </e2> , Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	0	Miochol	Carboptic
Other eye drops or medications such as acetylcholine chloride ( <e1> Miochol </e1> ) and carbachol (Carboptic, <e2> Isopto Carbachol </e2> ) may decrease the effects of suprofen ophthalmic.	0	Miochol	Isopto Carbachol
Other eye drops or medications such as acetylcholine chloride ( <e1> Miochol </e1> ) and carbachol (Carboptic, Isopto Carbachol) may decrease the effects of <e2> suprofen </e2> ophthalmic.	1	Miochol	suprofen
Other eye drops or medications such as acetylcholine chloride (Miochol) and <e1> carbachol </e1> ( <e2> Carboptic </e2> , Isopto Carbachol) may decrease the effects of suprofen ophthalmic.	0	carbachol	Carboptic
Other eye drops or medications such as acetylcholine chloride (Miochol) and <e1> carbachol </e1> (Carboptic, <e2> Isopto Carbachol </e2> ) may decrease the effects of suprofen ophthalmic.	0	carbachol	Isopto Carbachol
Other eye drops or medications such as acetylcholine chloride (Miochol) and <e1> carbachol </e1> (Carboptic, Isopto Carbachol) may decrease the effects of <e2> suprofen </e2> ophthalmic.	1	carbachol	suprofen
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol ( <e1> Carboptic </e1> , <e2> Isopto Carbachol </e2> ) may decrease the effects of suprofen ophthalmic.	0	Carboptic	Isopto Carbachol
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol ( <e1> Carboptic </e1> , Isopto Carbachol) may decrease the effects of <e2> suprofen </e2> ophthalmic.	1	Carboptic	suprofen
Other eye drops or medications such as acetylcholine chloride (Miochol) and carbachol (Carboptic, <e1> Isopto Carbachol </e1> ) may decrease the effects of <e2> suprofen </e2> ophthalmic.	1	Isopto Carbachol	suprofen
There is usually complete cross-resistance between <e1> PURINETHOL </e1> ( <e2> mercaptopurine </e2> ) and TABLOID brand Thioguanine.	0	PURINETHOL	mercaptopurine
There is usually complete cross-resistance between <e1> PURINETHOL </e1> (mercaptopurine) and <e2> TABLOID </e2> brand Thioguanine.	1	PURINETHOL	TABLOID
There is usually complete cross-resistance between <e1> PURINETHOL </e1> (mercaptopurine) and TABLOID brand <e2> Thioguanine </e2> .	1	PURINETHOL	Thioguanine
There is usually complete cross-resistance between PURINETHOL ( <e1> mercaptopurine </e1> ) and <e2> TABLOID </e2> brand Thioguanine.	1	mercaptopurine	TABLOID
There is usually complete cross-resistance between PURINETHOL ( <e1> mercaptopurine </e1> ) and TABLOID brand <e2> Thioguanine </e2> .	1	mercaptopurine	Thioguanine
There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and <e1> TABLOID </e1> brand <e2> Thioguanine </e2> .	0	TABLOID	Thioguanine
As there is in vitro evidence that <e1> aminosalicylate derivatives </e1> (e.g., <e2> olsalazine </e2> , mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	0	aminosalicylate derivatives	olsalazine
As there is in vitro evidence that <e1> aminosalicylate derivatives </e1> (e.g., olsalazine, <e2> mesalazine </e2> , or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	0	aminosalicylate derivatives	mesalazine
As there is in vitro evidence that <e1> aminosalicylate derivatives </e1> (e.g., olsalazine, mesalazine, or <e2> sulphasalazine </e2> ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	0	aminosalicylate derivatives	sulphasalazine
As there is in vitro evidence that <e1> aminosalicylate derivatives </e1> (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e2> thioguanine </e2> therapy.	1	aminosalicylate derivatives	thioguanine
As there is in vitro evidence that aminosalicylate derivatives (e.g., <e1> olsalazine </e1> , <e2> mesalazine </e2> , or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	0	olsalazine	mesalazine
As there is in vitro evidence that aminosalicylate derivatives (e.g., <e1> olsalazine </e1> , mesalazine, or <e2> sulphasalazine </e2> ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	0	olsalazine	sulphasalazine
As there is in vitro evidence that aminosalicylate derivatives (e.g., <e1> olsalazine </e1> , mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e2> thioguanine </e2> therapy.	1	olsalazine	thioguanine
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, <e1> mesalazine </e1> , or <e2> sulphasalazine </e2> ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.	0	mesalazine	sulphasalazine
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, <e1> mesalazine </e1> , or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e2> thioguanine </e2> therapy.	1	mesalazine	thioguanine
As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or <e1> sulphasalazine </e1> ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent <e2> thioguanine </e2> therapy.	1	sulphasalazine	thioguanine
The bioavailability of <e1> SKELID </e1> is decreased 80% by <e2> calcium </e2> , when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.	1	SKELID	calcium
The bioavailability of <e1> SKELID </e1> is decreased 80% by calcium, when <e2> calcium </e2> and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.	0	SKELID	calcium
The bioavailability of <e1> SKELID </e1> is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some <e2> aluminum </e2> - or magnesium-containing antacids, when administered 1 hour before SKELID.	0	SKELID	aluminum
The bioavailability of <e1> SKELID </e1> is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or <e2> magnesium </e2> -containing antacids, when administered 1 hour before SKELID.	0	SKELID	magnesium
The bioavailability of <e1> SKELID </e1> is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing <e2> antacids </e2> , when administered 1 hour before SKELID.	0	SKELID	antacids
The bioavailability of SKELID is decreased 80% by <e1> calcium </e1> , when calcium and <e2> SKELID </e2> are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.	0	calcium	SKELID
The bioavailability of SKELID is decreased 80% by <e1> calcium </e1> , when calcium and SKELID are administered at the same time, and 60% by some <e2> aluminum </e2> - or magnesium-containing antacids, when administered 1 hour before SKELID.	0	calcium	aluminum
The bioavailability of SKELID is decreased 80% by <e1> calcium </e1> , when calcium and SKELID are administered at the same time, and 60% by some aluminum- or <e2> magnesium </e2> -containing antacids, when administered 1 hour before SKELID.	0	calcium	magnesium
The bioavailability of SKELID is decreased 80% by <e1> calcium </e1> , when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing <e2> antacids </e2> , when administered 1 hour before SKELID.	0	calcium	antacids
The bioavailability of SKELID is decreased 80% by <e1> calcium </e1> , when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before <e2> SKELID </e2> .	0	calcium	SKELID
The bioavailability of SKELID is decreased 80% by calcium, when <e1> calcium </e1> and <e2> SKELID </e2> are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID.	0	calcium	SKELID
The bioavailability of SKELID is decreased 80% by calcium, when <e1> calcium </e1> and SKELID are administered at the same time, and 60% by some <e2> aluminum </e2> - or magnesium-containing antacids, when administered 1 hour before SKELID.	0	calcium	aluminum
The bioavailability of SKELID is decreased 80% by calcium, when <e1> calcium </e1> and SKELID are administered at the same time, and 60% by some aluminum- or <e2> magnesium </e2> -containing antacids, when administered 1 hour before SKELID.	0	calcium	magnesium
The bioavailability of SKELID is decreased 80% by calcium, when <e1> calcium </e1> and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing <e2> antacids </e2> , when administered 1 hour before SKELID.	0	calcium	antacids
The bioavailability of SKELID is decreased 80% by calcium, when <e1> calcium </e1> and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before <e2> SKELID </e2> .	0	calcium	SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and <e1> SKELID </e1> are administered at the same time, and 60% by some <e2> aluminum </e2> - or magnesium-containing antacids, when administered 1 hour before SKELID.	0	SKELID	aluminum
The bioavailability of SKELID is decreased 80% by calcium, when calcium and <e1> SKELID </e1> are administered at the same time, and 60% by some aluminum- or <e2> magnesium </e2> -containing antacids, when administered 1 hour before SKELID.	0	SKELID	magnesium
The bioavailability of SKELID is decreased 80% by calcium, when calcium and <e1> SKELID </e1> are administered at the same time, and 60% by some aluminum- or magnesium-containing <e2> antacids </e2> , when administered 1 hour before SKELID.	0	SKELID	antacids
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some <e1> aluminum </e1> - or <e2> magnesium </e2> -containing antacids, when administered 1 hour before SKELID.	0	aluminum	magnesium
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some <e1> aluminum </e1> - or magnesium-containing <e2> antacids </e2> , when administered 1 hour before SKELID.	0	aluminum	antacids
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some <e1> aluminum </e1> - or magnesium-containing antacids, when administered 1 hour before <e2> SKELID </e2> .	1	aluminum	SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or <e1> magnesium </e1> -containing <e2> antacids </e2> , when administered 1 hour before SKELID.	0	magnesium	antacids
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or <e1> magnesium </e1> -containing antacids, when administered 1 hour before <e2> SKELID </e2> .	1	magnesium	SKELID
The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing <e1> antacids </e1> , when administered 1 hour before <e2> SKELID </e2> .	0	antacids	SKELID
<e1> Aspirin </e1> may decrease bioavailability of <e2> SKELID </e2> by up to 50% when taken 2 hours after SKELID.	1	Aspirin	SKELID
<e1> Aspirin </e1> may decrease bioavailability of SKELID by up to 50% when taken 2 hours after <e2> SKELID </e2> .	0	Aspirin	SKELID
The bioavailability of <e1> SKELID </e1> is increased 2-4 fold by <e2> indomethacin </e2> but is not significantly altered by coadministration of diclofenac.	1	SKELID	indomethacin
The bioavailability of <e1> SKELID </e1> is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of <e2> diclofenac </e2> .	0	SKELID	diclofenac
The bioavailability of SKELID is increased 2-4 fold by <e1> indomethacin </e1> but is not significantly altered by coadministration of <e2> diclofenac </e2> .	0	indomethacin	diclofenac
The pharmacokinetic parameters of <e1> digoxin </e1> are not significantly modified by <e2> SKELID </e2> coadministration.	0	digoxin	SKELID
In vitro studies show that <e1> tiludronate </e1> does not displace <e2> warfarin </e2> from its binding site on protein.	0	tiludronate	warfarin
Since <e1> MEXITIL </e1> is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter <e2> mexiletine </e2> plasma concentrations.	0	MEXITIL	mexiletine
In a formal, single-dose interaction study (n = 6 males) the clearance of <e1> mexiletine </e1> was decreased by 38% following the coadministration of <e2> fluvoxamine </e2> , an inhibitor of CYP1A2.	1	mexiletine	fluvoxamine
In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of <e1> propafenone </e1> did not alter the kinetics of <e2> mexiletine </e2> in the poor CYP2D6 metabolizer group.	0	propafenone	mexiletine
In this crossover steady state study, the pharmacokinetics of <e1> propafenone </e1> were unaffected in either phenotype by the coadministration of <e2> mexiletine </e2> .	0	propafenone	mexiletine
Addition of <e1> mexiletine </e1> to <e2> propafenone </e2> did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone.	0	mexiletine	propafenone
Addition of <e1> mexiletine </e1> to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than <e2> propafenone </e2> alone.	0	mexiletine	propafenone
In a large compassionate use program <e1> Mexitil </e1> has been used concurrently with commonly employed antianginal, <e2> antihypertensive </e2> , and anticoagulant drugs without observed interactions.	0	Mexitil	antihypertensive
In a large compassionate use program <e1> Mexitil </e1> has been used concurrently with commonly employed antianginal, antihypertensive, and <e2> anticoagulant drugs </e2> without observed interactions.	0	Mexitil	anticoagulant drugs
In a large compassionate use program Mexitil has been used concurrently with commonly employed antianginal, <e1> antihypertensive </e1> , and <e2> anticoagulant drugs </e2> without observed interactions.	0	antihypertensive	anticoagulant drugs
A variety of <e1> antiarrhythmics </e1> such as <e2> quinidine </e2> or propranolol were also added, sometimes with improved control of ventricular ectopy.	0	antiarrhythmics	quinidine
A variety of <e1> antiarrhythmics </e1> such as quinidine or <e2> propranolol </e2> were also added, sometimes with improved control of ventricular ectopy.	0	antiarrhythmics	propranolol
A variety of antiarrhythmics such as <e1> quinidine </e1> or <e2> propranolol </e2> were also added, sometimes with improved control of ventricular ectopy.	0	quinidine	propranolol
When <e1> phenytoin </e1> or other hepatic enzyme inducers such as <e2> rifampin </e2> and phenobarbital have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported.	0	phenytoin	rifampin
When <e1> phenytoin </e1> or other hepatic enzyme inducers such as rifampin and <e2> phenobarbital </e2> have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported.	0	phenytoin	phenobarbital
When <e1> phenytoin </e1> or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with <e2> Mexitil </e2> , lowered Mexitil plasma levels have been reported.	1	phenytoin	Mexitil
When <e1> phenytoin </e1> or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil , lowered <e2> Mexitil </e2> plasma levels have been reported.	0	phenytoin	Mexitil
When phenytoin or other hepatic enzyme inducers such as <e1> rifampin </e1> and <e2> phenobarbital </e2> have been taken concurrently with Mexitil , lowered Mexitil plasma levels have been reported.	0	rifampin	phenobarbital
When phenytoin or other hepatic enzyme inducers such as <e1> rifampin </e1> and phenobarbital have been taken concurrently with <e2> Mexitil </e2> , lowered Mexitil plasma levels have been reported.	1	rifampin	Mexitil
When phenytoin or other hepatic enzyme inducers such as <e1> rifampin </e1> and phenobarbital have been taken concurrently with Mexitil , lowered <e2> Mexitil </e2> plasma levels have been reported.	0	rifampin	Mexitil
When phenytoin or other hepatic enzyme inducers such as rifampin and <e1> phenobarbital </e1> have been taken concurrently with <e2> Mexitil </e2> , lowered Mexitil plasma levels have been reported.	1	phenobarbital	Mexitil
When phenytoin or other hepatic enzyme inducers such as rifampin and <e1> phenobarbital </e1> have been taken concurrently with Mexitil , lowered <e2> Mexitil </e2> plasma levels have been reported.	0	phenobarbital	Mexitil
In a formal study, <e1> benzodiazepines </e1> were shown not to affect <e2> Mexitil </e2> plasma concentrations.	0	benzodiazepines	Mexitil
ECG intervals (PR, QRS, and QT) were not affected by concurrent <e1> Mexitil </e1> and <e2> digoxin </e2> , diuretics, or propranolol.	0	Mexitil	digoxin
ECG intervals (PR, QRS, and QT) were not affected by concurrent <e1> Mexitil </e1> and digoxin, <e2> diuretics </e2> , or propranolol.	0	Mexitil	diuretics
ECG intervals (PR, QRS, and QT) were not affected by concurrent <e1> Mexitil </e1> and digoxin, diuretics, or <e2> propranolol </e2> .	0	Mexitil	propranolol
ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil and <e1> digoxin </e1> , <e2> diuretics </e2> , or propranolol.	0	digoxin	diuretics
ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil and <e1> digoxin </e1> , diuretics, or <e2> propranolol </e2> .	0	digoxin	propranolol
ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil and digoxin, <e1> diuretics </e1> , or <e2> propranolol </e2> .	0	diuretics	propranolol
Concurrent administration of <e1> cimetidine </e1> and <e2> Mexitil </e2> has been reported to increase, decrease, or leave unchanged Mexitil plasma levels;	1	cimetidine	Mexitil
Concurrent administration of <e1> cimetidine </e1> and Mexitil has been reported to increase, decrease, or leave unchanged <e2> Mexitil </e2> plasma levels;	0	cimetidine	Mexitil
<e1> Mexitil </e1> does not alter serum <e2> digoxin </e2> levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels.	0	Mexitil	digoxin
<e1> Mexitil </e1> does not alter serum digoxin levels but <e2> magnesium-aluminum hydroxide </e2> , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels.	0	Mexitil	magnesium-aluminum hydroxide
<e1> Mexitil </e1> does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum <e2> digoxin </e2> levels.	0	Mexitil	digoxin
Mexitil does not alter serum <e1> digoxin </e1> levels but <e2> magnesium-aluminum hydroxide </e2> , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum digoxin levels.	0	digoxin	magnesium-aluminum hydroxide
Mexitil does not alter serum <e1> digoxin </e1> levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to <e2> Mexitil </e2> , has been reported to lower serum digoxin levels.	0	digoxin	Mexitil
Mexitil does not alter serum digoxin levels but <e1> magnesium-aluminum hydroxide </e1> , when used to treat gastrointestinal symptoms due to <e2> Mexitil </e2> , has been reported to lower serum digoxin levels.	0	magnesium-aluminum hydroxide	Mexitil
Mexitil does not alter serum digoxin levels but <e1> magnesium-aluminum hydroxide </e1> , when used to treat gastrointestinal symptoms due to Mexitil , has been reported to lower serum <e2> digoxin </e2> levels.	1	magnesium-aluminum hydroxide	digoxin
Mexitil does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to <e1> Mexitil </e1> , has been reported to lower serum <e2> digoxin </e2> levels.	0	Mexitil	digoxin
Concurrent use of <e1> Mexitil </e1> and <e2> theophylline </e2> may lead to increased plasma theophylline levels.	1	Mexitil	theophylline
Concurrent use of <e1> Mexitil </e1> and theophylline may lead to increased plasma <e2> theophylline </e2> levels.	0	Mexitil	theophylline
This increase was observed at the first test point which was the second day after starting <e1> Mexitil </e1> . <e2> Theophylline </e2> plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.	0	Mexitil	Theophylline
This increase was observed at the first test point which was the second day after starting <e1> Mexitil </e1> . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and <e2> theophylline </e2> are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.	0	Mexitil	theophylline
This increase was observed at the first test point which was the second day after starting <e1> Mexitil </e1> . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently, <e2> theophylline </e2> blood levels should be monitored, particularly when the Mexitil dose is changed.	0	Mexitil	theophylline
This increase was observed at the first test point which was the second day after starting Mexitil . <e1> Theophylline </e1> plasma levels returned to pre- <e2> Mexitil </e2> values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.	0	Theophylline	Mexitil
This increase was observed at the first test point which was the second day after starting Mexitil . <e1> Theophylline </e1> plasma levels returned to pre-Mexitil values within 48 hours after discontinuing <e2> Mexitil </e2> . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.	1	Theophylline	Mexitil
This increase was observed at the first test point which was the second day after starting Mexitil . <e1> Theophylline </e1> plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If <e2> Mexitil </e2> and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.	0	Theophylline	Mexitil
This increase was observed at the first test point which was the second day after starting Mexitil . <e1> Theophylline </e1> plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the <e2> Mexitil </e2> dose is changed.	0	Theophylline	Mexitil
This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- <e1> Mexitil </e1> values within 48 hours after discontinuing Mexitil . If Mexitil and <e2> theophylline </e2> are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.	0	Mexitil	theophylline
This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre- <e1> Mexitil </e1> values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently, <e2> theophylline </e2> blood levels should be monitored, particularly when the Mexitil dose is changed.	0	Mexitil	theophylline
This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing <e1> Mexitil </e1> . If Mexitil and <e2> theophylline </e2> are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.	0	Mexitil	theophylline
This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing <e1> Mexitil </e1> . If Mexitil and theophylline are to be used concurrently, <e2> theophylline </e2> blood levels should be monitored, particularly when the Mexitil dose is changed.	0	Mexitil	theophylline
This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If <e1> Mexitil </e1> and <e2> theophylline </e2> are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil dose is changed.	0	Mexitil	theophylline
This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If <e1> Mexitil </e1> and theophylline are to be used concurrently, <e2> theophylline </e2> blood levels should be monitored, particularly when the Mexitil dose is changed.	0	Mexitil	theophylline
This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and <e1> theophylline </e1> are to be used concurrently, theophylline blood levels should be monitored, particularly when the <e2> Mexitil </e2> dose is changed.	0	theophylline	Mexitil
This increase was observed at the first test point which was the second day after starting Mexitil . Theophylline plasma levels returned to pre-Mexitil values within 48 hours after discontinuing Mexitil . If Mexitil and theophylline are to be used concurrently, <e1> theophylline </e1> blood levels should be monitored, particularly when the <e2> Mexitil </e2> dose is changed.	0	theophylline	Mexitil
Additionally, in one controlled study in five normal subjects and seven patients, the clearance of <e1> caffeine </e1> was decreased 50% following the administration of <e2> Mexitil </e2> .	1	caffeine	Mexitil
Mutual inhibition of metabolism occurs with concurrent use of <e1> cyclosporin </e1> and <e2> methylprednisolone </e2> ;	1	cyclosporin	methylprednisolone
convulsions have been reported with concurrent use of <e1> methylprednisolone </e1> and <e2> cyclosporin </e2> .	1	methylprednisolone	cyclosporin
Drugs that induce hepatic enzymes such as <e1> phenobarbital </e1> , <e2> phenytoin </e2> , and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	0	phenobarbital	phenytoin
Drugs that induce hepatic enzymes such as <e1> phenobarbital </e1> , phenytoin, and <e2> rifampin </e2> may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	0	phenobarbital	rifampin
Drugs that induce hepatic enzymes such as <e1> phenobarbital </e1> , phenytoin, and rifampin may increase the clearance of <e2> methylprednisolone </e2> and may require increased in methylprednisolone dose to achieve the desired response.	1	phenobarbital	methylprednisolone
Drugs that induce hepatic enzymes such as <e1> phenobarbital </e1> , phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in <e2> methylprednisolone </e2> dose to achieve the desired response.	0	phenobarbital	methylprednisolone
Drugs that induce hepatic enzymes such as phenobarbital, <e1> phenytoin </e1> , and <e2> rifampin </e2> may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response.	0	phenytoin	rifampin
Drugs that induce hepatic enzymes such as phenobarbital, <e1> phenytoin </e1> , and rifampin may increase the clearance of <e2> methylprednisolone </e2> and may require increased in methylprednisolone dose to achieve the desired response.	1	phenytoin	methylprednisolone
Drugs that induce hepatic enzymes such as phenobarbital, <e1> phenytoin </e1> , and rifampin may increase the clearance of methylprednisolone and may require increased in <e2> methylprednisolone </e2> dose to achieve the desired response.	0	phenytoin	methylprednisolone
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and <e1> rifampin </e1> may increase the clearance of <e2> methylprednisolone </e2> and may require increased in methylprednisolone dose to achieve the desired response.	1	rifampin	methylprednisolone
Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and <e1> rifampin </e1> may increase the clearance of methylprednisolone and may require increased in <e2> methylprednisolone </e2> dose to achieve the desired response.	0	rifampin	methylprednisolone
Drugs such as <e1> troleandomycin </e1> and <e2> ketoconazole </e2> may inhibit the metabolism of methylprednisolone and thus decrease its clearance.	0	troleandomycin	ketoconazole
Drugs such as <e1> troleandomycin </e1> and ketoconazole may inhibit the metabolism of <e2> methylprednisolone </e2> and thus decrease its clearance.	1	troleandomycin	methylprednisolone
Drugs such as troleandomycin and <e1> ketoconazole </e1> may inhibit the metabolism of <e2> methylprednisolone </e2> and thus decrease its clearance.	1	ketoconazole	methylprednisolone
<e1> Methylprednisolone </e1> may increase the clearance of chronic high dose <e2> aspirin </e2> .	1	Methylprednisolone	aspirin
This could lead to decreased <e1> salicylate </e1> serum levels or increase the risk of salicylate toxicity when <e2> methylprednisolone </e2> is withdrawn.	0	salicylate	methylprednisolone
This could lead to decreased salicylate serum levels or increase the risk of <e1> salicylate </e1> toxicity when <e2> methylprednisolone </e2> is withdrawn.	1	salicylate	methylprednisolone
<e1> Aspirin </e1> should be used cautiously in conjunction with <e2> corticosteroids </e2> in patients suffering from hypoprothrombinemia.	0	Aspirin	corticosteroids
The effect of <e1> methylprednisolone </e1> on oral <e2> anticoagulants </e2> is variable.	0	methylprednisolone	anticoagulants
There are reports of enhanced as well as diminished effects of <e1> anticoagulant </e1> when given concurrently with <e2> corticosteroids </e2> .	1	anticoagulant	corticosteroids
The effects of <e1> metoclopramide </e1> on gastrointestinal motility are antagonized by <e2> anticholinergic drugs </e2> and narcotic analgesics.	1	metoclopramide	anticholinergic drugs
The effects of <e1> metoclopramide </e1> on gastrointestinal motility are antagonized by anticholinergic drugs and <e2> narcotic analgesics </e2> .	1	metoclopramide	narcotic analgesics
The effects of metoclopramide on gastrointestinal motility are antagonized by <e1> anticholinergic drugs </e1> and <e2> narcotic analgesics </e2> .	0	anticholinergic drugs	narcotic analgesics
Additive sedative effects can occur when <e1> metoclopramide </e1> is given with <e2> alcohol </e2> , sedatives, hypnotics, narcotics, or tranquilizers.	1	metoclopramide	alcohol
Additive sedative effects can occur when <e1> metoclopramide </e1> is given with alcohol, <e2> sedatives </e2> , hypnotics, narcotics, or tranquilizers.	1	metoclopramide	sedatives
Additive sedative effects can occur when <e1> metoclopramide </e1> is given with alcohol, sedatives, <e2> hypnotics </e2> , narcotics, or tranquilizers.	1	metoclopramide	hypnotics
Additive sedative effects can occur when <e1> metoclopramide </e1> is given with alcohol, sedatives, hypnotics, <e2> narcotics </e2> , or tranquilizers.	1	metoclopramide	narcotics
Additive sedative effects can occur when <e1> metoclopramide </e1> is given with alcohol, sedatives, hypnotics, narcotics, or <e2> tranquilizers </e2> .	1	metoclopramide	tranquilizers
Additive sedative effects can occur when metoclopramide is given with <e1> alcohol </e1> , <e2> sedatives </e2> , hypnotics, narcotics, or tranquilizers.	0	alcohol	sedatives
Additive sedative effects can occur when metoclopramide is given with <e1> alcohol </e1> , sedatives, <e2> hypnotics </e2> , narcotics, or tranquilizers.	0	alcohol	hypnotics
Additive sedative effects can occur when metoclopramide is given with <e1> alcohol </e1> , sedatives, hypnotics, <e2> narcotics </e2> , or tranquilizers.	0	alcohol	narcotics
Additive sedative effects can occur when metoclopramide is given with <e1> alcohol </e1> , sedatives, hypnotics, narcotics, or <e2> tranquilizers </e2> .	0	alcohol	tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, <e1> sedatives </e1> , <e2> hypnotics </e2> , narcotics, or tranquilizers.	0	sedatives	hypnotics
Additive sedative effects can occur when metoclopramide is given with alcohol, <e1> sedatives </e1> , hypnotics, <e2> narcotics </e2> , or tranquilizers.	0	sedatives	narcotics
Additive sedative effects can occur when metoclopramide is given with alcohol, <e1> sedatives </e1> , hypnotics, narcotics, or <e2> tranquilizers </e2> .	0	sedatives	tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, <e1> hypnotics </e1> , <e2> narcotics </e2> , or tranquilizers.	0	hypnotics	narcotics
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, <e1> hypnotics </e1> , narcotics, or <e2> tranquilizers </e2> .	0	hypnotics	tranquilizers
Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, <e1> narcotics </e1> , or <e2> tranquilizers </e2> .	0	narcotics	tranquilizers
The finding that <e1> metoclopramide </e1> releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving <e2> monoamine oxi-dase inhibitors </e2> .	0	metoclopramide	monoamine oxi-dase inhibitors
Absorption of drugs from the stomach may be diminished (e.g., <e1> digoxin </e1> ) by <e2> metoclopramide </e2> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine).	1	digoxin	metoclopramide
Absorption of drugs from the stomach may be diminished (e.g., <e1> digoxin </e1> ) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., <e2> acetaminophen </e2> , tetracycline, levodopa, ethanol, cyclosporine).	0	digoxin	acetaminophen
Absorption of drugs from the stomach may be diminished (e.g., <e1> digoxin </e1> ) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, <e2> tetracycline </e2> , levodopa, ethanol, cyclosporine).	0	digoxin	tetracycline
Absorption of drugs from the stomach may be diminished (e.g., <e1> digoxin </e1> ) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, <e2> levodopa </e2> , ethanol, cyclosporine).	0	digoxin	levodopa
Absorption of drugs from the stomach may be diminished (e.g., <e1> digoxin </e1> ) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, <e2> ethanol </e2> , cyclosporine).	0	digoxin	ethanol
Absorption of drugs from the stomach may be diminished (e.g., <e1> digoxin </e1> ) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, <e2> cyclosporine </e2> ).	0	digoxin	cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by <e1> metoclopramide </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., <e2> acetaminophen </e2> , tetracycline, levodopa, ethanol, cyclosporine).	1	metoclopramide	acetaminophen
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by <e1> metoclopramide </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, <e2> tetracycline </e2> , levodopa, ethanol, cyclosporine).	0	metoclopramide	tetracycline
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by <e1> metoclopramide </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, <e2> levodopa </e2> , ethanol, cyclosporine).	0	metoclopramide	levodopa
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by <e1> metoclopramide </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, <e2> ethanol </e2> , cyclosporine).	0	metoclopramide	ethanol
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by <e1> metoclopramide </e1> , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, <e2> cyclosporine </e2> ).	0	metoclopramide	cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., <e1> acetaminophen </e1> , <e2> tetracycline </e2> , levodopa, ethanol, cyclosporine).	0	acetaminophen	tetracycline
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., <e1> acetaminophen </e1> , tetracycline, <e2> levodopa </e2> , ethanol, cyclosporine).	0	acetaminophen	levodopa
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., <e1> acetaminophen </e1> , tetracycline, levodopa, <e2> ethanol </e2> , cyclosporine).	0	acetaminophen	ethanol
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., <e1> acetaminophen </e1> , tetracycline, levodopa, ethanol, <e2> cyclosporine </e2> ).	0	acetaminophen	cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, <e1> tetracycline </e1> , <e2> levodopa </e2> , ethanol, cyclosporine).	0	tetracycline	levodopa
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, <e1> tetracycline </e1> , levodopa, <e2> ethanol </e2> , cyclosporine).	0	tetracycline	ethanol
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, <e1> tetracycline </e1> , levodopa, ethanol, <e2> cyclosporine </e2> ).	0	tetracycline	cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, <e1> levodopa </e1> , <e2> ethanol </e2> , cyclosporine).	0	levodopa	ethanol
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, <e1> levodopa </e1> , ethanol, <e2> cyclosporine </e2> ).	0	levodopa	cyclosporine
Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, <e1> ethanol </e1> , <e2> cyclosporine </e2> ).	0	ethanol	cyclosporine
Because the action of <e1> metoclopramide </e1> will influence the delivery of food to the intestines and thus the rate of absorption, <e2> insulin </e2> dosage or timing of dosage may require adjustment.	0	metoclopramide	insulin
<e1> Melatonin </e1> may interact with the following drugs: <e2> aspirin </e2> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	Melatonin	aspirin
<e1> Melatonin </e1> may interact with the following drugs: aspirin and other <e2> NSAIDs </e2> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	Melatonin	NSAIDs
<e1> Melatonin </e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e2> fluvoxamine </e2> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	Melatonin	fluvoxamine
<e1> Melatonin </e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e2> beta blockers </e2> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	Melatonin	beta blockers
<e1> Melatonin </e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e2> fluoxetine </e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	Melatonin	fluoxetine
<e1> Melatonin </e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2> progestin </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	Melatonin	progestin
<e1> Melatonin </e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2> progestin </e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	Melatonin	progestin
<e1> Melatonin </e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2> benzodiazepenes </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	Melatonin	benzodiazepenes
<e1> Melatonin </e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	Melatonin	corticosteroids
<e1> Melatonin </e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	Melatonin	corticosteroids
<e1> Melatonin </e1> may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	Melatonin	corticosteroids
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other <e2> NSAIDs </e2> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	NSAIDs
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower <e2> melatonin </e2> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	melatonin
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), <e2> fluvoxamine </e2> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	fluvoxamine
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e2> melatonin </e2> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	melatonin
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e2> beta blockers </e2> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	beta blockers
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e2> melatonin </e2> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	melatonin
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e2> fluoxetine </e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	fluoxetine
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2> progestin </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	progestin
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e2> melatonin </e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	melatonin
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2> progestin </e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	progestin
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2> benzodiazepenes </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	benzodiazepenes
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	corticosteroids
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2> melatonin </e2> and corticosteroids may interfere with the efficacy of the corticosteroids).	0	aspirin	melatonin
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	aspirin	corticosteroids
Melatonin may interact with the following drugs: <e1> aspirin </e1> and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	aspirin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower <e2> melatonin </e2> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	NSAIDs	melatonin
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), <e2> fluvoxamine </e2> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	NSAIDs	fluvoxamine
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral <e2> melatonin </e2> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	NSAIDs	melatonin
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e2> beta blockers </e2> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	NSAIDs	beta blockers
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e2> melatonin </e2> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	NSAIDs	melatonin
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e2> fluoxetine </e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	NSAIDs	fluoxetine
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2> progestin </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	NSAIDs	progestin
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e2> melatonin </e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	NSAIDs	melatonin
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2> progestin </e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	NSAIDs	progestin
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2> benzodiazepenes </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	NSAIDs	benzodiazepenes
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	NSAIDs	corticosteroids
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2> melatonin </e2> and corticosteroids may interfere with the efficacy of the corticosteroids).	0	NSAIDs	melatonin
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	NSAIDs	corticosteroids
Melatonin may interact with the following drugs: aspirin and other <e1> NSAIDs </e1> (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	NSAIDs	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1> melatonin </e1> levels), <e2> fluvoxamine </e2> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	fluvoxamine
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1> melatonin </e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e2> beta blockers </e2> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	beta blockers
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1> melatonin </e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e2> fluoxetine </e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	fluoxetine
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1> melatonin </e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2> progestin </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1> melatonin </e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2> progestin </e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1> melatonin </e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2> benzodiazepenes </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	benzodiazepenes
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1> melatonin </e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1> melatonin </e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower <e1> melatonin </e1> levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1> fluvoxamine </e1> (bioavailability of oral <e2> melatonin </e2> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluvoxamine	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1> fluvoxamine </e1> (bioavailability of oral melatonin is increased with coadministration), <e2> beta blockers </e2> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluvoxamine	beta blockers
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1> fluvoxamine </e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e2> melatonin </e2> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluvoxamine	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1> fluvoxamine </e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e2> fluoxetine </e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluvoxamine	fluoxetine
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1> fluvoxamine </e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2> progestin </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluvoxamine	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1> fluvoxamine </e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e2> melatonin </e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluvoxamine	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1> fluvoxamine </e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2> progestin </e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluvoxamine	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1> fluvoxamine </e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2> benzodiazepenes </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluvoxamine	benzodiazepenes
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1> fluvoxamine </e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluvoxamine	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1> fluvoxamine </e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2> melatonin </e2> and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluvoxamine	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1> fluvoxamine </e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	fluvoxamine	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), <e1> fluvoxamine </e1> (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	fluvoxamine	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1> melatonin </e1> is increased with coadministration), <e2> beta blockers </e2> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	beta blockers
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1> melatonin </e1> is increased with coadministration), beta blockers (may decrease melatonin levels), <e2> fluoxetine </e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	fluoxetine
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1> melatonin </e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2> progestin </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1> melatonin </e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2> progestin </e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1> melatonin </e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2> benzodiazepenes </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	benzodiazepenes
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1> melatonin </e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1> melatonin </e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral <e1> melatonin </e1> is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1> beta blockers </e1> (may decrease <e2> melatonin </e2> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	beta blockers	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1> beta blockers </e1> (may decrease melatonin levels), <e2> fluoxetine </e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	beta blockers	fluoxetine
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1> beta blockers </e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e2> progestin </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	beta blockers	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1> beta blockers </e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e2> melatonin </e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	beta blockers	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1> beta blockers </e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2> progestin </e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	beta blockers	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1> beta blockers </e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2> benzodiazepenes </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	beta blockers	benzodiazepenes
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1> beta blockers </e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	beta blockers	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1> beta blockers </e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2> melatonin </e2> and corticosteroids may interfere with the efficacy of the corticosteroids).	0	beta blockers	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1> beta blockers </e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	beta blockers	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), <e1> beta blockers </e1> (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	beta blockers	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1> melatonin </e1> levels), <e2> fluoxetine </e2> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	fluoxetine
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1> melatonin </e1> levels), fluoxetine (reports of psychotic episodes when coadministered), <e2> progestin </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1> melatonin </e1> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2> progestin </e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1> melatonin </e1> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2> benzodiazepenes </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	benzodiazepenes
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1> melatonin </e1> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1> melatonin </e1> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease <e1> melatonin </e1> levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1> fluoxetine </e1> (reports of psychotic episodes when coadministered), <e2> progestin </e2> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluoxetine	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1> fluoxetine </e1> (reports of psychotic episodes when coadministered), progestin (coadministration of <e2> melatonin </e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluoxetine	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1> fluoxetine </e1> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e2> progestin </e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluoxetine	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1> fluoxetine </e1> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2> benzodiazepenes </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluoxetine	benzodiazepenes
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1> fluoxetine </e1> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluoxetine	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1> fluoxetine </e1> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2> melatonin </e2> and corticosteroids may interfere with the efficacy of the corticosteroids).	0	fluoxetine	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1> fluoxetine </e1> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	fluoxetine	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), <e1> fluoxetine </e1> (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	fluoxetine	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1> progestin </e1> (coadministration of <e2> melatonin </e2> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	progestin	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1> progestin </e1> (coadministration of melatonin with progestin can inhibit ovarian function in women), <e2> benzodiazepenes </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	progestin	benzodiazepenes
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1> progestin </e1> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	progestin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1> progestin </e1> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2> melatonin </e2> and corticosteroids may interfere with the efficacy of the corticosteroids).	0	progestin	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1> progestin </e1> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	progestin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), <e1> progestin </e1> (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	progestin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e1> melatonin </e1> with <e2> progestin </e2> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	1	melatonin	progestin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e1> melatonin </e1> with progestin can inhibit ovarian function in women), <e2> benzodiazepenes </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	benzodiazepenes
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e1> melatonin </e1> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e1> melatonin </e1> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of <e1> melatonin </e1> with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e1> progestin </e1> can inhibit ovarian function in women), <e2> benzodiazepenes </e2> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	progestin	benzodiazepenes
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e1> progestin </e1> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	progestin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e1> progestin </e1> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2> melatonin </e2> and corticosteroids may interfere with the efficacy of the corticosteroids).	0	progestin	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e1> progestin </e1> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	progestin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with <e1> progestin </e1> can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	progestin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e1> benzodiazepenes </e1> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e2> corticosteroids </e2> (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).	0	benzodiazepenes	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e1> benzodiazepenes </e1> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e2> melatonin </e2> and corticosteroids may interfere with the efficacy of the corticosteroids).	0	benzodiazepenes	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e1> benzodiazepenes </e1> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	0	benzodiazepenes	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), <e1> benzodiazepenes </e1> and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	benzodiazepenes	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and <e1> corticosteroids </e1> (coadministration of <e2> melatonin </e2> and corticosteroids may interfere with the efficacy of the corticosteroids).	0	corticosteroids	melatonin
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e1> melatonin </e1> and <e2> corticosteroids </e2> may interfere with the efficacy of the corticosteroids).	1	melatonin	corticosteroids
Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of <e1> melatonin </e1> and corticosteroids may interfere with the efficacy of the <e2> corticosteroids </e2> ).	0	melatonin	corticosteroids
Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between <e1> FLOMAX </e1> capsules and other <e2> alpha-adrenergic blocking agents </e2> have not been determined.	0	FLOMAX	alpha-adrenergic blocking agents
However, interactions may be expected and <e1> FLOMAX </e1> capsules should NOT be used in combination with other <e2> alpha-adrenergic blocking agents </e2> .	0	FLOMAX	alpha-adrenergic blocking agents
The pharmacokinetic interaction between <e1> cimetidine </e1> and <e2> FLOMAX </e2> capsules was investigated.	0	cimetidine	FLOMAX
Therefore, <e1> FLOMAX </e1> capsules should be used with caution in combination with <e2> cimetidine </e2> , particularly at doses higher than 0.4 mg.	0	FLOMAX	cimetidine
Results from limited in vitro and in vivo drug-drug interaction studies between <e1> tamsulosin HCI </e1> and <e2> warfarin </e2> are inconclusive.	0	tamsulosin HCI	warfarin
Therefore, caution should be exercised with concomitant administration of <e1> warfarin </e1> and <e2> FLOMAX </e2> capsules.	0	warfarin	FLOMAX
The concomitant use of <e1> oxybutynin </e1> with other <e2> anticholinergic drugs </e2> or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.	1	oxybutynin	anticholinergic drugs
Mean <e1> oxybutynin chloride </e1> plasma concentrations were approximately 2 fold higher when <e2> DITROPAN XL </e2> was administered with ketoconazole, a potent CYP3A4 inhibitor.	0	oxybutynin chloride	DITROPAN XL
Mean <e1> oxybutynin chloride </e1> plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with <e2> ketoconazole </e2> , a potent CYP3A4 inhibitor.	0	oxybutynin chloride	ketoconazole
Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when <e1> DITROPAN XL </e1> was administered with <e2> ketoconazole </e2> , a potent CYP3A4 inhibitor.	1	DITROPAN XL	ketoconazole
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e1> antimycotic agents </e1> (e.g., <e2> itraconazole </e2> and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	antimycotic agents	itraconazole
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e1> antimycotic agents </e1> (e.g., itraconazole and <e2> miconazole </e2> ) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	antimycotic agents	miconazole
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e1> antimycotic agents </e1> (e.g., itraconazole and miconazole) or <e2> macrolide antibiotics </e2> (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	antimycotic agents	macrolide antibiotics
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e1> antimycotic agents </e1> (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., <e2> erythromycin </e2> and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	antimycotic agents	erythromycin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e1> antimycotic agents </e1> (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and <e2> clarithromycin </e2> ), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	antimycotic agents	clarithromycin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as <e1> antimycotic agents </e1> (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter <e2> oxybutynin </e2> mean pharmacokinetic parameters (i.e., Cmax and AUC).	1	antimycotic agents	oxybutynin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., <e1> itraconazole </e1> and <e2> miconazole </e2> ) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	itraconazole	miconazole
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., <e1> itraconazole </e1> and miconazole) or <e2> macrolide antibiotics </e2> (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	itraconazole	macrolide antibiotics
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., <e1> itraconazole </e1> and miconazole) or macrolide antibiotics (e.g., <e2> erythromycin </e2> and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	itraconazole	erythromycin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., <e1> itraconazole </e1> and miconazole) or macrolide antibiotics (e.g., erythromycin and <e2> clarithromycin </e2> ), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	itraconazole	clarithromycin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., <e1> itraconazole </e1> and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter <e2> oxybutynin </e2> mean pharmacokinetic parameters (i.e., Cmax and AUC).	1	itraconazole	oxybutynin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and <e1> miconazole </e1> ) or <e2> macrolide antibiotics </e2> (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	miconazole	macrolide antibiotics
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and <e1> miconazole </e1> ) or macrolide antibiotics (e.g., <e2> erythromycin </e2> and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	miconazole	erythromycin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and <e1> miconazole </e1> ) or macrolide antibiotics (e.g., erythromycin and <e2> clarithromycin </e2> ), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	miconazole	clarithromycin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and <e1> miconazole </e1> ) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter <e2> oxybutynin </e2> mean pharmacokinetic parameters (i.e., Cmax and AUC).	1	miconazole	oxybutynin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or <e1> macrolide antibiotics </e1> (e.g., <e2> erythromycin </e2> and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	macrolide antibiotics	erythromycin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or <e1> macrolide antibiotics </e1> (e.g., erythromycin and <e2> clarithromycin </e2> ), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	macrolide antibiotics	clarithromycin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or <e1> macrolide antibiotics </e1> (e.g., erythromycin and clarithromycin), may alter <e2> oxybutynin </e2> mean pharmacokinetic parameters (i.e., Cmax and AUC).	1	macrolide antibiotics	oxybutynin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., <e1> erythromycin </e1> and <e2> clarithromycin </e2> ), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).	0	erythromycin	clarithromycin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., <e1> erythromycin </e1> and clarithromycin), may alter <e2> oxybutynin </e2> mean pharmacokinetic parameters (i.e., Cmax and AUC).	1	erythromycin	oxybutynin
Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and <e1> clarithromycin </e1> ), may alter <e2> oxybutynin </e2> mean pharmacokinetic parameters (i.e., Cmax and AUC).	1	clarithromycin	oxybutynin
Concurrent ingestion of <e1> antacid </e1> (20 mL of antacid containing <e2> aluminum hydroxide </e2> , magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	0	antacid	aluminum hydroxide
Concurrent ingestion of <e1> antacid </e1> (20 mL of antacid containing aluminum hydroxide, <e2> magnesium hydroxide </e2> , and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	0	antacid	magnesium hydroxide
Concurrent ingestion of <e1> antacid </e1> (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and <e2> simethicone </e2> ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	0	antacid	simethicone
Concurrent ingestion of <e1> antacid </e1> (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of <e2> oxybutynin </e2> or desethyloxybutynin.	0	antacid	oxybutynin
Concurrent ingestion of <e1> antacid </e1> (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or <e2> desethyloxybutynin </e2> .	0	antacid	desethyloxybutynin
Concurrent ingestion of antacid (20 mL of <e1> antacid </e1> containing <e2> aluminum hydroxide </e2> , magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	0	antacid	aluminum hydroxide
Concurrent ingestion of antacid (20 mL of <e1> antacid </e1> containing aluminum hydroxide, <e2> magnesium hydroxide </e2> , and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	0	antacid	magnesium hydroxide
Concurrent ingestion of antacid (20 mL of <e1> antacid </e1> containing aluminum hydroxide, magnesium hydroxide, and <e2> simethicone </e2> ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	0	antacid	simethicone
Concurrent ingestion of antacid (20 mL of <e1> antacid </e1> containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of <e2> oxybutynin </e2> or desethyloxybutynin.	0	antacid	oxybutynin
Concurrent ingestion of antacid (20 mL of <e1> antacid </e1> containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or <e2> desethyloxybutynin </e2> .	0	antacid	desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing <e1> aluminum hydroxide </e1> , <e2> magnesium hydroxide </e2> , and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	0	aluminum hydroxide	magnesium hydroxide
Concurrent ingestion of antacid (20 mL of antacid containing <e1> aluminum hydroxide </e1> , magnesium hydroxide, and <e2> simethicone </e2> ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	0	aluminum hydroxide	simethicone
Concurrent ingestion of antacid (20 mL of antacid containing <e1> aluminum hydroxide </e1> , magnesium hydroxide, and simethicone) did not significantly affect the exposure of <e2> oxybutynin </e2> or desethyloxybutynin.	0	aluminum hydroxide	oxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing <e1> aluminum hydroxide </e1> , magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or <e2> desethyloxybutynin </e2> .	0	aluminum hydroxide	desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, <e1> magnesium hydroxide </e1> , and <e2> simethicone </e2> ) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.	0	magnesium hydroxide	simethicone
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, <e1> magnesium hydroxide </e1> , and simethicone) did not significantly affect the exposure of <e2> oxybutynin </e2> or desethyloxybutynin.	0	magnesium hydroxide	oxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, <e1> magnesium hydroxide </e1> , and simethicone) did not significantly affect the exposure of oxybutynin or <e2> desethyloxybutynin </e2> .	0	magnesium hydroxide	desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and <e1> simethicone </e1> ) did not significantly affect the exposure of <e2> oxybutynin </e2> or desethyloxybutynin.	0	simethicone	oxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and <e1> simethicone </e1> ) did not significantly affect the exposure of oxybutynin or <e2> desethyloxybutynin </e2> .	0	simethicone	desethyloxybutynin
Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of <e1> oxybutynin </e1> or <e2> desethyloxybutynin </e2> .	0	oxybutynin	desethyloxybutynin
Administration of <e1> paclitaxel </e1> in combination with <e2> HERCEPTIN </e2> resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.	1	paclitaxel	HERCEPTIN
Administration of <e1> paclitaxel </e1> in combination with HERCEPTIN resulted in a two-fold decrease in <e2> HERCEPTIN </e2> clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.	0	paclitaxel	HERCEPTIN
Administration of <e1> paclitaxel </e1> in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in <e2> HERCEPTIN </e2> serum levels in clinical studies.	0	paclitaxel	HERCEPTIN
<e1> Scopolamine </e1> should be used with care in patients taking other drugs that are capable of causing CNS effects such as <e2> sedatives </e2> , tranquilizers, or alcohol.	0	Scopolamine	sedatives
<e1> Scopolamine </e1> should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, <e2> tranquilizers </e2> , or alcohol.	0	Scopolamine	tranquilizers
<e1> Scopolamine </e1> should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or <e2> alcohol </e2> .	0	Scopolamine	alcohol
Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as <e1> sedatives </e1> , <e2> tranquilizers </e2> , or alcohol.	0	sedatives	tranquilizers
Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as <e1> sedatives </e1> , tranquilizers, or <e2> alcohol </e2> .	0	sedatives	alcohol
Scopolamine should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, <e1> tranquilizers </e1> , or <e2> alcohol </e2> .	0	tranquilizers	alcohol
e.g., other <e1> belladonna alkaloids </e1> , <e2> antihistamines </e2> (including meclizine), tricyclic antidepressants, and muscle relaxants.	0	belladonna alkaloids	antihistamines
e.g., other <e1> belladonna alkaloids </e1> , antihistamines (including <e2> meclizine </e2> ), tricyclic antidepressants, and muscle relaxants.	0	belladonna alkaloids	meclizine
e.g., other <e1> belladonna alkaloids </e1> , antihistamines (including meclizine), <e2> tricyclic antidepressants </e2> , and muscle relaxants.	0	belladonna alkaloids	tricyclic antidepressants
e.g., other <e1> belladonna alkaloids </e1> , antihistamines (including meclizine), tricyclic antidepressants, and <e2> muscle relaxants </e2> .	0	belladonna alkaloids	muscle relaxants
e.g., other belladonna alkaloids, <e1> antihistamines </e1> (including <e2> meclizine </e2> ), tricyclic antidepressants, and muscle relaxants.	0	antihistamines	meclizine
e.g., other belladonna alkaloids, <e1> antihistamines </e1> (including meclizine), <e2> tricyclic antidepressants </e2> , and muscle relaxants.	0	antihistamines	tricyclic antidepressants
e.g., other belladonna alkaloids, <e1> antihistamines </e1> (including meclizine), tricyclic antidepressants, and <e2> muscle relaxants </e2> .	0	antihistamines	muscle relaxants
e.g., other belladonna alkaloids, antihistamines (including <e1> meclizine </e1> ), <e2> tricyclic antidepressants </e2> , and muscle relaxants.	0	meclizine	tricyclic antidepressants
e.g., other belladonna alkaloids, antihistamines (including <e1> meclizine </e1> ), tricyclic antidepressants, and <e2> muscle relaxants </e2> .	0	meclizine	muscle relaxants
e.g., other belladonna alkaloids, antihistamines (including meclizine), <e1> tricyclic antidepressants </e1> , and <e2> muscle relaxants </e2> .	0	tricyclic antidepressants	muscle relaxants
Hypokalemia may develop during concomitant use of <e1> steroids </e1> or <e2> ACTH </e2> .	0	steroids	ACTH
<e1> Thiazides </e1> may decrease arterial responsiveness to <e2> norepinephrine </e2> .	1	Thiazides	norepinephrine
<e1> Thiazide drugs </e1> may increase the responsiveness of <e2> tubocurarine </e2> .	1	Thiazide drugs	tubocurarine
<e1> Lithium </e1> renal clearance is reduced by <e2> thiazides </e2> , increasing the risk of lithium toxicity.	1	Lithium	thiazides
Lithium renal clearance is reduced by <e1> thiazides </e1> , increasing the risk of <e2> lithium </e2> toxicity.	0	thiazides	lithium
<e1> Thiazides </e1> may add to or potentiate the action of other <e2> antihypertensive drugs </e2> .	1	Thiazides	antihypertensive drugs
Potentiation occurs with <e1> ganglionic adrenergic blocking drugs </e1> - <e2> peripheral adrenergic blocking drugs </e2> .	0	ganglionic adrenergic blocking drugs	peripheral adrenergic blocking drugs
These include <e1> sympathomimetic bronchodilators </e1> , <e2> methylxanthines </e2> , and oral and inhaled steroids.	0	sympathomimetic bronchodilators	methylxanthines
These include <e1> sympathomimetic bronchodilators </e1> , methylxanthines, and oral and inhaled <e2> steroids </e2> .	0	sympathomimetic bronchodilators	steroids
These include sympathomimetic bronchodilators, <e1> methylxanthines </e1> , and oral and inhaled <e2> steroids </e2> .	0	methylxanthines	steroids
However, the co administration of <e1> SPIRIVA </e1> with other <e2> anticholinergic </e2> containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.	0	SPIRIVA	anticholinergic
However, the co administration of <e1> SPIRIVA </e1> with other anticholinergic containing drugs (e.g., <e2> ipratropium </e2> ) has not been studied and is therefore not recommended.	0	SPIRIVA	ipratropium
However, the co administration of SPIRIVA with other <e1> anticholinergic </e1> containing drugs (e.g., <e2> ipratropium </e2> ) has not been studied and is therefore not recommended.	0	anticholinergic	ipratropium
<e1> Pyrimethamine </e1> may be used with <e2> sulfonamides </e2> , quinine and other antimalarials, and with other antibiotics.	0	Pyrimethamine	sulfonamides
<e1> Pyrimethamine </e1> may be used with sulfonamides, <e2> quinine </e2> and other antimalarials, and with other antibiotics.	0	Pyrimethamine	quinine
<e1> Pyrimethamine </e1> may be used with sulfonamides, quinine and other <e2> antimalarials </e2> , and with other antibiotics.	0	Pyrimethamine	antimalarials
<e1> Pyrimethamine </e1> may be used with sulfonamides, quinine and other antimalarials, and with other <e2> antibiotics </e2> .	0	Pyrimethamine	antibiotics
Pyrimethamine may be used with <e1> sulfonamides </e1> , <e2> quinine </e2> and other antimalarials, and with other antibiotics.	0	sulfonamides	quinine
Pyrimethamine may be used with <e1> sulfonamides </e1> , quinine and other <e2> antimalarials </e2> , and with other antibiotics.	0	sulfonamides	antimalarials
Pyrimethamine may be used with <e1> sulfonamides </e1> , quinine and other antimalarials, and with other <e2> antibiotics </e2> .	0	sulfonamides	antibiotics
Pyrimethamine may be used with sulfonamides, <e1> quinine </e1> and other <e2> antimalarials </e2> , and with other antibiotics.	0	quinine	antimalarials
Pyrimethamine may be used with sulfonamides, <e1> quinine </e1> and other antimalarials, and with other <e2> antibiotics </e2> .	0	quinine	antibiotics
Pyrimethamine may be used with sulfonamides, quinine and other <e1> antimalarials </e1> , and with other <e2> antibiotics </e2> .	0	antimalarials	antibiotics
<e1> Folinic acid </e1> ( <e2> leucovorin </e2> ) should be administered until normal hematopoiesis is restored.	0	Folinic acid	leucovorin
Mild hepatotoxicity has been reported in some patients when <e1> lorazepam </e1> and <e2> pyrimethamine </e2> were administered concomitantly.	1	lorazepam	pyrimethamine
The concomitant use of other <e1> CNS depressants </e1> including <e2> sedatives </e2> , hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	CNS depressants	sedatives
The concomitant use of other <e1> CNS depressants </e1> including sedatives, <e2> hypnotics </e2> , tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	CNS depressants	hypnotics
The concomitant use of other <e1> CNS depressants </e1> including sedatives, hypnotics, <e2> tranquilizers </e2> , general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	CNS depressants	tranquilizers
The concomitant use of other <e1> CNS depressants </e1> including sedatives, hypnotics, tranquilizers, general <e2> anesthetics </e2> , phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	CNS depressants	anesthetics
The concomitant use of other <e1> CNS depressants </e1> including sedatives, hypnotics, tranquilizers, general anesthetics, <e2> phenothiazines </e2> , other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	CNS depressants	phenothiazines
The concomitant use of other <e1> CNS depressants </e1> including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other <e2> opioids </e2> , tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	CNS depressants	opioids
The concomitant use of other <e1> CNS depressants </e1> including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, <e2> tricyclic antidepressants </e2> , monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	CNS depressants	tricyclic antidepressants
The concomitant use of other <e1> CNS depressants </e1> including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects.	0	CNS depressants	monoamine oxidase (MAO) inhibitors
The concomitant use of other <e1> CNS depressants </e1> including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2> alcohol </e2> may produce additive CNS depressant effects.	0	CNS depressants	alcohol
The concomitant use of other CNS depressants including <e1> sedatives </e1> , <e2> hypnotics </e2> , tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	sedatives	hypnotics
The concomitant use of other CNS depressants including <e1> sedatives </e1> , hypnotics, <e2> tranquilizers </e2> , general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	sedatives	tranquilizers
The concomitant use of other CNS depressants including <e1> sedatives </e1> , hypnotics, tranquilizers, general <e2> anesthetics </e2> , phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	sedatives	anesthetics
The concomitant use of other CNS depressants including <e1> sedatives </e1> , hypnotics, tranquilizers, general anesthetics, <e2> phenothiazines </e2> , other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	sedatives	phenothiazines
The concomitant use of other CNS depressants including <e1> sedatives </e1> , hypnotics, tranquilizers, general anesthetics, phenothiazines, other <e2> opioids </e2> , tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	sedatives	opioids
The concomitant use of other CNS depressants including <e1> sedatives </e1> , hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, <e2> tricyclic antidepressants </e2> , monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	sedatives	tricyclic antidepressants
The concomitant use of other CNS depressants including <e1> sedatives </e1> , hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects.	0	sedatives	monoamine oxidase (MAO) inhibitors
The concomitant use of other CNS depressants including <e1> sedatives </e1> , hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2> alcohol </e2> may produce additive CNS depressant effects.	0	sedatives	alcohol
The concomitant use of other CNS depressants including sedatives, <e1> hypnotics </e1> , <e2> tranquilizers </e2> , general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	hypnotics	tranquilizers
The concomitant use of other CNS depressants including sedatives, <e1> hypnotics </e1> , tranquilizers, general <e2> anesthetics </e2> , phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	hypnotics	anesthetics
The concomitant use of other CNS depressants including sedatives, <e1> hypnotics </e1> , tranquilizers, general anesthetics, <e2> phenothiazines </e2> , other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	hypnotics	phenothiazines
The concomitant use of other CNS depressants including sedatives, <e1> hypnotics </e1> , tranquilizers, general anesthetics, phenothiazines, other <e2> opioids </e2> , tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	hypnotics	opioids
The concomitant use of other CNS depressants including sedatives, <e1> hypnotics </e1> , tranquilizers, general anesthetics, phenothiazines, other opioids, <e2> tricyclic antidepressants </e2> , monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	hypnotics	tricyclic antidepressants
The concomitant use of other CNS depressants including sedatives, <e1> hypnotics </e1> , tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects.	0	hypnotics	monoamine oxidase (MAO) inhibitors
The concomitant use of other CNS depressants including sedatives, <e1> hypnotics </e1> , tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2> alcohol </e2> may produce additive CNS depressant effects.	0	hypnotics	alcohol
The concomitant use of other CNS depressants including sedatives, hypnotics, <e1> tranquilizers </e1> , general <e2> anesthetics </e2> , phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	tranquilizers	anesthetics
The concomitant use of other CNS depressants including sedatives, hypnotics, <e1> tranquilizers </e1> , general anesthetics, <e2> phenothiazines </e2> , other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	tranquilizers	phenothiazines
The concomitant use of other CNS depressants including sedatives, hypnotics, <e1> tranquilizers </e1> , general anesthetics, phenothiazines, other <e2> opioids </e2> , tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	tranquilizers	opioids
The concomitant use of other CNS depressants including sedatives, hypnotics, <e1> tranquilizers </e1> , general anesthetics, phenothiazines, other opioids, <e2> tricyclic antidepressants </e2> , monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	tranquilizers	tricyclic antidepressants
The concomitant use of other CNS depressants including sedatives, hypnotics, <e1> tranquilizers </e1> , general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects.	0	tranquilizers	monoamine oxidase (MAO) inhibitors
The concomitant use of other CNS depressants including sedatives, hypnotics, <e1> tranquilizers </e1> , general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2> alcohol </e2> may produce additive CNS depressant effects.	0	tranquilizers	alcohol
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general <e1> anesthetics </e1> , <e2> phenothiazines </e2> , other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	anesthetics	phenothiazines
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general <e1> anesthetics </e1> , phenothiazines, other <e2> opioids </e2> , tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	anesthetics	opioids
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general <e1> anesthetics </e1> , phenothiazines, other opioids, <e2> tricyclic antidepressants </e2> , monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	anesthetics	tricyclic antidepressants
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general <e1> anesthetics </e1> , phenothiazines, other opioids, tricyclic antidepressants, <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects.	0	anesthetics	monoamine oxidase (MAO) inhibitors
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general <e1> anesthetics </e1> , phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2> alcohol </e2> may produce additive CNS depressant effects.	0	anesthetics	alcohol
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, <e1> phenothiazines </e1> , other <e2> opioids </e2> , tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	phenothiazines	opioids
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, <e1> phenothiazines </e1> , other opioids, <e2> tricyclic antidepressants </e2> , monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	phenothiazines	tricyclic antidepressants
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, <e1> phenothiazines </e1> , other opioids, tricyclic antidepressants, <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects.	0	phenothiazines	monoamine oxidase (MAO) inhibitors
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, <e1> phenothiazines </e1> , other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2> alcohol </e2> may produce additive CNS depressant effects.	0	phenothiazines	alcohol
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other <e1> opioids </e1> , <e2> tricyclic antidepressants </e2> , monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects.	0	opioids	tricyclic antidepressants
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other <e1> opioids </e1> , tricyclic antidepressants, <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects.	0	opioids	monoamine oxidase (MAO) inhibitors
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other <e1> opioids </e1> , tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and <e2> alcohol </e2> may produce additive CNS depressant effects.	0	opioids	alcohol
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, <e1> tricyclic antidepressants </e1> , <e2> monoamine oxidase (MAO) inhibitors </e2> , and alcohol may produce additive CNS depressant effects.	0	tricyclic antidepressants	monoamine oxidase (MAO) inhibitors
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, <e1> tricyclic antidepressants </e1> , monoamine oxidase (MAO) inhibitors, and <e2> alcohol </e2> may produce additive CNS depressant effects.	0	tricyclic antidepressants	alcohol
The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, <e1> monoamine oxidase (MAO) inhibitors </e1> , and <e2> alcohol </e2> may produce additive CNS depressant effects.	0	monoamine oxidase (MAO) inhibitors	alcohol
<e1> Anticholinergics </e1> or other medications with anticholinergic activity when used concurrently with <e2> opioid analgesics </e2> may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.	1	Anticholinergics	opioid analgesics
It has been reported that the incidence of bradycardia was increased when <e1> oxymorphone </e1> was combined with <e2> propofol </e2> for induction of anesthesia.	1	oxymorphone	propofol
In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of <e1> cimetidine </e1> with <e2> opioid analgesics </e2> ;	1	cimetidine	opioid analgesics
Limited published data indicate that <e1> GH </e1> treatment increases cytochrome P450 (CP450) mediated <e2> antipyrine </e2> clearance in man.	1	GH	antipyrine
These data suggest that <e1> GH </e1> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., <e2> corticosteroids </e2> , sex steroids, anticonvulsants, cyclosporin).	1	GH	corticosteroids
These data suggest that <e1> GH </e1> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, <e2> sex steroids </e2> , anticonvulsants, cyclosporin).	1	GH	sex steroids
These data suggest that <e1> GH </e1> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, <e2> anticonvulsants </e2> , cyclosporin).	1	GH	anticonvulsants
These data suggest that <e1> GH </e1> administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, <e2> cyclosporin </e2> ).	1	GH	cyclosporin
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., <e1> corticosteroids </e1> , <e2> sex steroids </e2> , anticonvulsants, cyclosporin).	0	corticosteroids	sex steroids
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., <e1> corticosteroids </e1> , sex steroids, <e2> anticonvulsants </e2> , cyclosporin).	0	corticosteroids	anticonvulsants
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., <e1> corticosteroids </e1> , sex steroids, anticonvulsants, <e2> cyclosporin </e2> ).	0	corticosteroids	cyclosporin
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, <e1> sex steroids </e1> , <e2> anticonvulsants </e2> , cyclosporin).	0	sex steroids	anticonvulsants
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, <e1> sex steroids </e1> , anticonvulsants, <e2> cyclosporin </e2> ).	0	sex steroids	cyclosporin
These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, <e1> anticonvulsants </e1> , <e2> cyclosporin </e2> ).	0	anticonvulsants	cyclosporin
<e1> SKELAXIN </e1> may enhance the effects of <e2> alcohol </e2> , barbiturates and other CNS depressants.	1	SKELAXIN	alcohol
<e1> SKELAXIN </e1> may enhance the effects of alcohol, <e2> barbiturates </e2> and other CNS depressants.	1	SKELAXIN	barbiturates
<e1> SKELAXIN </e1> may enhance the effects of alcohol, barbiturates and other <e2> CNS depressants </e2> .	1	SKELAXIN	CNS depressants
SKELAXIN may enhance the effects of <e1> alcohol </e1> , <e2> barbiturates </e2> and other CNS depressants.	0	alcohol	barbiturates
SKELAXIN may enhance the effects of <e1> alcohol </e1> , barbiturates and other <e2> CNS depressants </e2> .	0	alcohol	CNS depressants
SKELAXIN may enhance the effects of alcohol, <e1> barbiturates </e1> and other <e2> CNS depressants </e2> .	0	barbiturates	CNS depressants
A study published in 2002 found that <e1> vigabatrin </e1> causes a statistically significant increase in plasma clearance of <e2> carbamazepine </e2> .	1	vigabatrin	carbamazepine
In 1984, Drs Rimmer and Richens at the University of Wales reported that administering <e1> vigabatrin </e1> with <e2> phenytoin </e2> lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy.	1	vigabatrin	phenytoin
In 1984, Drs Rimmer and Richens at the University of Wales reported that administering <e1> vigabatrin </e1> with phenytoin lowered the serum <e2> phenytoin </e2> concentration in patients with treatment-resistant epilepsy.	0	vigabatrin	phenytoin
Dosages of concomitantly administered <e1> opioids </e1> should be reduced by approximately half, because <e2> levomepromazine </e2> amplifies the therapeutic actions and side-effects of opioids.	1	opioids	levomepromazine
Dosages of concomitantly administered opioids should be reduced by approximately half, because <e1> levomepromazine </e1> amplifies the therapeutic actions and side-effects of <e2> opioids </e2> .	1	levomepromazine	opioids
Combination with <e1> tramadol </e1> ( <e2> Ultram </e2> ) is associated with increased risk of seizures.	0	tramadol	Ultram
Additive sedative effects and confusional states may emerge if <e1> levomepromazine </e1> is given with <e2> benzodiazepines </e2> or barbiturates.	1	levomepromazine	benzodiazepines
Additive sedative effects and confusional states may emerge if <e1> levomepromazine </e1> is given with benzodiazepines or <e2> barbiturates </e2> .	1	levomepromazine	barbiturates
Additive sedative effects and confusional states may emerge if levomepromazine is given with <e1> benzodiazepines </e1> or <e2> barbiturates </e2> .	0	benzodiazepines	barbiturates
Exert particular caution in combining <e1> levomepromazine </e1> with other <e2> anticholinergic drugs </e2> (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	0	levomepromazine	anticholinergic drugs
Exert particular caution in combining <e1> levomepromazine </e1> with other anticholinergic drugs ( <e2> tricyclic antidepressants </e2> and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	0	levomepromazine	tricyclic antidepressants
Exert particular caution in combining <e1> levomepromazine </e1> with other anticholinergic drugs (tricyclic antidepressants and <e2> antiparkinsonian-agents </e2> ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	0	levomepromazine	antiparkinsonian-agents
Exert particular caution in combining levomepromazine with other <e1> anticholinergic drugs </e1> ( <e2> tricyclic antidepressants </e2> and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	0	anticholinergic drugs	tricyclic antidepressants
Exert particular caution in combining levomepromazine with other <e1> anticholinergic drugs </e1> (tricyclic antidepressants and <e2> antiparkinsonian-agents </e2> ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	0	anticholinergic drugs	antiparkinsonian-agents
Exert particular caution in combining levomepromazine with other anticholinergic drugs ( <e1> tricyclic antidepressants </e1> and <e2> antiparkinsonian-agents </e2> ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.	0	tricyclic antidepressants	antiparkinsonian-agents
<e1> Caffeine </e1> and/or stimulantes of the <e2> ephedrine </e2> /amphetamine type may counteract the specific actions of levomepromazine.	0	Caffeine	ephedrine
<e1> Caffeine </e1> and/or stimulantes of the ephedrine/ <e2> amphetamine </e2> type may counteract the specific actions of levomepromazine.	0	Caffeine	amphetamine
<e1> Caffeine </e1> and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of <e2> levomepromazine </e2> .	1	Caffeine	levomepromazine
Caffeine and/or stimulantes of the <e1> ephedrine </e1> / <e2> amphetamine </e2> type may counteract the specific actions of levomepromazine.	0	ephedrine	amphetamine
Caffeine and/or stimulantes of the <e1> ephedrine </e1> /amphetamine type may counteract the specific actions of <e2> levomepromazine </e2> .	1	ephedrine	levomepromazine
Caffeine and/or stimulantes of the ephedrine/ <e1> amphetamine </e1> type may counteract the specific actions of <e2> levomepromazine </e2> .	1	amphetamine	levomepromazine
<e1> Methysergide </e1> may reverse the analgesic activity of <e2> narcotic analgesics </e2> .	1	Methysergide	narcotic analgesics
Concurrent use with <e1> vasoconstrictor agents </e1> including <e2> ergot alkaloids </e2> , sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	0	vasoconstrictor agents	ergot alkaloids
Concurrent use with <e1> vasoconstrictor agents </e1> including ergot alkaloids, <e2> sumatriptan </e2> , and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	0	vasoconstrictor agents	sumatriptan
Concurrent use with <e1> vasoconstrictor agents </e1> including ergot alkaloids, sumatriptan, and <e2> nicotine </e2> (e.g. smoking) may result in enhanced vasoconstriction.	0	vasoconstrictor agents	nicotine
Concurrent use with vasoconstrictor agents including <e1> ergot alkaloids </e1> , <e2> sumatriptan </e2> , and nicotine (e.g. smoking) may result in enhanced vasoconstriction.	0	ergot alkaloids	sumatriptan
Concurrent use with vasoconstrictor agents including <e1> ergot alkaloids </e1> , sumatriptan, and <e2> nicotine </e2> (e.g. smoking) may result in enhanced vasoconstriction.	0	ergot alkaloids	nicotine
Concurrent use with vasoconstrictor agents including ergot alkaloids, <e1> sumatriptan </e1> , and <e2> nicotine </e2> (e.g. smoking) may result in enhanced vasoconstriction.	0	sumatriptan	nicotine
<e1> Ketoconazole </e1> : Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of <e2> terfenadine </e2> demonstrate QT interval prolongation and rare serious cardiac events, e.g.	0	Ketoconazole	terfenadine
Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant <e1> ketoconazole </e1> with recommended doses of <e2> terfenadine </e2> demonstrate QT interval prolongation and rare serious cardiac events, e.g.	1	ketoconazole	terfenadine
Pharmacokinetic data indicate that <e1> ketoconazole </e1> markedly inhibits the metabolism of <e2> terfenadine </e2> , resulting in elevated plasma terfenadine levels.	1	ketoconazole	terfenadine
Pharmacokinetic data indicate that <e1> ketoconazole </e1> markedly inhibits the metabolism of terfenadine, resulting in elevated plasma <e2> terfenadine </e2> levels.	0	ketoconazole	terfenadine
Concomitant administration of <e1> ketoconazole </e1> and <e2> terfenadine </e2> is contraindicated.	0	ketoconazole	terfenadine
<e1> Itraconazole </e1> : Torsades de pointes and elevated parent <e2> terfenadine </e2> levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	0	Itraconazole	terfenadine
<e1> Itraconazole </e1> : Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of <e2> terfenadine </e2> and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources.	0	Itraconazole	terfenadine
Itraconazole: Torsades de pointes and elevated parent <e1> terfenadine </e1> levels have been reported during concomitant use of terfenadine and <e2> itraconazole </e2> in clinical trials of itraconazole and from foreign post-marketing sources.	0	terfenadine	itraconazole
Itraconazole: Torsades de pointes and elevated parent <e1> terfenadine </e1> levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of <e2> itraconazole </e2> and from foreign post-marketing sources.	0	terfenadine	itraconazole
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of <e1> terfenadine </e1> and <e2> itraconazole </e2> in clinical trials of itraconazole and from foreign post-marketing sources.	1	terfenadine	itraconazole
Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of <e1> terfenadine </e1> and itraconazole in clinical trials of <e2> itraconazole </e2> and from foreign post-marketing sources.	0	terfenadine	itraconazole
Concomitant administration of <e1> itraconazole </e1> and <e2> terfenadine </e2> is contraindicated.	0	itraconazole	terfenadine
Due to the chemical similarity of other <e1> azole-type antifungal agents </e1> (including <e2> fluconazole </e2> , metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	azole-type antifungal agents	fluconazole
Due to the chemical similarity of other <e1> azole-type antifungal agents </e1> (including fluconazole, <e2> metronidazole </e2> , and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	azole-type antifungal agents	metronidazole
Due to the chemical similarity of other <e1> azole-type antifungal agents </e1> (including fluconazole, metronidazole, and <e2> miconazole </e2> ) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	azole-type antifungal agents	miconazole
Due to the chemical similarity of other <e1> azole-type antifungal agents </e1> (including fluconazole, metronidazole, and miconazole) to <e2> ketoconazole </e2> , and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	azole-type antifungal agents	ketoconazole
Due to the chemical similarity of other <e1> azole-type antifungal agents </e1> (including fluconazole, metronidazole, and miconazole) to ketoconazole, and <e2> itraconazole </e2> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	azole-type antifungal agents	itraconazole
Due to the chemical similarity of other <e1> azole-type antifungal agents </e1> (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with <e2> terfenadine </e2> is not recommended pending full examination of potential interactions.	0	azole-type antifungal agents	terfenadine
Due to the chemical similarity of other azole-type antifungal agents (including <e1> fluconazole </e1> , <e2> metronidazole </e2> , and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	fluconazole	metronidazole
Due to the chemical similarity of other azole-type antifungal agents (including <e1> fluconazole </e1> , metronidazole, and <e2> miconazole </e2> ) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	fluconazole	miconazole
Due to the chemical similarity of other azole-type antifungal agents (including <e1> fluconazole </e1> , metronidazole, and miconazole) to <e2> ketoconazole </e2> , and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	fluconazole	ketoconazole
Due to the chemical similarity of other azole-type antifungal agents (including <e1> fluconazole </e1> , metronidazole, and miconazole) to ketoconazole, and <e2> itraconazole </e2> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	fluconazole	itraconazole
Due to the chemical similarity of other azole-type antifungal agents (including <e1> fluconazole </e1> , metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with <e2> terfenadine </e2> is not recommended pending full examination of potential interactions.	0	fluconazole	terfenadine
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, <e1> metronidazole </e1> , and <e2> miconazole </e2> ) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	metronidazole	miconazole
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, <e1> metronidazole </e1> , and miconazole) to <e2> ketoconazole </e2> , and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	metronidazole	ketoconazole
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, <e1> metronidazole </e1> , and miconazole) to ketoconazole, and <e2> itraconazole </e2> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	metronidazole	itraconazole
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, <e1> metronidazole </e1> , and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with <e2> terfenadine </e2> is not recommended pending full examination of potential interactions.	0	metronidazole	terfenadine
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and <e1> miconazole </e1> ) to <e2> ketoconazole </e2> , and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	miconazole	ketoconazole
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and <e1> miconazole </e1> ) to ketoconazole, and <e2> itraconazole </e2> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	miconazole	itraconazole
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and <e1> miconazole </e1> ) to ketoconazole, and itraconazole, concomitant use of these products with <e2> terfenadine </e2> is not recommended pending full examination of potential interactions.	0	miconazole	terfenadine
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to <e1> ketoconazole </e1> , and <e2> itraconazole </e2> , concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions.	0	ketoconazole	itraconazole
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to <e1> ketoconazole </e1> , and itraconazole, concomitant use of these products with <e2> terfenadine </e2> is not recommended pending full examination of potential interactions.	0	ketoconazole	terfenadine
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and <e1> itraconazole </e1> , concomitant use of these products with <e2> terfenadine </e2> is not recommended pending full examination of potential interactions.	0	itraconazole	terfenadine
<e1> Macrolides </e1> : Clinical drug interaction studies indicate that <e2> erythromycin </e2> and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	0	Macrolides	erythromycin
<e1> Macrolides </e1> : Clinical drug interaction studies indicate that erythromycin and <e2> clarithromycin </e2> can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	0	Macrolides	clarithromycin
<e1> Macrolides </e1> : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on <e2> terfenadine </e2> metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	0	Macrolides	terfenadine
<e1> Macrolides </e1> : Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of <e2> ketoconazole </e2> , but to a lesser extent.	0	Macrolides	ketoconazole
Macrolides: Clinical drug interaction studies indicate that <e1> erythromycin </e1> and <e2> clarithromycin </e2> can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	0	erythromycin	clarithromycin
Macrolides: Clinical drug interaction studies indicate that <e1> erythromycin </e1> and clarithromycin can exert an effect on <e2> terfenadine </e2> metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	1	erythromycin	terfenadine
Macrolides: Clinical drug interaction studies indicate that <e1> erythromycin </e1> and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of <e2> ketoconazole </e2> , but to a lesser extent.	0	erythromycin	ketoconazole
Macrolides: Clinical drug interaction studies indicate that erythromycin and <e1> clarithromycin </e1> can exert an effect on <e2> terfenadine </e2> metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent.	1	clarithromycin	terfenadine
Macrolides: Clinical drug interaction studies indicate that erythromycin and <e1> clarithromycin </e1> can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of <e2> ketoconazole </e2> , but to a lesser extent.	0	clarithromycin	ketoconazole
Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on <e1> terfenadine </e1> metabolism by a mechanism which may be similar to that of <e2> ketoconazole </e2> , but to a lesser extent.	0	terfenadine	ketoconazole
A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving <e1> erythromycin </e1> or <e2> troleandomycin </e2> .	0	erythromycin	troleandomycin
Concomitant administration of <e1> terfenadine </e1> with <e2> clarithromycin </e2> , erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	0	terfenadine	clarithromycin
Concomitant administration of <e1> terfenadine </e1> with clarithromycin, <e2> erythromycin </e2> , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	0	terfenadine	erythromycin
Concomitant administration of <e1> terfenadine </e1> with clarithromycin, erythromycin, or <e2> troleandomycin </e2> is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	0	terfenadine	troleandomycin
Concomitant administration of <e1> terfenadine </e1> with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other <e2> macrolide antibiotics </e2> , including azithromycin, is not recommended.	0	terfenadine	macrolide antibiotics
Concomitant administration of <e1> terfenadine </e1> with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including <e2> azithromycin </e2> , is not recommended.	0	terfenadine	azithromycin
Concomitant administration of terfenadine with <e1> clarithromycin </e1> , <e2> erythromycin </e2> , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	0	clarithromycin	erythromycin
Concomitant administration of terfenadine with <e1> clarithromycin </e1> , erythromycin, or <e2> troleandomycin </e2> is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	0	clarithromycin	troleandomycin
Concomitant administration of terfenadine with <e1> clarithromycin </e1> , erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e2> terfenadine </e2> with other macrolide antibiotics, including azithromycin, is not recommended.	0	clarithromycin	terfenadine
Concomitant administration of terfenadine with <e1> clarithromycin </e1> , erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other <e2> macrolide antibiotics </e2> , including azithromycin, is not recommended.	0	clarithromycin	macrolide antibiotics
Concomitant administration of terfenadine with <e1> clarithromycin </e1> , erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including <e2> azithromycin </e2> , is not recommended.	0	clarithromycin	azithromycin
Concomitant administration of terfenadine with clarithromycin, <e1> erythromycin </e1> , or <e2> troleandomycin </e2> is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended.	0	erythromycin	troleandomycin
Concomitant administration of terfenadine with clarithromycin, <e1> erythromycin </e1> , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e2> terfenadine </e2> with other macrolide antibiotics, including azithromycin, is not recommended.	0	erythromycin	terfenadine
Concomitant administration of terfenadine with clarithromycin, <e1> erythromycin </e1> , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other <e2> macrolide antibiotics </e2> , including azithromycin, is not recommended.	0	erythromycin	macrolide antibiotics
Concomitant administration of terfenadine with clarithromycin, <e1> erythromycin </e1> , or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including <e2> azithromycin </e2> , is not recommended.	0	erythromycin	azithromycin
Concomitant administration of terfenadine with clarithromycin, erythromycin, or <e1> troleandomycin </e1> is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e2> terfenadine </e2> with other macrolide antibiotics, including azithromycin, is not recommended.	0	troleandomycin	terfenadine
Concomitant administration of terfenadine with clarithromycin, erythromycin, or <e1> troleandomycin </e1> is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other <e2> macrolide antibiotics </e2> , including azithromycin, is not recommended.	0	troleandomycin	macrolide antibiotics
Concomitant administration of terfenadine with clarithromycin, erythromycin, or <e1> troleandomycin </e1> is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including <e2> azithromycin </e2> , is not recommended.	0	troleandomycin	azithromycin
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e1> terfenadine </e1> with other <e2> macrolide antibiotics </e2> , including azithromycin, is not recommended.	0	terfenadine	macrolide antibiotics
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of <e1> terfenadine </e1> with other macrolide antibiotics, including <e2> azithromycin </e2> , is not recommended.	0	terfenadine	azithromycin
Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other <e1> macrolide antibiotics </e1> , including <e2> azithromycin </e2> , is not recommended.	0	macrolide antibiotics	azithromycin
Studies to evaluate potential interactions of <e1> terfenadine </e1> with <e2> azithromycin </e2> are in progress.	0	terfenadine	azithromycin
An inhibitor of CYP2C8 (such as <e1> gemfibrozil </e1> ) may increase the AUC of <e2> rosiglitazone </e2> and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone.	1	gemfibrozil	rosiglitazone
An inhibitor of CYP2C8 (such as <e1> gemfibrozil </e1> ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as <e2> rifampin </e2> ) may decrease the AUC of rosiglitazone.	0	gemfibrozil	rifampin
An inhibitor of CYP2C8 (such as <e1> gemfibrozil </e1> ) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of <e2> rosiglitazone </e2> .	0	gemfibrozil	rosiglitazone
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of <e1> rosiglitazone </e1> and an inducer of CYP2C8 (such as <e2> rifampin </e2> ) may decrease the AUC of rosiglitazone.	0	rosiglitazone	rifampin
An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as <e1> rifampin </e1> ) may decrease the AUC of <e2> rosiglitazone </e2> .	1	rifampin	rosiglitazone
When administered concurrently, <e1> testolactone </e1> may increase the effects of oral <e2> anticoagulants </e2> ;	1	testolactone	anticoagulants
While co-administration of <e1> ZAVESCA </e1> appeared to increase the clearance of <e2> Cerezyme </e2> by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme.	1	ZAVESCA	Cerezyme
While co-administration of <e1> ZAVESCA </e1> appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of <e2> Cerezyme </e2> .	0	ZAVESCA	Cerezyme
Combination therapy with <e1> Cerezyme </e1> ( <e2> imiglucerase </e2> ) and ZAVESCA is not indicated.	0	Cerezyme	imiglucerase
Combination therapy with <e1> Cerezyme </e1> (imiglucerase) and <e2> ZAVESCA </e2> is not indicated.	0	Cerezyme	ZAVESCA
Combination therapy with Cerezyme ( <e1> imiglucerase </e1> ) and <e2> ZAVESCA </e2> is not indicated.	0	imiglucerase	ZAVESCA
Limited evidence suggests that <e1> ascorbic acid </e1> may influence the intensity and duration of action of <e2> bishydroxycoumarin </e2> .	1	ascorbic acid	bishydroxycoumarin
The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of <e1> selegiline </e1> and <e2> meperidine </e2> .	1	selegiline	meperidine
This is typical of the interaction of <e1> meperidine </e1> and <e2> MAOIs </e2> .	0	meperidine	MAOIs
Severe toxicity has also been reported in patients receiving the combination of <e1> tricyclic antidepressants </e1> and <e2> ELDEPRYL </e2> and selective serotonin reuptake inhibitors and ELDEPRYL.	1	tricyclic antidepressants	ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of <e1> tricyclic antidepressants </e1> and ELDEPRYL and <e2> selective serotonin reuptake inhibitors </e2> and ELDEPRYL.	0	tricyclic antidepressants	selective serotonin reuptake inhibitors
Severe toxicity has also been reported in patients receiving the combination of <e1> tricyclic antidepressants </e1> and ELDEPRYL and selective serotonin reuptake inhibitors and <e2> ELDEPRYL </e2> .	0	tricyclic antidepressants	ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and <e1> ELDEPRYL </e1> and <e2> selective serotonin reuptake inhibitors </e2> and ELDEPRYL.	0	ELDEPRYL	selective serotonin reuptake inhibitors
Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and ELDEPRYL and <e1> selective serotonin reuptake inhibitors </e1> and <e2> ELDEPRYL </e2> .	1	selective serotonin reuptake inhibitors	ELDEPRYL
One case of hypertensive crisis has been reported in a patient taking the recommended doses of <e1> selegiline </e1> and a <e2> sympathomimetic medication </e2> (ephedrine).	1	selegiline	sympathomimetic medication
One case of hypertensive crisis has been reported in a patient taking the recommended doses of <e1> selegiline </e1> and a sympathomimetic medication ( <e2> ephedrine </e2> ).	1	selegiline	ephedrine
One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a <e1> sympathomimetic medication </e1> ( <e2> ephedrine </e2> ).	0	sympathomimetic medication	ephedrine
When <e1> methyldopa </e1> is used with other <e2> antihypertensive drugs </e2> , potentiation of antihypertensive effect may occur.	1	methyldopa	antihypertensive drugs
Patients may require reduced doses of <e1> anesthetics </e1> when on <e2> methyldopa </e2> .	0	anesthetics	methyldopa
When <e1> methyldopa </e1> and <e2> lithium </e2> are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity.	0	methyldopa	lithium
When <e1> methyldopa </e1> and lithium are given concomitantly the patient should be carefully monitored for symptoms of <e2> lithium </e2> toxicity.	0	methyldopa	lithium
Several studies demonstrate a decrease in the bioavailability of <e1> methyldopa </e1> when it is ingested with <e2> ferrous sulfate </e2> or ferrous gluconate.	1	methyldopa	ferrous sulfate
Several studies demonstrate a decrease in the bioavailability of <e1> methyldopa </e1> when it is ingested with ferrous sulfate or <e2> ferrous gluconate </e2> .	1	methyldopa	ferrous gluconate
Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with <e1> ferrous sulfate </e1> or <e2> ferrous gluconate </e2> .	0	ferrous sulfate	ferrous gluconate
Coadministration of <e1> methyldopa </e1> with <e2> ferrous sulfate </e2> or ferrous gluconate is not recommended.	0	methyldopa	ferrous sulfate
Coadministration of <e1> methyldopa </e1> with ferrous sulfate or <e2> ferrous gluconate </e2> is not recommended.	0	methyldopa	ferrous gluconate
Coadministration of methyldopa with <e1> ferrous sulfate </e1> or <e2> ferrous gluconate </e2> is not recommended.	0	ferrous sulfate	ferrous gluconate
<e1> Methyldopa </e1> does not interfere with measurement of <e2> VMA </e2> (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin.	0	Methyldopa	VMA
<e1> Methyldopa </e1> does not interfere with measurement of VMA ( <e2> vanillylmandelic acid </e2> ), a test for pheochromocytoma, by those methods which convert VMA to vanillin.	0	Methyldopa	vanillylmandelic acid
<e1> Methyldopa </e1> does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert <e2> VMA </e2> to vanillin.	0	Methyldopa	VMA
<e1> Methyldopa </e1> does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to <e2> vanillin </e2> .	0	Methyldopa	vanillin
Methyldopa does not interfere with measurement of <e1> VMA </e1> ( <e2> vanillylmandelic acid </e2> ), a test for pheochromocytoma, by those methods which convert VMA to vanillin.	0	VMA	vanillylmandelic acid
Methyldopa does not interfere with measurement of <e1> VMA </e1> (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to <e2> vanillin </e2> .	0	VMA	vanillin
Methyldopa does not interfere with measurement of VMA ( <e1> vanillylmandelic acid </e1> ), a test for pheochromocytoma, by those methods which convert <e2> VMA </e2> to vanillin.	0	vanillylmandelic acid	VMA
Methyldopa does not interfere with measurement of VMA ( <e1> vanillylmandelic acid </e1> ), a test for pheochromocytoma, by those methods which convert VMA to <e2> vanillin </e2> .	0	vanillylmandelic acid	vanillin
Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert <e1> VMA </e1> to <e2> vanillin </e2> .	0	VMA	vanillin
<e1> Coumarin-Derivative Anticoagulants </e1> : Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving <e2> ZOLINZA </e2> concomitantly with coumarin-derivative anticoagulants.	0	Coumarin-Derivative Anticoagulants	ZOLINZA
Coumarin-Derivative Anticoagulants: Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving <e1> ZOLINZA </e1> concomitantly with <e2> coumarin-derivative anticoagulants </e2> .	1	ZOLINZA	coumarin-derivative anticoagulants
Physicians should carefully monitor PT and INR in patients concurrently administered <e1> ZOLINZA </e1> and <e2> coumarin derivatives </e2> .	0	ZOLINZA	coumarin derivatives
Other <e1> HDAC Inhibitors </e1> Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of <e2> ZOLINZA </e2> and other HDAC inhibitors (e.g., valproic acid).	0	HDAC Inhibitors	ZOLINZA
Other <e1> HDAC Inhibitors </e1> Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other HDAC inhibitors (e.g., <e2> valproic acid </e2> ).	0	HDAC Inhibitors	valproic acid
Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of <e1> ZOLINZA </e1> and other <e2> HDAC inhibitors </e2> (e.g., valproic acid).	1	ZOLINZA	HDAC inhibitors
Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of <e1> ZOLINZA </e1> and other HDAC inhibitors (e.g., <e2> valproic acid </e2> ).	1	ZOLINZA	valproic acid
Other HDAC Inhibitors Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of ZOLINZA and other <e1> HDAC inhibitors </e1> (e.g., <e2> valproic acid </e2> ).	0	HDAC inhibitors	valproic acid
Drug Interactions: Women on oral <e1> contraceptives </e1> have shown a significant increase in plasma <e2> vitamin A </e2> levels.	1	contraceptives	vitamin A
When administered concomitantly with <e1> ProAmatine </e1> , <e2> cardiac glycosides </e2> may enhance or precipitate bradycardia, A.V.	1	ProAmatine	cardiac glycosides
The use of drugs that stimulate alpha-adrenergic receptors (e.g., <e1> phenylephrine </e1> , <e2> pseudoephedrine </e2> , ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	0	phenylephrine	pseudoephedrine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., <e1> phenylephrine </e1> , pseudoephedrine, <e2> ephedrine </e2> , phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	0	phenylephrine	ephedrine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., <e1> phenylephrine </e1> , pseudoephedrine, ephedrine, <e2> phenylpropanolamine </e2> or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	0	phenylephrine	phenylpropanolamine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., <e1> phenylephrine </e1> , pseudoephedrine, ephedrine, phenylpropanolamine or <e2> dihydroergotamine </e2> ) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	0	phenylephrine	dihydroergotamine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., <e1> phenylephrine </e1> , pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of <e2> ProAmatine </e2> . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	1	phenylephrine	ProAmatine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., <e1> phenylephrine </e1> , pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when <e2> ProAmatine </e2> is administered concomitantly with agents that cause vasoconstriction.	0	phenylephrine	ProAmatine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, <e1> pseudoephedrine </e1> , <e2> ephedrine </e2> , phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	0	pseudoephedrine	ephedrine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, <e1> pseudoephedrine </e1> , ephedrine, <e2> phenylpropanolamine </e2> or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	0	pseudoephedrine	phenylpropanolamine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, <e1> pseudoephedrine </e1> , ephedrine, phenylpropanolamine or <e2> dihydroergotamine </e2> ) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	0	pseudoephedrine	dihydroergotamine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, <e1> pseudoephedrine </e1> , ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of <e2> ProAmatine </e2> . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	1	pseudoephedrine	ProAmatine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, <e1> pseudoephedrine </e1> , ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when <e2> ProAmatine </e2> is administered concomitantly with agents that cause vasoconstriction.	0	pseudoephedrine	ProAmatine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, <e1> ephedrine </e1> , <e2> phenylpropanolamine </e2> or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	0	ephedrine	phenylpropanolamine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, <e1> ephedrine </e1> , phenylpropanolamine or <e2> dihydroergotamine </e2> ) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	0	ephedrine	dihydroergotamine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, <e1> ephedrine </e1> , phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of <e2> ProAmatine </e2> . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	1	ephedrine	ProAmatine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, <e1> ephedrine </e1> , phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when <e2> ProAmatine </e2> is administered concomitantly with agents that cause vasoconstriction.	0	ephedrine	ProAmatine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, <e1> phenylpropanolamine </e1> or <e2> dihydroergotamine </e2> ) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	0	phenylpropanolamine	dihydroergotamine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, <e1> phenylpropanolamine </e1> or dihydroergotamine) may enhance or potentiate the pressor effects of <e2> ProAmatine </e2> . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	1	phenylpropanolamine	ProAmatine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, <e1> phenylpropanolamine </e1> or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when <e2> ProAmatine </e2> is administered concomitantly with agents that cause vasoconstriction.	0	phenylpropanolamine	ProAmatine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or <e1> dihydroergotamine </e1> ) may enhance or potentiate the pressor effects of <e2> ProAmatine </e2> . Therefore, caution should be used when ProAmatine is administered concomitantly with agents that cause vasoconstriction.	1	dihydroergotamine	ProAmatine
The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or <e1> dihydroergotamine </e1> ) may enhance or potentiate the pressor effects of ProAmatine . Therefore, caution should be used when <e2> ProAmatine </e2> is administered concomitantly with agents that cause vasoconstriction.	0	dihydroergotamine	ProAmatine
<e1> ProAmatine </e1> has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., <e2> fludrocortisone acetate </e2> ), with or without salt supplementation.	0	ProAmatine	fludrocortisone acetate
<e1> ProAmatine </e1> . <e2> Alpha-adrenergic blocking agents </e2> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	ProAmatine	Alpha-adrenergic blocking agents
<e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as <e2> prazosin </e2> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	ProAmatine	prazosin
<e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, <e2> terazosin </e2> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	ProAmatine	terazosin
<e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e2> doxazosin </e2> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	ProAmatine	doxazosin
<e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e2> desglymidodrine </e2> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	ProAmatine	desglymidodrine
<e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2> metformin </e2> , cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	ProAmatine	metformin
<e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2> cimetidine </e2> , ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	ProAmatine	cimetidine
<e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine.	0	ProAmatine	ranitidine
<e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2> procainamide </e2> , triamterene, flecainide, and quinidine.	0	ProAmatine	procainamide
<e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2> triamterene </e2> , flecainide, and quinidine.	0	ProAmatine	triamterene
<e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2> flecainide </e2> , and quinidine.	0	ProAmatine	flecainide
<e1> ProAmatine </e1> . Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2> quinidine </e2> .	0	ProAmatine	quinidine
ProAmatine. <e1> Alpha-adrenergic blocking agents </e1> , such as <e2> prazosin </e2> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	Alpha-adrenergic blocking agents	prazosin
ProAmatine. <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, <e2> terazosin </e2> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	Alpha-adrenergic blocking agents	terazosin
ProAmatine. <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and <e2> doxazosin </e2> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	Alpha-adrenergic blocking agents	doxazosin
ProAmatine. <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e2> ProAmatine </e2> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	1	Alpha-adrenergic blocking agents	ProAmatine
ProAmatine. <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e2> desglymidodrine </e2> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	Alpha-adrenergic blocking agents	desglymidodrine
ProAmatine. <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2> metformin </e2> , cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	Alpha-adrenergic blocking agents	metformin
ProAmatine. <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2> cimetidine </e2> , ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	Alpha-adrenergic blocking agents	cimetidine
ProAmatine. <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine.	0	Alpha-adrenergic blocking agents	ranitidine
ProAmatine. <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2> procainamide </e2> , triamterene, flecainide, and quinidine.	0	Alpha-adrenergic blocking agents	procainamide
ProAmatine. <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2> triamterene </e2> , flecainide, and quinidine.	0	Alpha-adrenergic blocking agents	triamterene
ProAmatine. <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2> flecainide </e2> , and quinidine.	0	Alpha-adrenergic blocking agents	flecainide
ProAmatine. <e1> Alpha-adrenergic blocking agents </e1> , such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2> quinidine </e2> .	0	Alpha-adrenergic blocking agents	quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as <e1> prazosin </e1> , <e2> terazosin </e2> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	prazosin	terazosin
ProAmatine. Alpha-adrenergic blocking agents, such as <e1> prazosin </e1> , terazosin, and <e2> doxazosin </e2> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	prazosin	doxazosin
ProAmatine. Alpha-adrenergic blocking agents, such as <e1> prazosin </e1> , terazosin, and doxazosin, can antagonize the effects of <e2> ProAmatine </e2> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	1	prazosin	ProAmatine
ProAmatine. Alpha-adrenergic blocking agents, such as <e1> prazosin </e1> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e2> desglymidodrine </e2> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	prazosin	desglymidodrine
ProAmatine. Alpha-adrenergic blocking agents, such as <e1> prazosin </e1> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2> metformin </e2> , cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	prazosin	metformin
ProAmatine. Alpha-adrenergic blocking agents, such as <e1> prazosin </e1> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2> cimetidine </e2> , ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	prazosin	cimetidine
ProAmatine. Alpha-adrenergic blocking agents, such as <e1> prazosin </e1> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine.	0	prazosin	ranitidine
ProAmatine. Alpha-adrenergic blocking agents, such as <e1> prazosin </e1> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2> procainamide </e2> , triamterene, flecainide, and quinidine.	0	prazosin	procainamide
ProAmatine. Alpha-adrenergic blocking agents, such as <e1> prazosin </e1> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2> triamterene </e2> , flecainide, and quinidine.	0	prazosin	triamterene
ProAmatine. Alpha-adrenergic blocking agents, such as <e1> prazosin </e1> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2> flecainide </e2> , and quinidine.	0	prazosin	flecainide
ProAmatine. Alpha-adrenergic blocking agents, such as <e1> prazosin </e1> , terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2> quinidine </e2> .	0	prazosin	quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1> terazosin </e1> , and <e2> doxazosin </e2> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	terazosin	doxazosin
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1> terazosin </e1> , and doxazosin, can antagonize the effects of <e2> ProAmatine </e2> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	1	terazosin	ProAmatine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1> terazosin </e1> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e2> desglymidodrine </e2> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	terazosin	desglymidodrine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1> terazosin </e1> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2> metformin </e2> , cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	terazosin	metformin
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1> terazosin </e1> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2> cimetidine </e2> , ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	terazosin	cimetidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1> terazosin </e1> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine.	0	terazosin	ranitidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1> terazosin </e1> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2> procainamide </e2> , triamterene, flecainide, and quinidine.	0	terazosin	procainamide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1> terazosin </e1> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2> triamterene </e2> , flecainide, and quinidine.	0	terazosin	triamterene
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1> terazosin </e1> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2> flecainide </e2> , and quinidine.	0	terazosin	flecainide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, <e1> terazosin </e1> , and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2> quinidine </e2> .	0	terazosin	quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1> doxazosin </e1> , can antagonize the effects of <e2> ProAmatine </e2> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	1	doxazosin	ProAmatine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1> doxazosin </e1> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e2> desglymidodrine </e2> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	doxazosin	desglymidodrine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1> doxazosin </e1> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2> metformin </e2> , cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	doxazosin	metformin
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1> doxazosin </e1> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2> cimetidine </e2> , ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	doxazosin	cimetidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1> doxazosin </e1> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine.	0	doxazosin	ranitidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1> doxazosin </e1> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2> procainamide </e2> , triamterene, flecainide, and quinidine.	0	doxazosin	procainamide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1> doxazosin </e1> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2> triamterene </e2> , flecainide, and quinidine.	0	doxazosin	triamterene
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1> doxazosin </e1> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2> flecainide </e2> , and quinidine.	0	doxazosin	flecainide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and <e1> doxazosin </e1> , can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2> quinidine </e2> .	0	doxazosin	quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1> ProAmatine </e1> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e2> desglymidodrine </e2> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	ProAmatine	desglymidodrine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1> ProAmatine </e1> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2> metformin </e2> , cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	ProAmatine	metformin
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1> ProAmatine </e1> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2> cimetidine </e2> , ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	ProAmatine	cimetidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1> ProAmatine </e1> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine.	0	ProAmatine	ranitidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1> ProAmatine </e1> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2> procainamide </e2> , triamterene, flecainide, and quinidine.	0	ProAmatine	procainamide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1> ProAmatine </e1> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2> triamterene </e2> , flecainide, and quinidine.	0	ProAmatine	triamterene
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1> ProAmatine </e1> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2> flecainide </e2> , and quinidine.	0	ProAmatine	flecainide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of <e1> ProAmatine </e1> . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2> quinidine </e2> .	0	ProAmatine	quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1> desglymidodrine </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e2> metformin </e2> , cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine.	1	desglymidodrine	metformin
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1> desglymidodrine </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e2> cimetidine </e2> , ranitidine, procainamide, triamterene, flecainide, and quinidine.	1	desglymidodrine	cimetidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1> desglymidodrine </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine.	1	desglymidodrine	ranitidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1> desglymidodrine </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e2> procainamide </e2> , triamterene, flecainide, and quinidine.	1	desglymidodrine	procainamide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1> desglymidodrine </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e2> triamterene </e2> , flecainide, and quinidine.	1	desglymidodrine	triamterene
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1> desglymidodrine </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e2> flecainide </e2> , and quinidine.	1	desglymidodrine	flecainide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of <e1> desglymidodrine </e1> (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2> quinidine </e2> .	1	desglymidodrine	quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1> metformin </e1> , <e2> cimetidine </e2> , ranitidine, procainamide, triamterene, flecainide, and quinidine.	0	metformin	cimetidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1> metformin </e1> , cimetidine, <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine.	0	metformin	ranitidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1> metformin </e1> , cimetidine, ranitidine, <e2> procainamide </e2> , triamterene, flecainide, and quinidine.	0	metformin	procainamide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1> metformin </e1> , cimetidine, ranitidine, procainamide, <e2> triamterene </e2> , flecainide, and quinidine.	0	metformin	triamterene
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1> metformin </e1> , cimetidine, ranitidine, procainamide, triamterene, <e2> flecainide </e2> , and quinidine.	0	metformin	flecainide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as <e1> metformin </e1> , cimetidine, ranitidine, procainamide, triamterene, flecainide, and <e2> quinidine </e2> .	0	metformin	quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e1> cimetidine </e1> , <e2> ranitidine </e2> , procainamide, triamterene, flecainide, and quinidine.	0	cimetidine	ranitidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e1> cimetidine </e1> , ranitidine, <e2> procainamide </e2> , triamterene, flecainide, and quinidine.	0	cimetidine	procainamide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e1> cimetidine </e1> , ranitidine, procainamide, <e2> triamterene </e2> , flecainide, and quinidine.	0	cimetidine	triamterene
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e1> cimetidine </e1> , ranitidine, procainamide, triamterene, <e2> flecainide </e2> , and quinidine.	0	cimetidine	flecainide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, <e1> cimetidine </e1> , ranitidine, procainamide, triamterene, flecainide, and <e2> quinidine </e2> .	0	cimetidine	quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e1> ranitidine </e1> , <e2> procainamide </e2> , triamterene, flecainide, and quinidine.	0	ranitidine	procainamide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e1> ranitidine </e1> , procainamide, <e2> triamterene </e2> , flecainide, and quinidine.	0	ranitidine	triamterene
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e1> ranitidine </e1> , procainamide, triamterene, <e2> flecainide </e2> , and quinidine.	0	ranitidine	flecainide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, <e1> ranitidine </e1> , procainamide, triamterene, flecainide, and <e2> quinidine </e2> .	0	ranitidine	quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e1> procainamide </e1> , <e2> triamterene </e2> , flecainide, and quinidine.	0	procainamide	triamterene
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e1> procainamide </e1> , triamterene, <e2> flecainide </e2> , and quinidine.	0	procainamide	flecainide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, <e1> procainamide </e1> , triamterene, flecainide, and <e2> quinidine </e2> .	0	procainamide	quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e1> triamterene </e1> , <e2> flecainide </e2> , and quinidine.	0	triamterene	flecainide
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, <e1> triamterene </e1> , flecainide, and <e2> quinidine </e2> .	0	triamterene	quinidine
ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, <e1> flecainide </e1> , and <e2> quinidine </e2> .	0	flecainide	quinidine
<e1> Alcohol </e1> : In a multiple-dose study in 30 normal weight subjects, coadministration of <e2> XENICAL </e2> and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	0	Alcohol	XENICAL
<e1> Alcohol </e1> : In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, <e2> orlistat </e2> pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	0	Alcohol	orlistat
<e1> Alcohol </e1> : In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to <e2> orlistat </e2> .	0	Alcohol	orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of <e1> XENICAL </e1> and 40 grams of <e2> alcohol </e2> (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	0	XENICAL	alcohol
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of <e1> XENICAL </e1> and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of <e2> alcohol </e2> pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	0	XENICAL	alcohol
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of <e1> XENICAL </e1> and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, <e2> orlistat </e2> pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	0	XENICAL	orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of <e1> XENICAL </e1> and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to <e2> orlistat </e2> .	0	XENICAL	orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of <e1> alcohol </e1> (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, <e2> orlistat </e2> pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	0	alcohol	orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of <e1> alcohol </e1> (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to <e2> orlistat </e2> .	0	alcohol	orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of <e1> alcohol </e1> pharmacokinetics, <e2> orlistat </e2> pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat.	0	alcohol	orlistat
Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of <e1> alcohol </e1> pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to <e2> orlistat </e2> .	0	alcohol	orlistat
<e1> Cyclosporine </e1> : Preliminary data from a <e2> XENICAL </e2> and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.	0	Cyclosporine	XENICAL
<e1> Cyclosporine </e1> : Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when <e2> XENICAL </e2> was coadministered with cyclosporine.	0	Cyclosporine	XENICAL
Cyclosporine: Preliminary data from a <e1> XENICAL </e1> and <e2> cyclosporine </e2> drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine.	0	XENICAL	cyclosporine
Cyclosporine: Preliminary data from a <e1> XENICAL </e1> and cyclosporine drug interaction study indicate a reduction in <e2> cyclosporine </e2> plasma levels when XENICAL was coadministered with cyclosporine.	0	XENICAL	cyclosporine
Cyclosporine: Preliminary data from a <e1> XENICAL </e1> and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with <e2> cyclosporine </e2> .	0	XENICAL	cyclosporine
Cyclosporine: Preliminary data from a XENICAL and <e1> cyclosporine </e1> drug interaction study indicate a reduction in cyclosporine plasma levels when <e2> XENICAL </e2> was coadministered with cyclosporine.	0	cyclosporine	XENICAL
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in <e1> cyclosporine </e1> plasma levels when <e2> XENICAL </e2> was coadministered with cyclosporine.	0	cyclosporine	XENICAL
Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when <e1> XENICAL </e1> was coadministered with <e2> cyclosporine </e2> .	1	XENICAL	cyclosporine
<e1> Digoxin </e1> : In 12 normal-weight subjects receiving <e2> XENICAL </e2> 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin.	0	Digoxin	XENICAL
<e1> Digoxin </e1> : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, <e2> XENICAL </e2> did not alter the pharmacokinetics of a single dose of digoxin.	0	Digoxin	XENICAL
Digoxin: In 12 normal-weight subjects receiving <e1> XENICAL </e1> 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of <e2> digoxin </e2> .	0	XENICAL	digoxin
Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, <e1> XENICAL </e1> did not alter the pharmacokinetics of a single dose of <e2> digoxin </e2> .	0	XENICAL	digoxin
<e1> Fat-soluble Vitamin Supplements </e1> and Analogues: A pharmacokinetic interaction study showed a 30% reduction in <e2> beta-carotene </e2> supplement absorption when concomitantly administered with XENICAL.	0	Fat-soluble Vitamin Supplements	beta-carotene
<e1> Fat-soluble Vitamin Supplements </e1> and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with <e2> XENICAL </e2> .	0	Fat-soluble Vitamin Supplements	XENICAL
Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in <e1> beta-carotene </e1> supplement absorption when concomitantly administered with <e2> XENICAL </e2> .	1	beta-carotene	XENICAL
<e1> XENICAL </e1> inhibited absorption of a <e2> vitamin E acetate </e2> supplement by approximately 60%.	1	XENICAL	vitamin E acetate
The effect of <e1> orlistat </e1> on the absorption of supplemental <e2> vitamin D </e2> , vitamin A, and nutritionally-derived vitamin K is not known at this time.	0	orlistat	vitamin D
The effect of <e1> orlistat </e1> on the absorption of supplemental vitamin D, <e2> vitamin A </e2> , and nutritionally-derived vitamin K is not known at this time.	0	orlistat	vitamin A
The effect of <e1> orlistat </e1> on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived <e2> vitamin K </e2> is not known at this time.	0	orlistat	vitamin K
The effect of orlistat on the absorption of supplemental <e1> vitamin D </e1> , <e2> vitamin A </e2> , and nutritionally-derived vitamin K is not known at this time.	0	vitamin D	vitamin A
The effect of orlistat on the absorption of supplemental <e1> vitamin D </e1> , vitamin A, and nutritionally-derived <e2> vitamin K </e2> is not known at this time.	0	vitamin D	vitamin K
The effect of orlistat on the absorption of supplemental vitamin D, <e1> vitamin A </e1> , and nutritionally-derived <e2> vitamin K </e2> is not known at this time.	0	vitamin A	vitamin K
<e1> Glyburide </e1> : In 12 normal-weight subjects receiving <e2> orlistat </e2> 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.	0	Glyburide	orlistat
<e1> Glyburide </e1> : In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, <e2> orlistat </e2> did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide.	0	Glyburide	orlistat
Glyburide: In 12 normal-weight subjects receiving <e1> orlistat </e1> 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of <e2> glyburide </e2> .	0	orlistat	glyburide
Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, <e1> orlistat </e1> did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of <e2> glyburide </e2> .	0	orlistat	glyburide
<e1> Nifedipine </e1> (extended-release tablets): In 17 normal-weight subjects receiving <e2> XENICAL </e2> 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets).	0	Nifedipine	XENICAL
<e1> Nifedipine </e1> (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, <e2> XENICAL </e2> did not alter the bioavailability of nifedipine (extended-release tablets).	0	Nifedipine	XENICAL
Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving <e1> XENICAL </e1> 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of <e2> nifedipine </e2> (extended-release tablets).	0	XENICAL	nifedipine
Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, <e1> XENICAL </e1> did not alter the bioavailability of <e2> nifedipine </e2> (extended-release tablets).	0	XENICAL	nifedipine
Oral <e1> Contraceptives </e1> : In 20 normal-weight female subjects, the treatment of <e2> XENICAL </e2> 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives.	0	Contraceptives	XENICAL
Oral Contraceptives: In 20 normal-weight female subjects, the treatment of <e1> XENICAL </e1> 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral <e2> contraceptives </e2> .	0	XENICAL	contraceptives
<e1> Phenytoin </e1> : In 12 normal-weight subjects receiving <e2> XENICAL </e2> 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.	0	Phenytoin	XENICAL
<e1> Phenytoin </e1> : In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, <e2> XENICAL </e2> did not alter the pharmacokinetics of a single 300-mg dose of phenytoin.	0	Phenytoin	XENICAL
Phenytoin: In 12 normal-weight subjects receiving <e1> XENICAL </e1> 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of <e2> phenytoin </e2> .	0	XENICAL	phenytoin
Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, <e1> XENICAL </e1> did not alter the pharmacokinetics of a single 300-mg dose of <e2> phenytoin </e2> .	0	XENICAL	phenytoin
<e1> Pravastatin </e1> : In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving <e2> XENICAL </e2> 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin.	0	Pravastatin	XENICAL
<e1> Pravastatin </e1> : In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, <e2> XENICAL </e2> did not affect the pharmacokinetics of pravastatin.	0	Pravastatin	XENICAL
Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving <e1> XENICAL </e1> 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of <e2> pravastatin </e2> .	0	XENICAL	pravastatin
Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, <e1> XENICAL </e1> did not affect the pharmacokinetics of <e2> pravastatin </e2> .	0	XENICAL	pravastatin
<e1> Warfarin </e1> : In 12 normal-weight subjects, administration of <e2> XENICAL </e2> 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).	0	Warfarin	XENICAL
Warfarin: In 12 normal-weight subjects, administration of <e1> XENICAL </e1> 120 mg three times a day for 16 days did not result in any change in either <e2> warfarin </e2> pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).	0	XENICAL	warfarin
Therefore, as <e1> vitamin K </e1> absorption may be decreased with <e2> XENICAL </e2> , patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.	1	vitamin K	XENICAL
Therefore, as <e1> vitamin K </e1> absorption may be decreased with XENICAL, patients on chronic stable doses of <e2> warfarin </e2> who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.	0	vitamin K	warfarin
Therefore, as <e1> vitamin K </e1> absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed <e2> XENICAL </e2> should be monitored closely for changes in coagulation parameters.	0	vitamin K	XENICAL
Therefore, as vitamin K absorption may be decreased with <e1> XENICAL </e1> , patients on chronic stable doses of <e2> warfarin </e2> who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.	0	XENICAL	warfarin
Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of <e1> warfarin </e1> who are prescribed <e2> XENICAL </e2> should be monitored closely for changes in coagulation parameters.	0	warfarin	XENICAL
<e1> Mequitazine </e1> can interact with <e2> CNS depressant </e2> , antichlolinergic, TCA, MAOIs, and alcohol.	0	Mequitazine	CNS depressant
<e1> Mequitazine </e1> can interact with CNS depressant, <e2> antichlolinergic </e2> , TCA, MAOIs, and alcohol.	0	Mequitazine	antichlolinergic
<e1> Mequitazine </e1> can interact with CNS depressant, antichlolinergic, <e2> TCA </e2> , MAOIs, and alcohol.	0	Mequitazine	TCA
<e1> Mequitazine </e1> can interact with CNS depressant, antichlolinergic, TCA, <e2> MAOIs </e2> , and alcohol.	0	Mequitazine	MAOIs
<e1> Mequitazine </e1> can interact with CNS depressant, antichlolinergic, TCA, MAOIs, and <e2> alcohol </e2> .	0	Mequitazine	alcohol
Mequitazine can interact with <e1> CNS depressant </e1> , <e2> antichlolinergic </e2> , TCA, MAOIs, and alcohol.	0	CNS depressant	antichlolinergic
Mequitazine can interact with <e1> CNS depressant </e1> , antichlolinergic, <e2> TCA </e2> , MAOIs, and alcohol.	0	CNS depressant	TCA
Mequitazine can interact with <e1> CNS depressant </e1> , antichlolinergic, TCA, <e2> MAOIs </e2> , and alcohol.	0	CNS depressant	MAOIs
Mequitazine can interact with <e1> CNS depressant </e1> , antichlolinergic, TCA, MAOIs, and <e2> alcohol </e2> .	0	CNS depressant	alcohol
Mequitazine can interact with CNS depressant, <e1> antichlolinergic </e1> , <e2> TCA </e2> , MAOIs, and alcohol.	0	antichlolinergic	TCA
Mequitazine can interact with CNS depressant, <e1> antichlolinergic </e1> , TCA, <e2> MAOIs </e2> , and alcohol.	0	antichlolinergic	MAOIs
Mequitazine can interact with CNS depressant, <e1> antichlolinergic </e1> , TCA, MAOIs, and <e2> alcohol </e2> .	0	antichlolinergic	alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, <e1> TCA </e1> , <e2> MAOIs </e2> , and alcohol.	0	TCA	MAOIs
Mequitazine can interact with CNS depressant, antichlolinergic, <e1> TCA </e1> , MAOIs, and <e2> alcohol </e2> .	0	TCA	alcohol
Mequitazine can interact with CNS depressant, antichlolinergic, TCA, <e1> MAOIs </e1> , and <e2> alcohol </e2> .	0	MAOIs	alcohol
<e1> Anticoagulants </e1> (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to <e2> methimazole </e2> .	0	Anticoagulants	methimazole
Anticoagulants (oral): The activity of oral <e1> anticoagulants </e1> may be potentiated by anti-vitamin-K activity attributed to <e2> methimazole </e2> .	1	anticoagulants	methimazole
<e1> Digitalis glycosides </e1> : Serum digitalis levels may be increased when hyperthyroid patients on a stable <e2> digitalis glycoside </e2> regimen become euthyroid;	0	Digitalis glycosides	digitalis glycoside
Because there is a theoretical basis that these effects may be additive, use of <e1> ergotamine </e1> -containing or <e2> ergot-type medications </e2> (like dihydroergotamine or methysergide) and sumatriptan within 24 hours of each other should be avoided.	0	ergotamine	ergot-type medications
Because there is a theoretical basis that these effects may be additive, use of <e1> ergotamine </e1> -containing or ergot-type medications (like <e2> dihydroergotamine </e2> or methysergide) and sumatriptan within 24 hours of each other should be avoided.	0	ergotamine	dihydroergotamine
Because there is a theoretical basis that these effects may be additive, use of <e1> ergotamine </e1> -containing or ergot-type medications (like dihydroergotamine or <e2> methysergide </e2> ) and sumatriptan within 24 hours of each other should be avoided.	0	ergotamine	methysergide
Because there is a theoretical basis that these effects may be additive, use of <e1> ergotamine </e1> -containing or ergot-type medications (like dihydroergotamine or methysergide) and <e2> sumatriptan </e2> within 24 hours of each other should be avoided.	0	ergotamine	sumatriptan
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or <e1> ergot-type medications </e1> (like <e2> dihydroergotamine </e2> or methysergide) and sumatriptan within 24 hours of each other should be avoided.	0	ergot-type medications	dihydroergotamine
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or <e1> ergot-type medications </e1> (like dihydroergotamine or <e2> methysergide </e2> ) and sumatriptan within 24 hours of each other should be avoided.	0	ergot-type medications	methysergide
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or <e1> ergot-type medications </e1> (like dihydroergotamine or methysergide) and <e2> sumatriptan </e2> within 24 hours of each other should be avoided.	0	ergot-type medications	sumatriptan
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like <e1> dihydroergotamine </e1> or <e2> methysergide </e2> ) and sumatriptan within 24 hours of each other should be avoided.	0	dihydroergotamine	methysergide
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like <e1> dihydroergotamine </e1> or methysergide) and <e2> sumatriptan </e2> within 24 hours of each other should be avoided.	0	dihydroergotamine	sumatriptan
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or <e1> methysergide </e1> ) and <e2> sumatriptan </e2> within 24 hours of each other should be avoided.	0	methysergide	sumatriptan
<e1> MAO-A inhibitors </e1> reduce <e2> sumatriptan </e2> clearance, significantly increasing systemic exposure.	1	MAO-A inhibitors	sumatriptan
Therefore, the use of <e1> sumatriptan succinate </e1> tablets in patients receiving <e2> MAO-A inhibitors </e2> is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	sumatriptan succinate	MAO-A inhibitors
Therefore, the use of <e1> sumatriptan succinate </e1> tablets in patients receiving MAO-A inhibitors is contraindicated . <e2> Selective serotonin reuptake inhibitors </e2> (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	sumatriptan succinate	Selective serotonin reuptake inhibitors
Therefore, the use of <e1> sumatriptan succinate </e1> tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( <e2> SSRIs </e2> ) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	sumatriptan succinate	SSRIs
Therefore, the use of <e1> sumatriptan succinate </e1> tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., <e2> fluoxetine </e2> , fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	sumatriptan succinate	fluoxetine
Therefore, the use of <e1> sumatriptan succinate </e1> tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	sumatriptan succinate	fluvoxamine
Therefore, the use of <e1> sumatriptan succinate </e1> tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	sumatriptan succinate	paroxetine
Therefore, the use of <e1> sumatriptan succinate </e1> tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	sumatriptan succinate	sertraline
Therefore, the use of <e1> sumatriptan succinate </e1> tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2> sumatriptan </e2> .	0	sumatriptan succinate	sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving <e1> MAO-A inhibitors </e1> is contraindicated . <e2> Selective serotonin reuptake inhibitors </e2> (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	MAO-A inhibitors	Selective serotonin reuptake inhibitors
Therefore, the use of sumatriptan succinate tablets in patients receiving <e1> MAO-A inhibitors </e1> is contraindicated . Selective serotonin reuptake inhibitors ( <e2> SSRIs </e2> ) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	MAO-A inhibitors	SSRIs
Therefore, the use of sumatriptan succinate tablets in patients receiving <e1> MAO-A inhibitors </e1> is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., <e2> fluoxetine </e2> , fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	MAO-A inhibitors	fluoxetine
Therefore, the use of sumatriptan succinate tablets in patients receiving <e1> MAO-A inhibitors </e1> is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	MAO-A inhibitors	fluvoxamine
Therefore, the use of sumatriptan succinate tablets in patients receiving <e1> MAO-A inhibitors </e1> is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	MAO-A inhibitors	paroxetine
Therefore, the use of sumatriptan succinate tablets in patients receiving <e1> MAO-A inhibitors </e1> is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	MAO-A inhibitors	sertraline
Therefore, the use of sumatriptan succinate tablets in patients receiving <e1> MAO-A inhibitors </e1> is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2> sumatriptan </e2> .	0	MAO-A inhibitors	sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1> Selective serotonin reuptake inhibitors </e1> ( <e2> SSRIs </e2> ) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	Selective serotonin reuptake inhibitors	SSRIs
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1> Selective serotonin reuptake inhibitors </e1> (SSRIs) (e.g., <e2> fluoxetine </e2> , fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	Selective serotonin reuptake inhibitors	fluoxetine
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1> Selective serotonin reuptake inhibitors </e1> (SSRIs) (e.g., fluoxetine, <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	Selective serotonin reuptake inhibitors	fluvoxamine
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1> Selective serotonin reuptake inhibitors </e1> (SSRIs) (e.g., fluoxetine, fluvoxamine, <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	Selective serotonin reuptake inhibitors	paroxetine
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1> Selective serotonin reuptake inhibitors </e1> (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	Selective serotonin reuptake inhibitors	sertraline
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . <e1> Selective serotonin reuptake inhibitors </e1> (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2> sumatriptan </e2> .	1	Selective serotonin reuptake inhibitors	sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ) (e.g., <e2> fluoxetine </e2> , fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	SSRIs	fluoxetine
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ) (e.g., fluoxetine, <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	SSRIs	fluvoxamine
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ) (e.g., fluoxetine, fluvoxamine, <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	SSRIs	paroxetine
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ) (e.g., fluoxetine, fluvoxamine, paroxetine, <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	SSRIs	sertraline
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors ( <e1> SSRIs </e1> ) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2> sumatriptan </e2> .	1	SSRIs	sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., <e1> fluoxetine </e1> , <e2> fluvoxamine </e2> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	fluoxetine	fluvoxamine
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., <e1> fluoxetine </e1> , fluvoxamine, <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	fluoxetine	paroxetine
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., <e1> fluoxetine </e1> , fluvoxamine, paroxetine, <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	fluoxetine	sertraline
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., <e1> fluoxetine </e1> , fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2> sumatriptan </e2> .	1	fluoxetine	sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, <e1> fluvoxamine </e1> , <e2> paroxetine </e2> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	fluvoxamine	paroxetine
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, <e1> fluvoxamine </e1> , paroxetine, <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	fluvoxamine	sertraline
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, <e1> fluvoxamine </e1> , paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2> sumatriptan </e2> .	1	fluvoxamine	sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, <e1> paroxetine </e1> , <e2> sertraline </e2> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with sumatriptan.	0	paroxetine	sertraline
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, <e1> paroxetine </e1> , sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2> sumatriptan </e2> .	1	paroxetine	sumatriptan
Therefore, the use of sumatriptan succinate tablets in patients receiving MAO-A inhibitors is contraindicated . Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, <e1> sertraline </e1> ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with <e2> sumatriptan </e2> .	1	sertraline	sumatriptan
If concomitant treatment with <e1> sumatriptan </e1> and an <e2> SSRI </e2> is clinically warranted, appropriate observation of the patient is advised.	0	sumatriptan	SSRI
<e1> Diuretics </e1> : <e2> Furosemide </e2> and probably other loop diuretics given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.	0	Diuretics	Furosemide
<e1> Diuretics </e1> : Furosemide and probably other <e2> loop diuretics </e2> given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.	0	Diuretics	loop diuretics
<e1> Diuretics </e1> : Furosemide and probably other loop diuretics given concomitantly with <e2> metolazone </e2> can cause unusually large or prolonged losses of fluid and electrolytes.	0	Diuretics	metolazone
Diuretics: <e1> Furosemide </e1> and probably other <e2> loop diuretics </e2> given concomitantly with metolazone can cause unusually large or prolonged losses of fluid and electrolytes.	0	Furosemide	loop diuretics
Diuretics: <e1> Furosemide </e1> and probably other loop diuretics given concomitantly with <e2> metolazone </e2> can cause unusually large or prolonged losses of fluid and electrolytes.	1	Furosemide	metolazone
Diuretics: Furosemide and probably other <e1> loop diuretics </e1> given concomitantly with <e2> metolazone </e2> can cause unusually large or prolonged losses of fluid and electrolytes.	1	loop diuretics	metolazone
Other <e1> Antihypertensives </e1> : When <e2> MYKROX </e2> Tablets are used with other antihypertensive drugs, care must be taken, especially during initial therapy.	0	Antihypertensives	MYKROX
Other <e1> Antihypertensives </e1> : When MYKROX Tablets are used with other <e2> antihypertensive drugs </e2> , care must be taken, especially during initial therapy.	0	Antihypertensives	antihypertensive drugs
Other Antihypertensives: When <e1> MYKROX </e1> Tablets are used with other <e2> antihypertensive drugs </e2> , care must be taken, especially during initial therapy.	0	MYKROX	antihypertensive drugs
<e1> Alcohol </e1> , <e2> Barbiturates </e2> , and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.	0	Alcohol	Barbiturates
<e1> Alcohol </e1> , Barbiturates, and <e2> Narcotics </e2> : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.	0	Alcohol	Narcotics
<e1> Alcohol </e1> , Barbiturates, and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with <e2> metolazone </e2> therapy.	0	Alcohol	metolazone
Alcohol, <e1> Barbiturates </e1> , and <e2> Narcotics </e2> : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with metolazone therapy.	0	Barbiturates	Narcotics
Alcohol, <e1> Barbiturates </e1> , and Narcotics: The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with <e2> metolazone </e2> therapy.	0	Barbiturates	metolazone
Alcohol, Barbiturates, and <e1> Narcotics </e1> : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with <e2> metolazone </e2> therapy.	0	Narcotics	metolazone
<e1> Digitalis Glycosides </e1> : <e2> Diuretic </e2> -induced hypokalemia can increase the sensitivity of the myocardium to digitalis.	0	Digitalis Glycosides	Diuretic
<e1> Digitalis Glycosides </e1> : Diuretic-induced hypokalemia can increase the sensitivity of the myocardium to <e2> digitalis </e2> .	0	Digitalis Glycosides	digitalis
Digitalis Glycosides: <e1> Diuretic </e1> -induced hypokalemia can increase the sensitivity of the myocardium to <e2> digitalis </e2> .	1	Diuretic	digitalis
<e1> Corticosteroids </e1> or <e2> ACTH </e2> : May increase the risk of hypokalemia and increase salt and water retention.	0	Corticosteroids	ACTH
<e1> Curariform Drugs </e1> : <e2> Diuretic </e2> -induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.	0	Curariform Drugs	Diuretic
<e1> Curariform Drugs </e1> : Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as <e2> tubocurarine </e2> ) the most serious effect would be respiratory depression which could proceed to apnea.	0	Curariform Drugs	tubocurarine
Curariform Drugs: <e1> Diuretic </e1> -induced hypokalemia may enhance neuromuscular blocking effects of <e2> curariform drugs </e2> (such as tubocurarine) the most serious effect would be respiratory depression which could proceed to apnea.	1	Diuretic	curariform drugs
Curariform Drugs: <e1> Diuretic </e1> -induced hypokalemia may enhance neuromuscular blocking effects of curariform drugs (such as <e2> tubocurarine </e2> ) the most serious effect would be respiratory depression which could proceed to apnea.	1	Diuretic	tubocurarine
Curariform Drugs: Diuretic-induced hypokalemia may enhance neuromuscular blocking effects of <e1> curariform drugs </e1> (such as <e2> tubocurarine </e2> ) the most serious effect would be respiratory depression which could proceed to apnea.	0	curariform drugs	tubocurarine
<e1> Salicylates </e1> and Other <e2> Non-Steroidal Anti-Inflammatory Drugs </e2> : May decrease the antihypertensive effects of MYKROX Tablets.	0	Salicylates	Non-Steroidal Anti-Inflammatory Drugs
<e1> Salicylates </e1> and Other Non-Steroidal Anti-Inflammatory Drugs: May decrease the antihypertensive effects of <e2> MYKROX </e2> Tablets.	1	Salicylates	MYKROX
Salicylates and Other <e1> Non-Steroidal Anti-Inflammatory Drugs </e1> : May decrease the antihypertensive effects of <e2> MYKROX </e2> Tablets.	1	Non-Steroidal Anti-Inflammatory Drugs	MYKROX
<e1> Sympathomimetics </e1> : <e2> Metolazone </e2> may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.	0	Sympathomimetics	Metolazone
<e1> Sympathomimetics </e1> : Metolazone may decrease arterial responsiveness to <e2> norepinephrine </e2> , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.	0	Sympathomimetics	norepinephrine
Sympathomimetics: <e1> Metolazone </e1> may decrease arterial responsiveness to <e2> norepinephrine </e2> , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.	1	Metolazone	norepinephrine
<e1> Methenamine </e1> : Efficacy may be decreased due to urinary alkalizing effect of <e2> metolazone </e2> .	1	Methenamine	metolazone
<e1> Anticoagulants </e1> : <e2> Metolazone </e2> , as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to anticoagulants;	0	Anticoagulants	Metolazone
<e1> Anticoagulants </e1> : Metolazone, as well as other <e2> thiazide-like diuretics </e2> , may affect the hypoprothrombinemic response to anticoagulants;	0	Anticoagulants	thiazide-like diuretics
Anticoagulants: <e1> Metolazone </e1> , as well as other <e2> thiazide-like diuretics </e2> , may affect the hypoprothrombinemic response to anticoagulants;	0	Metolazone	thiazide-like diuretics
Anticoagulants: <e1> Metolazone </e1> , as well as other thiazide-like diuretics, may affect the hypoprothrombinemic response to <e2> anticoagulants </e2> ;	1	Metolazone	anticoagulants
Anticoagulants: Metolazone, as well as other <e1> thiazide-like diuretics </e1> , may affect the hypoprothrombinemic response to <e2> anticoagulants </e2> ;	0	thiazide-like diuretics	anticoagulants
Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of <e1> REMERON SolTab </e1> ( <e2> mirtazapine </e2> ) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes.	0	REMERON SolTab	mirtazapine
While in vitro studies have shown that <e1> mirtazapine </e1> is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of <e2> REMERON SolTab </e2> with most other drugs metabolized by these enzymes has not been formally studied.	0	mirtazapine	REMERON SolTab
While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that <e1> mirtazapine </e1> is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of <e2> REMERON SolTab </e2> with most other drugs metabolized by these enzymes has not been formally studied.	0	mirtazapine	REMERON SolTab
<e1> Alcohol </e1> : Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of <e2> mirtazapine </e2> (15 mg) in 6 healthy male subjects.	0	Alcohol	mirtazapine
Alcohol: Concomitant administration of <e1> alcohol </e1> (equivalent to 60 g) had a minimal effect on plasma levels of <e2> mirtazapine </e2> (15 mg) in 6 healthy male subjects.	1	alcohol	mirtazapine
However, the impairment of cognitive and motor skills produced by <e1> REMERON </e1> were shown to be additive with those produced by <e2> alcohol </e2> .	1	REMERON	alcohol
Accordingly, patients should be advised to avoid <e1> alcohol </e1> while taking <e2> REMERON SolTab </e2> . Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	0	alcohol	REMERON SolTab
Accordingly, patients should be advised to avoid <e1> alcohol </e1> while taking REMERON SolTab. <e2> Diazepam </e2> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	0	alcohol	Diazepam
Accordingly, patients should be advised to avoid <e1> alcohol </e1> while taking REMERON SolTab. Diazepam: Concomitant administration of <e2> diazepam </e2> (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	0	alcohol	diazepam
Accordingly, patients should be advised to avoid <e1> alcohol </e1> while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of <e2> mirtazapine </e2> (15 mg) in 12 healthy subjects.	0	alcohol	mirtazapine
Accordingly, patients should be advised to avoid alcohol while taking <e1> REMERON SolTab </e1> . <e2> Diazepam </e2> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	0	REMERON SolTab	Diazepam
Accordingly, patients should be advised to avoid alcohol while taking <e1> REMERON SolTab </e1> . Diazepam: Concomitant administration of <e2> diazepam </e2> (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.	0	REMERON SolTab	diazepam
Accordingly, patients should be advised to avoid alcohol while taking <e1> REMERON SolTab </e1> . Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of <e2> mirtazapine </e2> (15 mg) in 12 healthy subjects.	0	REMERON SolTab	mirtazapine
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. <e1> Diazepam </e1> : Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of <e2> mirtazapine </e2> (15 mg) in 12 healthy subjects.	0	Diazepam	mirtazapine
Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of <e1> diazepam </e1> (15 mg) had a minimal effect on plasma levels of <e2> mirtazapine </e2> (15 mg) in 12 healthy subjects.	1	diazepam	mirtazapine
However, the impairment of motor skills produced by <e1> REMERON </e1> has been shown to be additive with those caused by <e2> diazepam </e2> .	1	REMERON	diazepam
Accordingly, patients should be advised to avoid <e1> diazepam </e1> and other similar drugs while taking <e2> REMERON SolTab </e2> .	0	diazepam	REMERON SolTab
<e1> Montelukast </e1> at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State - did not cause clinically significant changes in the kinetics of a single intravenous dose of <e2> theophylline </e2> (predominantly a cytochrome P450 1A2 substrate).	0	Montelukast	theophylline
- did not change the plasma concentration profile of <e1> terfenadine </e1> (a substrate of cytochrome P450 3A4) or <e2> fexofenadine </e2> , its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily.	0	terfenadine	fexofenadine
- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or <e1> fexofenadine </e1> , its carboxylated metabolite, and did not prolong the QTc interval following co-administration with <e2> terfenadine </e2> 60 mg twice daily.	0	fexofenadine	terfenadine
<e1> Montelukast </e1> at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral <e2> contraceptive </e2> containing norethindrone 1 mg/ethinyl estradiol 35 mcg.	0	Montelukast	contraceptive
<e1> Montelukast </e1> at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing <e2> norethindrone </e2> 1 mg/ethinyl estradiol 35 mcg.	0	Montelukast	norethindrone
<e1> Montelukast </e1> at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl <e2> estradiol </e2> 35 mcg.	0	Montelukast	estradiol
Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral <e1> contraceptive </e1> containing <e2> norethindrone </e2> 1 mg/ethinyl estradiol 35 mcg.	0	contraceptive	norethindrone
Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral <e1> contraceptive </e1> containing norethindrone 1 mg/ethinyl <e2> estradiol </e2> 35 mcg.	0	contraceptive	estradiol
Montelukast at Doses of 100 mg Daily Dosed to Pharmacokinetic Steady State: - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing <e1> norethindrone </e1> 1 mg/ethinyl <e2> estradiol </e2> 35 mcg.	0	norethindrone	estradiol
- did not cause any clinically significant change in plasma profiles of <e1> prednisone </e1> or <e2> prednisolone </e2> following administration of either oral prednisone or intravenous prednisolone.	0	prednisone	prednisolone
- did not cause any clinically significant change in plasma profiles of <e1> prednisone </e1> or prednisolone following administration of either oral prednisone or intravenous <e2> prednisolone </e2> .	0	prednisone	prednisolone
- did not cause any clinically significant change in plasma profiles of prednisone or <e1> prednisolone </e1> following administration of either oral <e2> prednisone </e2> or intravenous prednisolone.	0	prednisolone	prednisone
- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral <e1> prednisone </e1> or intravenous <e2> prednisolone </e2> .	0	prednisone	prednisolone
<e1> Phenobarbital </e1> , which induces hepatic metabolism, decreased the AUC of <e2> montelukast </e2> approximately 40% following a single 10-mg dose of montelukast.	0	Phenobarbital	montelukast
<e1> Phenobarbital </e1> , which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of <e2> montelukast </e2> .	0	Phenobarbital	montelukast
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e1> phenobarbital </e1> or <e2> rifampin </e2> , are co-administered with montelukast.	0	phenobarbital	rifampin
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e1> phenobarbital </e1> or rifampin, are co-administered with <e2> montelukast </e2> .	0	phenobarbital	montelukast
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or <e1> rifampin </e1> , are co-administered with <e2> montelukast </e2> .	0	rifampin	montelukast
In drug-interaction studies, the recommended clinical dose of <e1> montelukast </e1> did not have clinically important effects on the pharmacokinetics of the following drugs: <e2> theophylline </e2> , prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	montelukast	theophylline
In drug-interaction studies, the recommended clinical dose of <e1> montelukast </e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e2> prednisone </e2> , prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	montelukast	prednisone
In drug-interaction studies, the recommended clinical dose of <e1> montelukast </e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e2> prednisolone </e2> , oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	montelukast	prednisolone
In drug-interaction studies, the recommended clinical dose of <e1> montelukast </e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral <e2> contraceptives </e2> (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	montelukast	contraceptives
In drug-interaction studies, the recommended clinical dose of <e1> montelukast </e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives ( <e2> norethindrone </e2> 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	montelukast	norethindrone
In drug-interaction studies, the recommended clinical dose of <e1> montelukast </e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ <e2> ethinyl estradiol </e2> 35 mcg), terfenadine, digoxin, and warfarin.	0	montelukast	ethinyl estradiol
In drug-interaction studies, the recommended clinical dose of <e1> montelukast </e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e2> terfenadine </e2> , digoxin, and warfarin.	0	montelukast	terfenadine
In drug-interaction studies, the recommended clinical dose of <e1> montelukast </e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e2> digoxin </e2> , and warfarin.	0	montelukast	digoxin
In drug-interaction studies, the recommended clinical dose of <e1> montelukast </e1> did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and <e2> warfarin </e2> .	0	montelukast	warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1> theophylline </e1> , <e2> prednisone </e2> , prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	theophylline	prednisone
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1> theophylline </e1> , prednisone, <e2> prednisolone </e2> , oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	theophylline	prednisolone
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1> theophylline </e1> , prednisone, prednisolone, oral <e2> contraceptives </e2> (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	theophylline	contraceptives
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1> theophylline </e1> , prednisone, prednisolone, oral contraceptives ( <e2> norethindrone </e2> 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	theophylline	norethindrone
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1> theophylline </e1> , prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ <e2> ethinyl estradiol </e2> 35 mcg), terfenadine, digoxin, and warfarin.	0	theophylline	ethinyl estradiol
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1> theophylline </e1> , prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e2> terfenadine </e2> , digoxin, and warfarin.	0	theophylline	terfenadine
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1> theophylline </e1> , prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e2> digoxin </e2> , and warfarin.	0	theophylline	digoxin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: <e1> theophylline </e1> , prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and <e2> warfarin </e2> .	0	theophylline	warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1> prednisone </e1> , <e2> prednisolone </e2> , oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	prednisone	prednisolone
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1> prednisone </e1> , prednisolone, oral <e2> contraceptives </e2> (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	prednisone	contraceptives
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1> prednisone </e1> , prednisolone, oral contraceptives ( <e2> norethindrone </e2> 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	prednisone	norethindrone
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1> prednisone </e1> , prednisolone, oral contraceptives (norethindrone 1 mg/ <e2> ethinyl estradiol </e2> 35 mcg), terfenadine, digoxin, and warfarin.	0	prednisone	ethinyl estradiol
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1> prednisone </e1> , prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e2> terfenadine </e2> , digoxin, and warfarin.	0	prednisone	terfenadine
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1> prednisone </e1> , prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e2> digoxin </e2> , and warfarin.	0	prednisone	digoxin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, <e1> prednisone </e1> , prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and <e2> warfarin </e2> .	0	prednisone	warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e1> prednisolone </e1> , oral <e2> contraceptives </e2> (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	prednisolone	contraceptives
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e1> prednisolone </e1> , oral contraceptives ( <e2> norethindrone </e2> 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	prednisolone	norethindrone
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e1> prednisolone </e1> , oral contraceptives (norethindrone 1 mg/ <e2> ethinyl estradiol </e2> 35 mcg), terfenadine, digoxin, and warfarin.	0	prednisolone	ethinyl estradiol
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e1> prednisolone </e1> , oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e2> terfenadine </e2> , digoxin, and warfarin.	0	prednisolone	terfenadine
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e1> prednisolone </e1> , oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e2> digoxin </e2> , and warfarin.	0	prednisolone	digoxin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, <e1> prednisolone </e1> , oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and <e2> warfarin </e2> .	0	prednisolone	warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral <e1> contraceptives </e1> ( <e2> norethindrone </e2> 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin.	0	contraceptives	norethindrone
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral <e1> contraceptives </e1> (norethindrone 1 mg/ <e2> ethinyl estradiol </e2> 35 mcg), terfenadine, digoxin, and warfarin.	0	contraceptives	ethinyl estradiol
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral <e1> contraceptives </e1> (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e2> terfenadine </e2> , digoxin, and warfarin.	0	contraceptives	terfenadine
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral <e1> contraceptives </e1> (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e2> digoxin </e2> , and warfarin.	0	contraceptives	digoxin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral <e1> contraceptives </e1> (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and <e2> warfarin </e2> .	0	contraceptives	warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives ( <e1> norethindrone </e1> 1 mg/ <e2> ethinyl estradiol </e2> 35 mcg), terfenadine, digoxin, and warfarin.	0	norethindrone	ethinyl estradiol
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives ( <e1> norethindrone </e1> 1 mg/ethinyl estradiol 35 mcg), <e2> terfenadine </e2> , digoxin, and warfarin.	0	norethindrone	terfenadine
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives ( <e1> norethindrone </e1> 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e2> digoxin </e2> , and warfarin.	0	norethindrone	digoxin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives ( <e1> norethindrone </e1> 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and <e2> warfarin </e2> .	0	norethindrone	warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ <e1> ethinyl estradiol </e1> 35 mcg), <e2> terfenadine </e2> , digoxin, and warfarin.	0	ethinyl estradiol	terfenadine
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ <e1> ethinyl estradiol </e1> 35 mcg), terfenadine, <e2> digoxin </e2> , and warfarin.	0	ethinyl estradiol	digoxin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ <e1> ethinyl estradiol </e1> 35 mcg), terfenadine, digoxin, and <e2> warfarin </e2> .	0	ethinyl estradiol	warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e1> terfenadine </e1> , <e2> digoxin </e2> , and warfarin.	0	terfenadine	digoxin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), <e1> terfenadine </e1> , digoxin, and <e2> warfarin </e2> .	0	terfenadine	warfarin
In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, <e1> digoxin </e1> , and <e2> warfarin </e2> .	0	digoxin	warfarin
These medications included <e1> thyroid hormones </e1> , <e2> sedative hypnotics </e2> , non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants.	0	thyroid hormones	sedative hypnotics
These medications included <e1> thyroid hormones </e1> , sedative hypnotics, <e2> non-steroidal anti-inflammatory agents </e2> , benzodiazepines, and decongestants.	0	thyroid hormones	non-steroidal anti-inflammatory agents
These medications included <e1> thyroid hormones </e1> , sedative hypnotics, non-steroidal anti-inflammatory agents, <e2> benzodiazepines </e2> , and decongestants.	0	thyroid hormones	benzodiazepines
These medications included <e1> thyroid hormones </e1> , sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and <e2> decongestants </e2> .	0	thyroid hormones	decongestants
These medications included thyroid hormones, <e1> sedative hypnotics </e1> , <e2> non-steroidal anti-inflammatory agents </e2> , benzodiazepines, and decongestants.	0	sedative hypnotics	non-steroidal anti-inflammatory agents
These medications included thyroid hormones, <e1> sedative hypnotics </e1> , non-steroidal anti-inflammatory agents, <e2> benzodiazepines </e2> , and decongestants.	0	sedative hypnotics	benzodiazepines
These medications included thyroid hormones, <e1> sedative hypnotics </e1> , non-steroidal anti-inflammatory agents, benzodiazepines, and <e2> decongestants </e2> .	0	sedative hypnotics	decongestants
These medications included thyroid hormones, sedative hypnotics, <e1> non-steroidal anti-inflammatory agents </e1> , <e2> benzodiazepines </e2> , and decongestants.	0	non-steroidal anti-inflammatory agents	benzodiazepines
These medications included thyroid hormones, sedative hypnotics, <e1> non-steroidal anti-inflammatory agents </e1> , benzodiazepines, and <e2> decongestants </e2> .	0	non-steroidal anti-inflammatory agents	decongestants
These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, <e1> benzodiazepines </e1> , and <e2> decongestants </e2> .	0	benzodiazepines	decongestants
<e1> Phenobarbital </e1> , which induces hepatic metabolism, decreased the AUC of <e2> montelukast </e2> approximately 40% following a single 10-mg dose of montelukast.	0	Phenobarbital	montelukast
<e1> Phenobarbital </e1> , which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of <e2> montelukast </e2> .	0	Phenobarbital	montelukast
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e1> phenobarbital </e1> or <e2> rifampin </e2> , are co-administered with montelukast.	0	phenobarbital	rifampin
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as <e1> phenobarbital </e1> or rifampin, are co-administered with <e2> montelukast </e2> .	0	phenobarbital	montelukast
It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or <e1> rifampin </e1> , are co-administered with <e2> montelukast </e2> .	0	rifampin	montelukast
<e1> Anticholinesterases </e1> : Concurrent use of <e2> procaine hydrochloride </e2> and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	0	Anticholinesterases	procaine hydrochloride
<e1> Anticholinesterases </e1> : Concurrent use of procaine hydrochloride and <e2> anticholinesterase agents </e2> may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	0	Anticholinesterases	anticholinesterase agents
<e1> Anticholinesterases </e1> : Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of <e2> procaine hydrochloride </e2> .	0	Anticholinesterases	procaine hydrochloride
Anticholinesterases: Concurrent use of <e1> procaine hydrochloride </e1> and <e2> anticholinesterase agents </e2> may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of procaine hydrochloride.	1	procaine hydrochloride	anticholinesterase agents
Anticholinesterases: Concurrent use of <e1> procaine hydrochloride </e1> and anticholinesterase agents may result in increased systemic toxicity since <e2> anticholinesterases </e2> inhibit the breakdown of procaine hydrochloride.	0	procaine hydrochloride	anticholinesterases
Anticholinesterases: Concurrent use of procaine hydrochloride and <e1> anticholinesterase agents </e1> may result in increased systemic toxicity since <e2> anticholinesterases </e2> inhibit the breakdown of procaine hydrochloride.	0	anticholinesterase agents	anticholinesterases
Anticholinesterases: Concurrent use of procaine hydrochloride and <e1> anticholinesterase agents </e1> may result in increased systemic toxicity since anticholinesterases inhibit the breakdown of <e2> procaine hydrochloride </e2> .	0	anticholinesterase agents	procaine hydrochloride
Anticholinesterases: Concurrent use of procaine hydrochloride and anticholinesterase agents may result in increased systemic toxicity since <e1> anticholinesterases </e1> inhibit the breakdown of <e2> procaine hydrochloride </e2> .	1	anticholinesterases	procaine hydrochloride
<e1> CNS depressant </e1> medications: Concurrent use of <e2> procaine hydrochloride </e2> and CNS depressant medications may result in additive depressant effects.	0	CNS depressant	procaine hydrochloride
<e1> CNS depressant </e1> medications: Concurrent use of procaine hydrochloride and <e2> CNS depressant medications </e2> may result in additive depressant effects.	0	CNS depressant	CNS depressant medications
CNS depressant medications: Concurrent use of <e1> procaine hydrochloride </e1> and <e2> CNS depressant medications </e2> may result in additive depressant effects.	1	procaine hydrochloride	CNS depressant medications
<e1> Hyaluronidase </e1> : Hyaluronidase may increase the diffusion rate of <e2> procaine hydrochloride </e2> , resulting in a decreased time of onset, but an increase in systemic toxicity.	0	Hyaluronidase	procaine hydrochloride
Hyaluronidase: <e1> Hyaluronidase </e1> may increase the diffusion rate of <e2> procaine hydrochloride </e2> , resulting in a decreased time of onset, but an increase in systemic toxicity.	1	Hyaluronidase	procaine hydrochloride
<e1> Neuromuscular blocking agents </e1> (such as <e2> suxamethonium chloride </e2> ): Concurrent use of procaine hydrochloride and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.	0	Neuromuscular blocking agents	suxamethonium chloride
<e1> Neuromuscular blocking agents </e1> (such as suxamethonium chloride): Concurrent use of <e2> procaine hydrochloride </e2> and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.	0	Neuromuscular blocking agents	procaine hydrochloride
Neuromuscular blocking agents (such as <e1> suxamethonium chloride </e1> ): Concurrent use of <e2> procaine hydrochloride </e2> and neuromuscular blocking agents may result in prolongation or enhancement of the neuromuscular blockade.	0	suxamethonium chloride	procaine hydrochloride
Neuromuscular blocking agents (such as <e1> suxamethonium chloride </e1> ): Concurrent use of procaine hydrochloride and <e2> neuromuscular blocking agents </e2> may result in prolongation or enhancement of the neuromuscular blockade.	0	suxamethonium chloride	neuromuscular blocking agents
Neuromuscular blocking agents (such as suxamethonium chloride): Concurrent use of <e1> procaine hydrochloride </e1> and <e2> neuromuscular blocking agents </e2> may result in prolongation or enhancement of the neuromuscular blockade.	1	procaine hydrochloride	neuromuscular blocking agents
<e1> Sulfonamides </e1> : Concurrent use of <e2> procaine hydrochloride </e2> and sulfonamides may result in a reduction of the antibacterial action of the sulfonamide.	0	Sulfonamides	procaine hydrochloride
<e1> Sulfonamides </e1> : Concurrent use of procaine hydrochloride and sulfonamides may result in a reduction of the antibacterial action of the <e2> sulfonamide </e2> .	0	Sulfonamides	sulfonamide
Sulfonamides: Concurrent use of <e1> procaine hydrochloride </e1> and <e2> sulfonamides </e2> may result in a reduction of the antibacterial action of the sulfonamide.	1	procaine hydrochloride	sulfonamides
Sulfonamides: Concurrent use of <e1> procaine hydrochloride </e1> and sulfonamides may result in a reduction of the antibacterial action of the <e2> sulfonamide </e2> .	0	procaine hydrochloride	sulfonamide
Sulfonamides: Concurrent use of procaine hydrochloride and <e1> sulfonamides </e1> may result in a reduction of the antibacterial action of the <e2> sulfonamide </e2> .	0	sulfonamides	sulfonamide
<e1> Acetazolamide </e1> : Concurrent use of acetazolamide and <e2> procaine hydrochloride </e2> may extend the plasma half-life of procaine.	0	Acetazolamide	procaine hydrochloride
<e1> Acetazolamide </e1> : Concurrent use of acetazolamide and procaine hydrochloride may extend the plasma half-life of <e2> procaine </e2> .	0	Acetazolamide	procaine
Acetazolamide: Concurrent use of <e1> acetazolamide </e1> and <e2> procaine hydrochloride </e2> may extend the plasma half-life of procaine.	1	acetazolamide	procaine hydrochloride
Acetazolamide: Concurrent use of <e1> acetazolamide </e1> and procaine hydrochloride may extend the plasma half-life of <e2> procaine </e2> .	0	acetazolamide	procaine
Acetazolamide: Concurrent use of acetazolamide and <e1> procaine hydrochloride </e1> may extend the plasma half-life of <e2> procaine </e2> .	0	procaine hydrochloride	procaine
<e1> Cimetidine </e1> : The effects of chronic cimetidine use on the metabolism of <e2> rimantadine </e2> are not known.	0	Cimetidine	rimantadine
Cimetidine: The effects of chronic <e1> cimetidine </e1> use on the metabolism of <e2> rimantadine </e2> are not known.	0	cimetidine	rimantadine
When a single 100 mg dose of <e1> rimantadine HCl </e1> was administered one hour after the initiation of <e2> Cimetidine </e2> (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	1	rimantadine HCl	Cimetidine
When a single 100 mg dose of <e1> rimantadine HCl </e1> was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total <e2> rimantadine </e2> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	0	rimantadine HCl	rimantadine
When a single 100 mg dose of <e1> rimantadine HCl </e1> was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total <e2> rimantadine </e2> clearance in the same subjects in the absence of cimetidine).	0	rimantadine HCl	rimantadine
When a single 100 mg dose of <e1> rimantadine HCl </e1> was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of <e2> cimetidine </e2> ).	0	rimantadine HCl	cimetidine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of <e1> Cimetidine </e1> (300 mg four times a day), the apparent total <e2> rimantadine </e2> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine).	0	Cimetidine	rimantadine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of <e1> Cimetidine </e1> (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total <e2> rimantadine </e2> clearance in the same subjects in the absence of cimetidine).	0	Cimetidine	rimantadine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total <e1> rimantadine </e1> clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of <e2> cimetidine </e2> ).	0	rimantadine	cimetidine
When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total <e1> rimantadine </e1> clearance in the same subjects in the absence of <e2> cimetidine </e2> ).	0	rimantadine	cimetidine
<e1> Acetaminophen </e1> : <e2> Rimantadine HCl </e2> , 100 mg, was given twice daily for 13 days to 12 healthy volunteers.	0	Acetaminophen	Rimantadine HCl
Coadministration with <e1> acetaminophen </e1> reduced the peak concentration and AUC values for <e2> rimantadine </e2> by approximately 11%.	1	acetaminophen	rimantadine
<e1> Aspirin </e1> : <e2> Rimantadine HCl </e2> , 100 mg, was given twice daily fro 13 days to 12 healthy volunteers.	0	Aspirin	Rimantadine HCl
Peak plasma concentrations and AUC of <e1> rimantadine </e1> were reduced approximately 10% in the presence of <e2> aspirin </e2> .	1	rimantadine	aspirin
<e1> CHEMET </e1> is not known to interact with other drugs including <e2> iron </e2> supplements;	0	CHEMET	iron
Concomitant administration of <e1> CHEMET </e1> with other chelation therapy, such as <e2> CaNa 2 EDTA </e2> is not recommended.	0	CHEMET	CaNa 2 EDTA
Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with <e1> TRENTAL </e1> with and without <e2> anticoagulants </e2> or platelet aggregation inhibitors.	1	TRENTAL	anticoagulants
Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with <e1> TRENTAL </e1> with and without anticoagulants or <e2> platelet aggregation inhibitors </e2> .	1	TRENTAL	platelet aggregation inhibitors
Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without <e1> anticoagulants </e1> or <e2> platelet aggregation inhibitors </e2> .	0	anticoagulants	platelet aggregation inhibitors
Concomitant administration of <e1> TRENTAL </e1> and <e2> theophylline </e2> -containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals.	1	TRENTAL	theophylline
Concomitant administration of <e1> TRENTAL </e1> and theophylline-containing drugs leads to increased <e2> theophylline </e2> levels and theophylline toxicity in some individuals.	0	TRENTAL	theophylline
Concomitant administration of <e1> TRENTAL </e1> and theophylline-containing drugs leads to increased theophylline levels and <e2> theophylline </e2> toxicity in some individuals.	0	TRENTAL	theophylline
<e1> TRENTAL </e1> has been used concurrently with <e2> antihypertensive drugs </e2> , beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	0	TRENTAL	antihypertensive drugs
<e1> TRENTAL </e1> has been used concurrently with antihypertensive drugs, <e2> beta blockers </e2> , digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	0	TRENTAL	beta blockers
<e1> TRENTAL </e1> has been used concurrently with antihypertensive drugs, beta blockers, <e2> digitalis </e2> , diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	0	TRENTAL	digitalis
<e1> TRENTAL </e1> has been used concurrently with antihypertensive drugs, beta blockers, digitalis, <e2> diuretics </e2> , antidiabetic agents, and antiarrhythmics, without observed problems.	0	TRENTAL	diuretics
<e1> TRENTAL </e1> has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, <e2> antidiabetic agents </e2> , and antiarrhythmics, without observed problems.	0	TRENTAL	antidiabetic agents
<e1> TRENTAL </e1> has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and <e2> antiarrhythmics </e2> , without observed problems.	0	TRENTAL	antiarrhythmics
TRENTAL has been used concurrently with <e1> antihypertensive drugs </e1> , <e2> beta blockers </e2> , digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	0	antihypertensive drugs	beta blockers
TRENTAL has been used concurrently with <e1> antihypertensive drugs </e1> , beta blockers, <e2> digitalis </e2> , diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	0	antihypertensive drugs	digitalis
TRENTAL has been used concurrently with <e1> antihypertensive drugs </e1> , beta blockers, digitalis, <e2> diuretics </e2> , antidiabetic agents, and antiarrhythmics, without observed problems.	0	antihypertensive drugs	diuretics
TRENTAL has been used concurrently with <e1> antihypertensive drugs </e1> , beta blockers, digitalis, diuretics, <e2> antidiabetic agents </e2> , and antiarrhythmics, without observed problems.	0	antihypertensive drugs	antidiabetic agents
TRENTAL has been used concurrently with <e1> antihypertensive drugs </e1> , beta blockers, digitalis, diuretics, antidiabetic agents, and <e2> antiarrhythmics </e2> , without observed problems.	0	antihypertensive drugs	antiarrhythmics
TRENTAL has been used concurrently with antihypertensive drugs, <e1> beta blockers </e1> , <e2> digitalis </e2> , diuretics, antidiabetic agents, and antiarrhythmics, without observed problems.	0	beta blockers	digitalis
TRENTAL has been used concurrently with antihypertensive drugs, <e1> beta blockers </e1> , digitalis, <e2> diuretics </e2> , antidiabetic agents, and antiarrhythmics, without observed problems.	0	beta blockers	diuretics
TRENTAL has been used concurrently with antihypertensive drugs, <e1> beta blockers </e1> , digitalis, diuretics, <e2> antidiabetic agents </e2> , and antiarrhythmics, without observed problems.	0	beta blockers	antidiabetic agents
TRENTAL has been used concurrently with antihypertensive drugs, <e1> beta blockers </e1> , digitalis, diuretics, antidiabetic agents, and <e2> antiarrhythmics </e2> , without observed problems.	0	beta blockers	antiarrhythmics
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, <e1> digitalis </e1> , <e2> diuretics </e2> , antidiabetic agents, and antiarrhythmics, without observed problems.	0	digitalis	diuretics
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, <e1> digitalis </e1> , diuretics, <e2> antidiabetic agents </e2> , and antiarrhythmics, without observed problems.	0	digitalis	antidiabetic agents
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, <e1> digitalis </e1> , diuretics, antidiabetic agents, and <e2> antiarrhythmics </e2> , without observed problems.	0	digitalis	antiarrhythmics
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, <e1> diuretics </e1> , <e2> antidiabetic agents </e2> , and antiarrhythmics, without observed problems.	0	diuretics	antidiabetic agents
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, <e1> diuretics </e1> , antidiabetic agents, and <e2> antiarrhythmics </e2> , without observed problems.	0	diuretics	antiarrhythmics
TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, <e1> antidiabetic agents </e1> , and <e2> antiarrhythmics </e2> , without observed problems.	0	antidiabetic agents	antiarrhythmics
<e1> ARAMINE </e1> should be used with caution in digitalized patients, since the combination of <e2> digitalis </e2> and sympathomimetic amines may cause ectopic arrhythmias.	0	ARAMINE	digitalis
<e1> ARAMINE </e1> should be used with caution in digitalized patients, since the combination of digitalis and <e2> sympathomimetic amines </e2> may cause ectopic arrhythmias.	0	ARAMINE	sympathomimetic amines
ARAMINE should be used with caution in digitalized patients, since the combination of <e1> digitalis </e1> and <e2> sympathomimetic amines </e2> may cause ectopic arrhythmias.	1	digitalis	sympathomimetic amines
<e1> Monoamine oxidase inhibitors </e1> or <e2> tricyclic antidepressants </e2> may potentiate the action of sympathomimetic amines.	0	Monoamine oxidase inhibitors	tricyclic antidepressants
<e1> Monoamine oxidase inhibitors </e1> or tricyclic antidepressants may potentiate the action of <e2> sympathomimetic amines </e2> .	1	Monoamine oxidase inhibitors	sympathomimetic amines
Monoamine oxidase inhibitors or <e1> tricyclic antidepressants </e1> may potentiate the action of <e2> sympathomimetic amines </e2> .	1	tricyclic antidepressants	sympathomimetic amines
<e1> Trilostane </e1> may interact with <e2> aminoglutethimide </e2> or mitotane (causing too great a decrease in adrenal function).	0	Trilostane	aminoglutethimide
<e1> Trilostane </e1> may interact with aminoglutethimide or <e2> mitotane </e2> (causing too great a decrease in adrenal function).	0	Trilostane	mitotane
Trilostane may interact with <e1> aminoglutethimide </e1> or <e2> mitotane </e2> (causing too great a decrease in adrenal function).	0	aminoglutethimide	mitotane
however, in patients with Paget's Disease prior <e1> diphosphonate </e1> use appears to reduce the anti-resorptive response to <e2> Calcitonin (salmon) </e2> nasal spray.	1	diphosphonate	Calcitonin (salmon)
<e1> MAO inhibitors </e1> and <e2> beta adrenergic blockers </e2> increase the effects of pseudoephedrine.	0	MAO inhibitors	beta adrenergic blockers
<e1> MAO inhibitors </e1> and beta adrenergic blockers increase the effects of <e2> pseudoephedrine </e2> .	1	MAO inhibitors	pseudoephedrine
MAO inhibitors and <e1> beta adrenergic blockers </e1> increase the effects of <e2> pseudoephedrine </e2> .	1	beta adrenergic blockers	pseudoephedrine
<e1> Sympathomimetics </e1> may reduce the antihypertensive effects of <e2> methyldopa </e2> , mecamylamine, reserpine and veratrum alkaloids.	1	Sympathomimetics	methyldopa
<e1> Sympathomimetics </e1> may reduce the antihypertensive effects of methyldopa, <e2> mecamylamine </e2> , reserpine and veratrum alkaloids.	1	Sympathomimetics	mecamylamine
<e1> Sympathomimetics </e1> may reduce the antihypertensive effects of methyldopa, mecamylamine, <e2> reserpine </e2> and veratrum alkaloids.	1	Sympathomimetics	reserpine
<e1> Sympathomimetics </e1> may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and <e2> veratrum alkaloids </e2> .	1	Sympathomimetics	veratrum alkaloids
Sympathomimetics may reduce the antihypertensive effects of <e1> methyldopa </e1> , <e2> mecamylamine </e2> , reserpine and veratrum alkaloids.	0	methyldopa	mecamylamine
Sympathomimetics may reduce the antihypertensive effects of <e1> methyldopa </e1> , mecamylamine, <e2> reserpine </e2> and veratrum alkaloids.	0	methyldopa	reserpine
Sympathomimetics may reduce the antihypertensive effects of <e1> methyldopa </e1> , mecamylamine, reserpine and <e2> veratrum alkaloids </e2> .	0	methyldopa	veratrum alkaloids
Sympathomimetics may reduce the antihypertensive effects of methyldopa, <e1> mecamylamine </e1> , <e2> reserpine </e2> and veratrum alkaloids.	0	mecamylamine	reserpine
Sympathomimetics may reduce the antihypertensive effects of methyldopa, <e1> mecamylamine </e1> , reserpine and <e2> veratrum alkaloids </e2> .	0	mecamylamine	veratrum alkaloids
Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, <e1> reserpine </e1> and <e2> veratrum alkaloids </e2> .	0	reserpine	veratrum alkaloids
Caution is recommended when administering <e1> NEXAVAR </e1> with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. <e2> irinotecan </e2> ).	0	NEXAVAR	irinotecan
Concomitant treatment with <e1> NEXAVAR </e1> resulted in a 21% increase in the AUC of <e2> doxorubicin </e2> .	1	NEXAVAR	doxorubicin
Caution is recommended when administering <e1> doxorubicin </e1> with <e2> NEXAVAR </e2> .	0	doxorubicin	NEXAVAR
<e1> Anticoagulants </e1> <e2> Anabolic steroids </e2> may increase sensitivity to oral anticoagulants.	0	Anticoagulants	Anabolic steroids
Anticoagulants <e1> Anabolic steroids </e1> may increase sensitivity to oral <e2> anticoagulants </e2> .	1	Anabolic steroids	anticoagulants
<e1> Warfarin </e1> : A multidose study of <e2> oxandrolone </e2> , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.	0	Warfarin	oxandrolone
<e1> Warfarin </e1> : A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in <e2> S-warfarin </e2> half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.	0	Warfarin	S-warfarin
<e1> Warfarin </e1> : A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in <e2> R-warfarin </e2> half-life and AUC were also detected.	0	Warfarin	R-warfarin
Warfarin: A multidose study of <e1> oxandrolone </e1> , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with <e2> warfarin </e2> , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.	1	oxandrolone	warfarin
Warfarin: A multidose study of <e1> oxandrolone </e1> , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in <e2> S-warfarin </e2> half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.	0	oxandrolone	S-warfarin
Warfarin: A multidose study of <e1> oxandrolone </e1> , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in <e2> R-warfarin </e2> half-life and AUC were also detected.	0	oxandrolone	R-warfarin
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with <e1> warfarin </e1> , resulted in a mean increase in <e2> S-warfarin </e2> half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected.	0	warfarin	S-warfarin
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with <e1> warfarin </e1> , resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in <e2> R-warfarin </e2> half-life and AUC were also detected.	0	warfarin	R-warfarin
Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in <e1> S-warfarin </e1> half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in <e2> R-warfarin </e2> half-life and AUC were also detected.	0	S-warfarin	R-warfarin
When <e1> oxandrolone </e1> therapy is initiated in a patient already receiving treatment with <e2> warfarin </e2> , the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved.	0	oxandrolone	warfarin
When <e1> oxandrolone </e1> therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of <e2> warfarin </e2> adjusted as necessary until a stable target INR or PT has been achieved.	0	oxandrolone	warfarin
Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the <e1> warfarin </e1> dosage if indicated are recommended when the <e2> oxandrolone </e2> dose is changed or discontinued.	0	warfarin	oxandrolone
Oral <e1> hypoglycemic agents </e1> <e2> Oxandrolone </e2> may inhibit the metabolism of oral hypoglycemic agents.	0	hypoglycemic agents	Oxandrolone
Oral hypoglycemic agents <e1> Oxandrolone </e1> may inhibit the metabolism of oral <e2> hypoglycemic agents </e2> .	1	Oxandrolone	hypoglycemic agents
<e1> Adrenal steroids </e1> or <e2> ACTH </e2> In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema.	0	Adrenal steroids	ACTH
<e1> Adrenal steroids </e1> or ACTH In patients with edema, concomitant administration with <e2> adrenal cortical steroids </e2> or ACTH may increase the edema.	0	Adrenal steroids	adrenal cortical steroids
<e1> Adrenal steroids </e1> or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or <e2> ACTH </e2> may increase the edema.	0	Adrenal steroids	ACTH
Adrenal steroids or <e1> ACTH </e1> In patients with edema, concomitant administration with <e2> adrenal cortical steroids </e2> or ACTH may increase the edema.	0	ACTH	adrenal cortical steroids
Adrenal steroids or ACTH In patients with edema, concomitant administration with <e1> adrenal cortical steroids </e1> or <e2> ACTH </e2> may increase the edema.	0	adrenal cortical steroids	ACTH
Caution is advised for patients receiving high-dose <e1> aspirin </e1> and <e2> methazolamide </e2> concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.	0	aspirin	methazolamide
Caution is advised for patients receiving high-dose <e1> aspirin </e1> and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and <e2> carbonic anhydrase inhibitors </e2> .	0	aspirin	carbonic anhydrase inhibitors
Caution is advised for patients receiving high-dose aspirin and <e1> methazolamide </e1> concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose <e2> aspirin </e2> and carbonic anhydrase inhibitors.	0	methazolamide	aspirin
Caution is advised for patients receiving high-dose aspirin and <e1> methazolamide </e1> concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and <e2> carbonic anhydrase inhibitors </e2> .	0	methazolamide	carbonic anhydrase inhibitors
Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose <e1> aspirin </e1> and <e2> carbonic anhydrase inhibitors </e2> .	1	aspirin	carbonic anhydrase inhibitors
Do not exceed a 5 mg daily dose of <e1> VESIcare </e1> when administered with therapeutic doses of <e2> ketoconazole </e2> or other potent CYP3A4 inhibitors.	0	VESIcare	ketoconazole
Patients with Congenital or Acquired QT Prolongation In a study of the effect of <e1> solifenacin </e1> on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control <e2> moxifloxacin </e2> at its therapeutic dose.	0	solifenacin	moxifloxacin
Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with <e1> solifenacin </e1> 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control <e2> moxifloxacin </e2> at its therapeutic dose.	0	solifenacin	moxifloxacin
Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of <e1> solifenacin </e1> 30 mg did not appear as large as that of the positive control <e2> moxifloxacin </e2> at its therapeutic dose.	0	solifenacin	moxifloxacin
Improved parathyroid hormone control by <e1> cinacalcet </e1> is associated with reduction in <e2> darbepoetin </e2> requirement in patients with end-stage renal disease.	0	cinacalcet	darbepoetin
Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to <e1> erythropoietin </e1> ( <e2> EPO </e2> ) resistance.	0	erythropoietin	EPO
Medical treatment with <e1> cinacalcet </e1> is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on <e2> darbepoetin </e2> dosing is unknown.	0	cinacalcet	darbepoetin
The primary objective of the study was to ascertain the difference in <e1> darbepoetin </e1> responsiveness before and after 12 months of <e2> cinacalcet </e2> therapy.	0	darbepoetin	cinacalcet
Reduction of PTH by <e1> cinacalcet </e1> is associated with a decrease in <e2> darbepoetin </e2> requirement.	1	cinacalcet	darbepoetin
<e1> Calcium </e1> does not inhibit the absorption of 5 milligrams of <e2> nonheme iron </e2> at doses less than 800 milligrams in nonpregnant women.	0	Calcium	nonheme iron
<e1> Calcium </e1> does not inhibit the absorption of 5 milligrams of nonheme or <e2> heme iron </e2> at doses less than 800 milligrams in nonpregnant women.	0	Calcium	heme iron
Calcium does not inhibit the absorption of 5 milligrams of <e1> nonheme iron </e1> - <e2> heme iron </e2> at doses less than 800 milligrams in nonpregnant women.	0	nonheme iron	heme iron
<e1> Calcium </e1> is the only known component in the diet that may affect absorption of both <e2> nonheme iron </e2> .	1	Calcium	nonheme iron
<e1> Calcium </e1> is the only known component in the diet that may affect absorption of both nonheme and <e2> heme iron </e2> .	1	Calcium	heme iron
Calcium is the only known component in the diet that may affect absorption of both <e1> nonheme iron </e1> - <e2> heme iron </e2> .	0	nonheme iron	heme iron
However, the evidence for a <e1> calcium </e1> effect on <e2> iron </e2> absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies.	1	calcium	iron
However, the evidence for a calcium effect on <e1> iron </e1> absorption mainly comes from studies that did not isolate the effect of <e2> calcium </e2> from that of other dietary components, because it was detected in single-meal studies.	0	iron	calcium
Our objective was to establish potential effects of <e1> calcium </e1> on absorption of <e2> nonheme iron </e2> and the dose response for this effect in the absence of a meal.	0	calcium	nonheme iron
Our objective was to establish potential effects of <e1> calcium </e1> on absorption of nonheme and <e2> heme iron </e2> and the dose response for this effect in the absence of a meal.	0	calcium	heme iron
Our objective was to establish potential effects of calcium on absorption of <e1> nonheme iron </e1> - <e2> heme iron </e2> and the dose response for this effect in the absence of a meal.	0	nonheme iron	heme iron
We evaluated the effects of <e1> calcium </e1> doses between 200 and 1500 mg on absorption of 5 mg <e2> nonheme iron </e2> (as ferrous sulfate).	0	calcium	nonheme iron
We evaluated the effects of <e1> calcium </e1> doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as <e2> ferrous sulfate </e2> ).	0	calcium	ferrous sulfate
We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg <e1> nonheme iron </e1> (as <e2> ferrous sulfate </e2> ).	0	nonheme iron	ferrous sulfate
We also evaluated the effects of <e1> calcium </e1> doses between 200 and 800 mg on absorption of 5 mg <e2> heme iron </e2> [as concentrated RBC (CRBC)].	0	calcium	heme iron
<e1> Calcium </e1> was administered as <e2> calcium chloride </e2> in all studies and minerals were ingested on an empty stomach.	0	Calcium	calcium chloride
<e1> Calcium </e1> was administered as calcium chloride in all studies and <e2> minerals </e2> were ingested on an empty stomach.	0	Calcium	minerals
Calcium was administered as <e1> calcium chloride </e1> in all studies and <e2> minerals </e2> were ingested on an empty stomach.	0	calcium chloride	minerals
<e1> Calcium </e1> doses 1000 mg diminished <e2> nonheme iron </e2> absorption by an average of 49.6%.	1	Calcium	nonheme iron
A <e1> calcium </e1> dose of 800 mg diminished absorption of 5 mg <e2> heme iron </e2> by 37.7%.	1	calcium	heme iron
In conclusion, we demonstrated an isolated effect of <e1> calcium </e1> (as chloride) on absorption of 5 mg of iron provided as <e2> nonheme iron </e2> .	1	calcium	nonheme iron
In conclusion, we demonstrated an isolated effect of <e1> calcium </e1> (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and <e2> heme iron </e2> .	1	calcium	heme iron
In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as <e1> nonheme iron </e1> - <e2> heme iron </e2> .	0	nonheme iron	heme iron
<e1> Amphetamine </e1> locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with <e2> quinpirole </e2> .	0	Amphetamine	quinpirole
The objective was to analyze the effects of neonatal <e1> quinpirole </e1> treatment on effects of <e2> amphetamine </e2> in adolescent rats using locomotor sensitization and conditioned place preference procedures.	0	quinpirole	amphetamine
In female rats, neonatal <e1> quinpirole </e1> treatment enhanced <e2> amphetamine </e2> locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine.	1	quinpirole	amphetamine
In female rats, neonatal <e1> quinpirole </e1> treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to <e2> amphetamine </e2> .	0	quinpirole	amphetamine
In female rats, neonatal quinpirole treatment enhanced <e1> amphetamine </e1> locomotor sensitization compared with <e2> quinpirole </e2> -free controls sensitized to amphetamine.	0	amphetamine	quinpirole
In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with <e1> quinpirole </e1> -free controls sensitized to <e2> amphetamine </e2> .	0	quinpirole	amphetamine
Male rats demonstrated sensitization to <e1> amphetamine </e1> , although this was muted compared with female rats, and were unaffected by neonatal <e2> quinpirole </e2> .	0	amphetamine	quinpirole
Rats treated with neonatal <e1> quinpirole </e1> enhanced time spent in the <e2> amphetamine </e2> -paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	0	quinpirole	amphetamine
Rats treated with neonatal <e1> quinpirole </e1> enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with <e2> amphetamine </e2> , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	0	quinpirole	amphetamine
Rats treated with neonatal <e1> quinpirole </e1> enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with <e2> amphetamine </e2> spent more time in the drug-paired context compared with saline-treated controls.	0	quinpirole	amphetamine
Rats treated with neonatal quinpirole enhanced time spent in the <e1> amphetamine </e1> -paired context compared with <e2> quinpirole </e2> -free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	0	amphetamine	quinpirole
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with <e1> quinpirole </e1> -free controls conditioned with <e2> amphetamine </e2> , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls.	0	quinpirole	amphetamine
Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with <e1> quinpirole </e1> -free controls conditioned with amphetamine, but only female controls conditioned with <e2> amphetamine </e2> spent more time in the drug-paired context compared with saline-treated controls.	0	quinpirole	amphetamine
The <e1> 3-Deazaneplanocin A </e1> ( <e2> DZNep </e2> ), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia.	0	3-Deazaneplanocin A	DZNep
We also found that Bcl-2 was overexpressed in <e1> DZNep </e1> insensitive cells, and cotreatment with DZNep and <e2> ABT-737 </e2> , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.	0	DZNep	ABT-737
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with <e1> DZNep </e1> and <e2> ABT-737 </e2> , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells.	1	DZNep	ABT-737
We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and <e1> ABT-737 </e1> , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of <e2> DZNep </e2> insensitive MM cells.	0	ABT-737	DZNep
In addition, <e1> DZNep </e1> insensitivity might be associated with overexpression of Bcl-2, and the combination of <e2> ABT-737 </e2> and DZNep could synergistically induced apoptosis.	0	DZNep	ABT-737
In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of <e1> ABT-737 </e1> and <e2> DZNep </e2> could synergistically induced apoptosis.	1	ABT-737	DZNep
[Efficacy of fixed combination <e1> amlodipine </e1> / <e2> valsartan </e2> in hospitalized patients with hypertensive disease]	0	amlodipine	valsartan
Efficacy and tolerability of fixed <e1> amlodipine </e1> / <e2> valsartan </e2> combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology.	0	amlodipine	valsartan
All patients had indications for antihypertensive therapy and were randomized either to fixed combination <e1> amlodipine </e1> / <e2> valsartan </e2> (n=43) or to therapy which corresponded to the hospital formulary (n=43).	0	amlodipine	valsartan
Rate of achievement of target BP with fixed combination <e1> amlodipine </e1> / <e2> valsartan </e2> (93%) was comparable with that on traditional therapy (90%).	0	amlodipine	valsartan
But the use of fixed combination <e1> amlodipine </e1> / <e2> valsartan </e2> compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).	1	amlodipine	valsartan
But the use of fixed combination <e1> amlodipine </e1> /valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of <e2> antihypertensive drugs </e2> (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).	0	amlodipine	antihypertensive drugs
But the use of fixed combination amlodipine/ <e1> valsartan </e1> compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of <e2> antihypertensive drugs </e2> (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).	0	valsartan	antihypertensive drugs
We have demonstrated appropriateness of inhospital administration of fixed <e1> amlodipine </e1> / <e2> valsartan </e2> combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.	1	amlodipine	valsartan
We have demonstrated appropriateness of inhospital administration of fixed <e1> amlodipine </e1> /valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer <e2> antihypertensive drugs </e2> , and diminishing concealed inefficacy of treatment.	0	amlodipine	antihypertensive drugs
We have demonstrated appropriateness of inhospital administration of fixed amlodipine/ <e1> valsartan </e1> combination as an approach allowing to achieve target BP in shorter time, with the use of fewer <e2> antihypertensive drugs </e2> , and diminishing concealed inefficacy of treatment.	0	valsartan	antihypertensive drugs
Distinct synergistic action of <e1> piperacillin </e1> and <e2> methylglyoxal </e2> against Pseudomonas aeruginosa.	0	piperacillin	methylglyoxal
Results revealed that the strains were resistant to many drugs at high levels, only <e1> piperacillin </e1> , <e2> carbenicillin </e2> , amikacin and ciprofloxacin showed resistances at comparatively lower levels.	0	piperacillin	carbenicillin
Results revealed that the strains were resistant to many drugs at high levels, only <e1> piperacillin </e1> , carbenicillin, <e2> amikacin </e2> and ciprofloxacin showed resistances at comparatively lower levels.	0	piperacillin	amikacin
Results revealed that the strains were resistant to many drugs at high levels, only <e1> piperacillin </e1> , carbenicillin, amikacin and <e2> ciprofloxacin </e2> showed resistances at comparatively lower levels.	0	piperacillin	ciprofloxacin
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, <e1> carbenicillin </e1> , <e2> amikacin </e2> and ciprofloxacin showed resistances at comparatively lower levels.	0	carbenicillin	amikacin
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, <e1> carbenicillin </e1> , amikacin and <e2> ciprofloxacin </e2> showed resistances at comparatively lower levels.	0	carbenicillin	ciprofloxacin
Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, <e1> amikacin </e1> and <e2> ciprofloxacin </e2> showed resistances at comparatively lower levels.	0	amikacin	ciprofloxacin
Distinct and statistically significant synergism was observed between <e1> methylglyoxal </e1> and <e2> piperacillin </e2> by disc diffusion tests when compared with their individual effects.	1	methylglyoxal	piperacillin
Synergism was also noted when <e1> methylglyoxal </e1> was combined with <e2> carbenicillin </e2> and amikacin.	1	methylglyoxal	carbenicillin
Synergism was also noted when <e1> methylglyoxal </e1> was combined with carbenicillin and <e2> amikacin </e2> .	1	methylglyoxal	amikacin
Synergism was also noted when methylglyoxal was combined with <e1> carbenicillin </e1> and <e2> amikacin </e2> .	0	carbenicillin	amikacin
To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of <e1> adeno-associated virus-2 </e1> ( <e2> AAV2 </e2> ).	0	adeno-associated virus-2	AAV2
<e1> AAV2 </e1> containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including <e2> collagenase </e2> , hyaluronan lyase, heparinase III, or chondroitin ABC lyase.	0	AAV2	collagenase
<e1> AAV2 </e1> containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, <e2> hyaluronan lyase </e2> , heparinase III, or chondroitin ABC lyase.	0	AAV2	hyaluronan lyase
<e1> AAV2 </e1> containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, <e2> heparinase III </e2> , or chondroitin ABC lyase.	0	AAV2	heparinase III
<e1> AAV2 </e1> containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or <e2> chondroitin ABC lyase </e2> .	0	AAV2	chondroitin ABC lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including <e1> collagenase </e1> , <e2> hyaluronan lyase </e2> , heparinase III, or chondroitin ABC lyase.	0	collagenase	hyaluronan lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including <e1> collagenase </e1> , hyaluronan lyase, <e2> heparinase III </e2> , or chondroitin ABC lyase.	0	collagenase	heparinase III
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including <e1> collagenase </e1> , hyaluronan lyase, heparinase III, or <e2> chondroitin ABC lyase </e2> .	0	collagenase	chondroitin ABC lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, <e1> hyaluronan lyase </e1> , <e2> heparinase III </e2> , or chondroitin ABC lyase.	0	hyaluronan lyase	heparinase III
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, <e1> hyaluronan lyase </e1> , heparinase III, or <e2> chondroitin ABC lyase </e2> .	0	hyaluronan lyase	chondroitin ABC lyase
AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, <e1> heparinase III </e1> , or <e2> chondroitin ABC lyase </e2> .	0	heparinase III	chondroitin ABC lyase
The addition of <e1> heparinase III </e1> or <e2> chondroitin ABC lyase </e2> greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina.	0	heparinase III	chondroitin ABC lyase
<e1> Hyaluronan lyase </e1> had a limited effect and <e2> collagenase </e2> was ineffective.	0	Hyaluronan lyase	collagenase
Electroretinograms survived with higher concentrations of <e1> heparinase III </e1> and <e2> chondroitin ABC lyase </e2> than were required for optimal retinal transduction.	0	heparinase III	chondroitin ABC lyase
<e1> AAV2 </e1> -mediated retinal transduction is improved by co-injection of <e2> heparinase III </e2> or chondroitin ABC lyase.	1	AAV2	heparinase III
<e1> AAV2 </e1> -mediated retinal transduction is improved by co-injection of heparinase III or <e2> chondroitin ABC lyase </e2> .	1	AAV2	chondroitin ABC lyase
AAV2-mediated retinal transduction is improved by co-injection of <e1> heparinase III </e1> or <e2> chondroitin ABC lyase </e2> .	0	heparinase III	chondroitin ABC lyase
Phase I trial of <e1> lenalidomide </e1> and <e2> CCI-779 </e2> in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.	0	lenalidomide	CCI-779
Phase I trial of <e1> lenalidomide </e1> and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide- <e2> CCI-779 </e2> interaction via P-glycoprotein.	0	lenalidomide	CCI-779
Phase I trial of lenalidomide and <e1> CCI-779 </e1> in patients with relapsed multiple myeloma: evidence for <e2> lenalidomide </e2> -CCI-779 interaction via P-glycoprotein.	0	CCI-779	lenalidomide
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for <e1> lenalidomide </e1> - <e2> CCI-779 </e2> interaction via P-glycoprotein.	0	lenalidomide	CCI-779
The preclinical combination of <e1> lenalidomide </e1> with the mTOR inhibitor <e2> CCI-779 </e2> has displayed synergy in vitro and represents a novel combination in MM.	1	lenalidomide	CCI-779
Enhancement of humoral immune responses to inactivated Newcastle disease and <e1> avian influenza vaccines </e1> by oral administration of <e2> ginseng stem-and-leaf saponins </e2> in chickens.	0	avian influenza vaccines	ginseng stem-and-leaf saponins
The objective of this study was to evaluate the effect of oral administration of <e1> ginseng stem-and-leaf saponins </e1> ( <e2> GSLS </e2> ) on the humoral immune responses of chickens to inactivated ND and AI vaccines.	0	ginseng stem-and-leaf saponins	GSLS
The objective of this study was to evaluate the effect of oral administration of <e1> ginseng stem-and-leaf saponins </e1> (GSLS) on the humoral immune responses of chickens to <e2> inactivated ND vaccines </e2> .	0	ginseng stem-and-leaf saponins	inactivated ND vaccines
The objective of this study was to evaluate the effect of oral administration of <e1> ginseng stem-and-leaf saponins </e1> (GSLS) on the humoral immune responses of chickens to <e2> inactivated AI vaccines </e2> .	0	ginseng stem-and-leaf saponins	inactivated AI vaccines
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins ( <e1> GSLS </e1> ) on the humoral immune responses of chickens to <e2> inactivated ND vaccines </e2> .	0	GSLS	inactivated ND vaccines
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins ( <e1> GSLS </e1> ) on the humoral immune responses of chickens to <e2> inactivated AI vaccines </e2> .	0	GSLS	inactivated AI vaccines
The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to <e1> inactivated ND vaccines </e1> - <e2> inactivated AI vaccines </e2> .	0	inactivated ND vaccines	inactivated AI vaccines
In experiment 1, oral administration of <e1> GSLS </e1> at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with <e2> inactivated ND vaccine </e2> was evaluated.	0	GSLS	inactivated ND vaccine
In experiment 2, the same regimen of <e1> GSLS </e1> was administered to chickens inoculated with <e2> inactivated AI vaccines </e2> , and an enhanced serum antibody response to AI vaccination was also observed.	1	GSLS	inactivated AI vaccines
<e1> Lapatinib </e1> enhances <e2> herceptin </e2> -mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.	1	Lapatinib	herceptin
Although it was previously reported that <e1> lapatinib </e1> combined with <e2> Herceptin </e2> improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	1	lapatinib	Herceptin
Although it was previously reported that <e1> lapatinib </e1> combined with Herceptin improved the progression-free survival rate compared with lapatinib alone for patients with <e2> Herceptin </e2> -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	0	lapatinib	Herceptin
Although it was previously reported that lapatinib combined with <e1> Herceptin </e1> improved the progression-free survival rate compared with <e2> lapatinib </e2> alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	0	Herceptin	lapatinib
Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with <e1> lapatinib </e1> alone for patients with <e2> Herceptin </e2> -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.	0	lapatinib	Herceptin
We evaluated how <e1> lapatinib </e1> interacts with <e2> Herceptin </e2> in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC).	0	lapatinib	Herceptin
We evaluated how <e1> lapatinib </e1> interacts with Herceptin in HER2-positive breast cancer, with a particular focus on <e2> Herceptin </e2> -mediated antibody-dependent cellular cytotoxicity (ADCC).	0	lapatinib	Herceptin
In an in vitro assay, <e1> lapatinib </e1> induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of <e2> Herceptin </e2> -mediated ADCC.	1	lapatinib	Herceptin
Furthermore, we present a case report in which a second <e1> Herceptin </e1> treatment following <e2> lapatinib </e2> resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer.	1	Herceptin	lapatinib
<e1> Lapatinib </e1> may have the potential to convert <e2> Herceptin </e2> -refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	0	Lapatinib	Herceptin
<e1> Lapatinib </e1> may have the potential to convert Herceptin-refractory to <e2> Herceptin </e2> -sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.	0	Lapatinib	Herceptin
Effect of <e1> ketoconazole </e1> -mediated CYP3A4 inhibition on clinical pharmacokinetics of <e2> panobinostat </e2> (LBH589), an orally active histone deacetylase inhibitor.	0	ketoconazole	panobinostat
Effect of <e1> ketoconazole </e1> -mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat ( <e2> LBH589 </e2> ), an orally active histone deacetylase inhibitor.	0	ketoconazole	LBH589
Effect of <e1> ketoconazole </e1> -mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active <e2> histone deacetylase inhibitor </e2> .	0	ketoconazole	histone deacetylase inhibitor
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of <e1> panobinostat </e1> ( <e2> LBH589 </e2> ), an orally active histone deacetylase inhibitor.	0	panobinostat	LBH589
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of <e1> panobinostat </e1> (LBH589), an orally active <e2> histone deacetylase inhibitor </e2> .	0	panobinostat	histone deacetylase inhibitor
Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat ( <e1> LBH589 </e1> ), an orally active <e2> histone deacetylase inhibitor </e2> .	0	LBH589	histone deacetylase inhibitor
This study evaluated the effect of a potent CYP3A inhibitor, <e1> ketoconazole </e1> , on the pharmacokinetics and safety of <e2> panobinostat </e2> .	0	ketoconazole	panobinostat
On day 8, a single <e1> panobinostat </e1> dose was co-administered with <e2> ketoconazole </e2> .	0	panobinostat	ketoconazole
In the presence of <e1> ketoconazole </e1> , there was 1.6- and 1.8-fold increase in C (max) and AUC of <e2> panobinostat </e2> , respectively.	1	ketoconazole	panobinostat
<e1> Antidepressant </e1> - <e2> warfarin </e2> interaction and associated gastrointestinal bleeding risk in a case-control study.	0	Antidepressant	warfarin
We sought to evaluate whether initiation of an <e1> antidepressant </e1> increases the risk of hospitalization for gastrointestinal bleeding in <e2> warfarin </e2> users.	0	antidepressant	warfarin
<e1> Warfarin </e1> users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e2> citalopram </e2> (OR = 1.73 [95% CI, 1.25-2.38]), fluoxetine (OR = 1.63 [95% CI, 1.11-2.38]), paroxetine (OR = 1.64 [95% CI, 1.27-2.12]), amitriptyline (OR = 1.47 [95% CI, 1.02-2.11]).	1	Warfarin	citalopram
<e1> Warfarin </e1> users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = 1.73 [95% CI, 1.25-2.38]), <e2> fluoxetine </e2> (OR = 1.63 [95% CI, 1.11-2.38]), paroxetine (OR = 1.64 [95% CI, 1.27-2.12]), amitriptyline (OR = 1.47 [95% CI, 1.02-2.11]).	1	Warfarin	fluoxetine
<e1> Warfarin </e1> users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = 1.73 [95% CI, 1.25-2.38]), fluoxetine (OR = 1.63 [95% CI, 1.11-2.38]), <e2> paroxetine </e2> (OR = 1.64 [95% CI, 1.27-2.12]), amitriptyline (OR = 1.47 [95% CI, 1.02-2.11]).	1	Warfarin	paroxetine
<e1> Warfarin </e1> users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = 1.73 [95% CI, 1.25-2.38]), fluoxetine (OR = 1.63 [95% CI, 1.11-2.38]), paroxetine (OR = 1.64 [95% CI, 1.27-2.12]), <e2> amitriptyline </e2> (OR = 1.47 [95% CI, 1.02-2.11]).	1	Warfarin	amitriptyline
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e1> citalopram </e1> (OR = 1.73 [95% CI, 1.25-2.38]), <e2> fluoxetine </e2> (OR = 1.63 [95% CI, 1.11-2.38]), paroxetine (OR = 1.64 [95% CI, 1.27-2.12]), amitriptyline (OR = 1.47 [95% CI, 1.02-2.11]).	0	citalopram	fluoxetine
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e1> citalopram </e1> (OR = 1.73 [95% CI, 1.25-2.38]), fluoxetine (OR = 1.63 [95% CI, 1.11-2.38]), <e2> paroxetine </e2> (OR = 1.64 [95% CI, 1.27-2.12]), amitriptyline (OR = 1.47 [95% CI, 1.02-2.11]).	0	citalopram	paroxetine
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of <e1> citalopram </e1> (OR = 1.73 [95% CI, 1.25-2.38]), fluoxetine (OR = 1.63 [95% CI, 1.11-2.38]), paroxetine (OR = 1.64 [95% CI, 1.27-2.12]), <e2> amitriptyline </e2> (OR = 1.47 [95% CI, 1.02-2.11]).	0	citalopram	amitriptyline
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = 1.73 [95% CI, 1.25-2.38]), <e1> fluoxetine </e1> (OR = 1.63 [95% CI, 1.11-2.38]), <e2> paroxetine </e2> (OR = 1.64 [95% CI, 1.27-2.12]), amitriptyline (OR = 1.47 [95% CI, 1.02-2.11]).	0	fluoxetine	paroxetine
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = 1.73 [95% CI, 1.25-2.38]), <e1> fluoxetine </e1> (OR = 1.63 [95% CI, 1.11-2.38]), paroxetine (OR = 1.64 [95% CI, 1.27-2.12]), <e2> amitriptyline </e2> (OR = 1.47 [95% CI, 1.02-2.11]).	0	fluoxetine	amitriptyline
Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR = 1.73 [95% CI, 1.25-2.38]), fluoxetine (OR = 1.63 [95% CI, 1.11-2.38]), <e1> paroxetine </e1> (OR = 1.64 [95% CI, 1.27-2.12]), <e2> amitriptyline </e2> (OR = 1.47 [95% CI, 1.02-2.11]).	0	paroxetine	amitriptyline
Also <e1> mirtazapine </e1> , which is not believed to interact with <e2> warfarin </e2> , increased the risk of GI bleeding (OR = 1.75 [95% CI, 1.30-2.35]).	1	mirtazapine	warfarin
<e1> Warfarin </e1> users who initiated <e2> citalopram </e2> , fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	1	Warfarin	citalopram
<e1> Warfarin </e1> users who initiated citalopram, <e2> fluoxetine </e2> , paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	1	Warfarin	fluoxetine
<e1> Warfarin </e1> users who initiated citalopram, fluoxetine, <e2> paroxetine </e2> , amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	1	Warfarin	paroxetine
<e1> Warfarin </e1> users who initiated citalopram, fluoxetine, paroxetine, <e2> amitriptyline </e2> , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	1	Warfarin	amitriptyline
<e1> Warfarin </e1> users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or <e2> mirtazapine </e2> had an increased risk of hospitalization for gastrointestinal bleeding.	1	Warfarin	mirtazapine
Warfarin users who initiated <e1> citalopram </e1> , <e2> fluoxetine </e2> , paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	0	citalopram	fluoxetine
Warfarin users who initiated <e1> citalopram </e1> , fluoxetine, <e2> paroxetine </e2> , amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	0	citalopram	paroxetine
Warfarin users who initiated <e1> citalopram </e1> , fluoxetine, paroxetine, <e2> amitriptyline </e2> , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	0	citalopram	amitriptyline
Warfarin users who initiated <e1> citalopram </e1> , fluoxetine, paroxetine, amitriptyline, or <e2> mirtazapine </e2> had an increased risk of hospitalization for gastrointestinal bleeding.	0	citalopram	mirtazapine
Warfarin users who initiated citalopram, <e1> fluoxetine </e1> , <e2> paroxetine </e2> , amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	0	fluoxetine	paroxetine
Warfarin users who initiated citalopram, <e1> fluoxetine </e1> , paroxetine, <e2> amitriptyline </e2> , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	0	fluoxetine	amitriptyline
Warfarin users who initiated citalopram, <e1> fluoxetine </e1> , paroxetine, amitriptyline, or <e2> mirtazapine </e2> had an increased risk of hospitalization for gastrointestinal bleeding.	0	fluoxetine	mirtazapine
Warfarin users who initiated citalopram, fluoxetine, <e1> paroxetine </e1> , <e2> amitriptyline </e2> , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding.	0	paroxetine	amitriptyline
Warfarin users who initiated citalopram, fluoxetine, <e1> paroxetine </e1> , amitriptyline, or <e2> mirtazapine </e2> had an increased risk of hospitalization for gastrointestinal bleeding.	0	paroxetine	mirtazapine
Warfarin users who initiated citalopram, fluoxetine, paroxetine, <e1> amitriptyline </e1> , or <e2> mirtazapine </e2> had an increased risk of hospitalization for gastrointestinal bleeding.	0	amitriptyline	mirtazapine
The incubations were performed in the absence and presence of the non-specific CYP inhibitor, <e1> 1-aminobenzotriazole </e1> ( <e2> ABT </e2> ) and isoform-specific inhibitors.	0	1-aminobenzotriazole	ABT
<e1> ABT </e1> decreased the toxicity of <e2> precocene I </e2> , increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner.	1	ABT	precocene I
Of the isoform-specific CYP inhibitors tested for an effect on the <e1> precocene I </e1> metabolite profile, only <e2> tranylcypromine </e2> was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1.	0	precocene I	tranylcypromine
With respect to toxicity, the order of CYP inhibitor effectiveness was <e1> ABT </e1> > <e2> diethyldithiocarbamate </e2> ~tranylcypromine>ketoconazole.	0	ABT	diethyldithiocarbamate
With respect to toxicity, the order of CYP inhibitor effectiveness was <e1> ABT </e1> >diethyldithiocarbamate~ <e2> tranylcypromine </e2> >ketoconazole.	0	ABT	tranylcypromine
With respect to toxicity, the order of CYP inhibitor effectiveness was <e1> ABT </e1> >diethyldithiocarbamate~tranylcypromine> <e2> ketoconazole </e2> .	0	ABT	ketoconazole
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT> <e1> diethyldithiocarbamate </e1> ~ <e2> tranylcypromine </e2> >ketoconazole.	0	diethyldithiocarbamate	tranylcypromine
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT> <e1> diethyldithiocarbamate </e1> ~tranylcypromine> <e2> ketoconazole </e2> .	0	diethyldithiocarbamate	ketoconazole
With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~ <e1> tranylcypromine </e1> > <e2> ketoconazole </e2> .	0	tranylcypromine	ketoconazole
<e1> Furafylline </e1> and <e2> sulfaphenazole </e2> had no effect, while quinidine appeared to augment precocene I toxicity.	0	Furafylline	sulfaphenazole
<e1> Furafylline </e1> and sulfaphenazole had no effect, while <e2> quinidine </e2> appeared to augment precocene I toxicity.	0	Furafylline	quinidine
<e1> Furafylline </e1> and sulfaphenazole had no effect, while quinidine appeared to augment <e2> precocene I </e2> toxicity.	0	Furafylline	precocene I
Furafylline and <e1> sulfaphenazole </e1> had no effect, while <e2> quinidine </e2> appeared to augment precocene I toxicity.	0	sulfaphenazole	quinidine
Furafylline and <e1> sulfaphenazole </e1> had no effect, while quinidine appeared to augment <e2> precocene I </e2> toxicity.	0	sulfaphenazole	precocene I
Furafylline and sulfaphenazole had no effect, while <e1> quinidine </e1> appeared to augment <e2> precocene I </e2> toxicity.	1	quinidine	precocene I
In vitro activity of <e1> minocycline </e1> combined with <e2> fosfomycin </e2> against clinical isolates of methicillin-resistant Staphylococcus aureus.	0	minocycline	fosfomycin
In vitro activity of <e1> minocycline </e1> combined with fosfomycin against clinical isolates of <e2> methicillin </e2> -resistant Staphylococcus aureus.	0	minocycline	methicillin
In vitro activity of minocycline combined with <e1> fosfomycin </e1> against clinical isolates of <e2> methicillin </e2> -resistant Staphylococcus aureus.	0	fosfomycin	methicillin
This study aimed to evaluate the in vitro activity of <e1> minocycline </e1> combined with <e2> fosfomycin </e2> against isolates of methicillin-resistant Staphylococcus aureus (MRSA).	0	minocycline	fosfomycin
This study aimed to evaluate the in vitro activity of <e1> minocycline </e1> combined with fosfomycin against isolates of <e2> methicillin </e2> -resistant Staphylococcus aureus (MRSA).	0	minocycline	methicillin
This study aimed to evaluate the in vitro activity of minocycline combined with <e1> fosfomycin </e1> against isolates of <e2> methicillin </e2> -resistant Staphylococcus aureus (MRSA).	0	fosfomycin	methicillin
The susceptibility results for <e1> minocycline </e1> and <e2> fosfomycin </e2> were interpreted according to the most relevant criteria.	0	minocycline	fosfomycin
The combination of <e1> minocycline </e1> and <e2> fosfomycin </e2> can be synergistic against MRSA.	1	minocycline	fosfomycin
Interaction of <e1> celecoxib </e1> with different <e2> anti-cancer drugs </e2> is antagonistic in breast but not in other cancer cells.	1	celecoxib	anti-cancer drugs
This study investigates the ability of <e1> cyclooxygenase-2 inhibitors </e1> to sensitize cells from different origins to several <e2> chemotherapeutic agents </e2> .	0	cyclooxygenase-2 inhibitors	chemotherapeutic agents
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to <e1> 5-FU </e1> , <e2> cisplatin </e2> , doxorubicin and etoposide celecoxib following different incubation schedules were analyzed.	0	5-FU	cisplatin
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to <e1> 5-FU </e1> , cisplatin, <e2> doxorubicin </e2> and etoposide celecoxib following different incubation schedules were analyzed.	0	5-FU	doxorubicin
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to <e1> 5-FU </e1> , cisplatin, doxorubicin and <e2> etoposide </e2> celecoxib following different incubation schedules were analyzed.	0	5-FU	etoposide
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to <e1> 5-FU </e1> , cisplatin, doxorubicin and etoposide <e2> celecoxib </e2> following different incubation schedules were analyzed.	0	5-FU	celecoxib
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, <e1> cisplatin </e1> , <e2> doxorubicin </e2> and etoposide celecoxib following different incubation schedules were analyzed.	0	cisplatin	doxorubicin
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, <e1> cisplatin </e1> , doxorubicin and <e2> etoposide </e2> celecoxib following different incubation schedules were analyzed.	0	cisplatin	etoposide
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, <e1> cisplatin </e1> , doxorubicin and etoposide <e2> celecoxib </e2> following different incubation schedules were analyzed.	0	cisplatin	celecoxib
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, <e1> doxorubicin </e1> and <e2> etoposide </e2> celecoxib following different incubation schedules were analyzed.	0	doxorubicin	etoposide
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, <e1> doxorubicin </e1> and etoposide <e2> celecoxib </e2> following different incubation schedules were analyzed.	0	doxorubicin	celecoxib
The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and <e1> etoposide </e1> <e2> celecoxib </e2> following different incubation schedules were analyzed.	0	etoposide	celecoxib
We found antagonism between <e1> celecoxib </e1> and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and <e2> doxorubicin </e2> in all cell lines except for two combinations in HCT116 cells.	0	celecoxib	doxorubicin
We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between <e1> celecoxib </e1> and <e2> doxorubicin </e2> in all cell lines except for two combinations in HCT116 cells.	1	celecoxib	doxorubicin
These results, if confirmed in-vivo, indicate that <e1> celecoxib </e1> is not a suitable chemosensitizer for breast cancer or with <e2> doxorubicin </e2> for other cancers.	0	celecoxib	doxorubicin
<e1> Tamoxifen </e1> , an <e2> estrogen antagonist </e2> , is the standard hormone treatment for breast cancer.	0	Tamoxifen	estrogen antagonist
<e1> Paroxetine </e1> and <e2> fluoxetine </e2> reduce the plasma concentration of endoxifen by about 50%.	0	Paroxetine	fluoxetine
<e1> Paroxetine </e1> and fluoxetine reduce the plasma concentration of <e2> endoxifen </e2> by about 50%.	1	Paroxetine	endoxifen
Paroxetine and <e1> fluoxetine </e1> reduce the plasma concentration of <e2> endoxifen </e2> by about 50%.	1	fluoxetine	endoxifen
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e1> tamoxifen </e1> for breast cancer, especially <e2> SSRI antidepressants </e2> such as paroxetine and fluoxetine.	0	tamoxifen	SSRI antidepressants
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e1> tamoxifen </e1> for breast cancer, especially SSRI antidepressants such as <e2> paroxetine </e2> and fluoxetine.	0	tamoxifen	paroxetine
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with <e1> tamoxifen </e1> for breast cancer, especially SSRI antidepressants such as paroxetine and <e2> fluoxetine </e2> .	0	tamoxifen	fluoxetine
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially <e1> SSRI antidepressants </e1> such as <e2> paroxetine </e2> and fluoxetine.	0	SSRI antidepressants	paroxetine
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially <e1> SSRI antidepressants </e1> such as paroxetine and <e2> fluoxetine </e2> .	0	SSRI antidepressants	fluoxetine
It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as <e1> paroxetine </e1> and <e2> fluoxetine </e2> .	0	paroxetine	fluoxetine
Depression does not always require <e1> antidepressant drug </e1> therapy, and <e2> antidepressants </e2> have no proven preventive impact on hot flushes linked to the menopause.	0	antidepressant drug	antidepressants
If in certain cases, an <e1> antidepressant </e1> is considered necessary, it may be advisable to replace <e2> tamoxifen </e2> with anastrozole.	0	antidepressant	tamoxifen
If in certain cases, an <e1> antidepressant </e1> is considered necessary, it may be advisable to replace tamoxifen with <e2> anastrozole </e2> .	0	antidepressant	anastrozole
If in certain cases, an antidepressant is considered necessary, it may be advisable to replace <e1> tamoxifen </e1> with <e2> anastrozole </e2> .	0	tamoxifen	anastrozole
Influence of <e1> piperine </e1> on <e2> ibuprofen </e2> induced antinociception and its pharmacokinetics.	0	piperine	ibuprofen
In the present study <e1> piperine </e1> (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of <e2> ibuprofen </e2> evaluated by both acetic acid writhing and formalin test, when it was administered with ibuprofen.	1	piperine	ibuprofen
In the present study <e1> piperine </e1> (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both <e2> acetic acid </e2> writhing and formalin test, when it was administered with ibuprofen.	0	piperine	acetic acid
In the present study <e1> piperine </e1> (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both acetic acid writhing and formalin test, when it was administered with <e2> ibuprofen </e2> .	0	piperine	ibuprofen
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of <e1> ibuprofen </e1> evaluated by both <e2> acetic acid </e2> writhing and formalin test, when it was administered with ibuprofen.	0	ibuprofen	acetic acid
In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both <e1> acetic acid </e1> writhing and formalin test, when it was administered with <e2> ibuprofen </e2> .	0	acetic acid	ibuprofen
<e1> Ibuprofen </e1> plasma concentration was also increased when it was administered with <e2> piperine </e2> .	1	Ibuprofen	piperine
The synergistic antinociception activity of <e1> ibuprofen </e1> when administered with <e2> piperine </e2> can be attributed to increased plasma concentration of ibuprofen.	1	ibuprofen	piperine
The synergistic antinociception activity of ibuprofen when administered with <e1> piperine </e1> can be attributed to increased plasma concentration of <e2> ibuprofen </e2> .	0	piperine	ibuprofen
From this study it can be concluded that <e1> piperine </e1> can be used as a bioenhancer along with <e2> ibuprofen </e2> .	1	piperine	ibuprofen
The authors report the case of an infant with confirmed congenital hypothyroidism on <e1> levothyroxine </e1> who experienced a possible drug interaction with <e2> simeticone </e2> .	0	levothyroxine	simeticone
Questioning revealed the child was taking <e1> Infacol </e1> drops before feeds while on <e2> levothyroxine </e2> .	0	Infacol	levothyroxine
Drug interaction of <e1> thyroxine </e1> with <e2> simeticone </e2> has not been reported previously and is not listed in the British National Formulary for Children.	0	thyroxine	simeticone
In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist, <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1> , reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> .	0	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Weekly intramuscular <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> injections (0.2-0.5 mg/kg body weight), in combination with daily administration of <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
Weekly intramuscular <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1> or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	0	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1> or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /vehicle).	0	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> / <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle).	0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1> versus <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /vehicle).	0	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
After 21 weeks of <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> -treated monkeys were significantly affected.	0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> -treated monkeys were significantly affected.	0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> / <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> -treated monkeys were significantly affected.	1	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> / <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> -treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys.	1	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1> -treated animals than in <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /vehicle-treated monkeys.	0	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
The <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1> treatment also had a significant effect on the <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> -induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups.	1	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
In <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> /vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> -treated monkeys.	0	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> / <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> -treated monkeys.	1	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine
Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist, <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1> , significantly reduces <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> toxicity towards dopaminergic and noradrenergic cell groups in non-human primates.	1	3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
<e1> Ticagrelor </e1> ( <e2> Brilinta </e2> )--better than clopidogrel (Plavix)	0	Ticagrelor	Brilinta
<e1> Ticagrelor </e1> (Brilinta)--better than <e2> clopidogrel </e2> (Plavix)	0	Ticagrelor	clopidogrel
<e1> Ticagrelor </e1> (Brilinta)--better than clopidogrel ( <e2> Plavix </e2> )	0	Ticagrelor	Plavix
Ticagrelor ( <e1> Brilinta </e1> )--better than <e2> clopidogrel </e2> (Plavix)	0	Brilinta	clopidogrel
Ticagrelor ( <e1> Brilinta </e1> )--better than clopidogrel ( <e2> Plavix </e2> )	0	Brilinta	Plavix
Ticagrelor (Brilinta)--better than <e1> clopidogrel </e1> ( <e2> Plavix </e2> )	0	clopidogrel	Plavix
The FDA has approved <e1> ticagrelor </e1> ( <e2> Brilinta </e2> -AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).	0	ticagrelor	Brilinta
The FDA has approved <e1> ticagrelor </e1> (Brilinta-AstraZeneca), an oral <e2> antiplatelet drug </e2> , for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).	0	ticagrelor	antiplatelet drug
The FDA has approved <e1> ticagrelor </e1> (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose <e2> aspirin </e2> to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).	1	ticagrelor	aspirin
The FDA has approved ticagrelor ( <e1> Brilinta </e1> -AstraZeneca), an oral <e2> antiplatelet drug </e2> , for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).	0	Brilinta	antiplatelet drug
The FDA has approved ticagrelor ( <e1> Brilinta </e1> -AstraZeneca), an oral antiplatelet drug, for use with low-dose <e2> aspirin </e2> to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).	1	Brilinta	aspirin
The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral <e1> antiplatelet drug </e1> , for use with low-dose <e2> aspirin </e2> to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).	0	antiplatelet drug	aspirin
It will compete with <e1> clopidogrel </e1> ( <e2> Plavix </e2> ) and prasugrel (Effient) for such use.	0	clopidogrel	Plavix
It will compete with <e1> clopidogrel </e1> (Plavix) and <e2> prasugrel </e2> (Effient) for such use.	0	clopidogrel	prasugrel
It will compete with <e1> clopidogrel </e1> (Plavix) and prasugrel ( <e2> Effient </e2> ) for such use.	0	clopidogrel	Effient
It will compete with clopidogrel ( <e1> Plavix </e1> ) and <e2> prasugrel </e2> (Effient) for such use.	0	Plavix	prasugrel
It will compete with clopidogrel ( <e1> Plavix </e1> ) and prasugrel ( <e2> Effient </e2> ) for such use.	0	Plavix	Effient
It will compete with clopidogrel (Plavix) and <e1> prasugrel </e1> ( <e2> Effient </e2> ) for such use.	0	prasugrel	Effient
The role of p27(Kip1) in <e1> dasatinib </e1> -enhanced <e2> paclitaxel </e2> cytotoxicity in human ovarian cancer cells.	1	dasatinib	paclitaxel
The effect of <e1> dasatinib </e1> , an inhibitor of Src and Abl kinases, on <e2> paclitaxel </e2> sensitivity was measured in ovarian cancer cells and HEY xenografts.	0	dasatinib	paclitaxel
The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by <e1> dasatinib </e1> and <e2> paclitaxel </e2> were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry.	0	dasatinib	paclitaxel
HEY cells treated with <e1> dasatinib </e1> plus <e2> paclitaxel </e2> formed fewer colonies than did cells treated with either agent alone.	1	dasatinib	paclitaxel
Treatment of HEY xenograft-bearing mice with <e1> dasatinib </e1> plus <e2> paclitaxel </e2> inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	1	dasatinib	paclitaxel
Treatment of HEY xenograft-bearing mice with <e1> dasatinib </e1> plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + <e2> paclitaxel </e2> vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	0	dasatinib	paclitaxel
Treatment of HEY xenograft-bearing mice with <e1> dasatinib </e1> plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs <e2> paclitaxel </e2> : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	0	dasatinib	paclitaxel
Treatment of HEY xenograft-bearing mice with dasatinib plus <e1> paclitaxel </e1> inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, <e2> dasatinib </e2> + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	0	paclitaxel	dasatinib
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, <e1> dasatinib </e1> + <e2> paclitaxel </e2> vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	0	dasatinib	paclitaxel
Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, <e1> dasatinib </e1> + paclitaxel vs <e2> paclitaxel </e2> : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);	0	dasatinib	paclitaxel
<e1> dasatinib </e1> + <e2> paclitaxel </e2> vs.	0	dasatinib	paclitaxel
The siRNA knockdown of p27(Kip1) decreased <e1> dasatinib </e1> - and <e2> paclitaxel </e2> -induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017).	0	dasatinib	paclitaxel
Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that <e1> dasatinib </e1> -mediated induction of p27(Kip1) enhanced <e2> paclitaxel </e2> -induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression.	1	dasatinib	paclitaxel
Inhibition of Src family and Abl kinases with either siRNAs or <e1> dasatinib </e1> enhances <e2> paclitaxel </e2> sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.	1	dasatinib	paclitaxel
Exposure to oral <e1> S-ketamine </e1> is unaffected by <e2> itraconazole </e2> but greatly increased by ticlopidine.	0	S-ketamine	itraconazole
Exposure to oral <e1> S-ketamine </e1> is unaffected by itraconazole but greatly increased by <e2> ticlopidine </e2> .	1	S-ketamine	ticlopidine
Exposure to oral S-ketamine is unaffected by <e1> itraconazole </e1> but greatly increased by <e2> ticlopidine </e2> .	0	itraconazole	ticlopidine
This study examined drug-drug interactions of oral <e1> S-ketamine </e1> with the cytochrome P450 (CYP) 2B6 inhibitor <e2> ticlopidine </e2> and the CYP3A inhibitor itraconazole.	0	S-ketamine	ticlopidine
This study examined drug-drug interactions of oral <e1> S-ketamine </e1> with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor <e2> itraconazole </e2> .	0	S-ketamine	itraconazole
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor <e1> ticlopidine </e1> and the CYP3A inhibitor <e2> itraconazole </e2> .	0	ticlopidine	itraconazole
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg <e1> S-ketamine </e1> after pretreatments with oral <e2> ticlopidine </e2> (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.	0	S-ketamine	ticlopidine
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg <e1> S-ketamine </e1> after pretreatments with oral ticlopidine (250 mg twice daily), <e2> itraconazole </e2> (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.	0	S-ketamine	itraconazole
In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral <e1> ticlopidine </e1> (250 mg twice daily), <e2> itraconazole </e2> (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.	0	ticlopidine	itraconazole
<e1> Ticlopidine </e1> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral <e2> ketamine </e2> by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine.	1	Ticlopidine	ketamine
<e1> Ticlopidine </e1> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral ketamine by 2.4-fold, whereas <e2> itraconazole </e2> treatment did not increase the exposure to S-ketamine.	0	Ticlopidine	itraconazole
<e1> Ticlopidine </e1> treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to <e2> S-ketamine </e2> .	0	Ticlopidine	S-ketamine
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral <e1> ketamine </e1> by 2.4-fold, whereas <e2> itraconazole </e2> treatment did not increase the exposure to S-ketamine.	0	ketamine	itraconazole
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral <e1> ketamine </e1> by 2.4-fold, whereas itraconazole treatment did not increase the exposure to <e2> S-ketamine </e2> .	0	ketamine	S-ketamine
Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0- )) of oral ketamine by 2.4-fold, whereas <e1> itraconazole </e1> treatment did not increase the exposure to <e2> S-ketamine </e2> .	0	itraconazole	S-ketamine
The ratio of <e1> norketamine </e1> AUC(0- ) to <e2> ketamine </e2> AUC(0- ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo.	0	norketamine	ketamine
The ratio of <e1> norketamine </e1> AUC(0- ) to ketamine AUC(0- ) was significantly decreased in the <e2> ticlopidine </e2> (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo.	0	norketamine	ticlopidine
The ratio of <e1> norketamine </e1> AUC(0- ) to ketamine AUC(0- ) was significantly decreased in the ticlopidine (P &lt; 0.001) and <e2> itraconazole </e2> phases (P = 0.006) as compared to placebo.	0	norketamine	itraconazole
The ratio of norketamine AUC(0- ) to <e1> ketamine </e1> AUC(0- ) was significantly decreased in the <e2> ticlopidine </e2> (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo.	0	ketamine	ticlopidine
The ratio of norketamine AUC(0- ) to <e1> ketamine </e1> AUC(0- ) was significantly decreased in the ticlopidine (P &lt; 0.001) and <e2> itraconazole </e2> phases (P = 0.006) as compared to placebo.	0	ketamine	itraconazole
The ratio of norketamine AUC(0- ) to ketamine AUC(0- ) was significantly decreased in the <e1> ticlopidine </e1> (P &lt; 0.001) and <e2> itraconazole </e2> phases (P = 0.006) as compared to placebo.	0	ticlopidine	itraconazole
In the <e1> ticlopidine </e1> and <e2> itraconazole </e2> phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05).	0	ticlopidine	itraconazole
The findings suggest that the dosage of <e1> S-ketamine </e1> should be reduced in patients receiving <e2> ticlopidine </e2> .	0	S-ketamine	ticlopidine
In vivo CYP3A activity is significantly lower in <e1> cyclosporine </e1> -treated as compared with <e2> tacrolimus </e2> -treated renal allograft recipients.	0	cyclosporine	tacrolimus
In vitro studies have identified <e1> cyclosporine </e1> and <e2> tacrolimus </e2> as CYP3A inhibitors.	0	cyclosporine	tacrolimus
Systemic and apparent oral <e1> midazolam </e1> clearance were 24% (269 73 vs. 354 102 ml/min, P = 0.022) and 31% (479 190 vs. 688 265 ml/min, P = 0.013), respectively, lower in <e2> cyclosporine </e2> -treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20).	1	midazolam	cyclosporine
Systemic and apparent oral <e1> midazolam </e1> clearance were 24% (269 73 vs. 354 102 ml/min, P = 0.022) and 31% (479 190 vs. 688 265 ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched <e2> tacrolimus </e2> -treated patients (n = 20).	0	midazolam	tacrolimus
Systemic and apparent oral midazolam clearance were 24% (269 73 vs. 354 102 ml/min, P = 0.022) and 31% (479 190 vs. 688 265 ml/min, P = 0.013), respectively, lower in <e1> cyclosporine </e1> -treated patients (n = 20) than in matched <e2> tacrolimus </e2> -treated patients (n = 20).	0	cyclosporine	tacrolimus
The latter displayed <e1> midazolam </e1> clearances similar to those in two larger cohorts of nonmatched <e2> tacrolimus </e2> -treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6).	0	midazolam	tacrolimus
The latter displayed <e1> midazolam </e1> clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a <e2> calcineurin inhibitor </e2> -free regimen (n = 6).	0	midazolam	calcineurin inhibitor
The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched <e1> tacrolimus </e1> -treated patients (n = 58 and n = 80) and to those receiving a <e2> calcineurin inhibitor </e2> -free regimen (n = 6).	0	tacrolimus	calcineurin inhibitor
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving <e1> cyclosporine </e1> than in those receiving <e2> tacrolimus </e2> , indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition.	0	cyclosporine	tacrolimus
This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving <e1> tacrolimus </e1> , indicating that, at the doses generally used in clinical practice, <e2> cyclosporine </e2> is the stronger of the two with respect to CYP3A inhibition.	0	tacrolimus	cyclosporine
The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, <e1> cross-reacting material 197 </e1> ( <e2> CRM197 </e2> ).	0	cross-reacting material 197	CRM197
We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of <e1> CRM197 </e1> on these cells alone or in combination with <e2> anticancer agent </e2> .	0	CRM197	anticancer agent
<e1> CRM197 </e1> induced apoptosis, and furthermore, the combination of CRM197 plus <e2> doxorubicin </e2> enhanced cytotoxicity in a T-ALL cell line.	0	CRM197	doxorubicin
CRM197 induced apoptosis, and furthermore, the combination of <e1> CRM197 </e1> plus <e2> doxorubicin </e2> enhanced cytotoxicity in a T-ALL cell line.	1	CRM197	doxorubicin
Prevention of emergence agitation in seven children receiving low-dose <e1> ketamine </e1> and <e2> propofol </e2> total intravenous anesthesia.	0	ketamine	propofol
We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose <e1> ketamine </e1> in conjunction with <e2> propofol </e2> for total intravenous anesthesia (TIVA) repeatedly for radiation therapy.	0	ketamine	propofol
EA signs were observed in all 7 patients in association with <e1> propofol </e1> TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose <e2> ketamine </e2> was added to propofol.	0	propofol	ketamine
EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose <e1> ketamine </e1> was added to <e2> propofol </e2> .	0	ketamine	propofol
Based on this experience, we suggest that low-dose <e1> ketamine </e1> added to <e2> propofol </e2> may be associated with prevention of EA in children with a history of EA with propofol TIVA.	1	ketamine	propofol
Based on this experience, we suggest that low-dose <e1> ketamine </e1> added to propofol may be associated with prevention of EA in children with a history of EA with <e2> propofol </e2> TIVA.	0	ketamine	propofol
[Interaction between <e1> clopidogrel </e1> and <e2> proton pump inhibitors </e2> ].	0	clopidogrel	proton pump inhibitors
The drug interaction between <e1> proton pump inhibitors </e1> and <e2> clopidogrel </e2> has been the subject of much study in recent years.	0	proton pump inhibitors	clopidogrel
Contradictory results regarding the effect of <e1> proton pump inhibitors </e1> on platelet reactivity and on clinical outcome in <e2> clopidogrel </e2> -treated patients have been reported in literature.	0	proton pump inhibitors	clopidogrel
Concomitant use of <e1> omeprazole </e1> and <e2> clopidogrel </e2> was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme.	1	omeprazole	clopidogrel
Concomitant use of omeprazole and <e1> clopidogrel </e1> was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by <e2> omeprazole </e2> of CYP2C19, a cytochrome P450 (CYP) enzyme.	0	clopidogrel	omeprazole
<e1> Pantoprazole </e1> has a much weaker effect on <e2> clopidogrel </e2> 's pharmacokinetics and on platelet reactivity during concomitant use.	1	Pantoprazole	clopidogrel
The influence of the other <e1> proton pump inhibitors </e1> when used simultaneously with <e2> clopidogrel </e2> has not yet been investigated in adequately randomized studies.	0	proton pump inhibitors	clopidogrel
Regulatory agencies state that the combination of <e1> clopidogrel </e1> and the CYP2C19 inhibitors <e2> omeprazole </e2> and esomeprazole should be avoided.	0	clopidogrel	omeprazole
Regulatory agencies state that the combination of <e1> clopidogrel </e1> and the CYP2C19 inhibitors omeprazole and <e2> esomeprazole </e2> should be avoided.	0	clopidogrel	esomeprazole
Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors <e1> omeprazole </e1> and <e2> esomeprazole </e2> should be avoided.	0	omeprazole	esomeprazole
To date, there is no conclusive evidence of a clinically-relevant interaction between any of the <e1> proton pump inhibitors </e1> and <e2> clopidogrel </e2> .	0	proton pump inhibitors	clopidogrel
[Influence of <e1> hemantane </e1> and <e2> doxycycline </e2> on MPTP-evoked behavior violations in C57BL/6 mice].	0	hemantane	doxycycline
The effects of <e1> anti-parkinsonian drug </e1> <e2> hemantane </e2> [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.)	0	anti-parkinsonian drug	hemantane
The effects of <e1> anti-parkinsonian drug </e1> hemantane [ <e2> (2-adamantyl)hexamethylenimine </e2> ] (10 mg/kg, p. o.)	0	anti-parkinsonian drug	(2-adamantyl)hexamethylenimine
The effects of anti-parkinsonian drug <e1> hemantane </e1> [ <e2> (2-adamantyl)hexamethylenimine </e2> ] (10 mg/kg, p. o.)	0	hemantane	(2-adamantyl)hexamethylenimine
and/or <e1> antibiotic drug </e1> <e2> doxycycline </e2> (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.)	0	antibiotic drug	doxycycline
and/or <e1> antibiotic drug </e1> doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin <e2> 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine </e2> (MPTP) (4 x 20 mg/kg, i. p.)	0	antibiotic drug	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine
and/or <e1> antibiotic drug </e1> doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine ( <e2> MPTP </e2> ) (4 x 20 mg/kg, i. p.)	0	antibiotic drug	MPTP
and/or antibiotic drug <e1> doxycycline </e1> (100 mg/kg, p. o.), as well as that of neurotoxin <e2> 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine </e2> (MPTP) (4 x 20 mg/kg, i. p.)	0	doxycycline	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine
and/or antibiotic drug <e1> doxycycline </e1> (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine ( <e2> MPTP </e2> ) (4 x 20 mg/kg, i. p.)	0	doxycycline	MPTP
and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin <e1> 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine </e1> ( <e2> MPTP </e2> ) (4 x 20 mg/kg, i. p.)	0	1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine	MPTP
Acute administration of <e1> hemantane </e1> or <e2> doxycycline </e2> failed to influence locomotion in mice, while their combination normalized motor activity.	1	hemantane	doxycycline
Protective effect of <e1> acetyl-l-carnitine </e1> and <e2> alpha lipoic acid </e2> against the acute toxicity of diepoxybutane to human lymphocytes.	0	acetyl-l-carnitine	alpha lipoic acid
(ii) <e1> acetyl-l-carnitine </e1> elicits a significant protective effect on DEB induced toxicity, which was potentiated by <e2> alpha-lipoic acid </e2> .	1	acetyl-l-carnitine	alpha-lipoic acid
<e1> Implanon </e1> failure in an HIV-positive woman on <e2> antiretroviral </e2> therapy resulting in two ectopic pregnancies.	1	Implanon	antiretroviral
We present an interesting case of an HIV-positive woman on <e1> antiretroviral </e1> therapy having tubal pregnancies on two separate occasions with <e2> Implanon </e2> in place.	1	antiretroviral	Implanon
Interaction of <e1> dacarbazine </e1> and <e2> imexon </e2> , in vitro and in vivo, in human A375 melanoma cells.	0	dacarbazine	imexon
We evaluated mechanisms of interaction between the alkyating agent <e1> dacarbazine </e1> ( <e2> DTIC </e2> ) and the pro-oxidant, imexon, in the human A375 melanoma cell line.	0	dacarbazine	DTIC
We evaluated mechanisms of interaction between the alkyating agent <e1> dacarbazine </e1> (DTIC) and the pro-oxidant, <e2> imexon </e2> , in the human A375 melanoma cell line.	0	dacarbazine	imexon
We evaluated mechanisms of interaction between the alkyating agent dacarbazine ( <e1> DTIC </e1> ) and the pro-oxidant, <e2> imexon </e2> , in the human A375 melanoma cell line.	0	DTIC	imexon
The effect of <e1> DTIC </e1> and <e2> imexon </e2> , alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay).	0	DTIC	imexon
There was a >75% reduction in cellular glutathione and cysteine with <e1> imexon </e1> but not <e2> DTIC </e2> .	0	imexon	DTIC
<e1> Imexon </e1> and <e2> dacarbazine </e2> show additive effects in vitro but not in vivo in human A375 melanoma cells.	1	Imexon	dacarbazine
Synergistic interaction between <e1> sunitinib </e1> and <e2> docetaxel </e2> is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.	0	sunitinib	docetaxel
This study was aimed to investigate the efficacy of single use of <e1> sunitinib </e1> and that of concurrent or sequential administration of sunitinib and <e2> docetaxel </e2> in NSCLC cell lines that are resistant to EGFR TKIs.	0	sunitinib	docetaxel
This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of <e1> sunitinib </e1> and <e2> docetaxel </e2> in NSCLC cell lines that are resistant to EGFR TKIs.	0	sunitinib	docetaxel
NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either <e1> sunitinib </e1> or <e2> docetaxel </e2> or both based on various sequential administrations.	0	sunitinib	docetaxel
<e1> Sunitinib </e1> exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas <e2> docetaxel </e2> arrested at S phase.	0	Sunitinib	docetaxel
Although single or concurrent use of <e1> sunitinib </e1> and <e2> docetaxel </e2> has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity.	1	sunitinib	docetaxel
When cells were exposed to <e1> docetaxel </e1> followed by <e2> sunitinib </e2> , synergism was observed.	1	docetaxel	sunitinib
The molecular basis of this synergism is that the signaling pathways that were initially activated by <e1> docetaxel </e1> exposure were efficiently suppressed by the subsequent exposure to <e2> sunitinib </e2> .	1	docetaxel	sunitinib
<e1> Sunitinib </e1> as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e2> docetaxel </e2> followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.	0	Sunitinib	docetaxel
<e1> Sunitinib </e1> as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by <e2> docetaxel </e2> and concurrent administration.	0	Sunitinib	docetaxel
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e1> docetaxel </e1> followed by <e2> sunitinib </e2> is superior to sunitinib followed by docetaxel and concurrent administration.	1	docetaxel	sunitinib
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of <e1> docetaxel </e1> followed by sunitinib is superior to <e2> sunitinib </e2> followed by docetaxel and concurrent administration.	0	docetaxel	sunitinib
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by <e1> sunitinib </e1> is superior to sunitinib followed by <e2> docetaxel </e2> and concurrent administration.	0	sunitinib	docetaxel
Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to <e1> sunitinib </e1> followed by <e2> docetaxel </e2> and concurrent administration.	0	sunitinib	docetaxel
<e1> Ephedrine </e1> enhances the antinociceptive effect of <e2> dexmedetomidine </e2> in mice.	1	Ephedrine	dexmedetomidine
The purpose of this study was to evaluate whether the psychostimulant drug <e1> ephedrine </e1> has any effect on <e2> dexmedetomidine </e2> -induced antinociception and locomotor inhibitor activity in mice in acute application.	0	ephedrine	dexmedetomidine
saline + saline, <e1> ephedrine </e1> (10 mg/kg) + saline, saline + <e2> dexmedetomidine </e2> (15 g/kg) and ephedrine (10 mg/kg) + dexmedetomidine (15 g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	0	ephedrine	dexmedetomidine
saline + saline, <e1> ephedrine </e1> (10 mg/kg) + saline, saline + dexmedetomidine (15 g/kg) and ephedrine (10 mg/kg) + <e2> dexmedetomidine </e2> (15 g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	0	ephedrine	dexmedetomidine
saline + saline, ephedrine (10 mg/kg) + saline, saline + <e1> dexmedetomidine </e1> (15 g/kg) and <e2> ephedrine </e2> (10 mg/kg) + dexmedetomidine (15 g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	0	dexmedetomidine	ephedrine
saline + saline, ephedrine (10 mg/kg) + saline, saline + dexmedetomidine (15 g/kg) and <e1> ephedrine </e1> (10 mg/kg) + <e2> dexmedetomidine </e2> (15 g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.	0	ephedrine	dexmedetomidine
In the hot plate test in mice, co-administration of 15 g/kg <e1> dexmedetomidine </e1> with 10 mg/kg <e2> ephedrine </e2> intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine.	1	dexmedetomidine	ephedrine
In the hot plate test in mice, co-administration of 15 g/kg dexmedetomidine with 10 mg/kg <e1> ephedrine </e1> intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by <e2> dexmedetomidine </e2> .	0	ephedrine	dexmedetomidine
At the same time, the locomotor inhibitory effect of <e1> dexmedetomidine </e1> was counteracted by <e2> ephedrine </e2> .	1	dexmedetomidine	ephedrine
We concluded that the combined administration of <e1> dexmedetomidine </e1> with <e2> ephedrine </e2> may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.	1	dexmedetomidine	ephedrine
We concluded that the combined administration of <e1> dexmedetomidine </e1> with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an <e2> analgesic </e2> in humans.	0	dexmedetomidine	analgesic
We concluded that the combined administration of dexmedetomidine with <e1> ephedrine </e1> may have beneficial effects in the treatment of pain without causing sedation, which limits the use of <e2> dexmedetomidine </e2> as an analgesic in humans.	0	ephedrine	dexmedetomidine
We concluded that the combined administration of dexmedetomidine with <e1> ephedrine </e1> may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an <e2> analgesic </e2> in humans.	0	ephedrine	analgesic
We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of <e1> dexmedetomidine </e1> as an <e2> analgesic </e2> in humans.	0	dexmedetomidine	analgesic
Interaction study of <e1> moxifloxacin </e1> and <e2> lomefloxacin </e2> with co-administered drugs.	0	moxifloxacin	lomefloxacin
<e1> Moxifloxacin </e1> and <e2> lomefloxacin </e2> are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections.	0	Moxifloxacin	lomefloxacin
<e1> Moxifloxacin </e1> and lomefloxacin are <e2> fluoroquinolone antibiotics </e2> used in treating urinary and respiratory tract infections.	0	Moxifloxacin	fluoroquinolone antibiotics
Moxifloxacin and <e1> lomefloxacin </e1> are <e2> fluoroquinolone antibiotics </e2> used in treating urinary and respiratory tract infections.	0	lomefloxacin	fluoroquinolone antibiotics
Being <e1> moxifloxacin </e1> and lomefloxacin <e2> fluoroquinolones </e2> the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals.	0	moxifloxacin	fluoroquinolones
Being <e1> moxifloxacin </e1> and lomefloxacin fluoroquinolones the interaction study of was carried out with <e2> sucralfate </e2> , gelusil, erythromycin and multi minerals.	0	moxifloxacin	sucralfate
Being <e1> moxifloxacin </e1> and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, <e2> gelusil </e2> , erythromycin and multi minerals.	0	moxifloxacin	gelusil
Being <e1> moxifloxacin </e1> and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, <e2> erythromycin </e2> and multi minerals.	0	moxifloxacin	erythromycin
Being <e1> moxifloxacin </e1> and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and <e2> multi minerals </e2> .	0	moxifloxacin	multi minerals
Being moxifloxacin and lomefloxacin <e1> fluoroquinolones </e1> the interaction study of was carried out with <e2> sucralfate </e2> , gelusil, erythromycin and multi minerals.	0	fluoroquinolones	sucralfate
Being moxifloxacin and lomefloxacin <e1> fluoroquinolones </e1> the interaction study of was carried out with sucralfate, <e2> gelusil </e2> , erythromycin and multi minerals.	0	fluoroquinolones	gelusil
Being moxifloxacin and lomefloxacin <e1> fluoroquinolones </e1> the interaction study of was carried out with sucralfate, gelusil, <e2> erythromycin </e2> and multi minerals.	0	fluoroquinolones	erythromycin
Being moxifloxacin and lomefloxacin <e1> fluoroquinolones </e1> the interaction study of was carried out with sucralfate, gelusil, erythromycin and <e2> multi minerals </e2> .	0	fluoroquinolones	multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with <e1> sucralfate </e1> , <e2> gelusil </e2> , erythromycin and multi minerals.	0	sucralfate	gelusil
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with <e1> sucralfate </e1> , gelusil, <e2> erythromycin </e2> and multi minerals.	0	sucralfate	erythromycin
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with <e1> sucralfate </e1> , gelusil, erythromycin and <e2> multi minerals </e2> .	0	sucralfate	multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, <e1> gelusil </e1> , <e2> erythromycin </e2> and multi minerals.	0	gelusil	erythromycin
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, <e1> gelusil </e1> , erythromycin and <e2> multi minerals </e2> .	0	gelusil	multi minerals
Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, <e1> erythromycin </e1> and <e2> multi minerals </e2> .	0	erythromycin	multi minerals
The response of <e1> moxifloxacin </e1> and <e2> lomefloxacin </e2> after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector.	0	moxifloxacin	lomefloxacin
<e1> Moxifloxacin </e1> and <e2> Lomefloxacin </e2> reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	0	Moxifloxacin	Lomefloxacin
<e1> Moxifloxacin </e1> and Lomefloxacin reacts faster with <e2> sucralfate </e2> and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	1	Moxifloxacin	sucralfate
<e1> Moxifloxacin </e1> and Lomefloxacin reacts faster with sucralfate and <e2> gelusil </e2> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	1	Moxifloxacin	gelusil
<e1> Moxifloxacin </e1> and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with <e2> erythromycin </e2> in basic media and multi-minerals in neutral media.	1	Moxifloxacin	erythromycin
<e1> Moxifloxacin </e1> and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and <e2> multi-minerals </e2> in neutral media.	1	Moxifloxacin	multi-minerals
Moxifloxacin and <e1> Lomefloxacin </e1> reacts faster with <e2> sucralfate </e2> and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	1	Lomefloxacin	sucralfate
Moxifloxacin and <e1> Lomefloxacin </e1> reacts faster with sucralfate and <e2> gelusil </e2> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	1	Lomefloxacin	gelusil
Moxifloxacin and <e1> Lomefloxacin </e1> reacts faster with sucralfate and gelusil in acidic media whereas with <e2> erythromycin </e2> in basic media and multi-minerals in neutral media.	1	Lomefloxacin	erythromycin
Moxifloxacin and <e1> Lomefloxacin </e1> reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and <e2> multi-minerals </e2> in neutral media.	1	Lomefloxacin	multi-minerals
Moxifloxacin and Lomefloxacin reacts faster with <e1> sucralfate </e1> and <e2> gelusil </e2> in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media.	0	sucralfate	gelusil
Moxifloxacin and Lomefloxacin reacts faster with <e1> sucralfate </e1> and gelusil in acidic media whereas with <e2> erythromycin </e2> in basic media and multi-minerals in neutral media.	0	sucralfate	erythromycin
Moxifloxacin and Lomefloxacin reacts faster with <e1> sucralfate </e1> and gelusil in acidic media whereas with erythromycin in basic media and <e2> multi-minerals </e2> in neutral media.	0	sucralfate	multi-minerals
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and <e1> gelusil </e1> in acidic media whereas with <e2> erythromycin </e2> in basic media and multi-minerals in neutral media.	0	gelusil	erythromycin
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and <e1> gelusil </e1> in acidic media whereas with erythromycin in basic media and <e2> multi-minerals </e2> in neutral media.	0	gelusil	multi-minerals
Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with <e1> erythromycin </e1> in basic media and <e2> multi-minerals </e2> in neutral media.	0	erythromycin	multi-minerals
